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Abstract
Following five decades of kidney transplantation, increasingly high risk immunological kidney
transplantation (which previously was considered as sub-optimal) are carried out. The risk
stratification with the current available assays have allowed safe transplantation in low risk
non-sensitised patients and direct transplantation in high risk highly sensitised patients by
removal of circulating donor specific antibodies (DSA) with reasonable outcomes. However, a
large number of patients with chronic kidney disease and with low or intermediate antibody
levels measured by current assay, the best way forward is uncertain resulting in denial of
transplantation in some cases. Whilst in other cases, the solid phase Luminex assay may under
or overestimate the risks of rejection and graft failure following direct kidney transplantation.
Currently only IgG-class of DSA is considered immunologically important and routinely
measured in clinical laboratories. Other bio-physiological characteristics such as class, sub-
class and binding kinetics of DSA may be more specific for risk stratification of immunological
risks. In this thesis, we studied effect of de novo IgM class of HLA-specific antibodies on
outcome of kidney transplantation and characterised binding kinetics and strength of HLA-
specific antibodies.
De novo IgM or IgG HLA-specific responses alone were not associated with adverse outcomes
following kidney transplantation. Presence of both IgM and IgG responses, however, was
associated with poor graft function at 36 months. There was no temporal relationship of
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antibody response and episodes of rejections. De novo Donor specific responses were less
frequent compared to non-specific responses. A shorter follow-up and use of modern triple
immunosuppressant therapy (Tacrolimus, Mycophenolate and Steroid) may explain this.
Binding kinetics measured by biosensor assay- surface plasmon resonance (SPR) on purified
monoclonal HLA-specific antibodies showed binding kinetics and strength differed between
HLA alleles despite same epitope and paratope interactions. There was a tendency towards
higher affinity and faster association rate for HLA protein that was the initial immunizing
antigen for the corresponding monoclonal HLA-specific antibodies. The dissociation constant
(KD) of human monoclonal HLA-specific antibodies range between 10-8 to 10-10 M.
Thermodynamic analysis showed higher Gibbs free energy released for interactions with
higher binding strength. The binding strength of mixed monoclonal HLA-specific antibodies is
generally average of the strength of individual monoclonal HLA-specific antibodies.
Enriched polyclonal HLA-specific antibodies from clinical sample gave distinct binding
response on bio-sensor based on SPR assay. Quantification of polyclonal HLA-specific
antibodies using sandwich ELISA and SPR allowed quantitative measurement of binding
kinetics and strengths. A range of binding strength was observed between patients and within
same patient antibodies of different affinities was observed. Thus the antibodies could be
grouped in four groups based on the strength of binding and this can serve as additional
biomarker for risk stratifications.
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Thus three important observations have been made during this thesis –
1) Presence of both IgM and IgG de novo HLA-specific responses was associated with
poor graft outcomes
2) The difference in binding strength and binding energy may explain the difference of
reactivity of antibodies despite same epitope and paratope interactions.
3) Polyclonal HLA-specific antibodies can be grouped in to four groups based on their
binding strength and this can be used as an additional biomarker for risk stratification.
Further studies are required to establish clinical application of above observations.
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Introduction: Kidney transplantation – Success, challenges and
strategies
Transplantation is the optimal treatment for end-organ failure. Apart from cost effectiveness,
it has shown to improve QOL (Quality of Life) and life expectancy (Wolfe et al., 1999) (Figure
1-1). There have been significant improvements in reducing rates of acute rejection with the
advent of new drugs and greater understanding of HLA matching procedures. The US Renal
Data System (USRDS) data suggested acute rejection rate following kidney transplantation is
now less than 10% (Collins et al., 2014) (Figure 1-2 (A)). However the improvement in the
longer-term outcomes such as graft failure and return to dialysis has been slower
comparatively (Figure 1-2 (B): USRDS 2013 data). UK data show similar slow progress in
improving longer-term outcomes (Figure 1-3).
Figure 1-1: Adjusted relative risk of death following First Cadaveric Transplant. WL=
waiting list, Tx= transplant
(Study group = 23,275 recipients & control group = 46,164 patient on dialysis on waiting list)
Taken from ref (Wolfe et al., 1999)
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Figure 1-2: Outcome following first kidney transplantation
A – Acute rejection rate in the first year. B – Ten year outcomes following Living & Deceased donor Kidney Transplantation (Collins et al., 2014)
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Figure 1-3 : Long-term Graft survival after first deceased [A] (DBD) and Living donor [B]
kidney transplantation in UK (Modified from NHSBT (NHS Blood and Transplant)
Transplant activity 2012-13)
A Longitudinal biopsy study has shown increasing chronic damage with time following kidney
transplantation (Figure 1-4) (Nankivell et al., 2003). Graft failure could be due to many
aetiologies either working alone or in combinations (Nankivell and Chapman, 2006). A
significant number of these are thought to be mediated by antibodies directed against the
donor kidney, particularly HLA-specific antibodies (Mao et al., 2007, Worthington et al., 2003,
Lee et al., 2009, Terasaki and Cai, 2008).
Figure 1-4 : Mean Banff score from serial protocol biopsy from kidney transplant
recipients (Nankivell et al., 2003)
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Humoral theory
The humoral immune mechanism can damage a transplanted organ via antibody formation
against antigens on the tissue of graft. The most extensively studied are antibodies developed
against HLA proteins (Terasaki, 2012). Many believed the major effector response to the
transplanted organ was cell mediated and that the antibody response was a mere bystander
effect. Over last few decades the understanding of the humoral response has improved due
to availability of solid phase specific diagnostic assays. The majority of early work was done
by Terasaki et al., and proposed mechanism of graft damage as seen in Figure 1-5 (Mao et al.,
2007).
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Figure 1-5 : Humoral immune response and damage to allograft (taken from (Cai and Terasaki, 2005)
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
33
De novo donor specific antibodies (de novo DSA):
Antibodies appearing after kidney transplantation are termed as de novo. Such transplant
recipients did not have these antibodies historically or at the time of transplantation.
Prevalence of de novo HLA is reported up to in 24 % in the first year post transplantation
(Lachmann et al., 2006, Piazza et al., 2001, Terasaki and Ozawa, 2004). This is influenced by
the type of baseline immunosuppression regimen (Lederer et al., 2005), sensitisation status,
assays used to detect antibodies, time post-transplantation (Terasaki and Ozawa, 2004),
compliance to drugs (Wiebe et al., 2012) and induction agents (Tinckam et al., 2004). These
can be donor specific (DSA) or non-donor specific (NDSA) based on the presence or absence
of corresponding HLA expressions on the donor kidney.
A prospective study of 315 transplant recipients followed over a median follow-up of 6.2(+/-
2.9) years, showed that about 15% developed de novo DSA to HLA in a mean time of 4.6(+/-
3.0) years post-transplantation. The median 10 year graft survival was 57% in cases that
developed de novo DSA compared to 96% in cases who did not develop de novo DSAs (Wiebe
et al., 2012). Screening for the development of de novo HLA-specific antibodies is
recommended by BSHI/BTS (Howell et al., 2010), however this has been controversial (Cooper
et al., 2011, Gill et al., 2010, Wiebe et al., 2012).
NDSA are observed frequently following transplantation. Some of these appear together with
DSA, and are detected on assays due to shared epitopes on different alleles, or many may
appear without any detectable DSAs (thus not due to shared epitopes). Explanations for the
latter are not clear and could be due to a re-call response from past sensitisation or non-
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specific immune up-regulation following transplantation/ infections (Briggs et al., 2009). It has
also been suggested that some of these could be natural antibodies (such as observed in a
study of un-transfused males (Morales-Buenrostro et al., 2008)).
Prevention of HLA-specific antibody development post transplantation
Various strategies are proposed to reduce the development of de novo DSA post-
transplantation. This includes an immunosuppressant regimen that involves Mycophenolate
Mofetil (Lederer et al., 2005), and epitope matching (Duquesnoy, 2014a) and increased
adherence to the immunosuppressant regimen (Wiebe et al., 2012). It is also postulated that
certain HLA-antigens are more immunogenic than others and assays that could assess
immunogenicity are under development. Studying electrostatic potential over the epitope
surface has been put forward as a promising tool to quantify epitope immunogenicity (Mallon
et al., 2014, Kosmoliaptsis et al., 2011). Another important observation is that transplantation
across CREG (cross reactive group) of HLA-antigen reduces the risk of an alloresponse
(McKenna and Takemoto, 2000). The underlying mechanism is epitope matching between
donor and recipient HLA antigens. Epitope consists of antigen determinant amino acid residue
that differs between HLA alleles. However, epitopes can be shared between different HLA
alleles and as a result presence of antibody against specific epitope gives positive signal for
many HLA-specificities defined at antigen levels by current assays. Epitope matching can be
done using computer algorithm (Duquesnoy, 2014a). Section 1.7.1. discusses more on
concept of epitope. Current UNOS (United Network for Organ Sharing) proposals in the USA
will allow better matched kidneys to be transplanted in younger recipients. This will allow the
kidney to last longer with less risk of sensitisation (Reese and Caplan, 2011).
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Pre-formed HLA-specific antibodies and highly sensitised recipient
Many patients with CKD (Chronic kidney disease) have pre-formed HLA-specific antibodies
present whilst on the transplant waiting list. These antibodies develop in response to a
sensitising event where there has been previous exogenous HLA-antigen exposure; such as
pregnancy (Masson et al., 2013), blood product transfusion (Leffell et al., 2014), and/or
previous organ transplantation (Clatworthy et al., 2010). The presence of these antibodies is
measured as the breadth of reactivity against the last 10,000 donor HLA types on a national
database and expressed as the calculated reactive frequency (cRF) (see Table 1-1). The higher
the cRF, the more difficult it is to obtain a compatible transplant offer.
cRF HD PD Pre-emptive Total
<10% 51% 63% 71% 57%
10 to 85 % 19% 23% 21% 21%
>85% 30% 14% 8% 23%
Table 1-1 : Proportion of sensitised patients in UK (HD – Haemodialysis, PD – Peritoneal
dialysis, cRF – calculated reactive frequency) taken from Renal Registry annual report
2013
Patients with cRF > 85% are defined as Highly Sensitised Patients (HSP) and they have to wait
longer before a transplant offer. Some 43% of cases on the waiting list are sensitised and 23%
are highly sensitised (Table 1-1) (Pruthi et al., 2013). Transplantation in the presence of high
levels of pre-formed HLA-specific antibodies can result in immediate hyper acute rejection
(Patel and Terasaki, 1969) and poor transplant outcomes (Patel et al., 1971). Various
strategies are used to increase the chances of transplantation in such groups; 1) Prioritisation
of highly sensitised patients, 2) Modified unacceptable antigen listing, 3) Kidney sharing
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schemes and 4) Direct transplantation in the presence of donor specific antibodies. The first
two approaches are for cases that are on the national deceased donor waiting list.
Prioritisation of highly sensitised patient
1.2.3.1.1 UK kidney allocation scheme
In the UK, unacceptable antigens are listed with ODT (Organ Donor Transplantation) and
when a kidney becomes available it is allocated based on the national allocation scheme. In
2006, the kidney allocation scheme, which was largely based on HLA matching, was changed
with a view to reduce variations in waiting times (Higgins et al., 1997) (see Table 1-2). Prior to
the 2006 scheme, 15 % highly sensitised patients were on waiting lists for 5 or more years;
after implementing the new scheme it was reduced to 10%. However, subsequently this
remained static; hence in 2011 Level 3 HLA mismatch (0-DR and 2-B or 1-DR and 0/1-B)
kidneys were allowed for cases with cRF > 85%. But that only had minor improvement due to
the large residual pool. Recently, the scheme has changed to allow Level 2 HLA mismatch (0-
DR and 1/0-B) for cases with cRF > 85%. (KAG – Kidney advisor report UK, November 2013;
See Appendix 1) The effect of new changes will need to be assessed after its implementation
in 2014.
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Tier scheme Points
Tier A 000 mismatched children (DR
homozygous or HSP)
Tier B 000 mismatched children (all others)
Within tiers A and B: patients are
prioritised by waiting time only
Tier C 000 mismatched adults (DR
homozygous or HSP)
Tier D 000 mismatched adults & favourably
mismatched children
Tier E All other eligible patients
Within tiers C to E: patients are prioritised
by point score
Waiting time points: 1 point for each day on
list
HLA match & age points combined: max
3,500
Age difference points: –0.5*(donor-
recipient age diff)2
Location points: 900 same centre, 750 local
area
HLA homozygous points: HLA-B 100, HLA-DR
500
Blood group points: –1000 for B patients
when donor is O
Table 1-2 : UK National organ allocation scheme 2006
1.2.3.1.2 Euro-Transplant Acceptable Mismatch Program
The Euro-Transplant Acceptable Mismatch Program uses a computer algorithm (HLA match
maker) to identify HLA-antigens that are likely to give a negative cross match. Acceptable
antigens are defined as ones which the patient has never formed antibodies against (Claas et
al., 2004). When such a donor becomes available the kidney is shipped to the transplanting
centre, and wet cross match is performed. This strategy has allowed 65% of highly sensitive
patients on waiting lists to receive transplants within 2 years. However not all cases could be
transplanted using this strategy and the authors have suggested the role of desensitisation in
selected cases (Doxiadis and Claas, 2009).
Thus, although the strategy used in the UK and Euro-Transplant program has improved the
chances of a transplantation offer in highly sensitised cases, there are still a large number of
cases that need to wait longer; and thus we require additional approaches.
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Modified unacceptable HLA-specificities listing
In the UK, unacceptable HLA specificities are reported to ODT (Organ Donor Transplant).
Different profiles of unacceptable antigens can be registered for the deceased donor waiting
list. Individual clinicians go through the list of HLA-specificities in highly sensitised patients,
and if the levels are low, or historic positive and current negative, or deemed false positive,
these are considered negative and listed them as modified unacceptable HLA-antigens.
1.2.3.2.1 Historic positive but current negative HLA-specificities
Some HLA-specific antibodies can disappear following the initial response and these
specificities are removed from unacceptable list. This is supported by a study using AHG-CDC
(Anti-human globulin augmented complement dependent cytotoxicity) assay that showed no
difference in graft function or rejection between groups of patients with historic positive and
historic negative AHG-CDC (Baron et al., 2002). However other studies have given contrary
conclusions (Avlonitis et al., 2000); 10 out of the 14 cases lost their graft despite negative pre-
transplant flow cross match and five year survival was 43%. Similarly, another study suggested
higher peak historic Mean Fluorescence intensity (MFI) (Luminex assay) levels predicted
antibody mediated rejection better than current DSA levels (Lefaucheur et al., 2010). Ideally
such cases should have assessment for likelihood of memory response by studying memory B
cell (Eisen, 2014). A pragmatic approach is however taken in such cases with augmented
immunosuppressive treatment followed by careful monitoring.
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1.2.3.2.2 Low level (MFI) HLA-specific antibodies
Lack of standardisation, coupled with variability of assay protocols used across the world, has
led to different H&I Units having different cut-off points for positivity of MFI levels; which
ranges from 300 to 2000 MFI values. Each Unit sets up a cut-off threshold based on response
from the negative sera using their protocols. So it is difficult to compare results of
transplantation between various Centres. It is generally believed that transplantation across
low level MFI (<2000) carries low immunological risks.
Transplanting across low level antibodies need careful approach, as studies have shown poor
outcome in such cases (Gupta et al., 2008). We have reported that certain HLA-specificities
provoke more vigorous response than others and that this depends on the sensitisation event
that was responsible for synthesis of DSA in first instance (Higgins et al., 2014b). Thus history
of sensitisation events is important; this is of particular significance if the donor is the
husband or child for a female transplant recipients, as even a low level of DSA is important
(see Figure 1-6) (Higgins et al., 2014b).
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Figure 1-6 : Percentage changes in HLA-specific antibody levels (from pre-treatment levels) according to mode of original sensitisation event
(Higgins et al., 2014b)
Box plot showing median, 25%, 75% and inter-quartile range; A = no known sensitising event; B = pregnancy; C = transfusion; D = transplant,
repeat antigen mismatch; E = transplant, repeat epitope mismatch ( p <0.0001 (Independent samples Kruskal Wallis test))
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National living donor kidney sharing scheme (NLDKSS)
This is a collective scheme whereby the donated kidneys are shared across UK. This includes
paired/pooled donation (PPD) and altruistic donor chains (ADC). It was first proposed in 1986
(Ross et al., 1997) and later developed in Korea, Netherlands and USA (Kaplan et al., 2005,
Gentry et al., 2011, Montgomery et al., 2011a). A paired donation can take place between
two antibody incompatible pairs, where by the respective donors can donate kidney to the
opposite recipients such that the immunological risk is lower and the transplantation is
antibody compatible (Figure 1-7, A). More pairs can be added in to this and the best possible
donation is identified in the pool for every recipient and this is called pooled donation (Figure
1-7, B). The pooled donation can be facilitated further by participation of an altruistic (non-
directed) donor, whereby an additional kidney improves matching in the pool and one kidney
at the end goes to patient waiting on national waiting list (Figure 1-7, C). Thus by kidney
sharing scheme the highly sensitised patients with a living donor could have a compatible
kidney transplantation with lower immunological risks.
National kidney sharing scheme was introduced in UK (see Figure 1-7 and 1-8). However up
to 50% of incompatible pairs fails to find a suitable match (Montgomery, 2010). This is due to
the presence of larger numbers of blood group ‘O’ patients compared to fewer donor and
cases with cRF over 95%. This limitation could be partly overcome by allowing compatible
pairs (Gentry et al., 2007), altruistic donor (Johnson et al., 2008) and direct transplantation
with antibody removal treatment for selected cases (Montgomery et al., 2011a). See
Appendix – B (Kidney Advisory Report December 2014)
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Figure 1-7 : Kidney sharing scheme (adapted from NHSBT website)
A- Paired exchange between pair-1 and pair-2; B – kidney exchanged in three way swap (pooled
donation) and C – Altruistic donor donating to highly priority patient (Yellow colour) and in absence
of highly priority patient donates kidney to long waiting patients on paired or pooled donation (Green)
and then the corresponding recipient (blue colour) donates the kidney to patient on national waiting
list (brown colour)
Figure 1-8 : Profile of Living donor kidney transplantation in UK (adapted from UKT report)
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Direct transplantation with donor specific antibody removal
In highly sensitised patients, Antibody removal combined with other conditioning therapies
such as IVIg and Rituximab can render cross match negative (Genberg et al., 2008; Gloor &
Stegall, 2010; Higgins et al., 2010; Higgins et al., 2011b; Higgins et al., 2011c; Montgomery et
al., 2011b; Stegall et al., 2006), thus allowing kidney transplantation. (See Figure 1-9 for UK
activity). Following HLA-incompatible kidney transplantation, the dynamics of HLA-specific
antibodies over tine are monitored carefully (Higgins et al., 2009b) and treatment adapted
accordingly. Transplanting across higher levels of DSA (complement dependent cytotoxicity
(CDC) positive) is associated with poor graft survival compared to standard compatible kidney
transplantation.
Figure 1-9 : Antibody incompatible kidney transplantation in UK
(Taken from NHSBT Organ & Transplantation report 2013-14)
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Data from our Centre showed that graft survival is dependent on the level of antibodies (see
Figure 1-10), and that cases with CDC negative have similar 10-year graft survival as standard
kidney transplantation. Similarly, a multicentre study form US showed poor graft and patient
survival associated with higher levels of antibodies (Lentine et al., 2014, Orandi et al., 2014)
(see Figure 1-11). Hence Kidney Advisory Group (see Appendix B) recommended direct
transplant in pairs with positive CDC should be considered only in exceptional circumstances.
Despite of high clinical and immunological risk, direct transplantation with antibody removal
in highly sensitised patients confers survival benefit when compared to patient staying on
dialysis (Montgomery et al., 2011b) (Figure 1-12).
Figure 1-10: Death censored graft failure of HLA-incompatible kidney transplantation
stratified according to the reactivity of the donor antibodies (Higgins et al., 2014a)
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Figure 1-11 : Survival curve showing patient mortality based on antibody strength.
(Modified from ref (Orandi et al., 2014))
Figure 1-12: Patient survival comparing patients who underwent antibody incompatible
kidney transplantation with patients who stayed on dialysis (p < 0.001) (Montgomery et
al., 2011b)
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ABO-incompatible kidney transplantation (ABOi) is considered a lesser immunological risk
compared to HLA-incompatible kidney transplantation and single centre data show that the
outcome from ABOi is similar to compatible kidney transplantation (Higgins et al., 2011a,
Tyden et al., 2007, Takahashi and Saito, 2006, Ichimaru and Takahara, 2008, Tanabe et al.,
2013, Toma et al., 2001). Recent multi-centre European studies showed similar results of graft
survival at three years compared to standard transplantation (Opelz G1, 2014). A US multi-
centre study showed day 8 as higher risk for acute antibody mediated rejection with graft
failure (Montgomery et al., 2012) (see Figure 1-12).
Figure 1-13: Outcome of ABO-incompatible kidney transplantation(Montgomery et al.,
2012)
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Alloresponse following kidney transplantation
Following organ transplantation, the donor HLA-proteins are presented to recipient T cells by
antigen presenting cells through three distinct pathways (see Figure 1-14). On activation of
recipient T cell, they can drive T cell proliferation and B cell activation.
Figure 1-14 : Pathways for allorecognition following transplantation (taken from ref (Sagoo
et al., 2012)) (A – illustration of pathways and B – time-line of contribution from each
pathways)
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Direct pathway
As seen in the Figure 1-14, a donor antigen presenting cell (APC) presents donor MHC to
recipients T-cells. This alloimmune response is unique to organ transplantation and lasts as
long as the donor APC survives. The donor APC expresses MHC +/- peptides for both recipient
CD4 and CD8 T cells, and thus CD4 T cells provide direct help for cytotoxic CD8 T cell-mediated
alloimmunity. This pathway does not provide help for antibody production as demonstrated
in a murine adoptive-transfer mode (Taylor et al., 2007). This pathway is intense in the early
post-transplant period and is responsible for acute cellular rejection observed in first three
months post-transplantation.
Indirect pathway
As seen in the Figure 1-14, recipient APC MHC molecules present processed donor MHC class
II peptides to the recipient CD4 T cell leading to T cell activation and proliferation. This
pathway is similar to normal physiological responses to a foreign protein antigen and is
important for humoral immunity. The CD4 T cell help is delivered directly to the B cells,
resulting in alloantibody production (Steele et al., 1996).
Here CD4 T cell help is delivered indirectly to the CD8 T cell via the APC which acts as an
intermediary cell expressing MHC class I and presents antigen to the CD8 T cell (not shown in
the Figure 1-14).
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Semi-direct pathway
As seen in the Figure 1-14, donor class I MHC molecules can be presented on recipient APC
and donor peptide is presented through recipients’ class II MHC molecules. Thus both CD4
and CD8 T cell can interact with recipient APC and direct CD4 T cell help is provided to the
cytotoxic CD8 T cells (Figure 1-14).
Indirect and semi-direct pathways are responsible for continuing allorecognition long term
and responsible for rejection (both acute and chronic).
Direct allorecognition by pre-existing donor specific antibodies
Pre-existing donor specific antibodies circulating in the recipient’s circulation can recognise
the donor HLA molecules on endothelial cells and thus cause direct allorecognition. Following
binding of the antibodies, the complement system is activated which leads to activation of T
cells, neutrohils and macrophages. (Figure 1-25)
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
50
B cell activation and proliferation of B cells and Plasma cells
B cell activation and alloantibody production occurs via the indirect allorecognition pathway
described above. The Indirect pathway involves direct B cell and T cell interactions (cognate
interaction). Cognate interaction is important for immunoglobulin class-switching and affinity
maturation. Additionally, B cell can be activated by direct interaction with class I MHC on
donor APCs similar to CD8 T-cell in direct pathway described above. This is a non-cognate
interaction and the immune response is characterised by an IgM only response (Steele et al.,
1996).
As seen in the Figure 1-15, following allorecognition and activation, the B cells migrate to the
T/B border in secondary lymphoid organs and interact with CD4 helper T cells. This cognate
interaction is augmented via the costimulatory interactions between the molecules CD40 and
CD40L and is followed by local cytokine release (IL4) inducing clonal expansion and
differentiation. Cells entering germinal centres undergo somatic hypermutation and class
switch recombination. These further differentiate in to memory B cells and plasma cells.
Ectopic formation of germinal centre in transplant graft has been demonstrated (Thaunat et
al., 2010). Some activated B cells remain in extra-follicular / marginal zones and produce poly-
specific low affinity antibodies (IgM, IgG and IgA) (Baumgarth, 2011, Griffin et al., 2011). The
B cells These T-independent pathways of B cell activation are faster than T-dependent which
can take up to five to seven day in response to microbial exposure. These B cells differentiate
into short lived plasma cells or IgM+ memory B cells.
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Long lasting plasma cells are high affinity variants and migrate to bone marrow, where they
form a niche and become fully differentiated and continue to produce antibodies of high
affinity (Clatworthy, 2011). As seen in Figure 1-16, plasma cells reside in a cellular niche that
provides a microenvironment favorable for the survival of these long lived cells (Tangye,
2011). Various mediators take part in the activation and survival of plasma cells, particularly
IL6, BAFF (B-cell activating factor) and APRIL (a proliferation inducing ligand) (Tangye, 2011,
Clatworthy et al., 2010). FcγRIIB controls bone marrow plasma cell apoptosis (Xiang et al., 
2007). Long lived plasma cells do not express receptors for their cognate antigen, and give
rise to constitutive production of low levels of high affinity antibodies (Manz et al., 1998,
Manz et al., 2005). These circulating donor specific antibodies can be removed via an
assortment of plasma treatments to allow direct transplant in highly sensitised patients.
Figure 1-15: Alloantibody production (taken from (Clatworthy et al., 2010))
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Figure 1-16 : Survival factors for long lived plasma cell in bone marrow (taken from
(Tangye, 2011))
Memory B cells expresses antigen receptors and thus require antigens to mount a re-call
response. They rapidly expand and develop into short-lived plasma cell under cognate control
of memory helper T cells. This is characterised by increased concentrations of high affinity IgG
antibodies and can result in rejection in sensitised patients undergoing direct transplantation.
The antigen-driven reactivated memory B cells can return to germinal centres for further
maturation.
In mice, experiments have shown that the development of high avidity memory B cells occurs
in two stages. In the first stage following primary sensitisation, the IgG-bearing memory cells
do not require help from T cells. But in the second stage, there is production of high avidity
memory B cells due to interaction with T cell in presence of antigenic stimulation. IgM+
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Memory B cells, generated in a T-independent manner through innate responses (e.g. Toll like
receptor 9) are described (Weller et al., 2001) and they are thought to have role in fighting
infections (Capolunghi et al., 2013). The response regenerated by IgM+ memory B cells is
usually short lived (Rabant et al., 2013). These processes are not well delineated following
organ transplantation, and it is unclear which cells contribute to the antibody response.
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Response in highly sensitised patients
As discussed above, the humoral response is different for de novo alloantibody production
compared to a re-call response following a direct transplantation in highly sensitised patients.
In summary, the baseline antibody levels are due to long lived plasma cells residing in bone
marrow – antibodies which can be removed by depletion therapy (Higgins et al., 2010) but
the levels usually rise following direct transplantation (Higgins et al., 2009b). The rise is usually
after 4-7 days post transplantation and this could be due to saturation of adsorption of the
alloantibodies to the graft or soluble HLA molecules or increases in antibody synthesis
following secondary memory B cells responses which are T cell dependent
The high affinity baseline antibodies from long-lived plasma cells can cause direct
allorecognition and bind to the endothelial cells on the kidney graft causing complement
activation with subsequent tissue damage and rejection. This may not respond to the anti-T
cell treatment typically given to transplant patients, as the rejection process is ultimately
driven by long-lived plasma cells that do not typically respond to standard
immunosuppressive medications. However, the memory response is T cell dependant and can
potentially be ameliorated by anti-T cell treatment. The antibodies generated following
allorecognition in direct transplants within highly sensitised patients are polyclonal with
varied physio-chemical properties such as sub-class of IgG and target binding affinity. This
may partly explain the difference in humoral response following allorecognition. Thus
treatment of antibody mediated rejection needs the above consideration and a combination
of therapies may need to be used.
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Antibody (Immunoglobulin)
An antibody (also called immunoglobulin) molecule structure primarily consists of two heavy
(H) and two light (L) chains. Disulphide (covalent) bond holds these chains together and form
a ‘Y’ shape structured molecule. The antibody molecule is further divided in to variable (V)
and constant (C) regions. The N-terminal end (Fab) of heavy and light chains has variable
amino acid sequences and serves as the antigen binding site. The constant portion (Fc) serves
as the binding site for effector mechanisms such as Fc receptors and the complement system
(Figure 1-17). Based on variations in heavy chains (HC), the immunoglobulin molecule can be
further classified in to five classes or isotypes (Table 1-3). The light chains (LC) consist of two
types: kappa (κ) and lambda (λ).  
Figure 1-17: Structure of antibody (immunoglobulin) molecule (Bayry et al., 2007)
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Class IgA IgD IgE IgG IgM
Heavy chain α1,α2 Δ Ε γ1, γ2, γ3, γ4 µ
Molecular weight (D) 160,000 184,000 188,000 146,000 970,000
Serum concentration
(mg/ml)
0.5-3 0.03 0.00005 0.5-9 1.5
Half life (days) 6 3 2 7-21 10
intravascular
distribution
42% 75% 50% 45% 80%
Table 1-3: Classes of antibody
Antibody binding to the antigen
The antigen binding site (paratope) is located in the region of variable heavy chain (VH) and
variable light chain (VL) domains (Figure 1-18(A)). The antigen-binding site consists of amino
acid residues of six hyper variable loops (L1-3 are the LC CDR loops shown in the order of their
location in the amino acid sequence; H1-3 are the HC CDR loops) and these interacts with
epitope region on the antigen. The binding interaction consists of specific binding between
the paratope and epitope and non-specific binding to the surrounding amino acid residues.
The overall surface interacting determines stability of binding.
As antibody has more than one binding site (e.g. IgG = 2; IgM = 10) the overall binding strength
is a result of binding interaction at different site and this is called avidity. Affinity is used to
describe the binding strength at one specific interaction. Avidity will be affected by antigen
density whilst affinity is unaffected by antigen density.
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Figure 1-18: Epitope – Paratope interactions (adapted from (Altshuler et al., 2010))
A – IgG molecule; B – interaction of antigen and variable portion (V H and VL) of antibody shown in red oval area. Within the highlighted area, the CDR loops
are marked in red colour; C – Shows the CDR loops in color and labelled L1-3 and H1-3 on light and heavy chain respectively.
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Class switching
The IgM class can be produced by short lived plasma cells following direct B-cell interaction
with antigen, and this can happen independent of T cell help, or it could be produced by an
activated B cell with T cell help in a germinal centre. IgM has a pentameric structure. On
account of this clustering of Fc domains, it has strong complement activating properties, and
higher avidity when compared to the other immunoglobulins. Class-switching from IgM to IgG
or IgA generally requires T cell help and happens in germinal centres; but it can happen to a
lesser degree in extra-follicular regions due to innate system interactions. Within IgG, the
subclasses switch with IgG3 appearing first followed by IgG1-2-4.
Figure 1-19: Sequence of class switching of immunoglobulin molecule
The molecular mechanisms that underlie this class switching have been described. Briefly,
the sequence of class switch is summarised in Figure 1-19. Hereby, the VDJ exon that encodes
the heavy chain V (variable) domain recombines with a downstream C (constant) region gene
segment and the intervening DNA is deleted (Figure 1-20).
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Figure 1-20: Class switch recombination (taken from The Immune system, 3ed ©Garland
Science 2009)
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IgG subclasses differ in hinge region and amino acid residues within the constant domain of
the antibody structure (Figure 1-21). These structural differences give them functional
diversity, with IgG3 being the strongest complement activator followed by IgG1, and then
IgG2. IgG4 is believed to be a non-complement activating immunoglobulin. They also differ in
antigenic interactions; with IgG2 preferring carbohydrate antigen and IgG1 & IgG3 preferring
protein antigen. IgG4 has a unique property whereby it can exchange N-terminal Fab arms
and behave as a bispecific molecule interacting with two different antigens (Schuurman et al.,
1999). Isotype pattern varies according to the mode of B cell activation (Esser & Radbruch,
1990). This is dependent of antigen (e.g. Parasites strongly invoke switching to IgE), route of
immunisation (e.g. IgA induction to function at mucosa), the presence of regulatory cells, and
cytokines produced by CD4 helper T cells, and genetic factors. Apart from difference in
complement-fixing properties, IgG sub-class may differ in binding to Fc gamma receptors on
immune cells such as macrophages, neutrophils and dendritic cells and thus have variable
effects through antibody dependent cytotoxicity mechanism (Nimmerjahn et al., 2005;
Nimmerjahn & Ravetch, 2005).
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Figure 1-21 : Structure and properties of immunoglobulin G sub-classes (taken from
(Salfeld, 2007))
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Affinity maturation
Prolonged or repeated exposure to a specific antigen can lead to production of higher affinity
antibodies through a process called affinity maturation. This is brought about by the
introduction of somatic point mutations in V genes (Berek and Milstein, 1987) (Figure 1-22),
and T cell help is essential for this process (Figure 1-23) (Rizzo et al., 1992). Affinity maturation
takes place in germinal centres (Berek et al., 1991) through somatic hypermutation that is
exclusive to B cell differentiation pathways (Baltimore, 1981). This leads to intra-clonal
diversification and accumulation of memory B cells producing high affinity antibodies (Figure
1-22). The frequency of gene mutation is estimated to be one in 103 base pairs per cell per
division, which is 100 fold higher than for other genes, hence it is called hypermutation. As a
result, B cells of various clones are formed and the clones secreting higher affinity antibodies
are selected, the rest are removed via apoptosis (Phan et al., 2006). This process is called
clonal selection.
Figure 1-22 : Somatic mutations in Ig V genes and associated change in dissociation
constant (KD)
(Figure taken from chapter 11, Cellular and Molecular Immunology, Elsevier; ref Note here
Kd is used to represent KD)
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
63
Figure 1-23: Somatic hypermutation and clonal selection
(Adapted from
http://wenliang.myweb.uga.edu/mystudy/immunology/ScienceOfImmunology/index.html
Elsevier Science)
The selection of high affinity antibody producing B cells could be due to number of
mechanisms. The higher affinity immunoglobulin may act as cell surface receptor that binds
to antigen and seeks T-cell help for survival, or the immunoglobulin is secreted as antibody
which binds to antigen where the immune complexes (Song et al., 1998) are then displayed
by follicular dendritic cells in the germinal centre, and binding to the B cell that is secreting
higher affinity antibodies. The number of follicular dendritic cells is limited and high affinity
interactions are preferred, with no interaction with B cell with lower affinity BCR. Apoptosis
of B cells are ensured in absence of interactions with follicular dendritic cells. Follicular
dendritic cells prevents B cell apoptosis and this action is maintained through Toll-like
receptor (TLR)-4 activity (Garin et al., 2010). Thus antibodies produced by plasma cells can
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give feedback to germinal centre B cell responses. Immunisation with pre-formed immune
complex or administration of IgG shortly after antigen exposure results in augmented
germinal centre formation and hypermutation compared to administration of antigen alone
(Song et al., 1998). The T cell help may also drive clonal selection and this could be due to
endocytic receptors other than BCR. The progeny of high affinity, isotype switched B cells
differentiate into plasma cell and memory B cells.
The cycle of somatic hyper mutation could continue unchecked resulting in high affinity
oligoclonal antibodies. But heterogeneities of affinity are observed and this could be due to
B cell selection due to other favourable factors that enhances cognate interactions with
helper T cells and not just affinity-driven selection (Eisen, 2014). Additionally there are
regulation pathways that act as check points to arrest the process. A antibodies could form
immune complexes in the circulation and limit antigen access and thus antigen uptake which
can lead to inhibition of T:B cell interactions and ultimately lead to lymphocyte death by
neglect (Zhang et al., 2013). Other possible mechanisms wherein immunoglobulin class
switching may provide regulation is by reducing antibody potency once the response has
advanced.
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Binding region for Fc-gamma receptors
The Fc portion on the antibodies has binding sites for Fc-gamma receptors on immune cells
(e.g. dendritic cells, NK cells and monocytes). The interactions between immune complex and
Fc gamma receptors on dendritic cells allow the processing and presentation of antibody-
antigen complexes leading to effective stimulation of helper T cells and effector cytotoxic T
cells. Micro-array analysis from tissue of kidney biopsy with antibody mediated rejection,
showed evidence of Natural Killer cell signalling mediated through FCyRIIIA (Hidalgo et al.,
2010, JM et al., 2015). This may be another possible mechanism of antibody-mediated cell
cytotoxicity that is independent of the complement system (see Figure 1-24).
There are different types of FcyR. The FcyRIIB receptor is inhibitory and has been shown to
control plasma cell apoptosis (Xiang et al., 2007). This receptor is of lower affinity compared
to other FcyR. Binding of IgG to FcyRII and cross talk with the BCR results in an increase
threshold for B cell activation and reduction in antibody production (see Figure 1-23) In
addition to this it has other inhibitory mechanism and thus results in regulation of humoral
immune response (Smith and Clatworthy, 2010). Polymorphisms in FCyRIIB and
underexpression increases risk of developing auto-immune disease such as systemic lupus
erythromatosis (SLE) (Clatworthy et al., 2007). However, the polymorphism in FCyRIIB gene
in a study of renal transplant recipients did not show association with higher pre-transplant
PRA, acute rejection in first year and patient or graft survival at 10 years (Clatworthy et al.,
2014).
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Figure 1-24: Function of inhibitory Fc-gamma receptor IIB (taken from (Smith and
Clatworthy, 2010)
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
67
Antibody Mediated Rejection (AMR) of transplanted organ
Acute antibody-mediated rejection happens in about 5-7% of transplanted kidneys of
standard immunological risk (Roberts et al., 2012, Colvin and Smith, 2005). In high
immunological risks (Antibody incompatible transplantation) the prevalence is about 50%
(Higgins et al., 2011b). Following antigen-antibody interaction, the Fc portion of the antibody
activates effector mechanism such as Fc receptors and the complement system, and this
ultimately results in a pathogenic response effecting graft function (Figure 1-25).
Figure 1-25 : Mechanisms of donor-specific antibody-mediated endothelial injury in renal
allografts (Farkash and Colvin, 2012)
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The histology of antibody-mediated damage is evolving and has been defined by a consensus
of histopathologist across the world (leading to the Banff criteria) (Haas et al., 2014, Solez et
al., 2007, Sis et al., 2010).The difficulties faced in making clear diagnoses include the inability
to visualise immunoglobulin histologically and also the lack of specificity of complement
binding and activation. Due to this there is a big gap between what we can see histologically
and what might be happening immunologically.
Acute/active AMR; all three features must be present for diagnosis [clarify
this is the current BANFF] see Figure 1-26
1. Histologic evidence of acute tissue injury, including one or more of the following:
a. Microvascular inflammation (g>03 and/or ptc>0)
b. Intimal or transmural arteritis (v>0)
c. Acute thrombotic microangiopathy, in the absence of any other cause
d. Acute tubular injury, in the absence of any other apparent cause
2. Evidence of current/recent antibody interaction with vascular endothelium,
including at least one of the following:
a. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen
sections, or C4d>0 by IHC on paraffin sections)
b. At least moderate microvascular inflammation ([g+ptc]>2)
c. Increased expression of gene transcripts in the biopsy tissue indicative of
endothelial injury, if thoroughly validated
3. Serologic evidence of donor-specific antibodies (DSAs) (HLA or other antigens)
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Figure 1-26: Histology of acute antibody mediated rejection.
Left – peri-tubular capillaritis (arrow showing mono-nuclear cell); middle – glomeruli
capillary thrombosis; right – C4d staining positive.
Chronic, active AMR; all three features must be present for diagnosis
1. Morphologic evidence of chronic tissue injury, including one or more of the following:
a. Transplant glomerulopathy (TG) (cg>0), if no evidence of chronic thrombotic
microangiopathy
b. Severe peritubular capillary basement membrane multilayering (requires EM)
c. Arterial intimal fibrosis of new onset, excluding other causes
2. Evidence of current/recent antibody interaction with vascular endothelium, including
at least one of the following:
a. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen
sections, or C4d>0 by IHC on paraffin sections)
b. At least moderate microvascular inflammation ([g+ptc]>2)
c. Increased expression of gene transcripts in the biopsy tissue indicative of
endothelial injury, if thoroughly validated
3. Serologic evidence of DSAs (HLA or other antigens)
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C4d staining without evidence of rejection; all three features must be
present for diagnosis
1. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or
C4d>0 by IHC on paraffin sections)
2. g=0, ptc=0, cg=0 (by light microscopy and by EM if available), v=0; no TMA, no
peritubular capillary basement membrane multilayering, no acute tubular injury (in
the absence of another apparent cause for this)
3. No acute cell-mediated rejection (Banff 97 type 1A or greater) or borderline changes
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Varied pathogenic response to donor specific antibody
There has been intense debate with regards to pathogenicity of HLA-specific antibodies and
the humoral immune theory in transplantation. We have observed varied graft responses in
the presence of donor HLA-specific antibodies, in some instance causing acute rejection and
in other instances existing with perfectly functioning grafts or resolution of rejection in the
presence of high levels of antibodies (Higgins et al., 2007) (See Figure 1-27).
Figure 1-27 : Variable graft response to donor HLA-specific antibody (DSA)
A – Case who develops graft rejection accompanied with rise of DSA and B – Case whose
graft is functioning perfectly normal despite a steep rise of DSA
Similar findings have been reported in prospective studies of de novo HLA-specific antibodies;
the positive predictive value of rejection from de novo HLA-specific antibodies is poor (Cooper
et al., 2011, Gill et al., 2010). However, these studies were only followed for short periods of
time. Longer-term study demonstrated poorer outcomes of grafts that develop de novo DSA
(Wiebe et al., 2012). They suggested a model for de novo HLA-specific antibodies (Figure 1-
28). However there may be a complex overlap with the presence of antibodies and graft
damage (Figure 1-29).
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Figure 1-28 : Spectrum of Antibody mediated damage (Wiebe et al., 2012)
Figure 1-29 : Overlap of DSA and histology of antibody mediated rejection (AMR)
These variable responses could be due to antibody-specific factors (see Figure 1-33), and/or
host responses. However, although the mechanisms that underlie these variable responses
are complex, it is important to note that the mere presence or absence of antibodies does
not determine adverse events; either there is change in the immunological milieu or graft
environment, or there is change in the characteristics of these antibodies that determine
immunological response and graft fate.
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Mechanisms of variable responses of HLA-specific antibodies
Class switching
It is generally accepted that pre-formed IgM donor HLA-specific antibodies are not a
contraindication for transplantation (Suzuki et al., 2009, Chapman et al., 1986, Taylor et al.,
1989). The consequences of de novo HLA-specific IgM post-transplantation are variable and
poorly studied. The development of donor-specific IgM in itself may not be damaging to
allografts (Everly et al., 2014, Marcen et al., 1988) but subsequent class switching from IgM
to IgG has been associated with poorer outcome (Lietz et al., 2005). Others have found that
post-transplant donor-specific IgM responses are harmful (Stastny et al., 2009, Piatosa et al.,
2011, Bentall et al., 2014). Variations in immunosuppressive drugs, and different methods for
identifying the antibodies might in part explain these inconsistent observations. A larger study
determining exact association is required.
IgG DSA may result in variable responses and this could be due to different IgG sub-class
profiles. At our Centre in Coventry, we have shown significant heterogeneity of subclasses of
IgG in cases with pre-formed HLA-specific antibodies (Lowe et al., 2013a) (See Figure 1-30).
Studies on pre-formed HLA-specific antibodies have suggested that IgG (specifically IgG1 or
IgG3 subclasses) are associated with rejection (Chapman et al., 1986, Griffiths et al., 2004,
Lowe et al., 2011a). This may be due to different complement fixing abilities (Bindon et al.,
1988). IgG4 DSA are noted to be higher in patients with long-term graft function (Gao et al.,
2004). The effects of subclass variation pre-transplant is not significant in terms of outcome
following kidney transplantation (Hoenger et al., 2011). Studies at our Centre showed high
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total IgG4 DSA pre-transplantation is associated with higher rejection rates and the presence
of IgG4 pre-transplant is associated with poor 10-year graft survival (unpublished, submitted).
A study of de novo HLA-specific antibodies showed worse outcomes in cases that had
exclusive IgG1 & G3 subclasses compared to mixed panels of subclasses (Arnold et al., 2013).
Figure 1-30: Heterogeneity in sub-class profile for 138 HLA-specific antibodies (presence is
indicated by IgG subclass number (in order of class switch) and absence as ---)(Lowe et al.,
2013a)
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Complement fixing ability
Complement activation following the binding of antibodies to the HLA antigens on endothelial
cells is considered to be one of the most potent mechanisms for antibody mediated rejection
(see Figure 1-31). This can be studied further by C1q luminex binding (Chen et al., 2011), C4d
or C3d flow cytometry or CDC assays. Complement fixing HLA-specific antibodies (C4d & IgG
FC positive) have been associated with poorer graft outcome (Wahrmann et al., 2006, Yabu
et al., 2011). However, complement-fixing HLA-specific antibodies (C4d & IgG FC) have also
been observed in stable renal transplant recipients without mounting pathogenic responses
(Bartel et al., 2008). We have shown worse graft survival in HLA-incompatible kidney
transplantation recipients with a pre-desensitisation CDC positive status compared to Flow
cross match positive or high MFI on single antigen beads alone (Higgins et al., 2011b, Higgins
et al., 2014a). A study using a C1q binding assay protocol showed that the presence of C1q
fixing antibodies are associated with worse graft function (Loupy et al., 2013). The C1q
positivity, however, is related to higher IgG MFI levels (Schaub et al., 2014) and hence many
don’t feel it provides additional value over routine IgG MFI measurements. Recent study
showed measurement of C3d was better at predicting worse graft outcome compared to C1q
binding assays (Sicard et al., 2015). The complement fixing ability of an antibody is determined
by its class, subclass and degree of affinity maturation. However, it is important to appreciate
that antibodies can also mediate complement independent damage.
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Figure 1-31: Classical pathway of complement activation by antigen–antibody complexes
(Colvin and Smith, 2005)
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Affinity maturation
Studies have shown that profiles of antibodies demonstrate heterogeneous affinity across the
immune response, and that higher affinity antibodies cause increased pathogenic responses
(Williams et al., 1999, Werblin et al., 1973). This has been studied for autoantibodies against
double-stranded DNA, ANCA and GBM but not for HLA-specific antibodies (see section 1.6).
There are no studies that have looked at this directly and a recent study speculated that
higher binding strength of the interaction between the HLA epitope and HLA-specific
antibody, results in higher binding energy release which brings conformational change to the
immunoglobulin molecule; particularly to the complement fixing Fc portion. Thus it has been
speculated that complement fixation could serve as a surrogate marker for higher affinity
interactions (Duquesnoy et al., 2013). (See Table 1-4 where a monoclonal HLA-specific
antibody is classed as higher affinity if it causes a reaction on all three assays (Luminex SAB,
C1q and CDC assay)).
Reactivity Binding energy Interpretation
Negative in all 3 assays 0 No specific epitope recognition
Only Lum-Ig positive + Epitope is recognised but insufficient
conformational change in antibody
Lum-Ig positive
Lum-C1q positive
CDC negative
++ Epitope is recognised and conformational
change in antibody exposes C1q-binding
site but no complement activation
Positive in all 3 assays
+++ Epitope is recognised and C1q-binds on
antibody associated with conformational
change in C1q that activates C1qrs complex
and classical complement cascade
Table 1-4 : Mechanisms of reactivity of antigen-antibody interactions in various assay
(Duquesnoy et al., 2013)
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The authors have further postulated that the reactivity and strength depends on interaction
of antibody paratope with eplets and other residues within 15 Angstrom of the eplet in the
structural epitopes. The larger area of interactions will depend on the difference in presence
of critical amino acid residues around the functional specific epitope, which gives further
stability to the interaction. (Figure 1-32). The larger the area of interaction will give rise to
stronger binding force / affinity. HLA epitopes are discussed in more detail in section 1.7.
Figure 1-32: Mechanism of reactivity of antibody in various assays(Duquesnoy et al.,
2013).
Note the reactivity is dependant of surface area of interactions. The central circle with pink
residues is common to all the alleles but the area of interactions around the central area in
the yellow region circled differs. Overall fits between the Allele 3 and the immunizing allele is
same and hence highest reactivity compared to other alleles (Duquesnoy et al., 2013).
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Other factors
Antibodies against HLA may have different effect depending on class of HLA; e.g. DSA
antibodies to Class II HLA is considered as not higher risk if present pre-transplantation (Susal
and Opelz, 2004). Levels of MFI values are associated with poor outcomes (Mizutani et al.,
2007, Higgins et al., 2009b). However it is not clear if the association of high MFI levels is due
to higher concentration or higher affinity of HLA-specific antibodies.
Glycosylation pattern of HLA-specific antibodies may play important role in pathogenesis.
However, this has not been studied in a clinical setting. Similarly the effect of antibodies may
be neutralised by the presence of soluble HLA secreted by donor kidneys or by the formation
of anti-idiotypic antibodies (King et al., 1989, Suciufoca et al., 1991). Polymorphisms of the Fc
gamma receptor on immune cells have been shown to affect certain immune responses. Fc
gamma receptor III polymorphisms (158V/F) demonstrated varied effects on T cell depletion
following administration of anti-thymocyte globulins (ATG) (Ternant et al., 2014). Regulation
of immune response by IgG and activating Fc gamma receptor has not been studied in detail
in the context of human transplantation.
Other than antibody characteristics, activity of cellular immune response primarily T cell
cognate interactions with donor-specific B cells may drive chronic rejection. The cytokines
(predominantly IFN-γ and IL2) released during cognate interaction can cause direct damage 
independent of antibodies (Shiu and Dorling, 2014). Figure 1-33 summarises antibody
characteristics that has been investigated and in progress.
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Figure 1-33 : Summary of antibody characteristics that may contribute to damage to
transplant organ and current evidence (Higgins et al., 2014a)
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Studies on antibodies in other renal disease
ANCA-associated Vasculitis (AAV)
Screening for this condition is performed via with immuno-fluorescence to show the presence
of peri-nuclear or cytoplasmic ANCA. Following this, quantification of MPO or PR3 is done via
quantitative ELISA using selective antiserum standards (Hagen et al., 1996). Higher or rising
titres have been associated with relapse of ANCA-associated vasculitis. Similarly, IgG3 sub-
class levels are particularly associated with active renal disease in ANCA-associated vasculitis
(Jayne et al., 1991). A recent study has summarised all the studies that have looked at sub-
classes of IgG – ANCA and clinical manifestation (Colman et al., 2007) Table 1-5.
Table 1-5 : IgG-ANCA sub-classes and association with active disease (Colman et al., 2007)
The biophysical characteristics of anti-myeloperoxidase (MPO)-antibodies have been studied
in cases with vasculitis (Kokolina et al., 1994). A study of 28 cases showed no association
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between isotype, the level, or apparent affinity of anti-MPO antibodies and clinical symptoms
and severity of vasculitis. However, higher affinity was observed prior to requirement of
treatment and there was decreased apparent affinity following immunosuppressive therapy.
During relapse, lower affinity serum IgG was observed. The affinity was studied using a
competitive binding MPO-specific ELISA protocol. Higher affinity IgG molecules may not be
detectable in serum as they may be adsorbed on to the tissue; causing active disease (Esnault
et al., 1991). Using Inhibition binding on solid-phase radioimmunoassay (SPRIA) with
10/20mM DEA (Diethyl amine), the study observed affinity maturation of different sub-
classes of IgG and postulated that higher affinity IgG3 antibodies may be more pathogenic
than other sub-classes (Esnault et al., 1991). Surface plasmon resonance has been used to
study binding interactions between cANCA-IgG from patient sera and purified PR3 antigen in
the past to define epitope heterogeneity (Griffith et al., 2001, Colman et al., 2007, Short and
Lockwood, 1997).
Anti-GBM disease:
Goodpasture’s Disease or Anti-GBM (Glomerular Basement Membrane) disease is
characterised by the presence of autoantibodies to the alpha-3 chain of class IV collagen. This
is typically associated with alveolar lung haemorrhage and renal failure. The anti-GBM
antibodies can be measured using quantitative ELISA. IgG1 class is predominantly associated
with active clinical disease (Weber et al., 1988, Zhao et al., 2009). Unlike AAV this is usually a
monophasic illness with rare cases of relapses (Levy et al., 1996a). A study using antigen
inhibition ELISA defined avidity by EC50 (Effective Concentration required for 50% inhibition)
and found that high avidity anti-GBM antibodies were associated with increased severity of
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disease (Cui and Zhao, 2005). Surface plasmon resonance was used to study interaction of
monoclonal antibodies and polyclonal sera from patients with GBM disease (Levy et al.,
1996b).
Lupus Nephritis
Systemic Lupus Erythematous (SLE) is another auto-immune condition characterised by
presence of anti-nuclear antibody (ANA), and antibodies to DNA (especially dsDNA) and smith
(Sm) antigen. Studies have characterised pathogenic phenotypes of these antibodies and
have noted similar conclusions as above. IgG1 anti-dsDNA antibodies have been associated
with active lupus nephritis (Bijl et al., 2002). dsDNA-specific antibodies of higher relative
avidity and cationic charge were associated with active nephritis (Suenaga and Abdou, 1993).
Surface plasmon resonance has been used to detect and study the binding interactions of
dsDNA-specific antibodies (Buhl et al., 2007). Antibodies against C1q have also been
associated with active lupus (Wener et al., 1987) and surface plasmon resonance has
facilitated the investigation of the kinetics and affinities anti-C1q antibodies binding to
peptides on the C1q molecule (Vanhecke et al., 2012). A recent study in 99 patients showed
higher risk of lupus nephritis if the avidity of dsDNA was higher (Andrejevic et al., 2013).
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HLA antigens and epitopes
Human Leucocyte antigens (HLA) are proteins present on most of human cell surfaces and
patterns of multiple HLA allele expression are unique to the individual person. These proteins
help the Immune system differentiate self from non-self. The genes that encode the HLA
molecule are located on chromosome 6. They are high polymorphic, with over one thousand
variant alleles having been characterised (Marsh and HLA, 2011).
Figure 1-34: HLA molecule structure with peptide in the grove
(Class I on the left (with peptide (blue)) and Class II on right (with peptide (red)) (taken from
Immunology lectures by E Gheradi, University of Pavia website). A & C – front view; B&D –
top view
The HLA are divided into class I and class II molecules based on their structure and tissue
distribution (Figure 1-34). The archetypal class I HLA molecule has one chain with three
domains (α1-3) and forms a heterodimer with β2 microglobulin, whereas class II HLA has two 
homologous chains (α & β) with two domains each. Class I HLA is expressed on all nucleated 
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cells whereas Class II HLA is restricted to antigen presenting cells, some endothelial cells and
the thymus. Each cell typically expresses six class I alleles (A, B and C) and six to eight class II
alleles (DP, DQ & DR). These are further characterised based on haplotype. HLA proteins can
also be found in soluble form (sHLA) circulating in blood, even in healthy individuals (Rebmann
et al., 2009) and donor specific sHLA release is associated with rejection (Devito et al., 1993,
Mathew et al., 1996).
Non-self HLA molecules on the donor kidney serve as trigger for intrinsic immune responses
within the recipient, in addition to performing direct peptide presentation to T cells
potentially causing activation of T and B effector cells. Peptide-dependent HLA-specific
antibodies require peptide in the binding groove of the target HLA molecule in order to drive
an immune response (Mulder et al., 2005). The ability to induce an antibody response is called
HLA immunogenicity and ability to react with specific antibodies is called antigenicity
(Duquesnoy and Marrari, 2009). In an antibody-mediated humoral response, the paratope on
the variable regions of an antibody molecule binds to the antigenic determinant, called the
epitope and subsequently, trigger a cascade of responses (Figure 1-25). More than one
epitope can be present on a single HLA antigen (Figure 1-35).
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HLA Epitopes
An epitope consists of specific amino acid residues on antigen molecule that interacts and
binds to the CDR loops of variable region of antibody molecule. The structural epitope has
15-25 contact amino acid residues in an area of 700-900 mA. Within the structural epitope,
certain amino acid residues (4-8) are responsible for specific binding to CDR loops of antibody,
and these residues constitute the functional epitope. The accessible residues are called eplets
and are responsible for HLA-specific antibody responses (antigenicity) and immunogenicity
(Duquesnoy et al., 2012).
Epitope mapping improves our understanding of the protein structure-function relationship
that is important for biological processes. As multiple epitopes can be present on one HLA-
protein, and some are shared between HLA-proteins, epitope mapping allows one to
understand whether the reactivity is due to shared epitopes or not. Additionally, epitope
mapping may explain the development of de novo antibodies due to epitope spreading
following kidney transplantation (Yang et al., 1999, Papassavas et al., 2000, Nainani et al.,
2009). To date 110 epitopes to HLA class-I have been defined; 34 for HLA-A and 44 for HLA-B
locus antigens (El-Awar et al., 2009). The epitopes can be defined using monoclonal
antibodies or eluted alloantibodies using recombinant HLA class I cell lines (El-Awar et al.,
2009) or by using computer algorithms (e.g. HLA-match maker) to predict epitopes from
stereochemical modelling of epitope-paratope interfaces of antigen-antibody complexes
(Duquesnoy and Marrari, 2009, Duquesnoy et al., 2012). Table 1-6 shows an example of an
epitope against HLA-A locus antigens.
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Figure 1-35: Molecular models of crystalline HLA structure (Duquesnoy et al., 2012)
Note: yellow area represents structural epitope on the antigen molecule (left) and pink areas (69A and 71A) within defines specificity (middle
and right image - top and side view of surface residues within 15A radius.
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Table 1-6 : Class I HLA-A locus epitope specificities and the associated HLA antigen (adapted from Dave Lowe PhD thesis, University of
Warwick)
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Current assays to characterise HLA antigen and HLA-specific antibody
interactions: advantages and limitations
There are a number of assays developed to measure and characterise HLA-specific antibodies
in transplantation medicine (Figure 1-36). The assays can broadly be divided into two
categories: 1) Cell based assay and 2) Solid phase assay.
Figure 1-36 : Assays to measure and characterise HLA-specific antibodies
(Taken from Current Issues and Future Direction in Kidney Transplantation edited by Thomas
Rath, Publisher: InTech February 13, 2013 DOI: 10.5772/45909)
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Cell based assays
CDC (Complement dependent cytotoxicity) assay
First described in 1964 (Terasaki and McClelland, 1964, Terasaki and Rich, 1964), CDC has now
become the international standard test prior to any organ transplantation (Patel and
Terasaki, 1969). Donor lymphocytes are used to detect complement-fixing antibodies. Briefly,
the donor lymphocytes are isolated from peripheral blood, spleen or lymph nodes. The donor
lymphocytes are further separated in to T cell and B cell compartments and recipient’s serum
is mixed in the well followed by rabbit serum containing a source of active complement. If
donor-specific antibodies are present, they binds to the donor cells and the terminal
complement cascade is activated resulting in the lysis of lymphocytes.
Figure 1-37 : Complement Dependent Cytotoxicity (CDC) assay
Note: A = cell lysis seen in red colour, positive results, B = absence of lysis (red colour) –
negative result (Seen through microscope) (adapted from Dave Lowe PhD thesis, University
of Warwick)
The results are expressed as percentage of cell lysis and the serum can be titrated down to
obtain a titre at which there is no lysis of donor lymphocytes (Figure 1-37). The assay is not
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specific for any particular anti-HLA antibody nor its class and is usually a summative result of
all antibodies (HLA or non-HLA; Allo or Auto-antibodies; IgG or IgM) present in the serum of
the recipient. However despite being relatively non-specific, a positive CDC result pre-
transplant is associated with worse outcome (Higgins et al., 2011b) (see Figure 1-10). The CDC
assay can be made more specific by treating sera with dithiothreitol (DTT) (removing
autoantibodies of IgM class) and sometimes treating sera with autologous lymphocytes (to
remove auto-antibodies). AHG (anti-human globulin) enhancement improves sensitivity of
the assay by allowing detection of non-complement fixing antibodies.
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Flow cytometry
This was first described in 1983 (Garovoy et al., 1983) and is more sensitive than CDC assay
as it can detect both complement fixing and non-complement fixing donor specific antibodies.
Additionally, it is able to detect the antibody class without any modification of test serum.
Briefly, recipient’s serum is mixed with donor lymphocytes. Fluorescence labelled anti-human
IgG monoclonal antibody is added to detect the presence of donor-directed. The results are
expressed as relative median frequency (relative to a negative control) and shifts to right on
scatter plots suggest positive results (Figure 1-38).
Figure 1-38 : Flow cytometry cross match
Note positive result suggested by rightward shift as shown in A. (adapted from Dave Lowe
PhD thesis, University of Warwick)
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Solid phase assays
With the advent of purified or recombinant- HLA molecules, solid phase assays using ELISA on
microwell plates, and fluorescent beads (Flow and Luminex) were developed to detect HLA-
specific antibodies. Currently, the Luminex platform based assays are used extensively in the
UK.
Screening and single antigen bead assay to determine HLA-specific antibodies:
The commonest screen used is based on multiplex bead assay using the Luminex platform.
Typically 100 different antigen coated beads can be used to identify HLA-specific antibodies.
There are two types of beads – Mixed beads used to screen for HLA-specific antibodies and
SAB (Single Antigen Beads) that characterise specificities against single antigens (Figure 1-39).
The Luminex assay is very sensitive and positive cut-off values vary between laboratories due
to lack of clarity and consensus for clinically relevant thresholds. The cut-off could range from
500 to 3000 MFI and is based on experience and protocol of individual Centres. Even with
standardisation of the protocol, the coefficient of variation is around 25% (Reed et al., 2013).
MFI levels are affected by artefacts (Zachary et al., 2009) or presence of IgM HLA-specific
antibodies (hence treatment with DTT (Kosmoliaptsis et al., 2010)) or presence of
complement proteins (Weinstock and Schnaidt, 2013) (hence treatment with EDTA (Schnaidt
et al., 2011)). Finally, care should be taken to interpret the results, as some would equate the
MFI values to concentration of the HLA-specific antibodies.
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Figure 1-39 : Read-out from HLA fusion software on Single antigen bead Luminex assay (source – Medscape)
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Work from our Centre has shown that there is a ’hook effect’ and the assay has a tight linearity
range (Lowe et al., 2011b, Lowe et al., 2007) (See Figure 1-40). When the concentrations of
antibodies are high, there is a competition for binding site resulting in false low levels, this
phenomenon is called ‘hook effect’. Also as this is a protein-protein binding assay, the results
are likely to be influenced by affinity in addition to the absolute concentration of the
antibodies (Nimmo et al., 1984, Aldao and Vides, 1984).
Figure 1-40: Linear range of Luminex assay (Note dose response curve obtained for two
human monoclonal HLA-specific antibody (Lowe et al., 2011b).
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C1q assay to assess complement fixing properties of HLA-specific antibodies
Single antigen bead (SAB) based assays described above were modified and an intermediate
step is included in which C1q protein is added. C1q binds to the antigen-antibody complexes
and is then detected by an anti-C1q PE conjugate in same way as with the normal SAB assay.
Although specific for HLA, the results obtained could be due to other classes of HLA-specific
antibodies (especially IgM) that are bound to the recombinant-HLA proteins. Additional
characterising of HLA-specific antibodies detected by standard SAB Luminex assay has been
shown to be associated with worse outcomes (Loupy et al., 2013, Yabu et al., 2011). However
the additional value of this C1q assay is questioned as the positive result correlated with pan-
IgG levels (Schaub et al., 2014).
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Strength (affinity/avidity) of antigen-antibody interactions
The strength of binding between a single combining site of an antibody and an epitope of an
antigen is called the affinity of the antibody. This has not been studied directly in clinical
transplantation and is postulated that binding of antibodies to the epitopes can be inferred
indirectly by its ability to activate complement cascade following binding to the HLA-antigen
(Duquesnoy et al., 2013).
Binding interactions/ reactions can be described by set of equations and by curves (called
kinetic curves). According to the model of “law of mass action”
Ka
[Ab].[Ag] [Ab.Ag].
Kd
Where [Ab] and [Ag] are free antibody and antigen concentration and [Ab.Ag] is
concentration of complex. Kd = Dissociation rate constant and Ka= Association rate constant.
Equation 1 KA = 1/KD
Rate of association = [Ab].[Ag]. Ka
Rate of dissociation = [Ab.Ag]. Kd
At equilibrium, the rate of association and rate of dissociation are same, so
Equation 2 [Ab].[Ag]. Ka = [Ab.Ag]. Kd
Equation 3: KD = Kd/Ka = [Ab][Ag] / [Ab.Ag]
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The dissociation constant (KD) is a measure of the stability of an interaction and the ease with
which an antigen-antibody complex dissociates. A lower KD value indicates higher affinity and
vice versa. In general KD values derived for antibody-antigen interactions range from between
10-7 M to 10-11 M. It is quoted that KD values range between 10-7 M to 10-9 M in the primary
response antibodies and between 10-9 M to 10-11 M in the secondary immune response. This
upward trend in affinity is attributed to and associated with increases in somatic mutation
events (Berek and Milstein, 1987) (see Figure 1-22).
It is important to distinguish avidity from affinity; especially when approaching the
quantification of binding interactions; avidity is an overall binding strength at which an
antibody binds to the antigen and usually is sum of binding of all the Fab arms to different
epitopes on the antigen. Hence the avidity of IgM molecule which is pentameric and has ten
identical antigen binding sites could achieve enhanced binding strength via this multivalency
over a large surface area compared to other immunoglobulin molecules of lower order
structure such as IgG. Affinity refers more specifically to the non-covalent interactions
between defined, individual binding sites on two opposite binding partners and can be
calculated with greater fidelity.
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Binding forces involved in antigen-antibody interactions
Table 1-7 summarises the non-covalent forces involved in binding between epitope and
paratope. The overall strength of binding depends on the fitness and surface area of the
interfaces as defined by amino acid arrangements on the structural epitope. When studying
the binding forces in vitro, temperature, pH and ionic strength may influence these non-
covalent interactions. These binding forces can be manipulated and used for immuno-affinity
purification of HLA-specific antibodies or antigens. Electrostatic potential over the HLA
epitope can be measured (Kosmoliaptsis et al., 2011) and can be used to predict
immunogenicity of epitopes (ability to mount alloimmune response) (Mallon et al., 2014).
Table 1-7: Forces involved in Epitope-paratope bindings
(Modified from Janeway CA Jr et al. Garland Science; 2001)
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The binding of antibody can also be influenced by spatial arrangement of different epitopes
on a single HLA antigen (Table 1-8). At our Centre, using purified polyclonal HLA epitope-
specific antibodies, we have shown the importance of the spatial arrangements of epitopes
and their effects on CDC reactivity (Lowe et al., 2011b).
Spatial arrangement of
different epitopes
Effect Outcome on binding of
second antibody molecule
Overlapping Steric hindrance Reduce binding
Non-overlapping None Additive
Allosteric Conformational change in
antigen structure
Positive or negative influence
Table 1-8 : Spatial arrangement of epitopes and effect on outcome of binding in a
polyclonal antibody sample.
(Taken from book ‘Cellular and molecular immunology by Abbas et al., Saunders publisher)
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Methods to study affinity
There are various methods that can measure the dissociation constant (KD) – the consensus
quantitative expression of the affinity for a given protein-protein interaction. Broadly these
can be divided in to two categories depending on the approach used (Neri et al., 1996):
1) Equilibrium analysis
By measuring bound and free antibody (or antigen) at equilibrium,
Equation 4 : KD = [Ab][Ag] / [Ab.Ag]
Where [Ab] and [Ag] are free antibody and antigen concentration and [Ab.Ag] is the
concentration of the bound complex.
The time required to reach equilibrium is determined by the relative ratio of concentration of
analyte and ligand. Generally 90% saturation is acceptable to attempt equilibrium analysis. It
is suggested that concentration range of analyte should be between 10 x lower than the
anticipated KD to 100x higher.
Equilibrium analysis can be performed using various techniques (Table 1-9). In competition
(ELISA) assay or indirect ELISA (Friguet et al., 1985), the antigen and antibody are incubated
in solution to reach equilibrium. The antibody concentration is varied and antigen
concentration is kept constant. Then ELISA is used to measure the amount of free antibody
concentration. This ensures equilibrium is not severely affected by ELISA (Goldberg and
Djavadiohaniance, 1993). Similar competition assay can be performed using surface plasmon
resonance (SPR) assay (Heinrich et al., 2010).
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Method Measurement Sample requirement Sensitivity
Equilibrium dialysis Equilibrium across a
dialysis membrane, free
and bound analyte
measured
Small antigen that
can cross the dialysis
membrane
1 mM to 1 pM
Fluorescence
quench
Fractional fluorescence
quench upon binding
Pure material
needed
1 uM to 1nM
Isothermal titration
calorimetry
Heat produced on binding
of increasing titration of
antibody to concentrated
antigen solution
Pure material
needed in large
quantities
1 mM to 100nM
Higher affinity can be
measured by
increasing the
temperature
Band-shift on Gel Detection of free and
bound antibody on gel
Radioactive or
florescent labelling
of either antibody or
antigen
10 nM to 10pM
Physical separation Antibody in the complex is
separated by
chromatography or
magnetic beads and
detected by fluorescence
or
electrochemiluminescence
Labelling of antibody
is required
10 nM to 10 pM
Competition ELISA After incubation of
antibody with antigen, the
unbound antibody is
detected by ELISA
Purified antigen or
antibody to
immobilise on solid
surface
50 nM to 1 nM
Surface plasmon
resonance
Change in refractive index
upon binding is measured
Purified antigen or
antibody to
immobilise on
sensor chip
100mM to 1 nM
(higher affinity can be
measured by kinetic
analysis)
Table 1-9 : Methods to determine dissociation constant using equilibrium saturation
approach (Modified from ref- (Neri et al., 1996))
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The KD is determined at 50% fractional binding (FR), when the concentration of [Ab] is equal
to KD.
Equation 5 : FR = [Ab.Ag]/[Agtotal]= [Ab]/([Ab]+ K D)
Linear or non-linear curve fitting computer programs are used to derive the relationship
between analyte concentration and signal from antigen-antibody complexes (Glaser, 1993).
Figure 1-41 : Fitting linear regression model to data (Scatchard Plot)
Note– On left data obtained by plotting response (bound antibody) versus (free) antibody
concentration and on right scatchard plot obtained after transforming data by linearising
Scatchard plots (Figure 1-41) can be used to determine KD, by plotting the ratio of bound and
free ligand against the bound complex. A linear regression fitting is applied to a obtain slope.
(Slope = -1/ KD). The assumption here is the involvement of univalent and homogenous
interactions. With heterogeneous interactions, there is an increase in the degree of
curvilinearity and in such cases the parameter is obtained by fitting to a hyperbolic curve.
However linear regression assumptions are not met and the estimates are not accurate, so
use non-linear regression analysis is required. The curve obtained requires mathematical
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fitting to estimate accurate affinity readings (Delaage et al., 1992, Heinrich et al., 2010).
Clinical samples contain antibodies that are polyclonal in nature and have a range of affinity
values. Mathematical tools can be used to obtain two affinity values (Bobrovnik, 2003,
Stevens and Bobrovnik, 2007).
There are some limitations to measuring dissociation constant via equilibrium analysis. Firstly,
very low affinity antibodies will require prolonged periods to reach equilibrium and may result
in denaturing the antigen depending on the experimental conditions. Secondly, larger
samples (milligrams of protein) are required for competitive ELISA and SPR equilibrium assays
that make comprehensive studies prohibitively expensive and labour-intensive.
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2) Kinetic analysis –
This can be done in a single step, real time assay platform such as surface plasmon resonance
or several separate assays where several incubations of antigen-antibody in liquid phase are
interrupted after over a series of time points. (Table 1-10).
Method Measurement Sample requirement
ELISA KD and Ka is measured Purified antigen or antibody to
immobilise on solid surface
FP Change in polarisation of
antigen on antibody binding
KD and Kd is obtained
Antigen labelling with
fluorescence
SPR Change in refractive index on
chip due to binding
interactions
Ka and Kd is obtained by
fitting of curves
Purified antigen or antibody to
immobilise on sensor chip
Table 1-10 : Methods to determine dissociation constant using kinetic analysis
Several separate assays done in parallel cover the range of time points until the reaction
reaches its equilibrium as measured by ELISA. Alternatively, data can be obtained in a
staggered fashion such as in fluorescence polarisation spectroscopy.
Fluorescence polarisation method:
This is performed entirely in liquid phase and is a highly sensitive method for studying
molecular interactions in solution. The antigen labelled with fluorochrome is incubated with
the antibody until equilibrium is reached. After this the baseline polarisation (P0) is measured.
Following this unlabelled antigen is added to the solution and the change in polarisation (Pi)
is measured every six seconds. Fluorescence polarisation can be measured by a plate reader
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at 595 nm absorbance (depending on the fluorochrome used). The dissociation rate kd is
obtained using logarithm plot of (P0-Pi) against time. The dissociation constant KD is measured
using the conventional equilibrium method and the association rate Ka is derived using the
values of KD and Kd (Ka = Kd /KD).
Competition/Inhibition ELISA:
This can be done in various ways. A mixture of antigen and antibody in stoichiometric
proportion are incubated overnight. 1:100 dilution of the mixture is then added on to an ELISA
plate coated with the antigen (fixed concentration) at different time points (0 to 90 minutes)
and allowed to incubate for four minutes at room temperature and then the absorbance is
read following later steps of the conventional ELISA protocol (Larvor et al., 1994). The Kd is
calculated from the resulting curve derived from logarithmic plot of ((A∞)-(At))/ ((A∞)-(A0))
versus time. At = absorbance at given time, A∞ = absorbance at 90 minute and A0 = absorbance
of the blank well. The slope of line is equal to –Kd.
In a another method, a mixture of equal volume of antigen and antibody is incubated at
different time periods (such as 2, 4, 7, 10, 20 and 30 minutes)(Zhuang et al., 2001). ELISA with
coated antigen is used to detect the free antibody concentration after incubation of one
minute. The remaining steps are similar to conventional ELISA. A curve of binding fraction
(ratio of bound antibody/total antibody) versus time of incubation allows determination of Ka
using mathematical fitting. KD is determined using competitive ELSIA described above and Kd
is determined using values of KD and Ka.
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Surface Plasmon resonance (SPR):
The physical principle and methodology for this technique is described in detail in chapter 4.
This is a bio-sensor platform that allows direct real time measurement of Ka & Kd of antibody-
antigen interactions without any labelling or incubation steps. In the case of modern multi-
channel SPR instruments, different concentrations of solution-phase analyte are flowed
simultaneously over channels coated with immobilised ligand molecules injected to obtain
multiple kinetic curves, and all the data sets are fitted simultaneously by global analysis
software, typically built in to the manufacturer’s operating software package. Global analysis
gives good direct calculations of the kinetic parameters (Ka & Kd) unlike nonlinear fitting of
individual curves. There are number of commercial software packages available to carry out
curve fitting such as PRISM, MATLAB and the ProteOn XPR36 software, the latter being built
in to the SPR operating package provided by Bio-Rad and containing a good range of
interaction models from which to derive the best data fits. These use non-linear regression
analyses, with aims of reducing the sum of squares of the vertical distances of the points from
the curve.
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Summary
The presence of donor-directed antibody alone or a single characteristic of the antibody does
not determine humoral immune response. Various bio-physical properties of the antibody
itself and interactions with components of immune system are responsible for a pathogenic
immune response. Affinity/avidity of DSA has not been characterised before and correlation
of the avidity or change in avidity with other characteristics of the antibodies and graft
outcome will help delineate the characteristics of the humoral immune system.
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Hypothesis and Objectives of the study
Equity of access to transplantation is a major challenge for highly sensitised patients. Based
on current measurements in H & I laboratories, very high risk (CDC positive) and low risk (non-
sensitised) are identified with good confidence and immunosuppressive therapy are tailored
accordingly. Dilemma remains in a large number of patients on waiting list with low to
moderate levels (defined by MFI values) and various approaches has been taken to achieve
successful transplantation in these cases. With current strategies some cases may be denied
transplantation or some cases may be put through higher risks inadvertently.
Studies have shown adverse outcomes in cases that had pre-formed donor specific antibodies
and also cases that develops de novo donor specific antibodies. In the former, presence of
DSA is not always associated with rejection and in the latter it may take few years before
development of antibody mediated damage to the graft. Hence mere presence of antibodies
is not useful in predicting adverse outcomes. There are two schools of thought, first
supporting difference in biophysical characteristics of antibodies and second supporting
change in activity of cellular component of immune system responsible for adverse outcome.
In reality both these mechanisms will work in parallel to result immune damage. At our
Centre, we have extensively studied different characteristics of antibodies such as
specificities, dynamics of rise and fall, sub-classes of IgG and inhibitory factor such as soluble
HLA in circulation. The current thesis looks at two biophysical properties of antibodies; class
IgM and IgG of de novo HLA-specific antibodies and affinity of pre-formed IgG HLA-specific
antibodies in detail.
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Hypothesis:
The hypothesis to be examined herein is that HLA-specific antibodies within a highly sensitised
patient’s serum may possess varying affinities for relevant donor specific HLA molecules.
Greater understanding of this phenomenon may help to explain discrepancies between HLA-
specific antibody measurements made by current immunoassays such as Luminex and clinical
outcomes and deepen antibody analysis in order to allow for improved patient prognosis, risk
stratification and treatment.
Objective:
Primary objective:
To study the distribution of affinities of HLA-specific antibodies in highly sensitised patients
and to group the HLA-specific antibodies in risk stratification groups based on strength of
affinities.
Secondary objectives:
1. To study evolution of HLA-specific IgM and IgG antibodies in non-sensitised patients
and study effects on graft outcome prospectively.
2. To develop and validate surface plasmon resonance as a technique for characterising
HLA-specific antibody interactions with HLA proteins using available human
monoclonal HLA-specific antibodies.
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3. To characterise the binding kinetics of epitope – paratope interactions using same
monoclonal HLA-specific antibodies against different HLA proteins with shared
epitope.
4. To develop methods to quantify polyclonal HLA-specific antibodies
5. To develop protocols that allow for the study of polyclonal HLA-specific antibodies
from human serum for affinity measurements in highly sensitised patients
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Methods and materials
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This project used a range of laboratory methods to identify and purify HLA-specificantibodies and carry out further analysis of their biophysical and chemical properties.The following section describes all the techniques and protocols used in detail.Commercially available kit-based assays were all performed as per the manufacturer’sguidelines.
Materials and reagents
Soluble HLA proteins
Soluble HLA proteins were generously provided by Pure Protein LLC (Oklahoma City,USA) under the terms of an official collaborative agreement between University ofOklahoma, Pure Protein LLC, University of Warwick and University Hospital of Coventryand Warwickshire NHS Trust.
Figure 2-1 : Oklahoma protocol of sHLA production
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In brief, soluble Class I HLA protein producing clones, produced by transfection of aconstruct that deleted the transmembrane and cytoplasmic domain of the protein (Figure2.1) and replaced by VLDLr expression tag, were grown in serum free media. sHLAsecreted by these clones were harvested and purified using W6/32 (antibody to pan HLAclass I) affinity chromatography. The purity of the sHLA was assessed using massspectrometry and quantified using W6/32 ELISA.
2.1.1.1 Stability of sHLA protein
Forced degradation studies were conducted to assess physical and chemical stability of sHLA
proteins at Pure Protein LLC (Oklahoma, USA). sHLA-B7 was coated on beads and various
conditions were tested on the Luminex platform. Monoclonal antibodies W6/32 and HC-10
were used to look for integrity and damage to HLA structure respectively.
2.1.1.1.1 Temperature stability
HLA-proteins were stable within the range of temperatures (4 to 45o Celsius) up to one hour
duration (see Figure 2-2).
2.1.1.1.2 pH range
HLA-proteins were stable between pH 5.5 and 10.5 for varied buffer composition. See Figure
2-3.
2.1.1.1.3 Buffer composition
Buffers with different ionic strengths and reducing agents were tested. As shown in Figure
2-4, buffer with reducing agent and SDS denatures HLA proteins.
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Figure 2-2 : Effect of temperature on HLA-protein; top panel shows reactivity towards
W6/32 (pan-HLA class I monoclonal antibody) and bottom panel shows reactivity with HC-
10 (binds to denature HLA-protein)
Figure 2-3 : Effect of pH on reactivity of HLA-protein Top panel showing reactivity of
W6/32 at different pH values and bottom panel shows reactivity to HC-10 suggesting
denaturation of HLA protein
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Figure 2-4 : Effect of buffer composition on reactivity of HLA-protein Top panel showing
reactivity of W6/32 at different pH values and bottom panel shows reactivity to HC-10
suggesting denaturation of HLA protein
Biotinylated HLA proteins
HLA proteins were tagged to biotin so that they can be used to immobilise on assayplatform to study interactions with HLA-specific antibodies. Biotin forms a strongirreversible binding to neutravidin on typical Surface Plasmon Resonance (SPR) sensorchips. The biotin conjugation reagent NHS-PEG12-Biotin (Thermo Fisher Scientific;21312, Rockford, IL) was used, NHS esters readily react with free primary amines on HLAproteins to form stable covalent linkages. A 54 Angstrom PEG spacer was attached to thesHLA protein to allow for maximum protein bioavailability when captured onneutravidin/streptavidin surfaces.
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The biotin conjugation of sHLA was performed at Pure Protein laboratories at Oklahomaby chemical biotinylation. Briefly, a small-scale protocol was used starting with a 1 mgsHLA probe in PBS. The reaction was initiated by adding sodium bicarbonate buffer, pH9.0 (final 0.1 M) and NHS-PEG12-Biotin at a final concentration of 393 µg/ml. The finalmixture was incubation at room temperature for 2 hours at a total volume of 1 mL and afinal sHLA concentration of 1 mg/ml. To complete the procedure, the reaction wasterminated by adding Tris-HCl, pH 8.5 at a final concentration of 50 mM. An empiricallydetermined molar ratio of 20:1 (Biotin-NHS : sHLA protein) was applied to all Class Imolecules to assure that on average, not more than one biotin became attached to thesHLA protein to prevent disturbing the binding capability of the targeting antigen byexcess biotinylation. The extent of biotin incorporation was determined using a HABAassay. To remove excess biotin, sHLA molecules were buffer-exchanged with PBS at pH7.2 and concentrated using 10-kDa cut-off Macrosep centrifugal concentrators (PallFiltron, Northborough, MA). The final product was filter-sterilized and stored at 4 °C untilfurther use. The concentration of the purified biotinylated molecules was determinedusing the Micro BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL) using BGGas a standard.
Human monoclonal HLA-specific antibodies
These monoclonal antibodies were kindly provided by the A Mulder/ F Claas group atUniversity of Leiden. Briefly, the human monoclonal HLA-specific antibodies weresecreted by human hybridoma produced by EBV transformation of B-lymphocytes fromHLA antibody seropositive multi-parous women and sub-cloning of antibody producingEBV lines. Only human monoclonal antibodies of the IgG class were used.
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Clone (ID) Immunising Ag HLA-specificity
defined by CDC
Epitope Isotype
SN203G6(IHB-Hu-033) A2/B57 A2/B17 (B57,58) 62G IgG1, LSN607D8(IHB-Hu-081) A2/B57 A2/A28 (A68,69) 142T --H IgG1, KWK1D12(IHB-Hu-059) B27 B27,7,60 163EW+self73TE IgG1, KVTM9A10(IHB-Hu-093) B7 B7, 27 69A,71A IgG1, KVTM1F11(IHB-Hu-045) B7 B27,7,60 163E IgG1, KWAR5D5(IHB-Hu-074) B27 B7,27,42,55 62RN-QIYand 62R—QIC IgG1, KOUW4F11(IHB-Hu-041) Bw6 80I IgG1, L
Table 2-1 : Characteristics of Human monoclonal HLA-specific antibodies (provided by A
Mulder)
These monoclonal antibodies (MAb) were provided as culture supernatants in RPMI /IMDM with 10% FCS, 50 uM 2-ME; 0.02% sodium azide and stored at 4oC. The MAb wereisolated and purified from the supernatants by techniques described latter (section 2.2).
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Mouse anti-human HLA-class I specific monoclonal antibody
W6/32 monoclonal antibodies were generously provided by Pure Protein PLC (PAb028),Oklahoma, USA.
Human serum / plasma samples
Samples containing HLA-specific antibodies were obtained from subjects with ChronicKidney Disease (CKD) and kidney transplant recipients from two transplant centres.Ethical approval has been obtained for the use of samples towards this project (Table 2-4). Both the cohort were well defined with complete sets of clinical and outcome data.Samples collected include serum, plasma and plasma effluent (following plasmapharesistherapy). For validation of assays, control serum and plasma samples from NHSBT,Birmingham were used. Details of the samples and cases used can be found in the relevantsections.
Cohort Ethics reference Stored at
UHCW, Coventry, UK CREC-055/01/03 and13/WM/0090 CSRL, University ofWarwick, UK
UHB, Birmingham, UK CREC-08/H1204/103 NHSBT BirminghamUK
Table 2-2 : Clinical cohort used for the project
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Reagents / buffers
Chemical reagents and buffer used in this project are detailed in the relevant section.Ultra-pure water (ddH2O) was obtained from Super-Q TM water system (Millipore).Buffers were filtered through 0.45 micron size filter and de-gassed prior tochromatography or surface plasmon resonance assays.
Purification of HLA-specific IgG antibodies
Serum or plasma is a complex material that contains many components that mayinterfere with analysis of specific component. This effect is often called as “matrix effect”which can inhibit specific signal and cause non-specific signal (noise). Similarly, culturesupernatant can contain impurities too. Culture supernatant containing humanmonoclonal HLA-specific antibodies has albumin and/or transferrin as contaminants(added as supplements). Sometimes, foetal calf serum is used that has othercontaminants such as alpha-2 macroglobulin, serum proteins etc.
Various strategies has been utilised to overcome this interference such as treatment withDithiothreitol (DTT) to obliterate IgM interference, EDTA to obliterate interference byC1q and complement. Similarly albumin and lipid molecules can stick to the matrices ofaffinity columns and SPR chips, causing interference with assays.
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Preparation of sample prior to purification
Samples were centrifuged at 10,000 to 15,000 rpm for 30 minutes and pellet containing
debris, particulate matter and lipids was separated. If samples were still cloudy, filtration
using 0.45 um pore size filter was used.
Buffer exchange, phenol red removal and desalting was done prior to liquid chromatography.
This was done by dialysis into lower salt buffers or via spin concentrators.
Dialysis:
Sample was decanted into dialysis tubing with 8,000 MWCO (Spectra/Por ® Dialysismembrane) and incubated with stirring in a cylinder of the desired buffer (e.g. PBS)overnight at 4oC.
Viva Spin concentrator:
The sample were filled in 3000/ 10,000 MWCO cut off container (Vivaspin 2/20, SartoriusStedim, UK) and centrifuged for 15 minutes, further three cycles were done by addingPBS and centrifugation. This is added advantage of concentrating and buffer exchange atthe same time.
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
122
Sequential fractional precipitation
This method is especially effective for IgG enrichment from serum and works on the principle
of differential protein solubility, whereby increasing salt concentration enhances hydrophobic
interactions between proteins and causes precipitation. Differential precipitation ofproteins can be achieved by adding varying concentrations of octanoic acid andammonium sulphate in defined stages. Octanoic (Caprylic) acid selectively precipitates
bulk proteins and some α2 macroglobulins and immunoglobulins are left in the solution. This step is followed by addition of ammonium sulphate (45 % saturation) whichprecipitates immunoglobulin selectively. The concentration of immunoglobulin shouldbe at least 1 mg/ml for this protocol to work. Protocol described by an earlier study (Perosa
et al., 1990) was utilised (Protocol 2.1).
Protocol 2-1: Sequential precipitation using Octanoic acid and Ammonium sulphate
1. Centrifuge the sample at 10 000 x g for 30 minutes at 22 degree.2. Mix X ml fluid with 2 -4 times X ml acetate buffer 60 mM, pH 4.0.3. Adjust to pH 4.5 with 1M TRIS-HCl/Base4. Slowly add Caprylic acid 25 ul / ml drop by drop, stirring constantly. Continuestirring for 30 minutes room temp5. Centrifuge at 10 000 x g for 30 minutes at room temp6. Remove supernatant and filter through 0.8 um filter7. Adjust pH 7.4 with 1 M Tris-Base8. Cool the sample to 4 degree (10 minutes)9. Add ammonium sulphate 0.277 g/ ml and stir for 30 min at 4 degree10. Centrifuge at 10 000 x g for 15 minutes at 4 degree11. Discard the supernatant – re-suspend in PBS pH 7.4 (equal volume as startingserum vol)
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Affinity chromatography
Affinity purification using specific ligand coupled to Sepharose matrix allows for selectiveand high capacity purification of desired proteins. Protein G and HLA protein linked toSepharose matrices were used to affinity purify total IgG and HLA-specific antibodiesrespectively.
Cibacron Blue and alginate depletion chromatography were tested but not usedsubsequently. Cibacron blue adsorption resulted in removal of albumin but also 30 to50% reduction in MFI levels of HLA-specific antibodies. Alginate affinity chromatographydid not result in reduction of non-specific binding to sensor chips used for SPR assay.
2.2.3.1 Protein-G affinity chromatography
Protein G is a bacterial protein obtained from Group G streptococcus and has high affinityfor the Fc region of IgG-type antibodies. Protein G has a greater affinity for IgG thanProtein A and minimally binds to albumin. The binding capacity of commercial Protein GSepharose resin is about 17 to 20 mg/ml. Protein G Sepharose TM 4 Fast flow (Sigma) waspacked in 2-4 ml columns and used to purify IgG (protocol 2.2). Protein Gchromatography was adapted to automation using the Bio-Rad Duo Flow Fast ProteinLiquid Chromatography (FPLC) rig.
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Protocol 2-2 : Protein-G Affinity Chromatography
2.2.3.2 HLA affinity chromatography
HLA protein coupled to Sepharose was obtained from Pure Protein PLC. Oklahoma USA.
Columns of 4 ml and 60 ml size were prepared and the binding capacity of swollen matrix
determined as 150-200ug of HLA-specific antibodies per ml of HLA-protein resin. These
columns have been tested for specificity and efficiency for enrichment of HLA-specific
antibodies (McMurtrey et al., 2014). Column efficiency following repeated runs of antibody
elution was tested by depletion of a standard concentration of W6/32 monoclonal antibody.
For the 60 ml column, a peristaltic pump (Watson Marlow, Portsmouth, UK) was used to drive
sample at a flow rate of 50 ml/min. Protocol 2.3 was used to purify/ enrich for HLA-specific
antibodies.
1. Equilibrate the column with 20 ml (5 column volume) of 20 mM sodiumphosphate pH 7.0 (running buffer).2. Flow through: Pass 250 ml of dilute plasma effluent / culture supernatant (1:1)in 20 mM sodium phosphate pH 7.0 and allow the flow under the gravity slowly.Collect the flow through and store at 4oC.3. Wash through: Wash the column with 80 ml (20 column volume) of 20 mMsodium phosphate pH 7.0 until the OD on Nanodrop is less than 0.02.4. Elution in acidic condition with 20 ml of Glycine (100mM pH 2.5) and collect theelution fractions of 500 ul and analyse on Nanodrop. 1M Tris pH 9 was added tothe elution fraction to neutralise the antibody fractions. The fractionscorresponding to the peak were pooled together and concentrated5. Regenerate the column by washing with 20 column volumes (80 ml) of glycine100mM pH 2.8 followed by 0.5 M NaCl 10 column volume (40 ml). Store thecolumn with 20 % Ethanol at 4oC.
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Protocol 2-3 : HLA-protein Affinity Chromatography
1. The column was first equilibrated with running buffer (PBS pH 7.4) – 10 columnvolume (40 ml)2. Flow through: 20 ml of precipitated protein dissolved in PBS (pH 7.4) obtained fromsequential precipitation step (2.3.4.5) or 250 ml of dilute plasma effluent (1:1) wasloaded into the column slowly. The fluid was let to drip through by gravity by realisingthe flow tap at the bottom. Flow through was collected in bottle and stored (as theremay over-flow of interested and other HLA-specific antibodies)3. Wash through: The column was then washed with PBS until the OD at 280λ (Nanodrop) less than 0.02. Depending on the preparation up to 20 Column volume ofwash buffer was required.4. Elution: HLA-specific antibodies bound to the immobilised HLA protein in the columnwere eluted by elution buffer (Glycine 100mM pH 11.0). Four column volumes (24 ml)were passed through and the 250 ul elution fractions were collected and analysed onNanodrop. 1M Tris pH7 was added to the elution fraction to neutralise the antibodyfractions. The fractions corresponding to the peak were pooled together andconcentrated. Protease inhibitor tablets (Sigma) and 0.01 % NaN3 was added in theeluted antibody solution and stored for further characterisation studies.5. Recycle the column by washing with 20 column volume (80 ml) glycine 100mM pH11.0 followed by 0.5 M NaCl 10 column volume (40 ml) and then equilibrate with 20column volume (80 ml)of PBS(pH 7.4). Store the column with PBS and 0.01 % NaN3 at4oC.
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Ion exchange chromatography
Ion exchange chromatography separates proteins based on their net charge as they bind to
oppositely charged resin (Figure 2.5). It exploits the principle that the net surface charge of
proteins change according to the surrounding ionic strength and pH, so the bound proteins
are eluted differentially by increasing salt concentration or changing pH in a controlled
gradient (Figure 2.5). This allows for high capacity and high resolution purification steps.
Another advantage is that the target proteins are very often concentrated in the elution
fractions. Ideally, the pH of the loading buffer is selected as 0.5 to 1 pH unit away from the
isoelectric point (pI) of the target protein. At a pH above its isoelectric point, a protein
typically binds to a positively charged medium (Anion exchange, e.g. quaternary amine, or Q-
Sepharose) and, at a pH below its pI, a protein will bind to a negatively charged medium
(Cation exchange, e.g. sulfonic acid, or S-Sepharose). The pH of the running buffer is
determined by the isoelectric point (pI) of the desired protein, and generally the pI for IgG
pools is between 4 and 10 and it varies depending of the subclass (Prin et al., 1995).
The ion-exchange chromatography is best suited for separation of monoclonal HLA-specific
antibodies (most of them are IgG1 subclass) as they will be expected to elute as single peak.
This was used as final step in purification following HLA-protein affinity chromatography.
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Figure 2-5 : Principle of Ion-exchange chromatography
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Protocol 2-4 : Ion Exchange Chromatography (Anion and Cation Exchange)
Step 1 – Buffer exchange using dialysis of samples overnight against HEPES 10mM pH8.0 for Anion exchange and Acetate 10mM pH 5.2 for Cation exchange chroma tography(section 2.2.1)
Step 2 – Equilibrate the column with 20 ml of buffer A (HEPES or Acetate) until thebaseline pH and conductivity is stable. (Flow rate – 3 ml/min) This will wash away thestorage buffer (usually Ethanol),
Step 3 – Flush 2 ml of Buffer A in the loading loop and then load the sample using aperistaltic pump on the column (watch for any leaks). Following this connect thecolumn to the FPLC rig (GE AKTA or BioRad DuoFlow).
Step 4 – Elute the bound protein by increasing the ionic strength using Buffer B (B ufferA + 1 M NaCl) in a linear gradient fashion. The pH is maintained constant and is same asthe Buffer A. Peaks of proteins separated differentially based on the charge. The flow
rate and pressure is watched (limit – Resource Q pressure ⊁ 0.6 mPa, Q-Sepharose notmuch issue.) The eluted proteins in buffer are collected in fraction collector (Frac- 900).On-line pH, conductivity, gradient and UV are obtained on the software (UNICORN orBioRad) manager.
Step 5 – Wash the column with 100% Buffer B to elute any remaining ionically- boundmaterial. Store the column in 20 % Ethanol.
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
129
Size exclusion chromatography or Gel filtration
Size exclusion chromatography (SEC) separates the protein on basis of differences in themolecular size, specifically the Stokes radius of a specific protein. It is an effective finalpolishing step in the purification protocols when the sample volume is low or if sample ispolyclonal in nature. Samples are eluted isocratically, without salt or pH gradients. Lowsample volume requirement is a major limitation and hence prior steps of concentratingare required if samples have not gone through sequential precipitation protocols.
Figure 2-6 : Size exclusion chromatography – large size molecule runs through space
between the media by a shorter path compared to smaller size that travels through longer
path via pores / channels.
(Adapted from chapter 2, book Protein Engineering - Technology and Application, edited by
Dr Ogawa; Published InTech 2013)
A Superose 12 column was used for the purpose of preparing improved IgG samples. TheAKTA purifier (GE Healthcare) or BioRad Duo Flow fast protein liquid chromatographyworkstations were used to support the column and perform automated liquidchromatography and accurate fraction collection.
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Protocol 2-5 : Size exclusion chromatography
Multi-step purification protocols
To study the biophysical and chemical properties of IgG, it has to be substantially purifiedfrom complex mixtures such as tissue culture medium, serum or plasma effluent. Thereis no one-step purification process that is satisfactory; hence a combination of protocolswithin a strategy of combined is required and adapted according to complexity and otherproperties of the starting mixture. Table 2-3 summarises the choice depending on thecharacteristics of IgG molecule and Table 2-4 lists the chromatography columns used.
IgG property Technique
Charge and isoelectric pH (pI) Ion exchange chromatography
Size Size exclusion chromatography
Hydrophobicity Ammonium sulphate precipitation
Ligand specificity Affinity chromatography
Table 2-3 : Properties of IgG molecule and technique that can be used to purify/ separate
accordingly(Adapted from Antibody purification Handbook (18-1037-46, Amersham Biosciences)
Step 1: Concentrate the material or if precipitate following sequential precipitationtechnique dilute in 500 microlitre of PBS (pH 7.4). Centrifuge 13.5/15 K rpm prior toloading to the loop on the rig.Step 2: Superose 12 column is equilibrated with PBS (pH 7.4) and then sample isinjected automatically by the FPLC rig.Step 3: PBS (pH 7.4) is run through isocratic flow 0.5 ml/min through the column. Thesamples fractionated as per size are collected by fraction collector.Step 4: 40 ml of PBS (pH 7.4) is run through the column and finally is stored in 20%Ethanol.
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Column FPLC principle Compositions Binding capacity Max back pressure
Q Sepharose Anion Exchange Q – quaternary ammonia grouplinked to sepharose
Resource Q (Amersham
Bioscience)
Anion Exchange Q – quaternary ammonia grouplinked topolystyrene/divinylbenzen 1 ml – 45 mg BSA6 ml – 270 mg BSA 1 ml – 220 psi6 ml – 87 psi (0.6 MPa)
SP Sepharose Cation exchange Sulfopropyl (SP) linked tosepharose
Resource S Cation exchange Methyl sulfonate linked topolystyrene/divinylbenzen 1 ml – 80 mglysozyme6 ml –480 mglysozyme
1 ml – 220 psi6 ml – 87 psi (0.6 MPa)
Superose 12 (10/300 GL) Size exclusionchromatography Cross linker agarose 9-13um NA 435 psi (3 MPa)
Table 2-4 : Various columns used in Ion exchange and size exclusion chromatography
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Quality check
SDS PAGE gel electrophoresis was done after each step of purification described in section
2.2 to look for specificity or any impurities following a particular step. At the end of
purification protocol Luminex Single antigen bead assay was used to describe specificities of
HLA-specific antibodies. During the early stage of protocol development, mass spectrometer
was used to describe the proteins separated.
SDS PAGE Gel electrophoresis
Gel electrophoresis was used to assess the complexity of samples and efficacy of purification
techniques used for this project. SDS-PAGE (sodium dodecyl sulphate – polyacrylamide gel) 4
– 12% was used to separate proteins according to their size. A protein ladder (2-color SDS
marker, RunBlueTM) was used. Gel was performed in native and reducing (DTT) conditions
(Protocol 2-6). Silver staining protocol was used as per manufactures instructions, if the bands
were not visible or faint following SDS PAGE Gel electrophoresis and staining with coomassie
blue stain (protocol 2-7).
Acetone precipitation was used on samples with very low concentration of proteins. 1 ml of
sample was mixed with 9 ml of cold (4oC) acetone and left in the freezer for one hour.
Following this the sample was centrifuged at 4.5k rpm for 30 minutes and the supernatant
was discarded. The test tube with pellet was left on heat block (60oC) for 20 minutes prior to
suspending in 20 ul of LDS-DTT buffer for reducing condition gel electrophoresis.
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Protocol 2-6 : SDS PAGE gel electrophoresis
Protocol 2-7 : Silver staining of SDS PAGE gel
Step 1 - De-stain: If stained with coomassie stain, de-stain it with destaining solution (100 ml
of 40% Ethanol, 10% acetic acid) for 1 hour in rocker/shaker (or microwave on high power
for 40 seconds to 1 minute and incubate for 10 minute). Decant the solution and wash the
gel with 100ml of 30% Ethanol for 10 minutes (shaker). Decant the ethanol
Step 2 - Sensitiser: Add 100 ml of sensitizing solution (30 ml Ethanol+ 10 ml Sensitiser and
dH2O up to 100 ml). Incubate for 10 minutes. Decant the solution and wash the gel with
100ml of 30% Ethanol for 10 minutes (shaker). Decant the ethanol followed by wash the gel
with 100ml of dH2O for 10 minutes (shaker). Decant the dH2O
Step 3 - Stainer: Add 100 ml of staining solution (1 ml stainer in 100 ml dH2O) for 15
minutes. Decant the solution and wash the gel with 100ml of dH2O for 30-60 seconds
(shaker). Decant the dH2O
Step 4 - Developer: Add 100 ml of developing solution (10 ml developer, 1 drop of developer
enhancer to 100 ml of dH2O) for 4-8 minutes until bands start to appear and the desired
band intensity is reached
Step 5 - Stopper: Add 10 ml of stopper directly in above. Gently agitate the gel for 10
minutes. Colour changes from pink to colourless (indicating that the development has
stopped). Decant the solution and wash the gel with 100ml of dH2O for 10 minutes (shaker).
Decant and immerse in dH2O to keep it wet
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Luminex micro beads assay
Microbead coated with target HLA proteins are used in the Luminex platform. It requiresvery small amount of sample usually 5-20 microliters and is high throughput.Simultaneously over 90 HLA-proteins and HLA-specific antibody interactions occurwithin each microwells containing the micro beads. This is a very sensitive assay and candetect antibodies at very low concentrations. Hence it is used extensively in both clinicaland research laboratories.
Screening assays were used to detect the presence of HLA-specific antibodies in a givensample. This was used as first stage in characterisation samples followed by singleantigen beads to characterise the specificity of HLA-specific antibodies. Single antigenbead Luminex assay was also used to confirm specificity profiles of purified materialfollowing protocols described in section 2.2.
Samples were analysed as per protocol 2-8. MFI readouts of Luminex runs wereconsidered positive if the MFI values were over 500 for the One-Lambda kit. Whilst Life
code SAB assay, the positive assignment is based on company’s recommendation of two of
more positive adjusted ratio relative to control beads. The assay readout was used inqualitative and not in quantitative terms.
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
135
Protocol 2-8 : Luminex bead assay to detect and measure HLA-specific antibodies
Step 1: The samples were centrifuged at 13,000 rpm for ten minutes prior to the test.The reagents and beads were sonicated for 5 minutes, centrifuges for 10 seconds andvortex mixed for 30 seconds prior to use. The 96 well Luminex plate (Millipore UK) waswashed with 200 ul of wash buffer by vacuum suction method. Finally, 20ul of bufferwas pipetted in to each well.Step 2: Add beads (For screening of the samples, 2.5 microliter of Labscreen beads (OneLambda Inc, CA, USA) were used and for defining specificities 2.5 microliter of SingleAntigen Beads (One Lambda Inc, CA, USA) or 20 microliter of Gen-Probe single antigenbeads (Gen-Probe, CA, USA) were used.Step 3: Add sample – 10 ul (if using one-lambda beads) or 5 ul (if using Gen- Probebeads) of sample was added to the beads and incubated for 30 minutes at roomtemperature (22 degree Celsius). Positive and negative controls were used with eachexperiment.Step 4: Add fluorescence conjugated secondary antibodies – Wells were washed three tofour times with wash buffer and then 50 microliter of 1:100 dilution phycoerythrin (PE)conjugated goat anti-human IgG (supplied with One Lambda kit) or 25 µl of 1:10phycoerythrin (PE) conjugated goat anti-human IgG (supplied with Gen-Probe kit) wasadded and incubated for 30 minutes in dark at room temperature (22 degree Celsius) .For IgM analysis, phycoerythrin (PE) conjugated goat anti-human IgM was used insimilar dilutions.Step 5: Following above, the wells were washed four times using vacuum filtration andthen 90 microliter of wash buffer was added to each well. No wash steps wereperformed if using Gen-Probe kit.Step 6: Analysis were carried out using the Luminex® Xmap 100/200 platformFluoroanalyser (Luminex Corp, USA). HLA Fusion software (One Lambda Inc, USA) wasused to obtain raw median fluorescence intensity of different alleles. Life- matchQuicktype analysis software version 2.2 was used for Gen-probe kit.
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Mass spectrometry
This was carried out at Waters/Warwick Centre for BioMedical Mass Spectrometry and
Proteomics by Susan Slade. The Coomassie stained gel pieces were processed and digested
with trypsin using the manufacturer’s recommended protocol on the MassPrep robotic
protein handling system. The extracted peptides from the sample were analysed by means of
nanoLC-ESI-MS/MS using the NanoAcquity/Synapt HDMS instrumentation (Waters) using a
30 minute LC gradient. The data were used to interrogate the UniProt human reference
proteome database (http://www.uniprot.org/) using ProteinLynx Global Server v 2.5.1.
The mass spectrometry was performed to assess the efficacy of purification protocols andidentify any contaminant proteins to guide further steps of purification. Hence it was onlyused as a qualitative tool in the earlier stages in order to establish protocols.
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Quantification of antibody
Quantification of antibody content is required during purification/ enrichment protocols and
studying binding kinetics on biosensor platform. The methods to detect can be divided in to
two categories – 1) Methods that estimates protein concentration and 2) Methods that
estimates HLA-specific IgG concentration.
Methods to measure protein concentration –
Depending on the purification technique, this could estimate either IgG or HLA-specific IgG
content specifically however as described in section there are impurities following any
methods of purification and the aim of these methods is to enrich as pure as possible.
Methods that measure concentration either does this by detection of particular amino acids
by absorbance or by reaction of dyes or copper with amino acids and peptide bonds. Various
methods were used during this project and the choice was influenced by sample volume and
lower limit of detection of the methods.
2.4.1.1 Nanodrop® 1000 Spectrophotometer
The NanoDrop® 1000 (ND-1000) spectrophotometer (Thermo Scientific, LoughboroughUK) can measure concentration of protein at range of 100ug/ml to 100mg/ml of BSA.This is based on principle that protein containing tryptophan (Trp), Tyrosine (Tyr) orcys-cys disulphide bonds will absorb strongly at 280nm. The absorbance analysis isperformed and concentration is derived by the software. This is effective for purified
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preparations only. The advantage of Nanodrop is that it requires very small volume ofsample and is quick.
To assess protein concentration, select 280 nm absorbance on the ND-1000 3.7.1software and initialise the Nanodrop with 2.5 ul ddH2O. A blank measurement using 2.5ul of the sample buffer alone is performed prior to testing the samples. The blankmeasurement is subtracted from the measured absorbance of each sample to giveconcentration of sample protein.
2.4.1.2 Jenway® 6505 Spectrophotometer
This equipment is more sensitive than the Nanodrop, however requires larger volume foranalysis. 1 ml of neat sample (if low concentration) or 10 ul of sample in to 1 ml of 50mMNaOH (if high concentration) is placed in a quartz cuvette and absorbance measured at280 nm. Similar to the Nanodrop Spectrophotometer, a blank reading with dilutionbuffer is done to subtract background absorbance from the test samples.
2.4.1.3 Calorimetric plate assay
These assays are based on biuret reaction (reduction of Cu2+ to Cu+ by protein in an alkaline
medium). Cu+ reacts with reagent (folin in Lowry and bicinchonic acid (BCA) in BCA assay)
resulting in change in colour which is proportional to the concentration or protein in solution.
This is measured at 595 nm absorbance.
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Micro-plate assay Linear range Sample requirement
Lowry’s 0.2 to 1.5 mg/ml 5 ul (in duplicate)
BCA 0.02 to 2 mg/ml 25 ul (in duplicate)
Table 2-5 : Colorimetric micro-plate protein quantification assays
A standard curve is obtained using protein standard – Bovine serum Albumin (BSA) and fitting
is applied on the data points to obtained relationship between X and Y axes. If the data are
not linear then non-linear regression analysis (such as four-point parametric or polynomial
regression models) are applied to determine the concentration of protein in the sample.
Figure 2-7 : Dose response curve / standard curve for Lowry’s assay showing linear fit and
equation used to derive concentration of unknown samples
Reagents used in Lowry’s assay were obtained from BioRad (DC protein assay Reagent A, S &
B) and for BCA assay are obtained from Pierce Thermo scientific (Reagent A & B). Lowry’s
assay was used for samples with higher concentration as it consumes lesser amount of
volume of sample (protocol 2-9); whereas BCA for more dilute samples sample (protocol 2-
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
140
10). If the concentration is lower than the lower limit of linear range of BCA assay, then they
were re-tested following concentrating using viva spin concentrators.
Protocol 2-9 : Micro plate Lowry’s assay
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Protocol 2-10 : Micro plate BCA assay
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
142
HLA-specific IgG quantification
HLA-specific IgG quantification can be achieved using monoclonal HLA-specific antibodies as
standard on ELISA or Luminex based assay. However titration Luminex assay is very costly, so
we adapted ELISA assay developed by Rico Buchli at Pure Protein LLC, Oklahoma USA.
2.4.2.1 ELISA
Solid phase sandwich ELISA, whereby W6/32 monoclonal antibody was coated and then
specific soluble HLA protein was incubated in the microwells. Human monoclonal HLA-A2 and
HLA-B7 specific antibodies with known concentration were used as standards to derive
concentrations of unknown samples containing HLA-A2 or B7 specific antibodies.
Figure 2-8 : Sandwich ELISA for quantification of HLA-specific antibodies
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Protocol 2-11 : Sandwich ELISA for quantification of HLA-specific antibodies
Step 1 – Coating plate:
Mix W6/32 capture antibody in Phosphate buffer to a final 30ug/ml (changes= 4.59 ul in 5
ml) working solution and vortex well. Add 50 ul coating antibody per well. Put an adhesive
film cover on the plate and incubate overnight at 4 C
Step 2- Blocking plate:
Wash plate with PBS-T (on plate washer) and grip plate firmly, invert and slap excess liquid .
Add 200ul 3% BSA per well and incubate at RT for 2 hr.
You could do the step 1 for 2 hours at RT followed by step 2 – leave it at 4 oC overnight
incubation.
Step 3- Adding sHLA protein
Wash plate with PBS-T three times and grip plate firmly, invert and slap excess liquid . Add
50 ul of 250ng/ml of sHLA (HLAA*2:01 or HLAB*7:01) and incubate at room temperature for
1 hour.
Step 4 -Adding sample and standards
Human Monoclonal HLA-specific antibodies (SN607D8 for sHLA-A2 and WK1D12 for sHLA -
B7) were used as standard. Make mAb standard, stock conc of 1000ng/ml – make dilution
(480ng/ml, 240, 120, 80, 40, 20, 10 and 0 ng/ml). Set up ELISA template and make dilutions
for samples in 3% BSA (Neat, 1:10, 1:100 & 1:1000). Wash the ELISA plate with PBS-T
(on plate washer) and get rid of the excess water (slap). Finally add 100 ul standards and
samples to their corresponding wells based in your template and incubate at RT for 1 hr
Step 5 – Add detection antibody (Anti-human IgG HRP)
Make a dilution of 1:30000 of anti-human IgG HRP antibody in 3% BSA (10 ml needed per
plate). Wash the ELSIA plate with PBS-T & slap the excess fluid. Add 100ul per well of
dilution of detection antibody and incubate 1 hour at RT (away from light)
Step 6 – Adding substrate & developing
Add 2 tablet of OPD (o-Phenylenediamine dihydrochloride) in 10 ml Phosphate- citrate
buffer and vortex. Add 4 ul of H2O2 (hydrogen peroxide) right before use and vortex. Wash
the ELSIA plate with PBS-T (on plate washer) & slap the excess fluid. Add 100ul per well of
substrate and incubate 1-10 min at RT (away from light). Terminate the reaction by adding
100 ul of 3N H2SO4 per well.
Step 7 – Read plate on plate reader (Therma Electron Corporation, MULTISKAN ASCENT) at
absorbance of 490nm using Ascent software version 2.6. A standard curve is made and
curve fitting is done by the software SoftMax Pro 5.0.1 and concentration of HLA- specific
antibodies in the serum is derived.
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Protein concentrators
The HLA-specific antibodies in the samples following purification protocols are usuallyvery dilute and difficult to quantify accurately using protein assays described above.Hence methods to concentrate the protein were utilised in this project using 3000 and10000 molecular cut-off (MWCO) 2 or 20 ml centrifugal spin concentrators (Vivaspin2/20, Sartorius Stedim, UK). Another advantage of these concentrators is that they allowfor buffer exchange at the same time as protein concentration.
The concentrators are first washed by centrifugation in 2 ml of PBS pH 7.4 (4500 rpm for15 minutes.) The solution is collected in the filtrate vessel and discarded. The sample isadded and then centrifuged again at 4500 rpm for 30 minutes. Proteins larger thanMWCO are retained in the upper vessel and 250 ul of PBS pH 7.4 was topped and carefullyremoved using a fine tipped pipette. For larger sample volumes, 20 ml concentratorswere used.
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Statistics and data analysis
Statistical analysis and data presentation were done using Microsoft excel (Windows®), SPSS
IBM® and Graphpad ® online quick calculator. Mathematical modelling for kinetics data was
done using inbuilt XPR ProteOn software (BioRad®). Non-linear curve fitting on ELISA
experiments were done using SoftMax Pro software by collaborators at Oklahoma, USA. The
statistical functions used are mentioned in individual chapters.
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IgM and IgG de novo HLA specific
antibodies
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Introduction:
The detection of HLA-specific antibodies is used as a risk stratification tool to guide the
suitability of transplantation and the diagnosis of rejection. Post-transplantation, de novo
HLA specific antibodies (Tenhoor et al., 1993) can be of prognostic significance. The most
important general characteristic of these antibodies is donor specificity. Other characteristics
include quantity, antibody class and subclass, HLA isotype (HLA-A, B, C, DR, etc.) specificity,
and Fc mediated function such as complement activation. These have variously been shown
to be associated with transplant outcomes (Griffiths et al., 2004, Kushihata et al., 2004, Arnold
et al., 2013, Lowe et al., 2013a, Hoenger et al., 2011).
Pre-transplant donor HLA-specific IgG carries a high risk of hyper-acute rejection when
determining a positive complement-dependent cytotoxicity crossmatch and medium term
graft failure for lower levels. Post-transplant appearance of these antibodies is associated
with rejection (Higgins et al., 2009a, Mohamed et al., 2011, Reinsmoen et al., 2008, Wiebe et
al., 2012). It is generally accepted that preformed IgM donor HLA-specific antibodies are not
a contraindication for transplantation (Chapman et al., 1986, Taylor et al., 1989, Tenhoor et
al., 1993) and hence removing IgM by DTT treatment is recommended during sample
preparation in order to reduce false positive results. The consequence of HLA-specific IgM
developing post-transplantation may be more complicated. The development of donor-
specific IgM in itself may not be damaging to allografts (Everly et al., 2014, Marcen et al.,
1988) but subsequent class switching from IgM to IgG has been associated with poorer
outcome (Lietz et al., 2005). Others have found that post-transplant donor-specific IgM
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responses are harmful (Stastny et al., 2009, Piatosa et al., 2011, Bentall et al., 2014).
Variations and changes to immunosuppression, and different methods for identifying the
antibodies might in part explain these inconsistent observations.
The potential significance of donor-specific IgM is two-fold. Firstly, this immunoglobulin when
complexed with antigen is highly effective at activating the classical complement pathway.
Secondly, immunoglobulin heavy chain switching is a T-cell driven process, so a change from
IgM to IgG implicates specific T cell activity. Conversely, persistence of IgM without IgG
implies a certain lack of specific T cell activity. These phenomena will be influenced by the
immunosuppression used in organ transplantation. Sequential testing for HLA-specific IgG
and IgM may therefore provide a useful biomarker of in vivo T cell activation (Lietz et al.,
2005).
The purpose of this study was to describe the evolution of immune response early following
kidney transplantation in a prospectively collected cohort receiving triple therapy
immunosuppression (Tacrolimus, Mycophenolate and Prednisolone) and relate this to
adverse outcome during initial years post-transplantation.
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Materials and Methods:
Clinical samples
A group of 85 transplant recipients with no pre-transplant donor specific HLA antibodies (as
measured by CDC, Flow cross match and Luminex screen) followed prospectively at Queen
Elizabeth University Hospital, Birmingham UK were included in this study. These patients were
consented and blood samples and clinical data were collected by Dr Borrows’s team. I
designed the laboratory work and analysis of the samples and collected follow-up clinical and
biochemical data. Ethical approval was obtained (CREC-08/H1204/103) for this study. Five
cases were excluded, one case withdrew consent and four had low level pre-transplant IgG
donor specific HLA antibodies on subsequent analysis.
All cases received standard triple immunosuppressant therapy consisting of tacrolimus,
mycophenolate and prednisolone. Basiliximab was used as induction agent. For ABOi,
antibody removal with Glycosorb immunoadsorption column (Glycorex, Sweden) was carried
out pre-transplantation with the aim of lowering the haemagglutination titre below 1:8 prior
to transplantation. Additionally, Rituximab was given at day -20 and day 0 in cases with ABOi.
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Diagnosis and treatment of an rejection episode
Transplant recipients were biopsied to determine cause and the rejection was diagnosed as
per Banff criteria (Sis et al., 2010). Rejection episodes were treated with a course of
methylprednisolone, and for steroid resistant cases antithymocyte globulin (ATG) was given.
Additionally, cases with AMR had plasma exchange and IVIg treatment.
Identifying and defining HLA-specific antibodies
For serology, blood samples were taken weekly for the first month, then fortnightly for four
months, monthly until seven months, six weekly until twelve months and thereafter three
monthly. For non-sensitised cases, latest samples were screened using mixed screen bead
Luminex assays (One lambda) and if positive, the earlier samples were screened until they
became negative. Samples were also screened for day 0, 7, 30 to observe for early responses.
All the screen positive samples and a preceding negative sample were tested for HLA
specificity using single antigen beads (Life code). For sensitised cases, the pre-transplant and
latest samples were tested for HLA specificity using single antigen beads and if the profiles
differed the samples were tested backwards in order to find the specific time point for theof
appearance of de novo HLA-specific antibodies.
Luminex bead assays described in Cchapter 2 were used. Briefly, for screening 2.5 µl of lab
screen beads were incubated with 10 µl of serum at room temperature for 30 minutes. Wells
were then washed four times and incubated for a further 30 minutes with 1:100
phycoerythrin (PE) conjugated goat anti-human IgG or IgM. Samples were then washed a
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further four times and analysed using the Luminex® Fluoroanalyser. HLA Fusion software was
used to obtain raw median fluorescence intensity values of different alleles. Positive cut-off
was MFI of 500 for IgG (laboratory cut-off) and& 1000 for IgM HLA-specific antibodies.
Increased stringency for the IgM assay wasere introduced, as at the time of testing to ensure
that specificities were called only if significant increases in MFI were observed at the potential
risk of missing genuine but very weak reactions. Thus any effects of IgM anti-HLA responses
are therefore likely to be underestimated in this analysis.
HLA class I & II specific antibodies were analysed on Luminex Xmap 200 platform using
LIFECODE single antigen bead assays manufactured by Gen-Probe/Immucor/ QUEST. Briefly,
20 µl single antigen microbeads were incubated with 5 µl patient serum at room temperature
for 30 minutes. Wells were then washed three times and incubated for a further 30 minutes
with 25 µl of 1:10 phycoerythrin (PE) - conjugated goat anti-human IgG or IgM. Following this
75 ul of wash buffer was added and then the sample was analysed on Luminex® analyser. Life-
match software was used to obtain the results. The positive assignment is based on
company’s recommendation of two of more positive adjusted ratio relative to control beads.
Statistics:
The data were analysed using Microsoft excel and Ggraph pad Prism software. Fisher exact
test and un-paired t-test were used to compare outcomes between groups using SPSS IBM®
software. Groups were compared using one- way Aanova for parametric data, Kruskal-Wallis
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test for the non-parametric data and Pearson chi-square test for the categorical data using
SPSS IBM® software. Survival curves were generated using SPSS IBM® software.
Results:
The demographic characteristics of the recipients are summarised in Table 3-1. Baseline
characteristics of cases between the groups were not significant except PRA levels (≤ 5%) 
where the Pearson chi-square test was significant df = 3, P = 0.002). Thus PRA >5% associated
with development of de novo HLA-specific responses. None of the cases that received
rituximab (for ABO-incompatible kidney transplantation, N = 18) developed a de novo IgM
response (P = 0.018, 0/18 versus 15/47). There was no difference in de novo IgG response
according to prior Rituximab therapy (P = 0.37, 3/18 versus 18/62).
Prevalence and timing of de novo antibody responses
In eighty patients, NDSA were found to be more prevalent than DSA for both IgM (P = 0.0046)
and IgG (P = 0.0061) classes. NDSA tended to be seen earlier than DSA for both antibody
classes. IgM antibodies appeared earlier than IgG, but not statistical significance was seen
(data given in Table 3-2). IgG DSA appeared after a median of 362 days compared to IgM DSA
with median period day of 140 days. During the median follow-up of two years, the
prevalence of IgG de novo DSA was 8.8%. There was an apparent larger breadth (number of
antibody specificities) of responses for IgM compared to IgG (median no 4 (1-26) versus 2 (1-
6). However these differences did not reach statistical significance.
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All IgM-/IgG- IgM+IgG- IgM-/IgG+ IgM+/IgG+
No 80 50 9 15 6
Age (mean) 45 47.5 35.67 44.2 43.5
Female (no (%)) 32 (40) 21 (42) 2 (22) 7 (47) 2 (33)
Race (Caucasian no (%)) 58 (73) 40 (80) 7 (78) 8 (53) 3 (50)
PRA (≤ 5%) (no (%))* 72 (90) 48 (96) 9 (100) 12 (80) 3 (50)
HLA mm (mean) 3 3 3 2.8 2.3
DR mm ≥ 1 (no (%)) 49 (61) 32 (64) 6 (67) 9 (60) 2 (33)
DR mm >2 (no (%)) 14 (18) 7 (14) 3 (33) 3 (20) 1 (17)
First Transplant (no (%)) 72 (90) 45 (90) 9 (100) 13 (87) 5 (83)
Pre-emptive (no (%)) 21 (26) 15 (30) 1 (11) 3 (20) 2 (33)
ABOi (no (%)) 18 (23) 15 (30) 0 3 (20) 0
Deceased donor (no
(%))
39 (49) 21 (42) 5 (56) 8 (53) 5 (83)
SGF/DGF (no (%)) 19 (24) 12 (24) 1 (11) 4 (27) 2 (33)
Table 3-1 : Baseline characteristics of transplant recipients with different immunoglobulin
isotype profile
(PRA – Panel reactive antibody; mm – mismatch; SGF/DGF – Slow/delayed graft function)
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a. Prevalence (N (%)) b. Time of appearance (days post
transplantation)
IgM IgG IgM IgG
DSA 3 (3.8%) 7 (8.8%) 140 (73-433) 362 (225-542)
NDSA 15 (18.7%) 21 (26.3%) 54 (19-137) 141 (36-485)
Table 3-2 : De novo HLA specific antibodies in 80 renal transplant patients.
a. For both IgM and IgG there are more cases of NDSA than DSA (p=0.0046 and p=0.0061,
respectively). b. In general DSAs appear later than NDSAs (median (IQR)) (but statistically not
significant - Mann-Whitney U test p =0.654; and 0.219 respectively) and IgM appears earlier
than IgG (but not statistically significant p= 0.105 Mann-Whitney U test)
The majority of first time IgM responses were seen within six months post-transplantation
(12/15 (80%) versus 10/21 (48%) for IgG responses). The overall difference in the first
appearance of IgG and IgM was likely to be due to more de novo IgG cases after one year
although the difference was not significant (Figure 3-1a). There were more cases with Class I-
specific compared with Class II –specific antibodies for IgG (P = 0.016, Figure 3-1b). For IgM,
the appearance of antibodies against HLA Class I was similar to that for IgG but there were no
detectable de novo Class II-specific IgM (P < 0.001, Figure 3-1c).
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Figure 3-1: Kaplan-Meier analysis comparing the first appearance of HLA specific IgG and
IgM
A – De novo IgG versus IgM appearance; B – HLA class I versus class II appearance for IgG
and C – HLA class I versus class II appearance for IgM
De novo antibody responses class switch
In the six cases with dual IgM and IgG responses, both IgG and IgM against same HLA-
specificities were demonstrated in two cases. In the first case there was evidence of class
switching from IgM to IgG against HLA-Cw-7 as described in Figure 3-2a. Whilst, in the second
case IgG HLA-A2 DSA preceded IgM (Figure 3-2b); this was a case of non-compliance leading
to graft loss with AMR.
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Figure 3-2 : Trend of MFI values of specificities that had class switch from IgM to IgG (A)
and case with DSA for same allele (B) panel A
Outcomes
Rejection –
The post-transplant events associated with each antibody group are shown in Table 3-3.
Rejection episodes were seen in 24 (30%) transplant recipients. Of these 5 (6.25%) were
antibody mediated rejection (AMR) and 19 (24%) were acute T cell mediated rejection (ACR).
There were no episodes of AMR in the IgM+/IgG- group. There were two episodes of AMR in
IgM-/IgG- group but both of these had ABOi kidney transplantation. Although there is greater
IgG positivity (DSA and NDSA) amongst the rejection group of patients, this did not reach
statistical significance. Indeed the majority of IgG-positive cases (13/21, 62%) did not
experience rejection.
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Figure 3-3: Relationship of rejection episode and HLA-specific antibodies evolution along
time post Kidney transplantation
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Figure 3-3 shows the temporal relationship between rejection episodes and de novo HLA-
specific antibody appearances. De novo HLA-specific IgG preceded an episode of biopsy
proven antibody mediated damage in just three cases (2 AMR and 1 transplant
glomerulopathy (TG)). Only one of these had a detectable DSA response (case 9M; Figure 3-
2B). In 6 cases with an episode of rejection, there was a de novo antibody response detected
after the episode with a median of 263 days (IQR = 69 to 359 days). In the remaining 15 cases
with rejection there were no HLA-specific antibody responses during median follow-up of 671
days (IQR = 211 to 757 days).
Graft dysfunction –
Graft function measured by eGFR (MDRD) following transplantation was compared between
group IgM-/IgG-, IgM+/IgG- , IgM-/IgG+ and IgM+/IgG+ groups (Figure 3-4). The trend
analysed by Anova was not significant between the groups. Further analysis comparing the
groups revealed that, eGFR was significantly lower at month-3 (P = 0.039) and month-36 (P =
0.037) in the IgM+/IgG+ group compared to the IgM-/IgG- group (Games-Howell test). Early
graft function tended to be superior in the IgM+/IgG- group but did not reach statistical
significance. Within the IgM-/IgG+ group , year three eGFR was significantly lower in those
with a history of rejection compared to those with no rejection episodes (n = 5 versus 10; P
= 0.03, Kruskal-Wallis test).
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Figure 3-4 : eGFR (MDRD) following kidney transplantation in groups with de novo IgM+ (N=9) / IgG+ (N=15)/ IgM+/IgG+ (N=6) versus IgM-
/IgG- (N=50). No significant difference in mean eGFR (ANOVA test). However post-doc analysis showed significant difference between
IgM+/IgG+ and IgM-/IgG- at month-3 and –36 (Games-Howell test).
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Other outcomes –
All other outcomes such as new onset proteinuria, death, and graft failure did not show any
significant association with any of the antibody groups. (Table 3-3)
Groups All IgM-/IgG- IgM alone IgG alone IgM+/IgG+
N 80 50 9 15 6
None events N
(%)
49 (61.25) 30 (60) 10 (77) 10 (67) 2 (33)
Graft Failure N
(%)
6 (7.5) 4 (8) 0 (0) 1 (7) 1 (17)
Death N (%) 4 (5) 2 (4) 0 (0) 1 (7) 1 (17)
Rejection N (%) 24 (30) 15 (30) 1 (11) 5 (33) 3 (50)
ACR N (%) 19 (24) 13 (26) 1 (11) 3 (20) 2 (33)
AMR +/- ACR N
(%)
5 (6.25) 2 (4) 0 (0) 2 (13) 1 (17)
Proteinuria N
(%)*
13 (16.25) 10 (20) 1 (11) 1 (7) 1 (17)
Table 3-3 : Outcomes in relation to de novo development of HLA Ig class-specific
antibodies showed no significant difference between the groups **
(*Proteinuria – defined as Albumin Creatinine Ratio over 30mg/mmol persistent on two
occasions, and after 1 month of transplantation, ** Fisher exact 2-tail test).
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Discussions:
This prospective study looked at evolution of HLA-specific antibody (IgM & IgG) responses
following kidney transplantation in a cohort receiving standard triple immunosuppressant
regimen (tacrolimus, mycophenolate and prednisolone). The sampling was more rigorous
compared to other studies. The median time between the last negative sample and the first
positive was 21 (2-240) days for de novo IgM and 140 (3 to 497) days for de novo IgG
responses. The patients in this study were receiving a homogenous maintenance therapy, so
that the prevalence of HLA-specific antibodies relates to commonly used triple
immunosuppressive therapy (Tacrolimus, Mycophenolate Mofetil and Prednisolone).
Previous studies on IgM HLA response are limited, smaller in size, indicate conflicting results
and have used non-specific CDC or Flow cytometry assays (that use donor cells or panel of
cells to assess the response). (Worthington et al., 1998, Suzuki et al., 2009, Tardif and
McCalmon, 1995, Piatosa et al., 2011, Chapman et al., 1986, Taylor et al., 1989, Lietz et al.,
2005). Studies using microbeads coated with purified specific HLA proteins have focused on
pre-transplant sera from kidney transplant recipients. Studies by Khan et al, used the FlowPRA
(One Lambda) assay and analysed sera of failed transplant cases and revealed the presence
of DSA-IgM HLA class I-specific antibodies (Khan et al., 2003). Similarly, a study looking at pre-
transplantation sera from 34 kidney transplant recipients using Luminex assay (One Lambda
beads) noted that IgM+/IgG- DSAs were detected in higher proportion of cases with rejection
compared to cases without rejection (P < 0.02) (Stastny et al., 2009). They observed similar
findings in cardiac transplant recipients. Contrary to above, studies in 49 lung transplant
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recipients showed that the presence of both pre and post transplantation IgM HLA-specific
antibodies detected by screening beads was not associated with poor outcome (Paantjens et
al., 2011). Recently studies (Everly et al., 2014) using Luminex single antigen bead assay and
suggested that IgM DSA are significant as they were associated with higher grade of rejection
but overall graft survival was not affected. However, in this study the majority (60%) of cases
were receiving cyclosporine-based immunosuppressive treatment and proportions on
mycophenolate are not mentioned.
In the current study, we have shown that in a prospective cohort of transplant recipients on
standard triple immunosuppressive therapy, there were greater non-donor specific de novo
responses for both IgM and IgG classes. IgM de novo responses appeared to emerge earlier
than IgG but the difference in the median time was not statistically significant. IgG DSA
responses were noted mainly one year post-transplantation (5/7 cases) except in a case with
non-compliance at day 34 (class I) and in another case at day 90 (class II). All three cases with
IgM DSA, the de novo DSA response was within the first six months following kidney
transplantation. Responses to HLA class are interesting as no de novo class II responses were
observed for IgM class.
Another interesting finding was the lack of de novo IgM anti-HLA responses in cases with ABOi
kidney transplantation (p=0.018, Fisher’s exact test). The rate of de novo IgG anti-HLA
response in ABOi was no different from standard kidney transplantation (P = 0.37, Fisher’s
exact test). It is possible that Rituximab therapy was responsible for the reduced rate of IgM
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production, as this was the only systematic difference in therapy between the groups, apart
from ABO specific immunoadsorption therapy pre-transplant. Similar to the novel studies
described here, other studies have shown no effect on IgG response with prior Rituximab
therapy (Lobashevsky et al., 2013, Ashimine et al., 2014). Some of these de novo IgG
responses could be re-call responses from a previous sensitisation. So although they were not
present pre-transplantation, they may have been there historically due to prior sensitisation
events. The HLA types of donors were not routinely tested, so it is difficult to assess the re-
call responses. A non-donor specific re-call response could be due to generalised immune up-
regulation and may drive non-specific inflammation in allograft causing adverse outcomes.
Endogenous molecules released during tissue injury such as damage associated molecular
patterns (DAMPs) can activate cellular receptors and lead downstream inflammation (Rosin
and Okusa, 2011). TLRs mediate some of these effects (Krueger et al., 2009). Hence NDSA may
still serve as biomarkers for poor transplant outcome.
Similar to the previous study (Everly et al., 2014), this study also observed that IgM alone is
not associated with adverse outcome. Cases with dual positive (IgM+/IgG+) were small in
number but had significant poor graft function at month 3 and month 36 compared to group
with no antibody responses (IgM-/IgG-). Cases with de novo IgM alone (IgM+/IgG-) with no
observed class switch tend to have better graft function (eGFR; MDRD). This suggests a better
prognostic group. This finding is similar to a previous study on cardiac transplant recipients
(Lietz et al., 2005). In 267 primary heart transplant recipients with a mean follow-up of 3.1
years, 20 % produced IgM antibodies. The study observed the persistence of IgM (particularly
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anti-HLA class II) and the lack of IgG isotype switching, as measured by CDC, were associated
with protection against acute rejection.
IgG HLA-specific responses studied here confirm findings of previous prospective studies.
Particularly, that the de novo IgG response was not predictive of episodes of rejection and
that in most cases with rejection, the antibodies appeared following the episode (Gill et al.,
2010). Similarly, the present study noted that the group with rejection and IgG de novo
responses had worse 3 year eGFR (MDRD) compared to group with IgG de novo response
without any episodes of rejections (Cooper et al., 2011). Another similarity was the higher
incidence of AMR in the de novo IgG group (Heilman et al., 2014) but numbers were too small.
In contrast to the other prospective study, the de novo DSA response was earlier (Wiebe et
al., 2012). In keeping with observations by Wiebe et al, a patient developed de novo DSA
responses due to poor compliance resulting in AMR and graft failure.
A limitation of this study is the absence of protocol biopsy samples to detect sub-clinical
rejection. This was considered in the initial protocol, but was dropped because of the high
rate of failure to consent. The second limitation is the shorter clinical follow-up period (three
years) and it may be in the long-term that the de novo HLA-specific antibody response does
have significant effects similar to those observed by Wiebe et al. The third limitation is that
the antibodies were defined by Luminex assay alone post transplantation and some of the
positive results may be false positive (Gombos et al., 2013). However, the positive threshold
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for IgM was raised to 1000 MFI on screening to increase the confidence of genuine anti-HLA
reactivity.
Conclusion:
This three year prospective study of 80 cases following kidney transplantation showed that
early de novo responses for both IgM and IgG de novo HLA-specific antibody production did
not increase adverse events in the short term in cases receiving standard triple
immunosuppressant therapy, except in a group of cases with dual positive responses.
Rituximab therapy abolished de novo IgM responses but had no effect on de novo IgG
responses. Prospective screening for IgM or IgG HLA-specific antibodies does not predict
rejection or adverse events in early years post-transplantation in cases on the standard triple
immunosuppressant regimen.
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Biosensor assay to study interactions of
HLA-specific antibodies and HLA-
proteins
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Biosensor assay based on surface plasmon resonance has advantage of studying the binding
of antibody to the antigens in label free and real time. Additional biophysical characteristics
such as dissociation constants (KD) and kinetic rates (on rate Ka and off rates Kd) can be
quantified. These additional characteristics have not been studied in transplantation
medicine.
Surface plasmon resonance assay
This is an optical biosensor technique based on surface plasmon resonance principle.
Principle
Electrons within metallic surfaces such as a thin gold film/layer can be excited upon shining
light over them. This excitation creates plasmons that travel along the metallic layer (Figure
4-1). Also, at same time an electromagnetic wave field is created in the fluid above the
metallic film called Evanescent Wave (EW) field. The EW decays exponentially from the
surface, resulting in energy being transferred from the plasmon creating a resonance. Hence
it is called surface plasmon resonance. These resonance occurs on the interface between the
gold surface and the liquid medium in the instrument flow cell, hence it is very sensitive to
changes in surface proximal to the gold following adsorption of any molecules. When the
refractive index changes, the energy and momentum of the plasmon also changes, resulting
in the shift of the sensorgram dip/ curve. The reflected light can be plotted on a reflective
curve (Figure 4-2).
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Figure 4-1 : Principle of surface plasmon resonance (taken form http://phys.org)
Figure 4-2: Sensorgram obtained during change in mass over the surface layer. This is
monitored real time as a plot of resonance signal versus time
(Adapted from Cooper et al, Nature Reviews Drug Discovery 1, 515-528 (July 2002).
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The BioRad Proteon XPR36 platform was used for this project. It allowed simultaneous study
of 36 spot interactions. Hence a range of concentrations of analyte (HLA-specific antibody)
could be studied against different immobilised ligands (HLA protein) or different ligand
densities simultaneously. These high throughput features meant that different combinations
of interactions could be studied together using the same solution-phase sample (Figure 4-3).
Figure 4-3 : Multiplex array set-up on XPR proteon platform
Mass transport and diffusion limitation
The analyte is transported to the chip surface initially by convection and then diffusion. The
diffusion rate depends on the diffusion constant of the molecules. The larger molecule usually
takes few seconds to diffuse through the unstirred layer. Hence the concentration will be
lower than the sample; this is called mass transport limitation. (Figure 4-4).
Figure 4-4: Convection and diffusion of analyte through the fluidic system (Adapted from
the handbook of surface Plasmon resonance, page 179, chapter 6)
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Ways to overcome mass transport limitation –
a) Flow rate – Increasing flow rate will increase the convection
b) Lowering ligand density and increasing analyte concentration
This will allow constant supply of analyte as the binding sites on ligands are limited
and thus there will no depletion of antibody in the layer. Another advantage of lower
ligand density is that it facilitates the resolution of interactions in affinity-dependent
terms rather than avidity-dependant.
c) Compact matrix layer on the sensor chip
Matrix layers on the chip can vary in depth. The 2-D matrix provides a compact layer
(10nm) and allow only one mono-layer of immobilised ligand. The analyte in the
diffusion layer rarely gets depleted. This is beneficial for kinetic analysis as mass
transport limitation and re-binding of analyte in the dissociation phase is reduced
(Figure 4-5).
Figure 4-5 : matrix layer on the sensor chip (A – 2D matrix and B – 3D matric)
(Adapted from the handbook of surface Plasmon resonance, chapter 6)
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The NLC chip (NeutrAvidin) has a compact layer of modified alginate polymer and utilises
neutravidin to capture biotinylated proteins directly (biotinylated HLA proteins). See Figure
4-6.
Figure 4-6 : Sensor chip for XPR platform (A – GLC chip with carboxyl group and B – NLC chip
with avidin)
Optimisation of experimental conditions
In first instance to develop the assay, we studied optimal conditions and protocols using
human monoclonal HLA-specific antibodies which were generously provided by University of
Leiden (A Mulder and F Claas). This chapter describes the purification and accurate
quantification of human monoclonal HLA-specific antibodies, use of equilibrium and kinetic
analysis and ELISA to quantify dissociation constants, advantage and limitations of current
approaches to quantify binding parameters. Although only two HLA-A2 specific monoclonal
antibodies were later used, this chapter also describes purification of other human
monoclonal HLA-specific antibodies used for experiments in Chapter 5. The insights obtained
from work shown in this chapter were latter used to translate the assay for testing of clinical
samples in chapter 6. Optimal conditions for monoclonal HLA-specific antibodies were latter
used to study and distinguish reactivity for same epitope shared between different HLA-
proteins and competitive binding in chapter 4.
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Sample preparation
Purification of human monoclonal HLA-specific antibodies
Supernatants from hybridoma cultures containing secreted human monoclonal HLA-specific
antibodies underwent series of upstream purification steps as described in the Methodology
(Chapter 2.2). High quality protein purification was required due to strong evidence of
impurities in the raw supernatants and even IgG-enriched fractions that resulted in non-
specific binding to the highly sensitive sensor chip matrix that is inherent to the SPR
experimental scheme (Figure 4-7).
Figure 4-7 : Non-specific binding from un-purified monoclonal HLA-A2 specific antibody
(IHB-HU-081 (SN607D8)) to empty reference channel as shown in B.
Whilst it was noted that despite some non-specific binding, a distinguishable signal could be
obtained for monoclonal antibodies without rigorous multi-dimensional purification, the
accurate quantification of monoclonal antibodies by BCA or Lowry protein assay was
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hampered due to the presence of bystander protein impurities. This was evident even after
subjecting raw HLA-specific antibody preparations to HLA-protein and Protein G-Sepharose
affinity chromatography. Hence two different protocols were used to purify monoclonal HLA-
specific antibodies (Figure 4-8).
Figure 4-8 : Protocols for purification of human monoclonal HLA specific antibodies
Human monoclonal HLA-specific antibodies were recovered from hybridoma culture
supernatant kindly supplied by Arend Mulder and colleagues at the University of Leiden. All
the human monoclonal antibodies in the culture supernatants underwent dialysis against PBS
overnight prior to centrifugation and affinity chromatography. HLA-protein and Protein G
affinity chromatography were used as intermediate enrichment steps prior to either ion-
exchange or size exclusion chromatography. The choice of combination of purification steps
was determined by the biophysical and chemical characteristics of antibodies, in addition to
potential for maximum yield of highly purified protein.
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Purification of Monoclonal Antibody SN607D8 (IHB-Hu-081)
Culture supernatant (100 ml) containing SN607D8 (IHB-Hu-081) was dialysed overnight
against PBS (pH 7.4) to achieve buffer exchange and remove dyes and culture medium solutes
and then centrifuged at 10,000 rpm for 10 minutes to remove particulates. The material was
subsequently diluted in an equal volume of PBS (pH 7.4). The total volume was then run over
a HLA-A2-Sepharose column (50 ml settled volume) and semi-automated affinity
chromatography performed with a peristaltic pump at a flow rate of 50 ml/min. A 500 ml
volume of PBS was used to wash the affinity column prior to eluting with one litre (20 column
volumes) of 100 mM Glycine, pH 11.0. The elution material was immediately neutralised with
125 ml of 1M TRIS (pH 7.0) and tested with Luminex single antigen beads giving MFI levels of
over 20,000 for HLA-A2, -A68 and –A69 beads and over 1000 but less than 2000 MFI for HLA-
B57 & -B58 beads.
The eluted and pH-neutralised material was dialysed against 10 mM HEPES pH 8.0 overnight
prior to Anion exchange chromatography. Figure 4-10 shows separation of various protein
species (peaks of absorbance at 280 nm) based on anion exchange chromatography runs
using a 20 ml Q-Sepharose column with a 0 – 500 mM sodium chloride gradient. The top half
shows multiple peaks demonstrating presence of multiple impurities in the raw culture
supernatant containing monoclonal HLA-specific antibody, to be expected due to the use of
foetal bovine serum in hybridoma culturing. Whereas the bottom part shows material
undergone purification protocol-A (summarised in Figure 4-10). Gel electrophoresis (Figure
4-9) and Luminex by Single Antigen Beads (SAB) were performed to confirm the purity of the
material and reactivity to specific HLA alleles respectively. Luminex testing gave MFI values
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>20,000 for HLA-A2, -A68 and –A69 beads. The samples corresponding to the IgG elution peak
was quantified using Lowry’s assay and the concentration was 1 mg/ml.
Figure 4-9: SDS PAGE gel electrophoresis done in reducing condition (DTT) shows bands of
proteins in different fractions during anion exchange chromatography of raw and affinity
purified SN607D8 (IHB-Hu-081).
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Figure 4-10 : Ion-exchange chromatography (Q-Sepharose column) for purification of SN607D8 (IHB-Hu-081) (A – raw supernatant
containing antibody and B – supernatant through HLA-A2 affinity chromatography)
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Purification of Monoclonal antibody SN230G6 (IHB-Hu-033)
Similar to the procedures above, the IHB-HU-033 (SN230G6) was purified via multi-
dimensional liquid chromatography (protocol A, Figure 4-8). Luminex single antigen beads
show MFI values over 10,000 for HLA-A2, -B57 & -B58 beads and negative for all other beads
following the selective HLA-A2 affinity chromatography step. Anion exchange
chromatography failed to purify SN230G6 (IHB-Hu-033) as there was no binding either to
neither Q-Sepharose nor Resource-Q (Figure 4-12 (A)). The flow through was then buffer
exchanged with 10 mM sodium acetate pH 5.5 overnight and cation exchange using a
negatively-charged SP-Sepharose column was performed. Cation exchange chromatography
was able to purify SN230G6 (IHB-Hu-033) with a distinct peak as seen in Figure 4-12 (B). Gel
electrophoresis of fractions pre- and post-cation exchange chromatography is shown in Figure
4-11.
Figure 4-11 : SDS PAGE Gel electrophoresis showing protein bands pre and post Cation
exchange chromatography of SN230G6 (IHB-Hu-033).
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Figure 4-12 : Ion exchange chromatography for SN230G6 (IHB-Hu-033) monoclonal HLA-specific antibody (A – Anion exchange using
Resource-Q and B – Cation exchange using SP-Sepharose)
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Purification of the WK1D12 monoclonal antibody (IHB-Hu-059)
Culture supernatant (100 ml) containing WK1D12 was dialysed overnight against PBS (pH 7.4).
This was followed by HLA-B7-Sepharose affinity chromatography (4 ml column), with protein
eluted in 100 mM Glycine pH 11.0. The peak elution fractions were pooled together and
neutralised with 1M TRIS and the solution was dialysed against 10 mM HEPES pH 8.0
overnight. Following this, anion exchange chromatography was utilised for purifying WK1D12
(Figure 4-13). Luminex assay was performed on the pre-, flow-through samples (material that
did not bind to HLA-B7-Sepharose and Resource-Q columns) and peak elution samples. Both
the flow-through and peak elution fractions from the HLA-B7-Sepharose affinity column were
positive by Luminex assay (MFI > 15,000) for HLA-B7/B27-specific reactivity suggesting
saturation of the smaller HLA-B7-Sepharose column in addition to pH-mediated elution. Flow-
through fractions from the Resource-Q were negative by Luminex assay (MFI < 500),
indicating that the HLA-specific antibodies were binding to this anion exchange column.
Elution had two distinct peaks and the concentration was too low.
Figure 4-13 : Anion exchange chromatography (Resource-Q) for purification of WK1D12
(IHB-Hu-059) monoclonal HLA-B7/27 specific antibody.
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A second batch (100 ml of culture supernatant) containing WK1D12 was purified using
protocol B (Figure 4-8). The culture supernatant was dialysed against 10 mM sodium
phosphate buffer pH 7.0 followed by affinity chromatography using 4 ml of Protein G-
Sepharose. The peak elution was broad. Hence the elution fractions were pooled together
and the solution was concentrated using spin concentrator (MWCO of 30,000) using PBS (pH
7.4) as exchange buffer. The material was concentrated to a volume of 2 ml and subjected to
size exclusion chromatography (gel filtration) using a 30 cm Superose-12 column, at 1 ml per
run in isocratic flow at a rate of 0.5 ml per minute. Figure 4-15 shows a large peak saturating
the upper limit of detection by the A280 optical absorbance detector. Gel electrophoresis
(Figure 4-14) and Luminex single antigen bead assay confirmed purity for IgG.
Figure 4-14 : Gel electrophoresis of elution fractions following size exclusion
chromatography of WK1D12 (IHB-Hu-059)
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Figure 4-15 : Size exclusion chromatography using Superose-12 column showing elution peak of WK1D12 (D11-E2 fractions)
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Other monoclonal HLA-specific antibody purification
Four other human monoclonal HLA-specific antibodies reacting against B7/B27 (WAR5D5,
VTM1F11, VTM9A10 and OUW1F11) were purified as protocol-B (Figure 4-8). All of them
underwent protein-G affinity purification followed by size exclusion chromatography (see
Figure 4-17). Purity was checked by SDS PAGE gel electrophoresis (Figure 4-16) and Luminex
single antigen bead analysis.
Figure 4-16 : SDS PAGE gel electrophoresis (reducing condition) showing bands of
purification of monoclonal HLA-specific antibodies using protocol B.
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Figure 4-17 : Purification of monoclonal HLA-B7 specific antibody (VTM1F11) via protein-G affinity chromatography (A) followed by Size
exclusion chromatography (B).
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Analyte and ligand concentration measurement
Biotinylated HLA proteins kindly provided by Pure Protein LLC laboratories, Oklahoma, USA
were quantified using both BCA protein assay and soluble HLA ELISA. Purified Monoclonal
HLA-specific antibody (analyte) concentration was measured using Lowry and BCA protein
assay as described in section 2.4.3. (See Table 4-1)
Biotinylated class I HLA proteins (described in chapter 2.1.2) were immobilised on
neutravidin-coated NLC SPR biosensor chips. A 54 Angstrom linker was incorporated into the
biotinylated HLA proteins in order to optimise and stabilise epitope availability in the SPR
interaction experiments and reduce non-specific binding.
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Fractions Luminex (MFI values) Concentration
(mg/ml)
SN607D8 (IHB-Hu-081)
AEC F-11/12 A2 – 23,000; A69 - 22,0000 & A68 – 23,000 1.06
AEC F-13 0.118
SN230G6 (IHB-Hu-033)
SEC F-11 A2 – 22,000; B57 – 20,000 & B58 – 18,000 0.01
SEC F-12 A2 – 19,000; B57 – 18,000 & B58 – 17,000 0.118
WK1D12 (IHB-Hu-059)
SEC 12 F B7 – 16459; B27:05 – 15479; B40:01 – 13159; B40:02 – 13792 0.47
SEC 13F B7 – 18087; B27:05 – 15722; B40:01 – 13494; B40:02 - 14179 0.44
WAR5D5 (IHB-Hu-074)
SEC 12F B7 – 18375; B27:05 – 18532 0.01
SEC 13F B7 – 18042; B27:05 - 18178 0.31
VTM9A10 (IHB-Hu-093)
SEC 12F B7 – 17744; B27:05 – 16941 0.12
SEC 13F B7 – 18083; B27:05 – 17012 0.60
VTM1F11 (IHB-Hu-045)
SEC 12F B7 – 17815; B27:05 – 14756; B40:01 – 12981; B40:02 – 13107 0.06
SEC 13F B7 – 18801; B27:05 – 15558; B40:01 – 12699; B40:02 - 12321 0.23
OUW4F11 (IHB-Hu-041)
SEC 12F B7 – 8612; B27:05 – 4381; B40:01 – 8153; B40:02 – 6899 0.01
SEC 13F B7 – 16231; B27:05 – 10099; B40:01 – 12792; B40:02 - 11478 0.23
Table 4-1 : Concentration & MFI levels of purified human monoclonal HLA-specific
antibodies (AEC – Anion exchange chromatography & SEC – Size exclusion
chromatography)
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Optimising surface plasmon resonance assay condition
Purified monoclonal HLA-specific antibodies were used to optimise surface plasmon
resonance assays for studying the binding kinetics of HLA-anti-HLA antibody interactions.
Physicochemical properties such as temperature, pH and ionic strength for optimal HLA-
antigen and antibody interactions were investigated and established.
Temperature settings for studying binding interactions
A higher temperature can increase the binding reaction rate for both association and
dissociation phases. Data from Pure Protein LLC, suggests that soluble HLA-proteins are
stable at 37o Celsius up to one hour of exposure (Figure 2-2). Hence, we compared two
temperatures to assess the effect in our SPR instrument: 22o and 37oC. It was noted that at
37oC the binding reaction reached equilibrium earlier and the dissociation curve was slightly
more pronounced compared with 22˚C, thus facilitating calculation of the dissociation rate 
(Figure 4-18). Additionally, 37oC was considered more biological due to similar body
temperature. The sensorgram data indicated that both the soluble HLA proteins immobilised
on the chips and the antibodies flowed over in solution phase were stable at 37˚C. 
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Figure 4-18 : Binding curves at 22o (A&B) and 37o (C&D) Celsius for a range of concentration of human monoclonal HLA-A2 specific antibody
(SN607D8 (IHB-Hu-081)) studied at two different ligand density (A&C – 2.5 mcg/ml and B&D – 0.25mcg/ml).
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Running buffer
PBS x 1 with pH 7.2-7.4 was chosen as the running buffer and detergent composition was
tested to examine sensorgram fidelity. The use of detergents in SPR experiments is
commonplace as a means of reducing non-specific binding artefacts during experiments and
also preventing the formation of protein deposits in the instrument’s microscale flow cells.
Occasionally, and depending on the interacting system under investigation, higher quantities
of detergent (>0.01%) are required for optimal results. Two different strengths of Tween-20
(0.05 and 0.005% v/v) were added to PBS pH 7.4. At the higher Tween-20 concentration of
0.05%, the HLA proteins showed lower reactivity to the monoclonal HLA-specific antibodies
compared with 0.005% Tween-20, indicated by reduced Rmax levels at relative
concentrations (Figure 4-19).
Figure 4-19 : HLA-A2 protein and HLA-specific antibody (IHB-HU-033 (SN230G6))
interaction at two different concentration of Tween 20 (A – 0.05% and B – 0.005%)
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Regeneration buffer selection
Following establishment of the optimal conditions for studying the binding interactions of
HLA-protein and HLA-specific antibodies, further experiments focused on identifying the most
effective regeneration buffers. These buffers are similar to elution buffers that displace the
antibody from antibody-antigen complexes without damaging or denaturing the antigen
attached to the solid matrix (in the case of affinity chromatography, the folded protein
covalently bound to the Sepharose resin). Ideally, this allows re-use of the sensor chip with
coated HLA-proteins without compromising the signal. Regeneration steps are kept as short
as possible to avoid damage to the HLA-protein; in the SPR assay we consistently used 18
seconds exposure time.
Initially, the elution conditions similar to HLA-column affinity chromatography were used for
regeneration of sensor chips, i.e. 100 mM Glycine pH 11.0. However, this was not universally
effective. As seen in the Figure 4-20, binding of monoclonal HLA-specific antibodies differed
in regeneration; IHB-HU-033 (SN230G6) binding showed incomplete regeneration with 100
mM glycine whilst IHB-HU-081 (SN607D8) had complete regeneration. Hence other
regeneration conditions were studied.
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Figure 4-20 : Regeneration of HLA-protein coated sensor chip using Glycine (100nM, pH 11.0) A – IHB-HU-081 (SN607D8) showed complete
regeneration B – IHB-HU-033 (SN230G6) – incomplete regeneration
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High pH regeneration - 10 mM sodium hydroxide pH 14
The use of 10 mM sodium hydroxide pH 14 resulted in removal of antibody bound to the HLA-
protein as shown in Figure 4-21. However, denaturation of HLA protein was evident as there
was no binding of monoclonal HLA-specific antibody following treatment with sodium
hydroxide (Figure 4-22).
Figure 4-21 : Regeneration buffers R1 – Glycine 100mM pH 11.0 and R2 – NaOH; shows
elution of IHB-HU-033 (SN230G6) with NaOH but not with glycine pH 11.0 (compared to
IHB-HU-081 (SN607D8) – orange colour).
Figure 4-22 : Lack of binding following prior NaOH regeneration
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High ionic strength regeneration - 1 M NaCl and 1 M MgCl2
The 1M NaCl buffer alone did not have any regeneration effect on monoclonal antibody IHB-
HU-081 (SN607D8) (Figure 4-23, regeneration R1). The combination of 1M NaCl and 100mM
Glycine (pH 11.0) was attempted with the very tight IHB-HU-033 (SN230G6) monoclonal
interactions with HLA-A2 protein, but the addition of 1 M NaCl did not result in any
improvement in regeneration (see Figure 4-24).
Figure 4-23 : Regeneration buffers R1 –1 M NaCl alone and R2 – 1M NaCl and Glycine
100mM pH 11.0; shows elution of IHB-HU-081 (SN607D8) with Glycine but not with NaCl
Figure 4-24 : Regeneration buffers; R1 - 1M NaCl and Glycine 100mM pH 11.0; shows
release of IHB-HU-081 (SN607D8) but not with IHB-HU-033 (SN230G6); and R2 – 1 M MgCl2
had no effect on regeneration of IHB-HU-033 (SN230G6)
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Other regeneration buffers – Acetate, CHAPS and chaotrope 4 M MgCl2
Additional regeneration buffers - 10mM sodium acetate pH 5.5, 20 mM CHAPS (a non-
denaturing Zwitterionic detergent) and the very ionic strength chaotrope 4 M MgCl2 were
attempted. The sodium acetate and CHAPS had no regeneration effect and following 4 M
MgCl2, there was complete denaturation of the HLA-protein (Figure 4-25).
Figure 4-25 : HLA-protein denaturation following treatment with 4 M MgCl2 step -
subsequent run with two monoclonal HLA-specific antibody did not have any binding to
HLA-A2 protein.
Vigorous regeneration conditions necessary for release of certain antibodies resulted in
damage to HLA-protein and hence further attempts at regeneration in these cases were
closed. 100mM Glycine pH 11.0 was used as the best general regeneration buffer and if no
regeneration occurred in certain HLA protein/antibody binding experiments, then further
experiments was carried out using an adjacent, uncoupled sensor channel or a fresh sensor
chip.
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Established protocol standards for real-time kinetic experiments
Step 1 – Preparation
Running Buffer - PBS-Tween 0.005% (0.05 ml of TWEEN-20 in 1L PBS, pH 7.4) – filtered(0.45 µm filter) and degassed prior to use.
Samples - centrifuged 13000 rpm for 10 minutes prior to running on SPR.
Step 2 – Ligand immobilisation
Biotinylated HLA protein used at 2.5 or 0.25 µg/ml is immobilised on chip with flow rateof 25 µl/min over 300 seconds. A volume of 150 µl for each sample is required for thisstep and taking in to account of void volume intrinsic to the instrument, the total volumeof ligand solution required is 250 µl.
Step 3 - Association
The samples are pipetted in the sample rack (sampler temperature – 22oC) and themachine aspirates and goes through the fluidics and finally over the chip at rate of 25
µl/min for 960 seconds (at 37oC). This will require 400 µl of sample for the associationand taking in to account of void fill, one will require 600 µl of sample per well.
Step 3 - Dissociation
The running buffer (PBS-T) is passed over for 960 seconds at a flow rate of 25 µl/min.
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Step 4 - Regeneration
Regeneration buffer (100 mM Glycine pH 11.0) is passed through at rate of 100 µl/minfor 18 seconds.
Step 5 – Data fitting and kinetic analysis
The Biorad XPR36 ProteOn Manager software was used to fit data to sets of establishedkinetic algorithms. Equilibrium analysis was used to calculate equilibrium dissociation
constants (KD) and kinetic analysis using bivalent analyte or heterogonousligand/analyte model were used to obtain the kinetic association (ka) and dissociation(kd) rates that can also be used to calculate KD via an alternative route using the simpleequation - KD = kd / ka.
Experiments were performed using two ligand (biotinylated HLA) densities (loading
concentrations of 2.5 and 0.25 µg/ml yielding loading level Response Maxima (RU; Rmax)
values of 1200 and 400 respectively) using the NLC sensor chip. Ranges of concentration of
analyte (HLA-specific antibodies) were tested against the different ligand densities. The
concentrations of monoclonal HLA-specific antibodies ranged from 1.6 to 100 nM.
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Data analysis and estimation of affinity parameters
Data obtained from the experiments can be processed within the Proteon Manager Software
suite and also exported into Microsoft Excel for potential analysis using a remote system.
Equilibrium analysis
A range of concentrations of HLA-specific antibody analyte is allowed to interact with
constant amount of immobilised HLA-protein and until equilibrium or near-equilibrium is
reached (see Figure 4-26 & 4-27). The Rmax (maximum RU at a particular concentration at a
particular time point) is plotted against the concentration to obtain curve for equilibrium
analysis and apparent KD is obtained (see Chapter 1-9). A lower KD indicates higher binding
affinity.
Using this method, the apparent KD value of HLA-A2 interaction with IHB-HU-033 (SN230G6)
(2.39 E-09 M) is lower than IHB-HU-081 (SN607D8) (3.975 E-09 M) by a factor of 1.67. The
data suggests IHB-HU-033 (SN230G6) has stronger affinity for HLA-A2 compared to IHB-HU-
081 (SN607D8). The apparent KD calculated from higher concentration of monoclonal
antibodies may not be accurate as seen the values were spread out compared to lower
concentrations for both antigen/ligand densities over the chip. This is secondary to steric
hindrance at higher concentration of antibody competing for the same epitope over the
antigen. However the estimation from lower concentration may be not accurate either as the
reactions did not reach equilibrium.
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Figure 4-26 : Equilibrium analysis of SN607D8 (IHB-Hu-081) at different concentration
against two different HLA protein densities (A&C – 2.5 µg/ml and B&D – 0.25 µg/ml).
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Figure 4-27 : Equilibrium analysis of SN230G6 (IHB-Hu-033) at different concentration
against two different HLA-protein density (A&C – 2.5 mcg/ml and B&D – 0.25 mcg/ml).
Kinetic analysis
Langmuir with mass transport and bivalent analyte models was used for analysis of binding
kinetics for monoclonal HLA-specific antibodies tested individually (Muller et al., 1998).
Kinetic analysis of SN230G6 interactions with HLA-A2 (IHB-Hu-033)
The experiments were performed at two ligand densities described in Section 3.3 and shown
in Figures 4-28 and 4-30 respectively. Concentrations of IHB-HU-033 (SN230G6) used in these
experiments ranged between 12.5 and 100 nM (A-B) and 1.6 to 12.5 nM (C-D). Data fitted
using the bivalent analyte model (B and D) was better compared to the simpler Langmuir with
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
199
mass transport model (A and C) as seen by the better quality of residuals except the
combination of lower ligand and lower concentration experiments from Figure 4-30;D. (Figure
4-29 and 4-31). Kinetic binding parameters obtained from the anlaysis are shown in Table 4-
2.
Model HLA-A2 Ligand
density
Concentration range
of IHB-HU-033
(SN230G6)
Kinetic rate KD
Langmuir
with Mass
transport
2.5 µg/ml 100 to 12.5 nM ka : 6.3E+05 1/Ms
Kd : 1.55E-04 1/s
2.44E-10 M
12.5 to 1.6 nM ka : 1.07E+06 1/Ms
Kd : 1.74E-04 1/s
1.63E-10 M
0.25 µg/ml 100 to 12.5 nM ka : 1.07E+06 1/Ms
Kd : 2.70E-04 1/s
2.52E-10 M
12.5 to 1.6 nM ka : 4.16E+05 1/Ms
Kd : 2.49E-03 1/s
5.98E-09 M
Bivalent
analyte
2.5 µg/ml 100 to 12.5 nM ka : 2.87E+05 1/Ms
Kd : 7.25E-04 1/s
2.53E-09 M
12.5 to 1.6 nM ka : 6.95E+05 1/Ms
Kd : 5.01E-05 1/s
7.21E-11 M
0.25 µg/ml 100 to 12.5 nM ka : 2.13E+06 1/Ms
Kd: 1.54E-04 1/s
7.25E-11 M
12.5 to 1.6 nM ka : 1.12E+06 1/Ms
Kd : 1.18E-04 1/s
1.05E-10 M
Table 4-2: Binding kinetics of IHB-HU-033 (SN230G6) using different kinetic models
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Figure 4-28 : Langmuir with mass transport (A and C) and Bivalent analyte (B and D) model fitted to the kinetic data obtained from IgG
monoclonal HLA-A2 specific antibody (IHB-HU-033 (SN230G6)) at higher ligand concentration (HLA-A2 = 2.5 µg/ml).
Figure 4-29 : Residual plots for kinetic model fittings corresponding to the Figure 4-28.
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Figure 4-30 : Langmuir with mass transport (A and C) and Bivalent analyte (B and D) model fitted to the kinetic data obtained from IgG
monoclonal HLA-A2 specific antibody (IHB-HU-033 (SN230G6)) at lower ligand concentration (HLA-A2 = 0.25 µg/ml).
Figure 4-31 : Residual plots for kinetic model fittings corresponding to the Figure 4-30
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Kinetic analysis of SN607D8 interactions with HLA-A2 (IHB-Hu-081)
Similar to previous sets of experiments, binding kinetics of HLA-A2 specific monoclonal
antibody SN607D8 were studied at two different concentration of antigen density and at
antibody concentration range of 100 to 6.25 nM (A-B) and 6.25 to 1.6 nM (C-D) (Figures 4-32
and 4-34 respectively). Data fitting using Bivalent analyte model (B&D) was better compared
to Langmuir with mass transport model. Kinetic binding values obtained from the analysis are
shown in the Table 4-3.
Model HLA-A2
Ligand
density
Concentration range
of SN607D8 (IHB-Hu-
081)
Kinetic rate KD
Langmuir
with Mass
transport
2.5 µg/ml 100 to 6.25 nM ka : 2.76E+05 1/Ms
kd : 2.61E-04 1/s
9.44E-10 M
6.25 to 1.6 nM ka : 5.52E+05 1/Ms
kd : 1.58E-04 1/s
2.86E-10 M
0.25 µg/ml 100 to 6.25 nM ka : 4.46E+05 1/Ms
kd : 2.83E-04 1/s
6.34E-10 M
6.25 to 1.6 nM ka : 6.59E+05 1/Ms
kd : 1.15E-04 1/s
1.75E-10 M
Bivalent
analyte
2.5 µg/ml 100 to 6.25 nM ka : 1.43E+05 1/Ms
kd : 6.62E-04 1/s
4.63E-09 M
6.25 to 1.6 nM ka : 2.69E+05 1/Ms
kd : 1.89E-04 1/s
7.01E-10 M
0.25 µg/ml 100 to 6.25 nM ka : 1.38E+05 1/Ms
kd : 2.454E-03 1/s
1.78E-08 M
6.25 to 1.6 nM ka : 2.29E+05 1/Ms
kd : 3.13E-04 1/s
1.36E-09 M
Table 4-3 : Binding kinetics of SN607D8 (IHB-HU-081) using different kinetic models
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Figure 4-32 : Langmuir with mass transport (A and C) and Bivalent analyte (B and D) model fitted to the kinetic data obtained from IgG
monoclonal HLA-A2 specific antibody (IHB-HU-081 (SN607D8)) at higher concentration (HLA-A2 = 2.5 µg/ml).
Figure 4-33 : Residual plots for kinetic model fitting corresponding to the Figure 4-32
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Figure 4-34 : Langmuir with mass transport (A and C) and Bivalent analyte (B and D) model fitted to the kinetic data obtained from IgG
monoclonal HLA-A2 specific antibody (IHB-HU-081 (SN607D8)) at lower concentration (HLA-A2 = 0.25 µg/ml).
Figure 4-35 : Residual plots for kinetic model fitting corresponding for the Figure 4-3.
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Comparison of average apparent KD from the kinetic analysis shows the IHB-HU-033
(SN230G6) monoclonal antibody (KD = 2.77 nM) is 2.5 times stronger than IHB-HU-081
(SN607D8) (7.08 nM). This is secondary to faster association rate of IHB-HU-033 (SN230G6)
compared to IHB-HU-081 (SN607D8) antibody.
EC50 estimation using ELISA
Sandwich ELISA described in chapter 2 was used to calculate effective concentration of
antibody that gave fifty percent of maximal response (EC50). In equilibrium, the concentration
corresponding to the EC50 is equal to apparent KD. Both the HLA-A2 specific monoclonal
antibodies were tested in triplicates to derive the titration curve (Figure 4-36).
Figure 4-36 : Titration curve showing relationship between the concentration and relative
absorbance measured in ELLISA assay for HLA-A2 specific monoclonal antibodies
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Comparison of EC50 of the two monoclonal antibodies show the IHB-HU-033 (SN230G6) is 3.7
times stronger than IHB-HU-081 (SN607D8). EC50 values were 15.68 and 58 for SN230G6 and
SN607D8 respectively.
Sensitivity, specificity and Reproducibility of assay
Sensitivity
Sensitivity depends to some extent upon the ligand density on the sensor chip. A lower ligand
density has added advantages to signal quality as discussed in Chapter 2.7. Monoclonal HLA-
specific antibodies were diluted down to 1.6 nM and tested against ligand density of 0.25
µg/ml. (Figure 4-37).
Figure 4-37 : Sensitivity of SPR assay – distinct signal with lowering concentration of
monoclonal HLA-specific antibody
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Upper limit of detection
Higher concentration of monoclonal HLA-specific antibodies resulted in blunting of maximal
response of antigen-antibody binding. Both saturation and hook effects were observed. In
hook effect, higher concentration of analyte results in reduction or inhibition of binding
responses. As seen in Figure 4-38 (A), a concentration of 150 nM of monoclonal HLA-specific
antibodies resulted in hooking effect for interaction with HLA-A2 protein. However this
depends on the HLA-proteins such that despite same epitope interactions, there was
increment effect on interaction with HLA-A69 protein (Figure 4-38 (B)).
Figure 4-38 : Binding responses to higher concentration of monoclonal HLA-specific
antibodies to HLA-A2 (A) and HLA-A69 (B) proteins
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Specificity
Two monoclonal human HLA-specific antibodies with known reactivity to specific HLA
proteins on Luminex and CDC assay were tested on surface plasmon resonance assay for
specificity. As seen in Figure 4-39, SN607D8 (IHB-Hu-081) had binding to A2, A68 & A69 but
not to A1 and B57 proteins, and similarly SN230G6 (IHB-Hu_033) bound to A2 and B57 but
not to A1, A68 or A69. The binding pattern was consistent with the reactivity on Luminex and
CDC assays, and also with the epitope distribution associated with the alleles used in the
experiments.
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Figure 4-39 : Binding reactivity of two human monoclonal HLA-specific antibodies against different HLA proteins
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Reproducibility
Binding experiments were done in duplicates for both the human monoclonal anti-HLA-A2
antibodies and kinetic values were calculated using Langmuir with mass transport and
bivalent analyte models. Differences in KD and standard deviation between experiments are
shown in Table 3-4 and Table 3-5.
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Table 4-4: Binding kinetics from two separate experiments for assessment of reproducibility (SN230G6)
Model HLA-A2 density Concentration range (nM) KD1 (nM) KD2 (nM) AVG KD (nM) StdDev
SN230G6 (IHB-Hu-033)
Langmuir with
Mass transport
2.5 µg/ml 100 to 12.5 2.66E-10 2.44E-10 2.55E-10 1.56E-11
12.5 to 1.6 1.63E-10 1.63E-10
0.25 µg/ml 100 to 12.5 2.52E-10 2.76E-10 2.64E-10 1.70E-11
12.5 to 1.6 1.33E-10 0.725E-10 1.03E-10 4.28E-11
Bivalent analyte 2.5 µg/ml 100 to 12.5 1.74E-09 2.53E-09 2.14E-09 5.59E-10
12.5 to 1.6 6.50E-11 7.21E-11 6.86E-11 5.02E-12
0.25 µg/ml 100 to 12.5 5.98E-09 3.77E-09 4.88E-09 1.56E-09
12.5 to 1.6 1.10E-10 1.05E-10 1.08E-10 3.54E-12
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Table 4-5: Binding kinetics from two separate experiments for assessment of reproducibility (SN607D8)
Model HLA-A2 density Concentration range
(nM)
KD1 (nM) KD2 (nM) AVG KD (nM) StdDev
SN607D8 (IHB-Hu-081)
Langmuir with Mass
transport
2.5 µg/ml 100 to 6.25 9.44E-10 7.27E-10 8.36E-10 1.53E-10
6.25 to 1.6 1.33E-10 2.86E-10 2.10E-10 1.08E-10
0.25 µg/ml 100 to 6.25 6.34E-10 5.23E-10 5.79E-10 7.85-11
6.25 to 1.6 1.75E-10 9.30E-11 1.34E-10 5.80E-11
Bivalent analyte 2.5 µg/ml 100 to 6.25 1.46E-09 4.63E-09 3.05E-09 2.24E-09
6.25 to 1.6 5.63E-10 7.01E-10 6.32E-10 9.76E-11
0.25 µg/ml 100 to 6.25 1.78E-08 1.31E-08 1.55E-08 3.32E-09
6.25 to 1.6 1.36E-09 1.09E-09 1.23E-09 1.91E-10
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Discussions
Biosensor based assay can be successfully applied to measure binding kinetics and binding
strength in real time. Using two HLA-A2 specific monoclonal antibodies, the experiments
described in this chapter established optimal conditions to study the binding kinetics.
Sensitivity of SPR is quoted in pico-molar range for kinetic analysis (Bravman et al., 2008) but
for purpose of affinity determination 1 to 100 nM is sufficient. Specificity of assay is consistent
with quality of HLA-protein used and shows clear epitope fashion binding (Figure 4-39). Upper
limit of detection of the assay is dependent on the ligand density and is limited by steric
hindrance at higher concentration (Figure 4-38). The experiments also demonstrated
importance of purification of monoclonal HLA-specific antibodies. Following establishment of
protocol to study binding kinetics, demonstrated the assay was sensitive down to 1.6 nM
concentrations of antibodies (with the antigen density at 0.25 mcg/ml) and was specific to
intended HLA-proteins. The difference in apparent KD calculated using equilibrium and kinetic
analysis was similar to obtained from sandwich ELISA.
Purification of monoclonal HLA-specific antibodies provided generously in culture
supernatant by University of Leiden required a two-step protocol (affinity purification
followed by either ion exchange or size exclusion chromatography). Single step using HLA-
specific affinity chromatography had non-specific impurities that resulted in non-specific
binding on the sensor chips and inaccurate calculation of antibody concentration using
protein assays. It was interesting to observe the difference in requirements for purification of
different monoclonal HLA-specific antibodies despite all been IgG1 isotype. The difference in
charges of monoclonal antibodies attributed to different ion exchange chromatography
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technique. IHB-HU-081 (SN607D8) bound to anion exchange resin compared to IHB-HU-033
(SN230G6) bound to cation exchange resin. The only structural difference between them was
difference of light chains; IHB-HU-081 (SN607D8) had κ-light chain compared to IHB-HU-033 
(SN230G6) which has λ-light chains. The binding of IHB-HU-033 (SN230G6) to HLA-proteins 
on sensor chip could not be disrupted using 100mM Glycine at pH 11.0. And finally the
apparent KD was lower for IHB-HU-033 secondary to faster association rate. The third
monoclonal HLA-specific antibody IHB-Hu-059 (WK1D12) had two peaks with anion exchange
chromatography and hence size exclusion chromatography was used. This suggests the
charge and binding strength of monoclonal HLA-specific antibodies dictates the purification
protocols. However, both of these monoclonal antibodies interacted with different epitopes
on HLA-A2 proteins and the difference could just be due the difference in structural epitope
itself.
Optimal conditions for binding studies were established and the data from forced degradation
study by Pure Protein LLC at Oklahoma, USA (Chapter -2) were a useful guide. Temperature
of 37o C was chosen as it was physiological temperature. Both association and dissociation
rates increased with increase in temperature from 22 to 37 oC. This may suggest that the
increase in temperature facilitated more hydrophilic interactions. Also at 22 oC there was
minimal dissociation for monoclonal antibodies which would make calculation of dissociation
rate difficult in the set time of 960 seconds. Thus for the above reasons further experiments
were carried out at 37 oC. Higher Tween-20 concentration resulted in reduction of specific
binding and hence a concentration of 0.005% was chosen for the running buffer. The most
difficult part was regeneration condition and this was limited by damage of HLA-proteins in
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harsh conditions. Increase in ionic concentration (1 M) did not help to disrupt the binding of
IHB-HU-033 to HLA-A2 proteins whilst other conditions such as sodium bicarbonate or higher
ionic concentration (2-4 M) resulted in damage to HLA-proteins with subsequent reduction
or abolishment of binding response. This resulted in continuing use of 100 mM Glycine at pH
11.0 irrespective if it allowed disruption of binding or not. Where the regeneration buffer was
not effective the sensor chip was not re-used.
Both the monoclonal HLA-A2 specific antibodies were studied using equilibrium, kinetic
analysis using data from surface plasmon resonance and dose response curves using sandwich
ELISA. All three analyses showed that IHB-HU-033 (SN230G6) monoclonal antibodies against
HLA-A2 (epitope 62G) were stronger with higher affinity compared to IB-Hu-081 (SN607D8,
epitope 142T). The absolute values obtained differed due to different assumptions used. For
the equilibrium analysis ideally the experiments are required to be conducted until all the
samples with range of concentration reaches equilibrium and then the values obtained using
such a state should be used to derive dissociation constant. This depends on the association
rate and for the antibodies with faster association rate, this can be achieved easily. The
duration of association will be prolonged due to flow component of the biosensor assay used
here. This is limited due to scare availability of the purified material. Hence the values
obtained using kinetic analyses are more reliable. However, the challenge with kinetic
analysis is the appropriate and precise mathematical model used to fit the data. As shown in
these experiments Langmuir model based on 1:1 binding assumptions does not give better fit
and the bivalent analyte model improves these fits.
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Although the apparent KD values obtained have lesser standard deviation, coefficient of
variation is high at 160 to 190 %. This is due to comparison of KD obtained from different
combination of ligand and analyte concentration. At higher concentration of analyte, steric
hindrance blunt the binding responses such that the maximal response units are similar for
higher dilution of the antibodies. The coefficient of variance was better for lower
concentration of analyte (39 to 50 %) compared to higher antibody concentrations (64 to 84
%). There was no difference on comparing between low and high density ligand lanes. Hence
a lower density lane with lower concentration is better conditions to study monoclonal HLA-
specific antibodies due to lesser steric hindrance. This will improve the mathematical model
fitting and increase in accuracy of the estimates. The data obtained through these
experiments are used to develop newer mathematical models in collaboration with school of
engineering (Evans et al., 2013).
Conclusion:
Surface plasmon resonance assay can be optimised to study interaction of HLA-protein and
HLA-specific antibodies. The binding kinetics and dissociation constant (KD) were quantified
with mathematical model such as bivalent analyte model.
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Binding kinetics of epitope-paratope
interactions
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Recent studies have indicated that HLA-specific antibody reactivity (antigenicity) can differ
between different HLA alleles that possess the same defined epitopes and thus support
ostensibly the same epitope-paratope interactions (Duquesnoy et al., 2013). Using HLA class
I specific monoclonal antibodies (mainly of the IgM class), the study concluded that the
binding strength of epitope-paratope interactions may differ between different HLA proteins
and that this binding strength may influence the subsequent activities of these antibodies
within C1q-binding and CDC assays. Duquesnoy et al., proposed the concept of functional and
structural epitopes (chapter 1) and according to this the specific binding of paratope
(antibody) is with three amino acid residues on functional epitope but there is also non-
specific binding between other amino acid residues around the functional epitopes with the
CDR loops on the variable portion of the antigen constituting the structural epitope. As the
stability of binding depends on the best fit and the overall surface area interacting, the
structural epitope determines the binding strength / affinity. The study speculated that there
is higher energy released during the binding is proportional to the binding strength of the
interactions and this released free energy brings conformational change in the Fc portion of
the antibody molecule to enhance the binding of complement.
The real-time biosensor assay based on the surface plasmon resonance principle, described
in Chapter 4, provides an ideal opportunity to study and explore whether binding kinetics
differ between different HLA protein-HLA-specific antibody pairings that possess the same
epitope-paratope combinations. If possible, this would be a valuable tool to assess the
reactivity of HLA-specific antibodies to a particular HLA-antigen and potentially predict its
effector function activity. Simultaneously, we aim to determine whether the intrinsic binding
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kinetics and affinities of different IgG human monoclonal HLA-specific antibodies can be
distinguished quantitatively. Heterogeneity in these parameters could pioneer efforts to
correlate specific allele- and epitope-binding patterns with affinity and clinical outcome
following kidney transplantation. Additionally, we aim to investigate whether the SPR
biosensor platform can be used to study competitive binding in real time of separate antibody
clones with reactivity towards the same HLA protein. This is particularly helpful to assess the
relative affinities of HLA-specific antibodies in the context of their epitope specificities.
Aim
1. To determine the binding kinetics and affinities of IgG human monoclonal HLA-
specific antibodies using a real time assay platform.
2. To establish whether binding kinetics of the same epitope-paratope interactions
differ between different HLA haplotypes.
3. To explore whether dual and/or competitive binding of HLA-specific antibodies can
be studied using surface plasmon resonance and to study the effects on overall
affinity by mixing two different monoclonal antibodies with the same HLA haplotype
specificity.
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Method and materials:
The mouse IgG anti-human HLA Class I monoclonal antibody W6/32) was tested against range
of class-I HLA proteins. Similarly, five human IgG HLA Class I-specific antibodies were kindly
obtained from the University of Leiden (F Claas and A Mulder). See Table 5-1. These antibodies
were produced by hybridoma derived from B-cell that produced antibodies following
exposure of foetal HLA-types; described as immunising antigens.
Clone (ID) Immunising
Ag
HLA-specificity
defined by CDC
Epitope HLA
proteins
testedSN203G6(IHB-Hu-033) A2/B57 A2/B17 (B57,58) 62G A2 & B57SN607D8(IHB-Hu-081) A2/B57 A2/A28 (A68,69) 142T --H A2, A68 &A69WK1D12(IHB-Hu-059) B27 B27,7,60 163EW B7 &B27:05VTM1F11(IHB-Hu-045) B7 B27,7,60 163E B7, B27:05& B40:01WAR5D5(IHB-Hu-074) B27 B7,27,42,55 62RN-QIY and62R—QIC B7 &B27:05
Table 5-1 : Human monoclonal HLA-specific antibodies used for studying difference in
binding kinetics between different alleles.
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The immobilisation densities of all the HLA proteins on the sensor chips were kept constant
at a response unit level of 400 during the experiments. The human monoclonal HLA-specific
antibodies were used over the concentration range of 1.6 – 100 nM. Experiments and analysis
of binding data followed the protocols described in Chapter 4.
Results:
Binding kinetics of IgG monoclonal HLA-specific antibodies and
interactions with different HLA proteins
Mouse anti-human class-I HLA specific monoclonal antibody (W6/32)
The W6/32 antibody binds to a conformational epitope formed by residue 3 arginine amino
acid of β2 microglobulin and residue 121 on alpha-1 of the heavy chain of Class I HLA molecule 
(Ladasky et al., 1999). Interactions of W6/32 were studied against HLA proteins (Figure 5-1).
The apparent KD values calculated using bivalent analyte model and equilibrium analysis are
shown in Table 5-2. Interesting, the highest affinity (i.e. lowest KD value) is observed for HLA-
B57 (up to 3-fold lower KD) and a component of this appears to be attributable to both a faster
association rate and slower dissociation rate compared with the interactions with other HLA
haplotypes.
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W6/32 – HLA protein Bivalent analyte
Kinetics
Bivalent
analyte
KD
Equilibrium
KD
HLA-A2 ka = 1.14E+05 1/Ms
kd = 5.48E-04 1/s 4.80E-09 M 1.31E-08 M
HLA-A69 ka = 1.12E+05 1/Ms
kd = 6.64E-04 1/s 5.96E-09 M 8.75E-09 M
HLA-B57 ka = 2.07E+05 1/Ms
kd = 4.13E-04 1/s 2.00E-09 M 6.10E-09 M
HLA-A1 ka = 1.72E+05 1/Ms
kd = 4.79E-04 1/s 2.78E-09 M 1.65E-08 M
Table 5-2: Binding parameters of interactions of W6/32 with respective HLA proteins
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Figure 5-1 : W6/32 binding to HLA proteins (bivalent analyte model fits are shown as solid lines)
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Human monoclonal HLA-specific antibodies interactions with HLA-class I
proteins
6. SN607D8 (IHB-Hu-081)
SN607D8 is an IgG1 human monoclonal HLA-specific antibody with reactivity against the A2,
A68 & A69 haplotypes. The principal immunising antigen is HLA-A2, but SN607D8 has been
shown to bear specificity for the 142T epitope that is shared between HLA-A2,-68 & -69 but
not present on –B57 (Figure 4-33). Figure 5-2 shows reactivity to the respective proteins.
Figure 5-2 : SN607D8 binding to HLA proteins with data fitting using the bivalent analyte
model indicated as solid lines.
SN607D8 – HLA
protein
Bivalent analyte
Kinetics
Bivalent analyte
KD
Equilibrium
KD
HLA-A2 ka = 4.53E+04 1/Ms
kd = 5.05E-04 1/s 1.12E-08 M 2.65E-08 M
HLA-A68 ka = 4.46E+04 1/Ms
kd = 1.07E-03 1/s 2.41E-08 M 1.87E-08 M
HLA-A69 ka = 5.43E+04 1/Ms
kd = 4.94E-04 1/s 9.11E-09 M 2.63E-08 M
Table 5-3: Binding parameters of interaction of SN607D8 to HLA proteins
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Binding kinetics revealed that affinity values were similar for HLA-A2 and -69, and two-fold
higher compared to HLA-A68. The dissociation constant obtained from equilibrium analysis
showed similar findings. The association rate (ka) was highest for interactions with HLA-A69
and the dissociation rate was slower for interactions with HLA-A2 & A69 compared to HLA-
A68 (Table 5-3).
7. SN230G6 (IHB-Hu-033)
SN230G6 is an IgG1 human monoclonal HLA-specific antibody produced from the same
patient as for SN607D8 but interacts with A2, B57 & A58 class I HLA proteins. The immunising
antigens were HLA-A2 and –B57 and the epitope specificity is for 62G (which is absent on HLA-
A68 & -69) (Figure 4-33). Figure 5-3 shows binding data with respect to these proteins.
Figure 5-3. SN203G6 binding to HLA proteins with data fitting via the bivalent analyte
model shown as solid lines.
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SN230G6 – HLA protein Bivalent analyte
Kinetics
Bivalent
analyte
KD
Equilibrium
KD
HLA-A2 ka = 3.66E+05 1/Ms
kd = 6.48E-04 1/s 1.77E-09 M 2.72E-09
HLA-B57 ka = 4.27E+05 1/Ms
kd = 6.92E-04 1/s 1.62E-09 M 2.43E-09
Table 5-4 : Binding parameters of interaction of SN230G6 to the respected HLA-proteins
Binding data for SN230G6 were shown to be very similar between HLA-A2 & -B57, with closely
matching association and dissociation rate constants (Table 5-4). The dissociation constants
were similar for interactions with HLA-A2 and HLA-B57 measured by both bivalent analyte
model and equilibrium analysis.
8. WK1D12 (IHB-Hu-059)
WK1D12 is an IgG1 human monoclonal HLA-specific antibody that is directed against the HLA-
B7, B27 and B60 proteins. The immunising antigen is HLA-B27 and the specific epitope is
163EW. Figure 5-4 shows reactivity to HLA-B7 and –B27. The KD values calculated using the
bivalent analyte mathematical model and equilibrium analysis are shown in Table 5-5.
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Figure 5-4 : WK1D12 binding to HLA-protein- B7 &-B27 (with data fitting via bivalent
analyte model in solid lines)
WK1D12 – HLA protein Bivalent analyte
Kinetics
Bivalent
analyte
KD
Equilibrium
KD
HLA-B27 ka = 9.69E+04 1/Ms
kd = 3.34E-04 1/s
3.45E-09 M 1.00E-08
HLA-B7 ka = 1.43E+05 1/Ms
kd = 8.14E-04 1/s
5.89E-09 M 8.28E-09
Table 5-5 : Kinetic (Bivalent analyte) analysis of interaction of WK1D12 to the respected
HLA-proteins
The binding strength is 1.7 times higher for interactions with the immunising antigen HLA-
B27 compared to HLA-B7. The key contributing component causing the difference is the
slower dissociation rate (kd) for the interaction with HLA-B27 (Table 5-5).
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9. VTM1F11 (IHB-Hu-045)
VTM1F11 is an IgG1 human monoclonal HLA-specific antibody directed against the B7, B27
and B40:01 HLA Class I proteins. The immunising antigen is HLA-B7 and the specific epitope is
163E. Figure 5-5 shows the interactions of VTM1F11 with these proteins. The kinetic values
calculated using the bivalent analyte model and equilibrium analysis are shown in Table 5-6.
Figure 5-5 : Binding kinetics of VTM1F11 MAb against the HLA proteins B7, B27 & B40:01.
(Lines corresponds to concentration of the monoclonal antibodies – 100nM, 50 nM and 25
nM from top to bottom respectively).
VTM1F11 – HLA protein Bivalent analyte
Kinetics
Bivalent
analyte
KD
Equilibrium
KD
HLA-B7 ka = 4.43E+07 1/Ms
kd = 1.78E-02 1/s 4.01E-10 M 2.53E-09 M
HLA-B27:05 ka = 2.46E+06 1/Ms
kd = 9.40E-03 1/s 3.81E-09 M 6.87E-09 M
HLA-B40:01 ka = 1.54E+06 1/Ms
kd = 6.14E-03 1/s 3.99E-09 M 1.08E-09 M
Table 5-6 : Kinetic data for the interaction of VTM1F11 with the cognate HLA proteins
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The binding strength calculated using bivalent analyte kinetic model appears to be 10-fold
higher for VTM1F11 interactions with immunising antigen HLA-B7 compared to HLA-B27 and
–B40:01. This appears to be due to a faster association rate (ka) for interaction with HLA-B7
compared to other two.
10. WAR5D5 (IHB-Hu-074)
WAR5D5 is a human IgG1 monoclonal HLA-specific antibody directed against B7 and B27 class
I HLA proteins. The immunising antigen is HLA-B27 and the specific epitope is 62RN. Figure 5-
6 shows its interactions with the respective proteins. The KD values have been calculated using
the bivalent analyte model and equilibrium analysis are summarised in Table 5-7.
Figure 5-6 : Binding curves of WAR5D5 Mab against HLA-proteins B7 & B27. (lines
corresponds to concentration of the monoclonal antibodies – 100nM, 50 nM and 25 nM
from top to bottom respectively).
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WAR5D5 – HLA protein Bivalent analyte
Kinetics
Bivalent
analyte
KD
Equilibrium
KD
HLA-B27 ka = 3.10E+05 1/Ms
kd = 4.72E-03 1/s 1.52E-08 M 1.72E-09 M
HLA-B7 ka = 1.51E+05 1/Ms
kd = 1.94E-03 1/s 1.29E-08 M 1.11E-08 M
Table 5-7 : Kinetic data of interactions of WAR5D5 with HLA proteins
The apparent binding affinity is slightly higher for interactions with immunising antigen HLA-
B27 and this is due to faster association rate which is almost double compared to the
interactions with HLA-B7.
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EC50 analysis
The monoclonal HLA-B7 specific antibodies were analysed using sandwich ELISA for the
difference in relative binding strength using EC50 measurements. The EC50 analysis comparing
HLA-A2 specific monoclonal is shown in chapter 4 (Figure 4-30). Experiments were carried out
in triplicates and dose response curve was analysed as shown in Figure 5-7.
Figure 5-7 : Sandwich ELISA experiments for measurement of relative strength of
monoclonal HLA-specific antibodies (EC50)
The EC50 value for interaction between WK1D12 and HLA-B7 was 37.4 compared to 8.41 for
WAR5D5 monoclonal HLA-B7 specific antibody. Thus WAR5D5 is 4.5 times stronger than
WK1D12. Monoclonal OUW4F11 had very minimal binding suggesting weaker affinity
compared to other monoclonal HLA-B7 specific antibodies.
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Measurement of the thermodynamics parameters of antibody binding
The thermodynamics of protein-protein interactions provide vital information relating to the
binding energies involved and yield quantitative data pertaining to the energetic favourability
of a particular interaction. This information has not been obtained previously for HLA/HLA-
specific antibody interactions using real-time and quantitative techniques and thus warrants
exploration. A valuable feature of the XPR36 biosensor instrument is its ability to measure
binding kinetics over a range of temperatures, from which thermodynamic parameters (such
as enthalpy and entropy) can be determined via algorithms such as Van’t Hoff analysis. It has
therefore been possible to perform preliminary experiments aimed at probing not only the
kinetic but also the thermodynamic properties of HLA-specific antibodies.
For this sets of experiments human monoclonal HLA-A2 specific antibody (SN607D8 (IHB-Hu-
081)) was used and interactions were studied with HLA-A2 protein at a range of temperatures
(15 to 40 oC). The binding data obtained were analysed bivalent analyte model (Figure 5-8).
As expected, the dissociation rates (kd) and association rates (ka) increased with increasing
the temperature (Table 5-8 and Figure 5-9). The dissociation rates increase more markedly as
a function of temperature compared with the association rates, hence KD values increase with
increasing temperature, and overall affinity decreases. However, interactions with HLA-A68
did not show a steady trend and this may reflect effects of temperature on certain epitope-
antibody interactions (Johnstone et al., 1990), or the need for optimisation. Interestingly, the
fidelity of fitting the data using the bivalent analyte model varied with temperature such that
better fits were observed below 30˚C. As seen in Figure 5-8, residuals were less pronounced 
when fitting the data for lower temperatures.
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This offers some support to hypotheses that epitope and possibly even paratope exposure
and behaviour could be influenced by temperature. HLA proteins are acknowledged as highly
flexible molecules wherein complex changes in vibrational and conformational stability could
affect their ability to bind to specific antibodies (Mian et al., 1991).
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Figure 5-8 : Thermodynamic analysis of interactions of HLA-A2 and SN607D8 (IHB-Hu-081) at a range of temperatures (15 to 40 oC)
Shows binding sensorgram and residual plots at different temperatures. The binding curves from top to bottom corresponds to concentration dilution
(100nM to 3.175nM).
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
235
A2 A68 A69
Temp (Celsius) ka 1/Ms kd 1/s KD M ka 1/Ms kd 1/s KD M ka 1/Ms kd 1/s KD M
15 4.25E+04 8.23E-05 1.94E-09 4.67E+04 1.13E-04 2.43E-09 4.75E+04 1.09E-04 2.30E-09
20 5.29E+04 2.77E-04 5.22E-09 4.97E+04 2.94E-04 5.91E-09 5.43E+04 3.36E-04 6.18E-09
25 6.22E+04 3.85E-04 6.18E-09 1.01E+05 1.52E-04 1.50E-09 6.63E+04 2.91E-04 4.39E-09
30 7.05E+04 5.54E-04 7.86E-09 1.07E+05 2.27E-04 2.12E-09 7.46E+04 4.24E-04 5.68E-09
35 7.84E+04 3.04E-02 3.88E-07 7.42E+04 2.66E-02 3.58E-07 7.84E+04 5.51E-04 7.02E-09
40 6.75E+04 4.95E-04 7.33E-09 6.29E+04 4.38E-04 6.97E-09 5.81E+04 8.84E-04 1.52E-08
Table 5-8 : Kinetic parameter of binding interaction of HLA proteins – A2, -A68 & -69 to SN607D8 at different temperatures
Figure 5-9 : Kinetics of binding interactions between HLA-proteins (-A2,-A68 & -69) and SN607D8.
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Van’t Hoff analysis:
Thermodynamic parameters such as Gibbs free energy (∆G), Enthalpy (∆H) and Entropy (∆S) 
can be calculated using Van’t Hoff plot. Enthalpy is the amount of heat absorbed or released
during a chemical reaction. The value will be positive for endothermic reactions and negative
for exothermic reactions. Entropy is measure of increase in disorder or dispersal of the
energy; a positive value suggests increase in disorder. For an interactions to happen it needs
to overcome activation energy barrier and this reveals energy required for binding and
dissociations. Thermodynamic measurement using ProteOn BioRad platform has been
described and the current experiment follows same methodology (Bravman et al., 2008).
Gibbs free energy is described by following equations
Gibbs free energy (∆G) = ∆H - T∆S and 
(∆G) = RT log (KD)
Thus, log (KD) = ∆H/RT -∆S/R 
Van’t Hoff plot is derived by plotting Inverse of temperature (in Kelvin) and logKD. The
assumption is both enthalpy and entropy are constant with temperature changes. From this
curve, slope is equal to ∆H/RT and intercept is equal to ∆S/R. As seen in the Figure 4-6, the 
relationship between temperature and logKD was linear for HLA-A2 and HLA-A69 but
inconsistent for HLA-A68. Binding enthalpy (∆H) is calculated by determining the slope of the 
curve obtained via the linear equation shown in the Figure 5-10.  ∆H is calculated by 
multiplying the coefficient of the slope with Universal Gas Constant (R = 8.314472 J/K.M) and
∆S is calculated by multiplying the intercept of the slope with the Universal Gas constant (R). 
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Figure 5-10 : Vant Hoff’s analysis for HLA-protein and SN607D8 Mab interactions
SN607D8 interaction with HLA-
protein
∆H KJ mol-1 K-1 ∆S J mol-1 K-1 ∆G at temp = 310 K (37 oC)
KJ mol-1 K-1
A2 -15.49 -17.5 -10
A68 -7.925 -44.15 5.76
A69 -20.75 0.79 -20.9
Table 5-9 : Thermodynamic parameters for interactions of HLA proteins and SN607D8
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Table 5-9 shows calculated thermodynamic parameter using van’t Hoff analysis. These data
suggests that binding enthalpy is most favourable for interactions with HLA-A69 compared
with HLA-A2 and HLA-A68. However, the limitation of Van’t Hoff analysis is the assumption of
linear relationship and as it can be seen the straight line obtained by linear regression gave
R2 value 0.6 for HLA-A2 and 0.8 for HLA-A69 interactions whilst it was very poor for
interactions with HLA-A68. This may be due to altered thermodynamics due to temperature
dependant process. Higher negative entropy value suggests the interaction resulted in lesser
randomness for HLA-A68 interactions. Equally the relationship of logKD and 1/T was very poor
and even a non-linear fitting would struggle to fit the data.
From the equation of Gibbs free energy, reaction is spontaneous at all temperature if ∆G and 
∆H are negative and ∆S is positive, like observed for interactions with HLA-A69. A reaction can 
be spontaneous even when ∆S is negative but the preference is at low temperature, such as 
observed with HLA-A2. If ∆S and ∆H are positive then the reaction is usually spontaneous at 
higher temperature. However if ∆G is positive the reactions are usually non-spontaneous such 
as observed with HLA-A68. Although the estimates are not highly accurate, the Van’t Hoff plot
analysis provides useful insight in to the thermodynamic and underlying chemical interactions
of HLA-protein and HLA-specific antibodies. This type of analysis can help understand the
predominant bonds involved in the interactions; such as if the reaction is better at higher
temperature that suggests involvement of hydrophobic bonds as their strengths increases
with increase in temperature. Whilst the interactions due to hydrogen bonds are more stable
at low temperature as they are exothermic reactions (Reverberi and Reverberi, 2007). The
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importance of insights in to thermodynamic of an interaction may allow manipulation of
conditions to disrupt the bond between the antigen-antibody interactions.
Competitive and additive binding of IgG human monoclonal HLA-specific
antibodies to selected HLA proteins
Biosensor platform provides an ideal opportunity to study interactions of different HLA-
specific antibodies with HLA-protein. Thus one could test the hypothesis of conformational
change following an earlier binding with the HLA protein, which may potentiate or inhibit
subsequent binding of second antibody to the same HLA-proteins. Similarly it could allow
testing competitive binding between two antibodies for the same epitope on the HLA-protein
thus confirming the epitope definition of the antibodies.
Due to steric hindrance at higher concentrations of antibodies binding to the HLA-proteins
(see Figure 4-32); the experiments were performed in sequential cross over fashion. Thus the
initial binding reaction was allowed between the maximal concentrations of the antibodies
on separate lanes followed by cross-over of the antibodies at same concentration in stepwise
fashion. This allowed binding to all the available binding sites (epitopes) during the first phase
of association and immediately after the initial association, the further binding in second
association phase was studied. Experiments below demonstrates additive binding by using
two human monoclonal HLA-specific antibodies that had specificities for different epitopes
that were located on different alpha chain of class I HLA molecules and the distance between
them was more than 30 Angstrom (Figure 5-11). For competitive binding, human monoclonal
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HLA-specific antibodies that had specificities against same epitopes or closely located
epitopes (with in 20 Angstrom) were selected (Figure 5-13). The distance was estimated using
Cn3D software (Madej et al., 2012).
Human monoclonal HLA-A2-specific antibodies: additive effect
Two separate IgG human monoclonal HLA-specific antibodies against HLA-A2 were studied
with known positional information for their respective target epitopes on the HLA-A2
molecule (Figure 5-11). These two monoclonal HLA-A2 specific antibodies (SN607D8 &
SN230G6) were investigated in such a fashion that 1) the first antibody was allowed to
associate with low-density immobilised HLA-A2 protein on the SPR channel; 2) Regeneration
at high pH was NOT performed, such that a proportion of antibody remained bound to the
channel; 3) the second antibody was flowed over the same channel in a second “association
phase”. This procedure was reciprocated and data are shown in Figure 5-12). In both cases,
the binding of the antibodies in the second association phase was not influenced by presence
of pre-bound antibodies as the distance between epitopes was more than 30 Angstrom. This
would suggest additive binding and the accommodation of two separate antibodies.
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Figure 5-11 : HLA-A2 protein structure showing epitope 62G & 142T
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Figure 5-12 : Sequential interactions of HLA-A2 protein and monoclonal antibodies against epitopes 142T (SN607D8) and 62G (SN230G6).
Clear evidence of accommodation with the appearance of concatenated sensorgrams in a “stacking” appearance.
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Human monoclonal HLA-B antibodies: competitive inhibition
Three human IgG monoclonal HLA-specific antibodies were available with the spatial position
of their epitopes known and mapped on their cognate HLA molecules (Figure 5-13). These
were used and tested in pairs (Figure 5-14 & 5-15). The epitope for WK1D12 and VTM1F11
was same 163E shared between B7, B27 and B40:01. Whereas second pair, WK1D12 and
OUW4F11 the epitopes were different but the distance between them was less than 20Angstrom. The OUW4F11 was specific for epitope 80I which is shared between HLA-B7 and
HLA-B40:01 but not HLA-B27. As seen in Figure 5-14, WK1D12 and VTM1F11 were studied in
sequential fashion (as described above), and evidence of blunting of the binding response
involving antibodies was seen in the “second association” phase. Similar observations were
noted involving interactions between WK1D12 and OUW1F11 (Figure 5-15). This suggests that
the monoclonal HLA-specific antibodies are competing for the same epitopes unlike the
accommodation phenomenon shown in Figure 5-12.
Figure 5-13 : Structure of HLA-B7 indicating location of epitopes 80I and 163E
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Figure 5-14 : Sequential binding experiments showing evidence of competitive inhibition / blunting and poor accommodation of binding
response to a second monoclonal antibody
Figure 5-15 : Sequential binding experiments showing binding interactions of WK1D12 and OUWF11
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Thus biosensor platform could be used to study effects of antibodies binding to epitopes on
same HLA-proteins. Above experiments demonstrate use of human monoclonal HLA-specific
antibodies, but these can be replicated for purified polyclonal HLA-specific antibodies from
patient material. For patient material the epitope specific purification can be done using
sequential HLA-protein affinity chromatography. We have demonstrated use of this principle
and tested CDC reactivity in presence of two epitope specific polyclonal HLA-specific
antibodies (Lowe et al., 2013b).
The pairs used here demonstrated additive (non-overlapping) and competitive (overlapping)
effects, but equally an allosteric effect can be studied using biosensor platform.
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Effect on overall affinity by mixing two IgG monoclonal HLA-specific
antibodies displaying accommodative binding
Human IgG monoclonal HLA-specific antibodies with known accommodative binding as
demonstrated Figure 5-12 (SN607D8 and SN203G6) were mixed in five different proportions
(0, 25, 50, 75 & 100% relative to SN607D8) in PBS prior to running kinetic binding experiments
in the established fashion. The effect of two monoclonal epitope specific antibodies was
assessed on overall binding response and calculated affinity. As both the monoclonal
antibodies bind to different epitopes located at distal regions of the HLA molecule target
region, the overall binding signal response (Rmax) was higher when mixed in all proportions
compared with one antibody applied to the chip exclusively (Figure 5-16). To calculate overall
apparent KD for the mixed solution, heterogeneous analyte model was used for fitting the
data for calculating the binding kinetic parameters and for individual monoclonal HLA-specific
antibodies, the bivalent analyte model was used (Table 5-10).
SN607D8:SN230G6 Kinetics KD
N: 0 ka = 4.53E+04 1/Ms
kd = 5.05E-04 1/s 1.12E-08 M
75:25 ka = 5.05E+04 1/Ms
kd = 3.82E-04 1/s 7.56E-09 M
50:50 ka = 5.40E+04 1/Ms
kd = 3.46E-04 1/s 6.42E-09 M
25:75 ka = 4.77E+04 1/Ms
kd = 3.28E-04 6.88E-09 M
0:N ka = 3.66E+05 1/Ms
kd = 6.48E-04 1/s 1.77E-09 M
Table 5-10 : Binding Kinetics of mixed monoclonal HLA-specific antibody solution
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Figure 5-16 : Binding kinetics of solution containing two human monoclonal HLA-A2
specific antibodies (SN607D8 & SN230G6) mixed in different proportions (A - SN607D8
100% (50nM); B – D8 75% (37.5 nM) & G6 25% (12.5nM); C – D8 & G6 50% (25nM each); D
= D8 25% (12.5nM) & G6 75% (37.5nM) and E – SN230G6 100%)
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Experiments using mixture of monoclonal HLA-specific antibodies demonstrated the binding
strength of the mixed solution is the average of individual binding strength and that even a
small concentration of high affinity antibody effects overall apparent binding strength.
Compared to the high affinity monoclonal HLA-specific antibodies (SN230G6) the binding
kinetics of mixed solution demonstrated slower kd and ka values.
Discussion
Binding kinetic parameters, including dissociation constants can be measured in real time
using surface plasmon resonance instruments such as the ProteOn XPR36. This has made
possible the measurement of simultaneous, multiple interactions across range of
concentrations. Binding assays of this kind possess added advantage over current assays since
they capture a broader, real-time picture of the binding events and levels, compared with
simpler end-point assays such as Luminex bead assay, ELISA and flow cytometry. In addition
to being semi-quantitative rather than fully-quantitative, these latter assays may also be
heavily influenced by protocol wash steps that are not easy to monitor precisely.
Wash steps applied in current Luminex and flow cytometry assays, whilst similar in some
aspects, are not the same as the dissociation phases recorded in a SPR biosensor assay. In the
former cases, wash steps are designed to remove non-specific, non-HLA-specific IgG and
other irrelevant serum proteins from the beads or cells. The washing times and mechanisms
are arrived at and settled upon in protocols largely due to satisfying a detection level
arbitrarily. Subsequently, the end point measured could very easily be affected by faster
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dissociation rates of certain studied antibodies. As seen in the Figure 5-17, the association
rates for monoclonal HLA-specific antibodies (SN230G6, VTM1F11 & WAR5D5) binding to
their cognate HLA proteins are fast, but the dissociation rates vary relative to Rmax, with
faster dissociation for VTM1F11 compared to SN230G6 and WAR5D5. Conversely, the
dissociation rate is slower for WK1D12 & SN607D8 compared to VTM1F11 and OUW4F11.
Thus WK1D12 and SN607D8 antibody appears to “stick” better.
Depending upon where the cut-off point of the wash (dissociation) phase, the relative signal
intensities can potentially vary substantially – a quality that would be missed in an end-point
assay (such as Luminex or ELISA). The discrepancy between dissociation constant derived
from EC50 calculation and kinetic analysis may be due to different equilibrium time for ELISA
and SPR but equally been end-point assay it may wash-out lower affinity binding such as
observed for OUW4F11 monoclonal antibody. Hence real time observations provide deeper
qualitative and quantitative information capable of highlighting biophysical differences
between discrete antibodies.
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
250
Figure 5-17 : Binding curves for different HLA-class I specific antibodies observed real time using biosensor assay
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Figure 5-18 : Dose response curves of monoclonal HLA-specific antibodies (SN607D8 & SN230G6) on Luminex assay
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In addition, Luminex assay is not able to evaluate the affinity of the same antibodies to
different HLA-proteins that share the same epitopes. In fact, using Luminex assay the
reactivity yields data that are virtually indistinguishable when showing binding to epitopes on
different HLA proteins. As seen in Figure 5-18, the MFI values derived are extremely similar
for binding responses of purified SN607D8 to HLA-A2,-A68 & -A69 proteins on the beads, and
also for SN230G6 binding to HLA-A2, HLA-B57 & HLA-B58 proteins. Luminex assay is
optimised for studying antibody binding at 22oC whilst biosensor assay can be studied at
varying temperatures and at physiological temperature of 37oC.
The ability now to purify sufficient HLA-specific antibodies to a very high standard and
perform real-time kinetic analysis generates additional antibody “metrics” such as ka, kd and
KD that could deepen and improve the ability to resolve relationships between HLA-specific
antibodies, their immunological potency and, ultimately, their potential to affect risk of
rejection. Another exciting opportunity lies in the ability of SPR experiments to obtain
thermodynamic data for these interactions, yielding further parameters of potential
physiological value plus deepening our understanding of antibody function and biophysics.
This is especially interesting here in the context of HLA-specific antibodies binding to different
HLA proteins that present the same functional epitope(s). The binding affinity is greatest for
interactions between antibody and the original immunising HLA protein. The difference in
dissociation constant measured ranged between 0.5 to 10 folds. Although the significant cut-
off difference is not established for antibody-antigen interactions, it is clear from the above
experiments that even a smaller difference can be due to different kinetic behaviours. Hence
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when evaluating differences between the interactions the full picture should be taken in to
account.
A recent study (Duquesnoy et al., 2013) suggested that reactivity on C1q-binding and CDC is
highest for interactions of monoclonal HLA-specific antibodies against the immunising HLA
protein and described a subjective and purely qualitative one/two/three-star property of
“binding energy”. The work described here goes much further in at least two capacities – 1)
the majority of antibodies used in the Duquesnoy et al., study were of the IgM class, in
contrast to the study in this thesis that has used IgG class HLA-specific antibodies. -2) The
thermodynamics of epitope-paratope interactions were calculated. Although not fully
optimised and precise, these experiments represent significant first steps towards
understanding new territories in the field of HLA-specific antibodies. It is acknowledged that
the best technique for measuring thermodynamic data in protein-protein interactions is
isothermal titration calorimetry. However, this technique requires very large amounts of each
purified component of the binding partnership – typically in the milligram range. This required
quantity of antibody and HLA protein is prohibitive, in addition to raising the risk of
experimental setbacks such as protein precipitation/solubility issues at high concentration
(Bravman et al., 2008).
In addition to providing a deeper and broader range of quantitative measurements, the real-
time SPR approach can also visualise competitive and accommodative binding between
monoclonal HLA-specific antibodies and the same HLA protein molecule. Interactions
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between SN230G6 and SN607D8 monoclonal HLA-specific antibodies against HLA-A2 protein
performed in sequence showed accommodative/additive binding. Also, when tested using
mixtures of these antibodies, the amplitudes of the concentration-rationalised responses
were higher than single species of antibody alone, in agreement with the notion of the greater
mass of individual monoclonal HLA-specific antibodies bound to the same immobilised HLA
protein. This accommodative phenomenon could reflect the physiological process of epitope
spreading following immunological exposure of non-self HLA alleles (N.B. both SN607D8 and
SN203G3 were derived from the same multiparous woman that had been exposed to foetal
HLA-A2 and HLA-B57) and the resultant rise in MFI and lytic activity when analysed by Luminex
and CDC assays respectively (Mulder et al., 2003, Marrari et al., 2010, Duquesnoy, 2014b).
The binding strength (Table 5-10) is constant for different proportion of monoclonal HLA-A2
specific antibodies and is roughly the average of affinities of individual antibodies. The
maximal response is similarly constant across the different proportions but is higher than the
individual maximal responses. Therefore, the overall apparent affinity from a polyclonal,
clinical sample could very well reflect the contribution of higher affinity antibodies and thus
could prove to be clinically applicable. Additionally, competitive binding experiments on this
assay could be used to validate and evaluate the key epitopes recognised by antibodies within
a polyclonal sample by competing with known concentrations of monoclonal antibodies of
defined epitope specificity.
Clinical cases usually display polyclonal HLA-specific antibody responses with antibodies
directed against different epitopes present on the same HLA-proteins. These observations can
vary with time and the appearance of newer antibodies may alter HLA binding responses as
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measured by changes in MFI levels or CDC positivity. A study looking at CDC-positive
responses have shown that the presence of two or more monoclonal antibody clones
augments CDC reactivity when compared to a single monoclonal antibody (Kushihata et al.,
2004) and this effect was observed if the antibodies reacted to different epitopes located at
critical distance. These overall antibody binding characteristics could be useful in pre-
transplantation settings such as early prediction of acute adverse clinical events (antibody
mediated rejection) and also in post-transplantation settings where longitudinal follow-up
could track changes in affinity predicting chronic rejection and its prognosis. Another
important application could be the ability to define non-detrimental donor HLA-specific
antibodies in highly sensitised cases, and thus make feasible transplants that would otherwise
be denied.
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Purification and quantification of
polyclonal HLA-specific antibodies and
characterisation of affinity
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Introduction
Using human monoclonal HLA-specific antibodies as described in Chapter 4, we have
validated the SPR biosensor platform for studying the binding kinetics and affinity of their
interactions with HLA proteins. Using the experience from these experiments and methods,
clinical samples can now be approached with a view to initiate description of the distribution
of affinity parameters across clinical sample cohorts. When serum samples were used as neat
or in a 1:50 dilution, two major problems emerged instantly. Firstly, there was massive non-
specific binding to the intrinsic matrix of biosensor chips and secondly, accurate quantification
of antibody concentration – a vital parameter required for calculating the binding to the
specific HLA-proteins quantitatively and rationally was not possible.
To be able to study clinical samples, various methods for purifying immunoglobulin G (IgG)
were tested for their efficacy and selectivity similar to protocols described for purification of
monoclonal human HLA-specific antibodies described in Chapter 4. Two additional techniques
were used for purification of polyclonal IgG – sequential precipitation from whole serum
(using octanoic acid and ammonium sulphate) and size exclusion chromatography (gel
filtration). Ion exchange chromatography techniques that were used in the purification of
monoclonal HLA-specific antibodies were not considered, since it was anticipated that
polyclonal antibodies possess a range of isoelectric points and would very likely give multiple
peaks contaminated with other serum proteins. A combination of affinity chromatography
and size exclusion chromatography yielded purified HLA-specific antibodies but overall
recovery was low due to the multiple protein dialysis and concentration steps required in
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between the two separate chromatography steps. Whilst the combination of sequential
precipitation and size exclusion chromatography was not specific for HLA, it is specific for IgG
enrichment and did not require multiple protein concentrating steps. The experiments below
show that commercial polyclonal IgG (i.e. not HLA-sensitised and extracted from pooled
normal human serum) did not cause any non-specific binding to SPR chips and thus the
strategy of enriching HLA-specific IgG antibodies alongside bystander, non-HLA-specific IgG
can resolve the HLA-specific binding response on SPR sensor chips and ultimately allow for
the study of relevant binding kinetics.
Methods to quantify HLA-specific antibodies were studied simultaneously with the
purification protocols. Protein quantification methods such as Nano drop, Lowry’s and BCA
assays were used for estimating and determining concentrations of the monoclonal HLA-
specific antibodies described previously, as they were available in large quantities and were
comparatively easy to purify using HLA-protein affinity chromatography and ion-exchange
chromatography. Experiments with polyclonal antibodies demonstrated that the
concentration levels of antibodies recovered from a patient sample were typically too low for
accurate detection using Nano drop, and gave inconsistent data when applied to eluted
fractions following affinity chromatography. Similarly, Lowry’s assay and BCA assay couldn’t
quantify polyclonal HLA-specific antibodies (in nanogram concentration) accurately due to
their being below the lower concentration threshold following affinity chromatography.
Hence, more sensitive quantification assays using standard curves calibrated with human
monoclonal HLA-specific antibodies were used.
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Here, three different quantification assays were approached to determine the relative
concentrations of polyclonal HLA-specific antibodies. Luminex assays can be used for this
purpose but they are limited by very high cost. The basic protocol of a sandwich ELISA assay
first developed by PTS, Oklahoma (R Buchli) was used with to probe HLA-A2- and HLA-B7-
specific antibodies, determined by the availability of these soluble HLA proteins for coating
the ELISA plates. In addition SPR experiments possess a unique faculty using binding data
obtained during first 30 seconds of analyte-ligand contact in isocratic flow (Lynch et al., 2014,
Karlsson et al., 1991). Advantages of this latter approach include its label free quantification
and potentially broader HLA haplotype range, since calibration uses monoclonal antibodies
with multiple haplotype specificity (e.g. SN607D8 to A2, A68 & A69; SN230G6 to A2, B57 &
B58 and WK1D12 to B7 & B27).
Material and methods - overview
Human sera and plasma effluent were collected from patients undergoing HLA-incompatible
kidney transplantation at University Hospital, Coventry UK, as discussed in Chapter 2.
Purification protocols were used as described in chapter-2 and various combinations and
chronologies were applied. SPR experiments followed tailored protocols established for
monoclonal antibodies (See Chapter 4). Preliminary kinetic data were calculated using the
heterogeneous analyte model (Gomes et al., 1999, Bowles et al., 1997).
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Purification of polyclonal HLA-specific antibodies
Non-specific binding related signal from plasma effluent and serum samples
Both serum and plasma effluent were tested in neat and dilution after centrifugation at
13,500 rpm for 15 minutes. This was sufficient to obtain distinct specific signal via Luminex
assay. However, there no specific signal in SPR experiments due to a very high level of noise,
attributable to non-specific or gross protein/serum component binding (Figure 6-1).
Binding experiments using serum from case LT65 (Anti-HLA-A2 MFI values of 7011) against
immobilised HLA-A2 protein showed non-specific binding (NSB) on both the test (A & B) and
blank reference channels (C). Remarkably, non-specific signal on the reference channel was
higher compared to the test channels and thus reference subtractions resulted in negative
binding curves such that affinity parameters could not be calculated in any way (see Figure 6-
2). Importantly, the level non-specific binding was present even at lower dilution levels of
serum sample for all channels.
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Figure 6-1 : Non-specific/undesirable binding to the matrix of the sensor chip with serum
from the LT65 case. Higher NSB to blank lane (C) compared to low density ligand lane (B)
and high density ligand lane (A)
Figure 6-2 : Effect of non-specific binding on data distortion following reference
subtraction against the blank channel (C); Low density ligand lane (B) and high density
ligand lane (A)
The presence of 0.005% Tween-20, and the addition of 1 M NaCl to the running buffer did
not reduce the non-specific binding, as seen in Figure 6-3.
Figure 6-3 : Persistence of NSB with PBS-TS running buffer and case LT65 interaction with
HLA-A2 protein and biosensor chip . Higher NSB to blank lane (C) compared to low density
ligand lane (B) and high density ligand lane (A)
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Monoclonal HLA-A2 specific antibody in negative serum sample:
Aliquots (900 µl) of negative (control) human serum (used in Luminex assay, NHSBT) was
spiked with 100 µl of SN607D8 (MFI – 20,000) from a 1 mg/ml stock to assess whether the
lack of signal be secondary to lower concentration of HLA-specific polyclonal antibodies in
above experiments. This gave a final concentration of HLA-specific antibody of 0.1 mg/ml,
which is very high and very likely supra-physiological.
This experiment demonstrated persistence of signal noise, but after reference subtractions
the test lanes had distinguishable signals as seen in Figure 6-4 and Figure 6-5. This
demonstrated that the concentrations of polyclonal HLA-specific antibodies were lower, as
expected and removal of noise through improvement of sample quality would be required.
Figure 6-4 : Mab spiked in human serum (NHSBT negative control). Blank reference lane
(C), Low density ligand lane (B) and High density ligand lane (A)
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Figure 6-5 Binding curve of monoclonal anti-HLA-A2 diluted with negative control human
serum (after ref subtraction)
Protocols for enriching HLA-specific antibodies from large volumes of plasma
effluent
Several purification techniques were considered as described in Chapter 2. Initial experiments
were done to determine what may be causing the non-specific binding. Human serum
albumin (Sigma) and commercial polyclonal IgG (Pierce) were tested in the SPR system.
Commercial polyclonal IgG was purified from human donor serum by ammonium sulphate
precipitation and ion exchange chromatography and was in 1% PBS buffer, according to the
supplier. Figure 6-6 shows relatively low non-specific binding and only the bulk mass effect
(positive for albumin (A) and negative for polyclonal IgG (B)) compared to running buffer.
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Figure 6-6 : Absence of non-specific binding signal with purified human serum albumin (A)
and polyclonal IgG (B)
These data show that neither human albumin nor human polyclonal IgG were significant
contributors to the noisy non-specific binding, implicating to other, unknown impurities
present in serum and effluent.
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HLA affinity chromatography alone as downstream purification
As described in Chapter 2, soluble HLA proteins immobilised on Sepharose were used for
specific capture of HLA-specific antibodies. Plasma effluent preparations, recovered from
three clinical cases (LT66, LT65 and LT45) were used.
Case LT66
Plasma effluent from case LT66 (250 ml) was centrifuged (13, 000 RPM for 15 minutes) and
affinity chromatography was performed using the 60 ml HLA-A2 column. The captured
antibodies were eluted, followed by spin concentration and buffer exchange into PBS. The
MFI of this preparation for A2 was determined as 19709 and the concentration of protein
measured by Lowry’s assay was measured as 0.72 mg/ml. Figure 6-7 shows the persistence
of non-specific binding to reference channel (B) and on test channel (A) despite antibody
enrichment. Similar to previous observations, the amplitude of the non-specific binding signal
was actually higher on empty reference channel, suggesting that unknown, non-IgG serum
components could be interacting preferentially with the SPR sensor chip alginate matrix.
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Figure 6-7 : Binding curves obtained from interaction of enriched plasma effluent sample (LT66) and HLA-A2 protein (A ) and
reference channel ( B)
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Cases LT65 and LT45
Similar results were obtained using IgG-enriched plasma effluent from cases LT65 and LT45
despite the recovered antibody-rich eluates possessing high MFI values for A2 of 12624 and
10,000 respectively. The concentration of protein measured by Lowry’s assay was 1.51 and
0.64 mg/ml for enriched sample from LT65 and LT45 respectively.
Thus effluent centrifugation and HLA protein affinity chromatography did not result in
samples of sufficient quality to yield distinct binding signals via SPR. These enriched materials
were further purified and following this gave distinct signal (described in section 6.3.1.4.2).
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Sequential precipitation followed by HLA-protein affinity chromatography
As antibody enrichment using HLA-protein affinity chromatography alone did not result in
specific binding on biosensor chips either at all or of sufficient quality, further enrichment and
purification techniques were applied. Sequential protein precipitation using octanoic acid
followed by ammonium sulphate has been shown to enrich IgG selectively (Perosa et al.,
1990). This precipitation protocol is also efficient at separating IgG from lipids, large
lipoproteins and adhesive molecules such as fibronectin within human serum and similar,
protein-dense preparations such as plasma effluent. It does not work well in preparations
such as tissue culture supernatants.
Case LT77 Plasma effluent:
Plasma effluent (400 ml) from case LT77 was processed using the sequential precipitation
method described in Chapter 2. The level of purity was assessed qualitatively by SDS-PAGE.
Figure 6-8 shows evidence of high molecular weight protein removal. The resulting precipitate
was dissolved in 1% PBS (10 ml) and passed through a guard column of uncoupled Sepharose
(4 ml) to allow further removal of unwanted adhesive proteins ahead of HLA affinity
chromatography. The flow-through from the guard column was then applied to 4 ml of HLA-
A2-Sepharose. The material was eluted in 100 mM glycine pH 11.0 and dialysed into 1% PBS
(2 ml) and protein quantified using nano drop (0.27 mg/ml) and Lowry’s assay (0.38 mg/ml).
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Figure 6-8 shows further reduction in high molecular weight and albumin bands. MFI values
of the eluate measured by Luminex SAB assay are shown in Table 6-1.
Figure 6-8 : SDS Page Gel electrophoresis (reducing gel) showing reduction in impurities by
sequential precipitation
(PM – Protein marker; HA – Human albumin; IgG – Commercial Polyclonal IgG; LT77 – test
sample code; ppt – post sequential precipitation; GC – post guard column; AC – post HLA
affinity column; HWt – Higher molecular weight protein band)
Based on measurements by Lowry’s assay, binding SPR experiments were performed using
immobilised HLA-A2 with LT77 at an apparent concentration of 100 nM, plus the positive
control antibody SN607D8 at 6.25 nM. Figure 6-9 shows lack of specific signal from LT77 and
in fact, the persistence of non-specific binding despite the modification of purification
protocols. The control monoclonal HLA-A2 specific antibody gave a clean, specific signal as
expected (Figure 6-10, C). The non-specific binding is pronounced in reference channel (figure
6-10, B). A repeat experiment using higher concentrations of this LT77 sample increased the
non-specific binding signal.
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Figure 6-9 : Binding experiments of case LT77 plasma effluent enriched by sequential
precipitation and affinity chromatography. High density ligand lane (A) & Blank reference
lane (B) and signal on high density lane after reference subtraction (C).
Case LT77 HLA-A2 HLA-B57 HLA-A69
Plasma effluent 5948 3084 2813
Post Sequential
precipitation
5057 2456 1460
Post Affinity
Chromatography
16158 17496 1861
POST SEC 10703 10647 612
Table 6-1 : MFI values on plasma effluent from case LT77 processed using various
enrichments
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Sequential precipitation followed by HLA-protein affinity and size exclusion
chromatography
The above enriched sample from LT77 plasma effluent was analysed using mass spectrometry
to identify molecules that could be targeted for removal in advanced purification processes.
Bands from SDS PAGE gels of LT77 were analysed using tandem mass spectrometry at the in-
house Facility at Warwick. This successfully identified a panel of proteins summarised in
Figure 6-11. No proteins were identified with confidence from band 1 when peptide data were
used to search stock proteome databases such as MASCOT – probably due to profound post-
translational modification and sub-optimal tryptic digestion. The mass spectrometry analysis
did however confirm the enrichment of IgG via our protocol but it also showed the presence
of albumin, IgM, IgA, a species called C9JA05 and CD5-like antigen.
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Figure 6-10 : Mass spectrometry analysis of processed sample from LT77 plasma effluent
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Figure 6-11 : Chromatogram following size exclusion chromatography of processed LT77 sample with an overlap of chromatogram from
polyclonal IgG standard experiment.
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
274
Due to the clear presence of other impurities, size exclusion chromatography (SEC) was
incorporated as a further purification step. This further separated proteins into two distinct
peaks as seen in Figure 6-11. A principle of SEC is that larger molecules emerge early in the
elution profile such that Peak 1 would contain high molecular weight proteins - very likely
IgM. Peak 2 overlaps very well with the pre-run standard IgG peak, strongly suggesting that
IgG-class antibodies from the clinical case are eluting at this point. SDS-PAGE analysis of SEC
fractions supported separation of high molecular weight bands (Figure 6-12, Lane 2) from IgG
heavy chain (Figure 6-12, Lane 3) compared to pre-SEC sample (Figure 6-12, Lane 1).
Figure 6-12 : SDS PAGE showing bands on pre (Lane 1) and peak fractions (Lane 2 – Peak 1;
Lane 3 – peak 2)
The fraction corresponding to the IgG peak was quantified using Lowry’s assay and there was
substantial reduction in amount (from 0.38 mg/ml to 0.08mg/ml). However, Luminex MFI
values were over 10,000 for HLA-A2 and B57 (see Table 6-1). Using neat fractions
corresponding to the IgG SEC peak (estimated to contain 500 nM antibody from Lowry’s
assay), a discernible binding signal to HLA-A2 was observed and compared with the SN607D8
monoclonal antibody control (6.25 nM), as shown in Figure 6-13. Given the high MFI value of
the this material, the apparently poor comparative binding response suggested that in spite
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of using the HLA-protein affinity steps, only a small proportion of the purified IgG recovered
was truly HLA-specific. However, the overall quality of the binding curve and its mirroring of
the monoclonal antibody signal showed more reassuring evidence that SEC was capable of
separating out the offending impurities responsible for a lot of the previous signal noise and
high non-specific binding responses.
Figure 6-13 : Binding curves from interactions of processed LT77 and HLA-A2 protein
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
276
Serial affinity and size exclusion chromatography
Alternative affinity chromatography strategies using HLA-A2-Sepharose or Protein G-
Sepharose with downstream SEC, were tested for a selection of patient cases.
1.1.1.1.1 Serial HLA-affinity and size exclusion chromatography:
Plasma effluents (400 ml volumes) from three cases (LT33, LT68 & LT79) were used. Following
1:1 dilution with PBS to reduce viscosity, samples were applied to the 60 ml of HLA-A2, eluted
as described in Chapter 2.
Following sample concentration and exchange into PBS using viva spin concentrators, second
runs of HLA-A2 affinity chromatography were performed using the 4 ml column. The protein
eluted was again concentrated down to a 1 ml volume and further purified via SEC at a flow
rate of 0.5 ml/ml. Fraction 14F, eluting at 13 ml/26 mins (Figure 6-14), consistently
corresponded to IgG (as determined via commercial standard) and was retained for analysis
for each patient case.
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Figure 6-14 : Size exclusion chromatography of processed polyclonal samples showing peaks corresponding to large molecular weight
proteins (1), IgG (2) and low molecular weight proteins (3-4).
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Case LT33:
Case LT33 and concentrated IgG HLA-specific antibodies as seen in MFI values indicated in
Table 6-2. The concentration of protein from Fraction 14F, measured by Lowry’s assay, was
0.1 mg/ml (compared to pre-SEC concentration of 0.54 mg/ml). This processed LT33 material
was studied via SPR (concentration range 0.03 to 1.2 nM measured by quantitative ELISA) and
gave dramatically improved signal for interactions with HLA-A2 and HLA-B57 (as seen Figure
6-15) from which meaningful, apparent kinetic measurements could be derived.
LT33 HLA-A2 HLA-B57 HLA-A69
Pl effluent 6626 3800 6507
Post 60 ml AC 4782 2488 3904
POST SEC 23215 21868 2700
Table 6-2 : MFI values measured by SAB assay on samples during enrichment of IgG in case
LT33
Figure 6-15: Binding sensorgrams of LT33 polyclonal antibodies interacting with HLA-A2
(A) and HLA-B57 (B)
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The binding data were calculated for interactions with HLA-A2 using equilibrium analysis
(Figure 6-16), yielding an apparent dissociation constant KD value of 0.267 nM. The quality of
HLA-B57 data was questionable and not considered accurate.
Figure 6-16: Equilibrium analysis of binding data for LT33 polyclonal antibody interactions
with HLA-A2)
Case LT79:
Following polyclonal antibody purification, MFI values were measured, as seen in Table 6-3.
Lowry’s assay indicated a protein concentration of 1 mg/ml. The LT79 antibodies
(concentration range 1.125 to 36 nM measured by quantitative ELISA) gave a clean and
impressive SPR signal for interactions with both HLA-A2 and HLA-B57 (Figure 6-17).
LT79 HLA-A2 HLA-B57 HLA-A69
Pl effluent 15824 5627 11435
Post 60 ml AC 14914 4311 9055
PRE SEC 21516 18964 17621
POST SEC 23289 21277 20906
Table 6-3 : MFI values from Luminex SAB during purification process of case LT79 plasma
effluent
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Figure 6-17 : Binding interactions between polyclonal antibodies from case LT79 and HLA-
A2 (A) and HLA-B57 (B)
Equilibrium analysis is indicated in Figure 6-18 and early indications suggest varying affinity
values between interactions measured simultaneously for the same polyclonal antibody
preparation for different HLA proteins.
Figure 6-18 : Equilibrium analysis of binding data from interaction between polyclonal
antibodies from case LT79 and HLA-A2 (A) and HLA-B57 (B).
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Case LT68
Polyclonal antibodies from case LT68 gave distinct binding signal, however compared to LT33
and LT79 the maximal response was lower and was keeping with lower concentration
measured by quantitative ELISA (range 0.26 to 0.016 nM) (Figure 6-19). The MFI values pre
and post SEC are given in Table 6-4. As only few points were in the equilibrium levels, the
dissociation constant was not estimated.
LT68 HLA-A2 HLA-B57 HLA-A69
PRE SEC 20431 20105 2673
POST SEC (1:2) 9396 8848 200
Table 6-4 : MFI values measured using Luminex SAB pre and post SEC on enriched plasma
effluent from case LT68
Figure 6-19 : Binding interactions between polyclonal antibodies from case LT68 and HLA-
A2 (A) and HLA-B57 (B)
Thus a protocol based on serial HLA-protein affinity chromatography followed by size
exclusion chromatography allowed for the purification of polyclonal IgG HLA-specific
antibodies and removal of materials giving non-specific binding signals on SPR.
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1.1.1.1.2 HLA-protein followed by protein-G affinity chromatography prior to sizeexclusion chromatography
Substantial loss of IgG between the two runs of HLA-affinity chromatography runs was noted.
Therefore, use of Protein G-Sepharose was considered as an intermediate purification step.
Plasma effluents from three cases (LT45, LT66 and LT68) were processed through HLA-A2
affinity chromatography (see section 6.3.1.1) and the eluted proteins were concentrated prior
to running through a Protein G-Sepharose (4 ml) column as described in Chapter 2. This was
followed by SEC as described above.
The Protein G-Sepharose column used for these experiments had previously been used for
the enrichment of human monoclonal antibody WK1D12 (Chapter 4) and given the
considerable expense of Protein G-Sepharose resin, it is customary in many laboratories to
re-use resin from which antibodies have been ostensibly eluted. Despite prolonged re-
generation after the particular previous use, WK1D12 remained attached which resulted in
contamination of polyclonal antibody preparations from this set of experiments (as seen in
Figure 6-20, B). However, it also gave specific binding signals to HLA-A2 which would not be
derived from the contaminating WK1D12 monoclonal antibody (Figure 6-20, A). This
interesting set of findings highlights the sensitivity of the SPR system and its ability to detect
antibodies even as contaminants and also the vulnerability of established antibody
purification techniques such as Protein G-Sepharose affinity chromatography.
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Figure 6-20 : Binding interactions between LT45 polyclonal antibodies to HLA-A2 (A) and
contamination from WK1D12 to HLA-B27 proteins (B), measured simultaneously. Curves
represent diluting concentration of purified antibodies.
Thus although the results obtained here are in some ways similar to serial HLA-protein affinity
chromatography, compromised regeneration of Protein G-Sepharose columns meant that
these could not be used repeatedly. Due to significant cost issues associated with this
approach, it was not used for subsequent experiments. HLA-protein chromatography is more
amenable to regeneration but the efficiency differs between effluent samples. Plasma
effluent from LT45 gave two elution profiles when tested on Luminex (Figure 6-21). Thus this
is dependent on epitope and as well as affinity of the antibodies. Additionally there was
concern that low affinity antibodies in a polyclonal clinical sample may not bind as effectively
to HLA-Sepharose and that the enrichment process would be biased for high affinity
antibodies. Therefore, for subsequent experiments, affinity chromatography as an
intermediate step was omitted and only sequential precipitation followed by size exclusion
chromatography was considered.
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Figure 6-21 : Different elution profiles following HLA-A2 affinity chromatography of polyclonal antibodies from case LT45
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Enrichment/purification protocols for serum samples
A major aim of this Project was to develop assays for the study of antibody binding kinetics
using amenable clinical samples such as serum obtained via phlebotomy. Based on
experiences from enrichment protocols of large volumes of plasma effluent described above,
two protocols for polyclonal antibody recovery from clinical serum samples were attempted.
Sequential precipitation and HLA-protein chromatography followed by size
exclusion chromatography
Six serum samples (20 - 30 ml each) from NHSBT, Birmingham were obtained. These were
typing sera from multi-parous women and were known to have high CDC titre for HLA-A2 and
HLA-B7 specificities.
Serum sample volume over 20 ml:
Serum sample B518
Serum from case B518 (20 ml), as distinct from plasma effluent, was processed using
sequential precipitation and HLA-A2 affinity column (4 ml) followed by SEC as described
above. The MFI values for HLA-A2, HLA-A69 and HLA-B57 specificities were 23207, 21967 and
13687 respectively. Concentration measured using quantitative ELISA was 3.2 nM. The
binding interactions observed are shown in Figure 6-22. The Rmax values were highest for
interactions with HLA-A2 protein followed by HLA-A69 and HLA-B57 and follow the trend with
MFI values. HLA-specific antibody quantification was carried out using ELISA as described
below in section 6.2.3. Equilibrium analysis is indicated in Figure 6-23.
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Figure 6-22 : Binding curves of interactions between polyclonal antibodies from case B518 and HLA-A2 (A), HLA-A69 (B) and HLA-B57 (C)
Figure 6-23 : Equilibrium analysis of binding data from interaction between polyclonal antibodies from case B518 and HLA-A2 (A) and HLA-
A69 (B)
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Serum sample B2007
Serum from case B2007 was processed as above, using sequential precipitation and HLA-B7
affinity column (4 ml) to enrich the HLA-B7-specific polyclonal antibodies (as opposed to HLA-
A2 used previously), followed by SEC. The MFI value was 22778 and binding interactions with
immobilised HLA-B7 via SPR are shown in Figure 6-24. The concentration measured by
quantitative ELISA was 7 nM. The dissociation constant measured using equilibrium analysis
is shown in Figure 6-25.
Figure 6-24 : Binding interactions between polyclonal antibodies from case B2007 and
HLA-B7 protein
Figure 6-25 : Equilibrium analysis of binding data from interaction between polyclonal
antibodies from case B2007 and HLA-B7
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Serum sample volume of 5 ml
Serum sample B572
Serum from case B572 was processed as a 5 ml sample using HLA-A2-Sepharose. MFI values
measured by Luminex SAB and were for HLA-A2, HLA-A24, HLA-A69 and HLA-B57 were 20639,
4956, 8139 and 16814 respectively. In spite of a lower volume of starting material, good-
quality binding interactions were still obtained with a discernable range of specificities for a
HLA-protein panel as shown in Figure 6-26. Non-specific binding artefacts were also low. The
dissociation constant calculated for interaction with HLA-A2 was 1.06E-07 M. For other
interactions the binding response gave only few data point to calculate dissociation constant
using equilibrium analysis.
Figure 6-26 : Binding curves from interactions of B572 and HLA-A2 (A), HLA-A24 (B), HLA-
A69 (C) and HLA-B57 (D)
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Sequential precipitation and size exclusion chromatography
Following the promising results from using 5 ml serum, the next step was to consider further
refinement to allow testing of antibodies recovered from 2 ml of serum. To achieve maximum
polyclonal antibody recovery and quantification, the protocol was simplified to a two-step
process that consisting of IgG precipitation with octanoic acid then ammonium sulphate,
followed by SEC. Affinity chromatography steps were removed so as to reduce the
considerable losses of IgG seen with the multi-step protocols, and also provide a more cost-
effective protocol for the preparation of meaningful polyclonal antibody samples suitable for
SPR analysis.
Two sera specific for HLA-B7 (cases B1170 & B1175) were used and the MFI values for B1170
were 23169, 18128 and 19200 against HLA specifities-B7, B40:01 and B40:02 respectively;
and B1175, the values were 21958, 16234 and 16566 against HLA-specifities-B7, B40:01 and
B40:02 respectively. The binding kinetics are shown in the Figure 6-27 and Figure 6-28
respectively.
These experiments demonstrated that clean and specific binding signals can be obtained
using this simplified protocol. The challenge ahead would consist of reliably quantifying the
HLA-specific antibodies within the enriched IgG pool eluting from the SEC column.
Interestingly both the above cases used were known to be highly CDC positive (personal
communication from NHSBT, Birmingham).
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Figure 6-27 : Binding kinetics of interactions of polyclonal antibodies B1170 with HLA-B7 (A), HLA-B40:01 (B), HLA-B40:02 (C) and
corresponding dissociation constant in D, E & F respectively.
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Figure 6-28 : Binding kinetics of interactions of polyclonal antibodies B1175 with HLA-B7 (A), HLA-B40:01 (B), HLA-B40:02 (C) and
corresponding dissociation constant in D, E & F respectively.
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Quantification of HLA-specific antibodies
Current assays do not quantify HLA-specific antibodies as a function of mass, from which
specific molar concentrations can be derived. This presents an impediment to binding analysis
via SPR, which requires knowledge of analyte molarity in order to generate rationalised,
quantitative data sets. Popular current assays such as Luminex SAB are semi-quantitative and
assays such as complement dependent cytotoxicity (CDC) yield important functional
information but do not express quantities that can be directly translated to SPR experiments.
Details of these assays are described in Chapter 2.
The development of quantitative assays for circulating HLA-specific antibodies is limited by
the diversity and heterogeneity of the HLA system. In clinical practice, quantitative ELISAs are
available for measuring serum antibody levels in conditions such as anti-GBM disease and
ANCA-associated vasculitis. For both of these conditions, international calibrating standards
have been agreed upon and are used in commercial diagnostic ELISAs worldwide. For
example, in the ANCA ELISA kit, the standard consists of a sample from a clinical case
containing a very high titre of polyclonal antibodies against ANCA autoantigens. In HLA-
sensitised patients with polyclonal antibodies directed against multiple epitopes that could
be on the same antigen or shared between many antigens, an attempt to develop an
ELISA/Luminex standard has not been explored in depth. However, with the availability of
several human monoclonal HLA-specific antibodies, early attempts to develop standards for
quantitative polyclonal antibody assays have been made herein.
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With respect to interaction techniques such as SPR, reliable quantification of HLA-specific
antibodies as a function of molar concentration is one of the prerequisites for the calculation
of binding kinetics. A highly accurate antibody concentration can only truly be obtained if the
sample is pure IgG with no interfering proteins and in sufficient quantity to yield a high quality
protein assay result. Various strategies were used to determine HLA-specific antibody
concentration as described in Chapter 2. Two broad strategies were approached – 1) direct
measurement of purified protein content from large clinical samples, purified using specific
HLA-protein affinity chromatography; and 2) measurement of the HLA-specific component of
isolated IgG fractions via ELISA using purified HLA proteins and an anti-HLA calibration
standard comprised of monoclonal antibodies.
Determination of protein concentration
Nanodrop spectrophotometry
This assay was used as a rough guide for estimating of protein content during purification
protocols. This was typically used for monitoring elution profiles during IgG purification from
plasma effluent via affinity chromatography. Figure 6-29 demonstrates gross changes in
protein concentration, as determined via A280nm, during various phases of affinity
chromatography. There was larger protein content in plasma effluent from the flow through
phase, as expected, followed by diminishing protein content during washing fractions. In the
elution phase, a relatively small peak of protein appears (typically at fraction 4 in the elution
protocol used - corresponding to approximately one column bed volume).
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When these elution profiles were analysed via Luminex, a prolonged “tail” of anti-HLA
reactivity was seen (Figure 6-30). Surprisingly, the standard 4 x column volume elution length
in high pH buffer was not sufficient for complete antibody recovery and regeneration of the
HLA affinity column. This “tail” could be due to high affinity and high pH-resistant antibodies
that either form very stable complexes with the immobilised HLA under the extreme elution
conditions, or require a much longer elution time in order to dissociate from the column.
Henceforth, larger elution volumes (20 x column volume) were used.
Figure 6-29 : Profile of protein content during different phases of HLA-A2 affinity
chromatography using plasma effluent from case LT79.
Figure 6-30 : Elution profile of case LT45 using the HLA-A2 affinity column
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Hence concentration measurement with Nanodrop is limited by the sensitivity and if used
alone can miss the tail end of elution fraction.
Determination of polyclonal HLA-specific antibody concentration
Luminex quantification
Two different purified monoclonal HLA-A2 specific antibodies of known concentration
(determined via Lowry’s and BCA protein assay) were used to study the effect of titration on
MFI levels using single antigen beads. Despite being used at identical concentrations, there
was a 10-fold difference in EC50 (Effective concentration that gives 50% of maximal response)
between these two antibodies with respect to HLA-A2 (10.4 and 1.3 ug/ml) (Figure 6-31). The
EC50 concentration value was lower for SN230G6, confirming earlier observations (Chapter 4)
that it is a higher affinity antibody compared to SN607D8.
Figure 6-31 : Titration curves showing relationship between sample dilution and MFI
values obtained via Luminex.
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These data indicated discrepancies in antibody concentration in relation to MFI and given the
expense of Luminex assays, optimisation and future use of this platform for explicit
determination HLA-specific antibody concentration would not be cost effective. Therefore the
ELISA platform was considered as a more practical alternative.
Sandwich ELISA quantification
Although ELISA and Luminex are similarly end-point immunoassays, the cost benefit and
adaptability of ELISA makes it easier to set up and optimise rapidly in the laboratory. The HLA-
A2-specific monoclonal antibodies SN607D8 and SN203G6 were tested in triplicate via ELISA
using HLA-A2-coated microwell plates to derive the titration curve (Figure 6-32). EC50 values
were calculated using dose-response curve fitting using PRISM software.
Figure 6-32 : Titration curve showing relationship between concentration and relative
absorbance measured via ELISA for HLA-A2 specific monoclonal antibodies. (X-axis values
are log conversion of concentration measured in ng/ml).
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The ELISA assay also confirmed that the SN230G6 stronger than SN607D8 as EC50 for SN230G6
was 3.7-fold lower than SN607D8. EC50 values were 15.68 and 58 for SN230G6 and SN607D8
respectively. The stability of the SN607D8 antibody, its good performance in SPR, and its
abundance in the laboratory made it the preferred calibration curve standard. For HLA-B7
quantification, the monoclonal antibody WK1D12 was used.
Five polyclonal antibody samples (3 derived from plasma effluent (LT33, LT68 & LT79 cases)
and 2 from serum (B518 & B572 cases)) that gave distinct binding to HLA-A2 via SPR were
quantified using the HLA-A2-specific sandwich ELISA. These samples were tested as neat
fraction, and also as 1:10, 1:100 and 1:1000 dilutions to obtain a titration range. The points in
the linear range of the standard curves obtained using SN607D8 were used to derive
polyclonal concentrations (see Figure 6-33). The concentrations of the neat polyclonal anti-
HLA-A2 preparations were determined to be as follows 8.55 nM for LT33, 36.45 nM for LT79,
3.23 nM for B518, and 1.07nM for samples B572 cases.
Similarly, a HLA-B7-specific sandwich ELISA assay was used to quantify three polyclonal
antibody samples as neat post-SEC fractions, and also dilutions of 1:10, 1:100 and 1:1000. The
concentrations derived were 7.13 nM for B2007, 71 nM for B1170 and 3.53 nM for B1175 (see
Figure 6-34). This sandwich ELISA protocol was therefore able to measure polyclonal antibody
concentration in nanomolar range.
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Figure 6-33 : Quantitative HLA-A2 specific ELISA. A – Standard curve using monoclonal antibody SN607D8, B-E – polyclonal HLA-A2 specific
antibodies in clinical samples (Red circle indicates values in the linear range of the standard curve)
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Figure 6-34 : HLA-B7 specific sandwich ELISA. A – Standard curve obtained from monoclonal antibody WK1D12, B-D – clinical, polyclonal
samples (Red circle indicates values in the linear range of the standard curve)
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The relative absorbance (OD494) obtained from ELISA were also correlated with associated
Luminex MFI values for samples quantified above (five samples against HLA-A2 and three
samples against HLA-B7) and Spearman correlation coefficient was determined as 0.952 (P <
0.001). See Figure 6-35.
Figure 6-35 : Correlation of Luminex MFI values and ELISA absorbance units at 494 nm
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Protein concentration determination via surface plasmon resonance
In addition to measurement via ELISA, there are various ways by which relevant analyte
concentrations can be calculated using surface plasmon resonance.
i. Using standard calibration curve
Purified human monoclonal HLA-specific antibodies of known concentration can be used to
obtain a standard curve of response units (RU) versus concentration. Polyclonal HLA-specific
antibody concentration can be derived from the standard curve. (Yurugi et al., 2007).
ii. By using prior knowledge of kinetic constants
In this approach the kinetic constant is already known and concentration parameters are
identified by fitting to binding data. An advantage of this approach, if applicable, is that it does
not require a calibration curve (Mehand et al., 2011).
iii. From initial reaction rate correlation
Under mass transport limitation, the initial (first 30 seconds) reaction rate is proportional to
antibody concentration and is independent of binding kinetics (Karlsson et al., 1991, Lynch et
al., 2014, Chavane et al., 2008).
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The first approach, using a standard curve of RU values had the inherent limitation of affinity
dependence, as it uses maximal response (which can be affinity dependent) and since it is
known that different interactions give rise to variations in Rmax, this method for
quantification in polyclonal antibodies is not reliable. The second approach assumes that
affinity is same for all HLA-specific antibodies and can only conceivably be used for quantifying
antibodies with the same or very similar physiochemical properties. It is known from
monoclonal antibody work (Chapter 4) that variation in affinity is wide and substantial.
The third approach can be used in conjunction with binding experiments and can be used off-
line to calculate the concentrations. The concentrations of enriched polyclonal HLA-A2
specific antibodies (LT33, LT79, B518 and B572) were calculated and compared results from
two different human monoclonal HLA-A2 specific antibodies as shown in Figure 6-35 and
Figure 6-37. Despite previous reports, it was noted that the concentration derived for each
monoclonal HLA-A2 specific antibody was different - the higher affinity antibody SN230G6
gave a 6-fold lower concentration reading than SN607D8. When calculating binding slope
versus concentration using the first 30 seconds of analyte contact, the SN230G6 sensorgram
already started to plateau. Hence only first 10 seconds were used for the standard curve for
this antibody. Figure 3-38 shows quantification of polyclonal HLA-B7-specific antibodies,
studied alongside the B7-specific WK1D12 monoclonal. The Rmax values correlated well with
the relative concentrations of the HLA-B7 specific antibodies but less so for the HLA-A2
specific antibodies. The anomalous negative value obtained for B572 case suggested that the
affinities some of the polyclonal antibodies were lower than both of the monoclonal
standards used, and lower limits of meaningful detection were being reached.
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Figure 6-36 : Determination of anti-HLA-A2 polyclonal antibody concentration. A – Calibration curve of monoclonal HLA-A2-specific
antibody SN607D8; B – relationship of concentration and binding slope giving standard curve; C – Binding curves of polyclonal HLA-B7
specific antibody samples, D – concentrations of samples
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Figure 6-37 Determination of anti-HLA-A2 polyclonal antibody concentration. A – Calibration curve of monoclonal HLA-A2-specific antibody
SN203G6; B – relationship of concentration and binding slope giving standard curve; C – Binding curves of polyclonal HLA-B7 specific
antibody samples, D – concentrations of samples
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Figure 6-38 : Determination of anti-HLA-B7 polyclonal antibody concentration. A – Calibration curve of monoclonal HLA-B7-specific
antibody WK1D12; B – relationship of concentration and binding slope giving standard curve; C – Binding curves of polyclonal HLA-B7
specific antibody samples, D – concentrations of samples
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Comparisons of antibody quantification methods
The concentrations of polyclonal HLA-specific antibodies obtained by sandwich ELISA and SPR
methods were compared and correlated relatively well (Linear R2 = 0.88; Pearson correlation
coefficient = 0.98, P = 0.002) (Figure 6-39) and were in agreement within one order of
magnitude. As seen in Table 6-5, the SPR calculations were generally higher than those
determined by ELISA, although low concentration/low affinity antibody samples highlighted the
lower limit of sensitivity within the SPR method.
Cases Relative concentration (nM)
SPR
Relative concentration (nM) ELISA
LT33 38.40 8.55
LT79 62.53 36.45
B518 32.52 3.23
B572 -6.15 1.07
B2007 54.68 7.13
B1170 258.3 71
B1175 16.87 3.53
Table 6-5 : Relative concentration of enriched clinical samples – comparison between SPR
and ELISA
Despite of these limitations, the SPR method would in principle allow for measurement of
concentrations from interactions across a range of different HLA proteins simultaneously on the
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XPR36 system. It is also represents a self-contained system for measuring both concentration
and subsequently affinity. Hence for the clinical studies involving polyclonal antibodies, the SPR
method was used to measure antibody concentration.
Figure 6-39 : Correlation between concentration calculated using SPR (initial 30 seconds
binding approach) and sandwich ELISA
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Summary and Discussion
This Chapter covers two important aspects in developing SPR techniques for measuring binding
kinetics of polyclonal HLA-specific antibodies derived directly from clinical samples with realistic
starting volumes of serum. Firstly, although labour-intensive at the outset, the protocols
described here clearly demonstrate that polyclonal HLA-specific IgG can be enriched and yield
meaningful SPR sensorgrams via a refined purification and sample polishing process that, very
importantly, was able to remove persistent, serious and impeding non-specific binding factors
in polyclonal antibody preparations otherwise considered acceptable in other assays. This work
demonstrates the effective combination of precipitation and chromatography techniques and
highlights the importance of diligent protein chemistry when approaching extremely sensitive
biophysical techniques such as SPR.
The second important aspect was quantifying HLA-specific antibodies. Mathematical models
used for calculating binding kinetics require a concentration value input. Currently there are no
assays that routinely quantify polyclonal HLA-specific antibody levels with accuracy. Luminex
assays measure HLA-specific antibody levels semi-quantitatively and the experiments have
shown that MFI vales can be influenced by the intrinsic affinity of antibodies. Protein assays such
as Lowry and BCA can quantify high purified HLA-specific antibodies following serial affinity and
size exclusion chromatography steps, but they are limited by sensitivity and consume valuable
amounts of protein, being only useful following large scale purification using plasma effluent.
With the availability of human monoclonal IgG HLA-specific antibodies, the developing of
quantitative assays using a standard curve approach was sought. ELISA work showed that
calibration curve characteristics were influenced by varying antibody affinities. Concentration
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determination via SPR that derives data from initial binding events in first 30 seconds was more
appealing, due to being applicable to multiple HLA-specificities simultaneously. Whilst
possessing a wider range, this unique SPR technique still presents imperfections and, ultimately,
further optimisation will be required.
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Binding kinetics and affinity measurement
on polyclonal clinical sample of highly
sensitised patients
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Introduction
One in four patients on transplant waiting list are highly sensitised and have HLA-specific
antibodies of various strength and specificities. The assessment of these HLA-specific antibodies
possesses a particular challenge pre-transplantation. With current assays it has been observed
that not all HLA-specific antibodies pose similar risk and various strategies described in chapter
1 are utilised in clinical practise to allow direct transplantation in presence of donor HLA-specific
antibodies (DSA). With the limitations of available clinical assays, the current PhD project aimed
at developing and validating an assay to measure binding characteristics of HLA-specific
antibodies to the HLA proteins in an in vitro assay based on biosensor platform.
Methods and materials
In previous chapter-6, the protocols were established that allowed purification of IgG HLA-
specific antibodies from larger plasma effluent samples and enrichment of IgG HLA-specific
antibodies from smaller volume of serum samples (2-5 ml). Enrichment of IgG polyclonal HLA-
specific antibodies together with ability to measure relative concentration allowed us to study
clinical samples.
Samples from 32 highly sensitised patients who underwent HLA-incompatible kidney
transplantation at University Hospital, Coventry were used. Cases were selected based on
presence of HLA-A2 and / or HLA-B7 specific antibodies detected by Luminex single antigen
beads. Ethical permission (CREC-055/01/03 and 13/WM/0090) and written informed consent
were taken from these patients. Table 7-1 shows baseline characteristics of these 32 highly
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sensitised patients. 1.5 to 3 ml of stored serum samples were used to characterise binding
kinetics pre-transplantation.
Characteristics results
Age median (IQR) 44 (38 to 49)
Gender (M:F) 15:17
Previous Transplant 0.87
ESRF median (IQR) years 13 (6 to 19.5)
Time on waiting list in years median (IQR) 3 (1.25 to 7.5)
Mismatch (mean) 3.13
Pre-transplant cross match status
CDC
FXM (Flow cross match)
Bead only
11
19
2
Table 7-1: Baseline characteristics of patients studied for binding kinetics
Purification and quantification
Serum samples with starting volume of 1.8 to 3 ml were processed using protocol consisting of
sequential precipitation and size exclusion chromatography. The peak fraction from size
exclusion chromatography was tested for enrichment and HLA-specificities using Luminex single
antigen bead (SAB) assay by One Lambda and Life code kits. A positive cut off for One Lambda
SAB assay was set as over 500 MFI. Whilst Life code SAB assay, the positive assignment is based
on company’s recommendation of two of more positive adjusted ratio relative to control beads.
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The enriched samples corresponding to the IgG peak on Size exclusion chromatography were
quantified using sandwich ELISA and SPR using initial binding reaction. Monoclonal HLA-specific
antibodies; SN607D8 (epitope – 142T) and WK1D12 (epitope – 163E) were used as standards for
calculating concentration of HLA-A2 and HLA-B7 specific antibodies respectively.
SPR experiments on enriched samples
The experimental condition and protocols were same as described in chapter 3. The only
difference was the association phase was reduced to 720 seconds due to limited volume of
samples. Initially the experiments were performed using ligand immobilisation of RU 400 (0.25
microgram/ml) but latter this was increased to RU of 1200 (2.5 microgram/ml). The data
obtained were modelled with heterogeneous ligand model.
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Results
Quantification of HLA-specific antibodies
The relative concentration obtained from sandwich ELISA and SPR (Initial binding response)
were correlated using linear regression. As seen in Figure 7-1, there is moderate linear
relationship between the measurements.
Figure 7-1 : Correlation of relative concentration measured by ELISA and SPR
There was poor relationship between concentration measurements and MFI values determined
by Luminex SAB assay (See Figures 7-2 and 7-3). Moreover the relative concentration
measurements using sandwich ELISA could only be used for HLA-specific antibodies against HLA-
A2 or B7 and cannot be extrapolated to antibodies against other HLA proteins.
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Figure 7-2 : Correlation between raw MFI (One Lambda SAB assay) and relative
concentration (ELISA)
The relative concentration obtained using SPR (initial binding slope) were not affected by
binding kinetics and affinity of interactions with HLA proteins. Additionally SPR method could
be used for quantification of antibodies interacting against various HLA proteins. Hence relative
concentration of antibodies obtained from SPR is more reliable and favoured for calculating the
binding parameters from the overall experiments.
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Binding response (qualitative assessment)
Out of 32 patients, five patients were excluded as the MFI was less than 500. There was no
specific binding response observed for nine patients. The MFI of the corresponding HLA
specificities were below 2700 for all except one case (MFI 7578). One case was further excluded
due to error in labelling. Rest enriched samples from 17 patients gave distinct signal against 26
out of 50 HLA-specificities tested. When the binding response was broken as per MFI values
obtained on the enriched samples, a MFI greater than 10,000 predicted successful binding (p =
0.0047, Fisher Exact 2-tail test) (Table 7-2).
MFI Binding on SPR
Yes No
<10,000 10 19
>10,000 16 5
Table 7-2: Correlation of MFI and binding response on SPR (Fisher exact two tail test used to
calculate significance).
When the binding response on SPR was correlated with positive response on Life code single
antigen beads, the relationship between positive response on both assay was statistically
significant (p=0.0001). Table 7-3 shows the relationship of responses on both the assays.
Life code Binding on SPR
Yes No
Positive 21 4
Negative 6 19
Table 7-3 : Correlation of positive response on Life code single antigen bead and binding on
SPR (Fisher exact two tail test used to calculate significance)
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A higher concentration is required to give binding response on surface plasmon resonance with
HLA-protein density of 2.5 mcg/ml. A mean relative concentration for binding responses for
HLA-A2 and HLA-B7 was 1381 ng/ml compared to 281.52 ng/ml for non-binding responses on
SPR. The median value was similarly higher for a binding response (617.74 ng/ml) compared to
non-binding response (171.35 ng/ml).
Binding kinetics and affinity (quantitative)
The binding affinities were calculated using equilibrium and kinetic analysis. As shown in the
Table 7-4, the dissociation constants derived from kinetic analysis can be divided into four
groups based on binding affinity. The green colour corresponds to low affinity antibodies,
orange for intermediate affinities, red for high affinities and dark red for very high affinity
antibodies. The kinetic values were measured using heterogeneous ligand mathematical model
(See Figure 7-3). Different kinetic values were observed for interaction against same HLA-A2
protein, suggesting diverse binding characteristics of polyclonal HLA-specific antibodies in
patients.
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Figure 7-3 : Binding sensorgram of polyclonal HLA-A2 specific antibodies and HLA-A2 proteins (solid lines are data fitting from heterogeneous
ligand model. Binding curves from top to bottom corresponds to diluting concentration of purified IgG HLA-specific antibodies
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Equilibrium Kinetic (Heterogeneous Ligand model)
KD ka kd KD
LT42 B27 6.09E-08 3.27E+01 7.57E-02 2.31E-03
LT50 B7 4.83E-04 8.45E+00 2.77E-03 3.28E-04
LT28 A2 2.78E+00 2.56E-04 9.20E-05
LT43 B27 1.29E+01 5.43E-04 4.20E-05
LT43 B40:01 3.95E-04 3.84E+00 1.04E-04 2.99E-05
LT39 B37 7.87E-05 1.55E+01 2.63E-04 1.69E-05
LT35 A24 3.47E-05 4.98E+01 5.75E-04 1.15E-05
LT33 B40:01 8.93E+00 5.26E-05 5.90E-06
LT66 A2 1.30E-05 9.21E+01 5.10E-04 5.53E-06
LT2 B27 2.77E-08 1.12E+04 3.42E-04 3.04E-08
LT43 B40:02 2.01E+00 4.88E-08 2.42E-08
LT36 A2 1.83E+04 2.00E-04 1.09E-08
LT65 A2 1.37E+03 1.28E-04 9.37E-08
LT42 B7 3.25E-08 4.56E+05 3.72E-03 8.16E-09
LT40 B27 1.26E-08 1.51E+06 9.66E-03 6.37E-09
LT40 B40:02 7.10E-09 1.20E+06 6.74E-03 5.61E-09
LT21 B57 2.71E+04 1.14E-04 4.20E-09
LT2 B7 8.12E-09 2.01E+06 6.98E-03 3.47E-09
LT36(LD) A69 5.09E+04 1.52E-04 2.99E-09
LT79 A2 (LD) 1.21E+05 2.66E-04 2.20E-09
LT42 B40:02 7.11E-08 6.62E+04 8.77E-05 1.33E-09
LT78 A2 1.35E+07 7.39E-03 5.46E-10
LT68 B57 1.97E+05 7.43E-05 3.78E-10
LT68 A2 2.44E+05 2.12E-06 8.70E-12
LT16 A1 1.17E+04 1.19E-09 1.02E-13
LT40 B8 1.21E+06 1.01E-11 8.38E-18
LT35 A1 4.94E-09 6.55E+06 2.36E-11 3.61E-18
LT43 B7 1.96E-08 1.06E+06 3.48E-16 3.28E-22
LT40 B40:01 7.30E-09 5.04E+06 1.91E-17 3.78E-24
Table 7-4 Binding kinetics and strength highly sensitised patient
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Although patients can be grouped in to four groups based on dissociation constants derived
from kinetic analysis, other parameters vary for patients with same overall dissociation
constants. For example in Table 7-4, the apparent dissociation constant is same for patients LT42
and LT21 for HLA-B7 and HLA-B57 respectively, the association and dissociation rates are faster
or patient LT21.
Similarly, the same patient can have range of affinities against different HLA-proteins, which
may be due to different stages of affinity maturation for the clones producing the respective
antibodies. Figure 7-4 shows different binding characteristics against different HLA-proteins
from same patients (LT40 & LT42). As seen in Table 7-5, patient LT43 has low affinities for HLA-
B27 and B40:01 but very high affinity for HLA-B7. Similarly, the apparent affinity values are
different for different antibody specificities in the case of LT42 and LT35. Whilst cases such as
LT40, LT66 and LT21 have consistently higher affinities for all of the specificities studied.
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Figure 7-4 : Binding sensorgram of polyclonal HLA-specific antibodies and different HLA-proteins. Binding curves from top to bottom
corresponds to diluting concentration of purified IgG HLA-specific antibodies
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Equilibrium Kinetic (Heterogeneous Ligand model)
KD ka kd KD
LT2 B27 2.77E-08 1.12E+04 3.42E-04 3.04E-08
B7 8.12E-09 2.01E+06 6.98E-03 3.47E-09
LT35 A24 3.47E-05 4.98E+01 5.75E-04 1.15E-05
A1 4.94E-09 6.55E+06 2.36E-11 3.61E-18
LT36 A2 1.83E+04 2.00E-04 1.09E-08
A69 5.09E+04 1.52E-04 2.99E-09
LT40 B27 1.26E-08 1.51E+06 9.66E-03 6.37E-09
B40:02 7.10E-09 1.20E+06 6.74E-03 5.61E-09
B8 1.21E+06 1.01E-11 8.38E-18
B40:01 7.30E-09 5.04E+06 1.91E-17 3.78E-24
LT42 B27 6.09E-08 3.27E+01 7.57E-02 2.31E-03
B7 3.25E-08 4.56E+05 3.72E-03 8.16E-09
B40:02 7.11E-08 6.62E+04 8.77E-05 1.33E-09
LT43 B27 1.29E+01 5.43E-04 4.20E-05
B40:01 3.95E-04 3.84E+00 1.04E-04 2.99E-05
B40:02 2.01E+00 4.88E-08 2.42E-08
B7 1.96E-08 1.06E+06 3.48E-16 3.28E-22
LT68 B57 1.97E+05 7.43E-05 3.78E-10
A2 2.44E+05 2.12E-06 8.70E-12
Table 7-5 : Comparisons of affinities and kinetic values from the same patient
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Relationship between Luminex MFI values, antibody concentration and binding
affinity of HLA-specific antibodies determined by SPR
The relationship between the affinity, concentration and MFI value (measured by One
Lambda SAB assay) is not linear. Higher MFI values do not correlate with high antibody
concentration nor higher affinity (Figure 7-5, A). As seen in Figure 7-5 (B), MFI values differed
4-6 fold for the same concentration and equally for a range of concentrations the MFI values
were similar (right side of figure). There was no linear relationship between MFI values and
dissociation constant (Figure 7-5, D) and similarly no linear relationship between relative
concentration and dissociation constant (Figure 7-5, C).
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-
Figure 7-5 : Relationship between MFI values, concentration (nM) and dissociation constant (KD)
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Relationship of affinity of polyclonal HLA-specific antibodies with
transplant outcomes (rejection and graft loss)
Out of the 32 cases selected, 18 cases had donor-specific responses and 14 cases had non-
donor specific responses against HLA-A2 or B7 on Luminex SAB assay using the One Lamba
kit. HLA-A2 and B7 reactivity were chosen, since the quantitative ELISA can be performed
against these specificities. However, out of 32 cases, only 10 cases demonstrated a
meaningful SPR binding response against HLA-A2 or HLA-B7 proteins. Only two cases (LT68
and LT43) had quantifiable binding responses against donor-specific HLA proteins (see Figure
7-6). From a graft outcome perspective, Case LT68 had acute AMR on day-0 and the graft
failed despite treatment with ecluzimab, ATG and plasma exchange in the early post-
transplant period.
In contrast, Case LT43 was stable with no clinical evidence of rejection. This difference in graft
outcome might be explained by differences in the affinities of other cross-reactive polyclonal
HLA-specific antibodies. As seen from Table 7-5, LT68 has higher affinity antibodies against
HLA-A2 and HLA-B57 whilst LT43 only has higher affinity polyclonal HLA-specific antibodies
against HLA-B7; other specificities were classified as having low to intermediate affinities. The
MFI values were lower for LT43 compared to LT68 (4000 versus 11,000).
Obviously, from only these two cases it is impossible to establish a reliable relationship
between antibody affinities and adverse outcome. Nevertheless, data from future, larger
studies are eagerly awaited, and the opportunity to incorporate antibody affinity parameters
is now available.
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Figure 7-6 : Binding kinetics of donor HLA-specific polyclonal IgG in cases LT68 and LT43. Binding curves from top to bottom corresponds to
diluting concentration of purified IgG HLA-specific antibodies and black line represents the fitting with mathematical model
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Discussions
This preliminary study of polyclonal HLA-specific antibody interactions with HLA-proteins using
antibodies recovered from manageable volumes of patient serum samples gave useful insights
and is probably the first in the world to indicate the associated binding kinetics.
The apparent affinity of polyclonal HLA-specific antibodies can be grouped in to four distinct
sets across a defined range of KD values. This has the potential to be used as additional tools to
risk stratify cases considered for direct transplantation (both against low and high MFI levels).
As seen in Figure 7-5, antibodies corresponding to high MFI could fall into the lower affinity
range. The antibody concentration measurements using SPR-IBR had reasonable correlation to
concentration measured by ELISA. The advantage of using SPR-IBR is that it allows the
simultaneous measurement of concentration against a range of HLA proteins, which is
important especially when studying clinical samples with very limited amounts of antibody.
In some cases the kinetics rates (ka, kd) differed between discrete antibody interactions that
yielded similar overall dissociation constants (KD). Thus the real time nature of SPR analysis
could provide additional useful parameters that further define antibody character which are
unavailable to end-point equilibrium analyses such as ELISA. Within the same patients, the
binding kinetics varied across different HLA proteins, and it is tempting to suggest that this might
reflect different stages of antibody affinity maturation produced from different clones,
something that may be due to differences in the duration following primary sensitization events
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within the same patient. Hence, when deciding the relevance of HLA-specific antibodies in
future, the binding kinetics of individual antibodies could be very valuable.
Dissociation constants calculated by equilibrium and kinetic analysis differed. This is because
the assumption for equilibrium analysis is that all the binding interactions reach an equilibrium
phase. However, due to limited amounts of patient sample and the sample loop volume limit of
the SPR instrument, prolonged contact times were not feasible and calculations had to depend
on data extrapolation by the analysis software. In principle, dissociation constants calculated via
kinetic analysis are more accurate; however, these analyses can be limited by the fidelity current
data fitting mathematical models that are designed around simpler interacting systems than
comparatively complex IgG and HLA molecules.
Other limitations of these preliminary protocols include the requirement for higher starting
concentration of HLA-specific antibodies for a distinct SPR binding signal compared with
Luminex or ELISA, largely due to SPR being a direct rather than indirect form of measurement
(i.e. no secondary conjugate step with a signal amplification capacity). The relative
concentrations of HLA-specific antibodies derived from ELISA for non-binding responses on SPR
were in the nanomolar range. Due to the scarcity of sample, these experiments examining a
larger range of HLA proteins could not be done in duplicate and thus we were not able to
establish reproducibility in full. However, the reproducibility and robustness of the analysis
platform as demonstrated using monoclonal HLA-specific antibodies lent a considerable degree
of confidence to the preliminary results.
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8. Summary and future direction
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Summary
HLA-specific antibodies have distinct and varied biochemical and biophysical characteristics (for
example different profiles of class or sub-class) and these may explain varied immune responses
associated with their presence in transplantation. Both class switching and affinity maturation
are dependent on T cell help and thus measurement of class/sub-class profile and binding
characteristics could offer further information regarding cellular and humoral immune system
activity. In principle, cellular responses and function can be studied in vitro via assays such as
ELISPOT. However, isolation of the relevant donor-specific B cells and T cells is extremely
challenging. The biophysical properties of antibodies such as affinity could directly influence
graft damage and could potentially serve as important indicators of both cellular and humoral
immune responses. In this thesis, the class switching of de novo HLA- specific antibodies
following standard transplantation and the binding kinetics of pre-formed HLA-specific
antibodies are studied in detail. The objectives set out in Chapter-1 are tackled below:
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Objectives and outcome:
1. To study the evolution of HLA-specific IgM and IgG antibodies in non-sensitised patients
and study effects on graft outcome prospectively.
In order to study the evolution of de novo HLA-specific antibodies and their impact on transplant
outcome, eighty patients receiving standard kidney transplantation were prospectively followed
over three years. The serological sampling was rigorous and both IgM and IgG de novo responses
were examined.
This study demonstrated that the prevalence of de novo IgM and IgG HLA-specific responses
were low with 8.8 % for IgG and 3.8% for IgM. There were large numbers of non-donor specific
antibodies present across the cohort. Baseline PRA of over 5% was associated with higher de
novo antibody development. Most of the IgG occurred without apparent prior IgM indication,
raising the question of whether genuine de novo responses were at play or whether this was a
re-call from previously undetected sensitisation, or as a result of nonspecific immune up-
regulation. IgG responses to class I HLA appeared earlier compared to class II HLA and IgM
responses were not detected against class II HLA in this study.
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When the patients were separated into four groups depending on the development of IgM or
IgG HLA-specific antibodies, the group with dual IgM and IgG positivity had a higher number of
adverse graft outcomes with poor eGFR (MDRD) at 36 months. There was no strong temporal
relationship between prior antibody appearance and rejection episodes, with 3 out of 9 cases
showing antibody prior to an antibody-mediated rejection episode. In fact, the majority of IgG-
positive cases did not show episodes of rejection (13/21). IgM alone did not have any adverse
effects. Thus either a class switch to IgG or the presence of both IgG and IgM together can lead
to graft damage.
Preformed IgM DSA prior to kidney transplantation has been considered benign previously but
recently small studies have shown them to be of importance. However, in this thesis we did not
study binding kinetics of IgM HLA-specific antibodies. Studying IgM binding kinetics will require
separate purification and experimental protocols due to its very different structure and
pentameric form.
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2. To develop and validate surface plasmon resonance as a technique for characterising HLA-
specific antibody interactions with HLA proteins using available human monoclonal IgG HLA-
specific antibodies.
Surface plasmon resonance using the BioRad ProteOn XPR system and NLC Sensor chips was
successfully employed following extensive sample preparation to remove trace contaminants
responsible for substantial signal noise. Purification of human monoclonal HLA-specific
antibodies was achieved by a protocol consisting of affinity chromatography (HLA protein or
protein G) followed by fast protein liquid chromatography (FPLC) techniques such as ion
exchange and size exclusion chromatography. These purification protocols yielded pure IgG
HLA-specific antibodies that could be accurately quantified and gave no non-specific binding
noise in the SPR instrument. Optimal conditions were subsequently used for studying the
binding interactions of HLA-specific antibodies, taking into account the stability of HLA
proteins. Physiological conditions, including a running temperature of 37oC, pH 7.4 and isotonic
buffer yielded high quality sensorgrams suitable for quantitative kinetic analysis.
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--------------------------------------------------------------------------------------------------------------------------------------3. To characterise the binding kinetics of epitope–paratope interactions using the same
monoclonal HLA-specific antibodies with different HLA proteins that possess shared epitopes.
Human monoclonal HLA-specific antibody kinetics were studied against multiple HLA proteins
that share various key epitopes. This showed that the binding kinetics of different human
monoclonal HLA-specific antibodies varied between different HLA proteins expressing same
epitope across a set of six monoclonal antibodies studied. This could be due to the differences
in net binding between the antibody and structural epitope.
Structural epitopes consist of amino acid residues that result in specific interactions (functional
epitope) and residues that interact with the antibody paratope. Thus both the best fit and
surface area involved in the overall interaction may determine the stability of binding. Although
the difference in dissociation constant is relatively small (within one order of magnitude), the
kinetic parameters such as association and dissociation rates differed more widely. Thus for
comparisons, dissociation constant alone may not give a full picture. These are useful
observations as current solid phase assays do not distinguish subtle differences in binding
characteristics which may be important in determining biological reactivity of the HLA-specific
antibodies and downstream effects. Importantly, the data suggest that higher affinity and faster
association rates exist for interactions involving HLA-specific antibodies and the selected HLA
protein that was originally attributed as the immunising antigen for antibody productions.
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The maximal response for certain HLA-proteins such as HLA-B7 and HLA-B57 were small despite
high affinity interactions and this could be due to a different and less favourable immobilisation
orientation for these particular HLA proteins. This could be due to the biotinylation technique
used by Pure Protein LLC at Oklahoma, which is based on chemical and not enzymatic biotin
conjugation. In future, an enzymatic biotinylation reaction via the BirA system could allow for
the site-selective attachment of biotin to all HLA molecules and ensure homogenous orientation
upon immobilisation.
In addition to kinetic analysis, preliminary thermodynamic analysis was also accomplished.
Thermodynamic experiments suggested that the Gibbs free energy value was double for the
interaction of SN607D8 (IHB-Hu-081) with HLA-A69 compared to HLA-A2 (Table 5-9). Both the
enthalpy and entropy components were favourable for the interactions with HLA-A69. The
capacity to study thermodynamics for HLA/anti-HLA interactions opens up new possibilities such
as understanding bond-making and bond-breaking processes, and whilst SPR is not the most
accurate technique, it can yield data with much less material than optimal techniques such as
isothermal titration calorimetry.
The SPR system was also used to study dual and competitive binding of HLA-specific antibodies
to the same HLA protein. Additive binding was observed when the target epitopes are located
far from each other. The epitopes 142T and 62G on HLA-A2 are located more than 30 Angstroms
apart and the antibodies against them - SN607D8 and SN230G6 respectively demonstrated this
additive binding effect (Figure 5-12). However if the epitopes are located within 20 Angstroms,
then, competitive binding occurs, as seen with the monoclonal HLA-B40:01-specific antibodies
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with different epitope specificities (WK1D12 – epitope 163E and OUW4F11 – epitope 80I)
(Figure 5-14). Similar observations were made when two different monoclonal anti-HLA-B27
antibodies (WK1D12 & VTM1F11) with the same epitope specificities (163E) were studied. This
is useful as it confirmed similar epitope specificities of antibodies obtained from different
patients.
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4. To develop methods for the molar quantification of polyclonal HLA-specific antibodies
recovered from clinical samples.
Absolute quantification of HLA-specific antibodies can be achieved using purified material from
large volumes of sample such as plasma effluent via serial HLA-affinity chromatography followed
by size exclusion chromatography followed by standard protein assays such as BCA assay. This
purification and quantification approach is not feasible for low volume samples such as those
from standard serum collection. Hence, concentration using a sandwich ELISA calibrated with
purified monoclonal HLA-specific antibodies was achievable. Cutting edge concentration
measurement via SPR-IBR was also achieved. The rigorous IgG purification protocols were
central to the success of this Objective.
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--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------5. To develop protocols for measuring the affinity of polyclonal HLA specific antibodies
purified from the serum of highly sensitised patients.
Unprocessed serum from patients caused significant and persistent non-specific binding to the
SPR sensor chips and severe signal distortion such that specific binding was unquantifiable. The
purification protocols for polyclonal HLA-specific antibodies from serum required substantial
investigation. Sequential use of HLA affinity chromatography followed by size exclusion
chromatography provided pure HLA-specific IgG antibodies but this protocol could only be
applied to large volumes such as plasma effluent. Use of protein G affinity chromatography was
surprisingly limited with incomplete regeneration.
For clinical patient serum samples, a simplified protocol using sequential precipitation followed
by size exclusion chromatography to enrich IgG was used and the polyclonal HLA- specific
antibodies were quantifiable by both ELISA and SPR-IBR. The material gave distinct and specific
binding responses from which defined kinetic data were obtained.
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--------------------------------------------------------------------------------------------------------------------------------------Primary objective
To study and determine the distribution of affinities of HLA-specific antibodies in highly
sensitised patients and to stratify the HLA-specific antibodies into groups based on the level
of affinity.
To study this, 32 highly sensitised patients receiving HLA-incompatible kidney transplants at
UHCW, Coventry were used. The analysis of binding kinetics of donor and non-donor specific
antibodies demonstrated a wide heterogeneity of affinity. This heterogeneity was observed
between both patients and different antibody specificities within the same patient. The
antibodies could be divided into four groups based on the quantitation of affinity. There was no
linear relationship between antibody concentration or MFI value with the dissociation
constants, suggesting that binding kinetics can serve as an additional, independent biomarker(s)
for risk stratification.
Although this opening study set out to distinguish binding kinetics for 14 DSA-positive cases,
only two yielded quantifiable binding signals on SPR. Interestingly, one of these two cases
rejected and was shown to have multiple higher affinity antibody specificities. In contrast, the
second case, had stable graft function and showed only one higher affinity antibody specificity.
Improved kinetic signal resolution and a larger cohort will be needed to develop this study
further.
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--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------Assay protocols developed here have achieved a significant breakthrough in the ability to obtain
meaningful binding kinetic data for polyclonal HLA-specific antibodies - possibly for the first time
worldwide. Importantly, during this thesis, significant insights have been gained in terms of
understanding the limitations in many areas of antibody and protein handling across the range
of techniques associated with HLA-related analysis and areas for improvement have been
illuminated.
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--------------------------------------------------------------------------------------------------------------------------------------Future directions
Development of an ideal biosensor platform to support transplantation
The biosensor platform used for this thesis is based on surface plasmon resonance and the
interaction happens over a chip with modified alginate. The ligand (antigen) was immobilised
and the analyte (antibodies) was passed over the immobilised antigen using a fluidics system.
The flow through the fluidics system could be adjusted and the rate was kept low to allow the
active analyte to diffuse through the flow and bind with the immobilised antigens. There are
number of disadvantages of the fluidics system; due to flow the analyte binding is affected by
diffusion and thus samples with lower concentration may give false low or negative signals.
Secondly, the fluidic system resulted in artefact in some samples due to air aspirated during
sample aspiration and also the fluidics system requires rigorous maintenance to prevent salt
precipitation in the system. Thus an ideal biosensor platform is the one that is not dependent
on the fluidic system; the surface used for interactions does not cause non-specific bindings and
allow recovery of sample used.
Preliminary work using a novel and different biosensor platform has been investigated during a
recent product demonstration. A novel biosensor technique based on the principle of BioLayer
Interferometry (BLI) using the ForteBio Octet instrument was used to study protein- protein
interactions (Abdiche et al., 2008).
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Figure 8-1 : Biosensor assay based on the BioLayer Interferometry principle
On the left side a single biosensor-tip is shown followed by a detailed illustration of the physics that allows analysis of the interference pattern of
white light reflected from two discrete biosensor tip surfaces: a layer of immobilized molecules on the biosensor tip, and an internal reference layer.
Any change in the number of molecules bound to the biosensor tip causes a shift in the interference pattern that can be measured in real-time. The
wavelength shift (Δλ) is a direct measure of the change in thickness of the biological layer as shown on the far right panel. Unbound molecules and 
changes in the refractive index of the surrounding medium do not affect the optical interference pattern, leading to improved performance and
greater robustness compared with SPR. Taken from (Wallner et al., 2013)
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--------------------------------------------------------------------------------------------------------------------------------------Streptavidin coated SA biosensor probes were used to immobilise biotinylated HLA proteins and
the Octet “dip-and-read” approach was used to test a range of W6/32 antibody concentrations
in a simple 96 well plate format. Thus there is no microfluidic flow system and the interaction
happens on the surface of the optical probe. Orbital flow is obtained by circular plate motion
within the instrument to overcome the mass transport limitation. The other advantage of BLI
system is that it quantifies the binding response as a direct function of distance in nanometres
- obtained from determined optical wavelength) rather than arbitrary response units.
Interactions between purified W6/32 (mouse anti-human class I specificity) against HLA-A24 and
HLA-A68 were studied. The HLA-antigen solution for immobilisation was prepared as 10.0 µg/ml
and the concentration range of W6/32 was 3.13 to 200 nM - prepared in 1% BSA. Very good
quality sensorgrams were obtained (Figure 8.2) and data seen in Table 8-1. Early impressions
suggest that affinity is higher for interactions with HLA-24 compared to HLA-A68.
W6/32 Maximal response Binding kinetics Dissociation
nm constant KDHLA-24 0.97 Ka = 8.93E+04 1/Ms 4.23E-10 M
HLA-68 0.82 Ka = 7.12E+04 1/Ms 1.73E-09 M
Table 8-1 : Binding kinetics obtained from Octect platform for interaction of W6/32 and HLA-
A24 and HLA-A68 proteins
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Figure 8-2 : Binding curves of interaction between W6/32 and HLA-A24 & HLA-A68 (data fitting in red lines using bivalent analyte model)
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Thus successful real time analysis of purified HLA-specific antibodies is highly feasible using the
Octet BLI platform, with similar binding curves to SPR, but with greater ease. Very importantly,
the dip-and-read approach here means that almost negligible amounts of antibody sample are
lost. In contrast, the flow requirement of SPR means that antibody samples invariably are
expended with each run and extremely difficult to recover effectively. For BLI analysis, it needs
to be established whether polyclonal anti-HLA antibodies can be analysed and BLI signal fidelity
also raises the exciting possibility of directly analysing serum, although it remains to be seen
whether the serum samples will give rise any non-specific binding. Nonetheless, a biosensor
assay based on BLI sounds extremely promising for both research work with minimal sample
requirement and future clinical applications.
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Improved mathematical modelling
One of the other major areas of work will be the development of novel mathematical models
that will allow better fitting for the kinetics data generated using biosensor assays. Data from
this thesis are currently being used to develop improved mathematical models tailored to the
features of antibodies (Mr Harry Moyse, and Dr Neil Evans, School of Engineering, University of
Warwick). As seen in Figure 8-3, early work using the Bivalent Effective Rate Constant model
with spatial effects shows a superior fit compared to bivalent analyte model, with far greater
potential for accurate kinetic data determination. The RSS values reduced to 1792, compared to
5991 in the earlier model.
Figure 8-3 : Mathematical fitting on binding kinetics data on WK1D12 monoclonal antibody;
A – Bivalent analyte model and B - Bivalent Effective Rate Constant model with spatial
effects (bERCs)
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Figure 8-4 : Mathematical fitting for polyclonal HLA-specific antibodies interaction with
HLA proteins using novel model (B) compared to current methods (A)
Similarly, fitting of kinetic data obtained from polyclonal samples were largely improved by
applying these novel models (Figure 8-4, B) that are still under development. As seen in Figure
8-4, data fitting was better both at higher (upper panels) and lower (lower panels)
concentrations of HLA-specific antibodies. These new mathematical models will undoubtedly
improve accuracy when measuring HLA-specific antibody interactions with HLA proteins with
potential impact on downstream clinical applications.
PhD thesis | Daga, Sunil Kumar Omprakash
--------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------
345
345
The SPR experiments described in this thesis relied heavily on the optimal preparation of HLA-
specific antibody samples. The protocols described here were successful in allowing the study
of clinical samples with a starting serum volume as low as 2 ml and has described preliminary
evidence of the heterogeneity of binding parameters for different sets of HLA-specific
antibodies in a cohort of highly sensitised patients.
Further studies using refined SPR or possibly BLI platforms are required to establish the range
of reproducible kinetic data on larger cohort numbers and correlate these data with clinical
outcomes in patients that received direct transplantation in the presence of donor specific
antibodies. The presence of a clinical correlation could serve as an extremely useful biomarker
for risk stratification when managing high-risk immunological organ transplantation. Similarly,
binding kinetics of de novo DSA studied longitudinally could serve as risk predication tools for
organ rejection. Three further studies are suggested to define the clinical relevance of the
binding kinetics and subsequent affinity values:
1. A larger study characterising the binding kinetics of highly sensitised patients on transplant
waiting lists.
2. Clinical correlation analysis between binding kinetics and adverse outcomes following direct
transplantation.
3. Longitudinal measurement of binding kinetics in cases with de novo HLA-specific IgG
responses (DSA) and relating these with adverse outcomes and success of medical intervention.
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Wider research applications
Purified HLA-specific polyclonal antibodies are valuable tools and following work described here
can now be obtained in meaningful quantities from plasma effluent of patients undergoing
plasma exchange for antibody removal pre or post-transplantation. The purified IgG material
will be particularly valuable for work such as assessing the impact of defined HLA- specific
antibody concentrations on models of renal damage such as in vitro glomerular endothelial cell
culture studies. These could examine the effects of HLA-specific antibodies on endothelial cell
function, complement activation and downstream intracellular signalling pathways that could
lead to cell damage. Purified HLA-specific antibodies can also be studied for glycosylation state
and glycoform – a very significant field emerging in Human Immunology. Furthermore, the
ability to recover purified polyclonal antibodies of this kind opens up the opportunity to study
them quantitatively via a host of exciting new biophysical techniques such as thermophoresis,
ion-mobility mass spectrometry and saturation transfer difference NMR spectroscopy. In
addition the capturing of anti-idiotypic antibodies could be achieved by immobilising the
purified HLA-specific antibodies to a solid-phase matrix via biotinylation or amine coupling and
applying autologous serum to this matrix for subsequent elution.
Through establishing the performance of purification techniques such as affinity, ion exchange
and size exclusion chromatography, the modification of sample handling and liquid
chromatography could allow for the purification of IgG molecules from biopsy material obtained
during rejection episodes. It would be remarkable to compare polyclonal HLA- specific
antibodies from serum during an episode of acute antibody mediated rejection with antibodies
eluted from biopsy materials.
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Appendix A - Kidney Advisory Group KAG(13)34
IMPROVING ACCESS TO TRANSPLANT FOR LONG WAITING KIDNEY PATIENTS
Alex Hudson, Susan Fuggle, Robert Higgins, Rachel Johnson; Nov 2013
1. One of the objectives of the Kidney Allocation Scheme (KAS) was to reduce the number of
long waiting patients on the transplant list by improving their access to transplantation. In
April 2006, 15% of the kidney only transplant list had been listed for five years or longer.
Within one year, the scheme had reduced this proportion to 10% although it has remained
unchanged ever since.
2. A previous study presented to the Kidney Advisory Group (KAG(10)9) found that long
waiting patients were predominantly highly sensitised and/or difficult to find an adequate
HLA-match within the national donor pool. In 2011, the scheme was amended to allow highly
sensitised patients access to Level 3 HLA-mismatched kidneys ([0 DR and 2 B] or [1 DR and
0/1 B]). This has not yet resulted in a noteworthy reduction in long-waiting patients with
around 11% of the current active transplant list having waited five years or longer and 6%
seven years or longer. At the last KAG meeting it was agreed that a subgroup of KAG would
agree an appropriate prioritisation for such patients in the 2006 DBD Kidney Allocation
Scheme.
3. Previous analysis showed that long waiting patients are predominately highly sensitised
and difficult to HLA-match. Specifically, at April 2013, there were 346 patients waiting more
than 7 years and 97% of them had a sensitisation of ≥ 85% (cRF%) and/or a matchability score 
of 8 to 10, inclusive. Further, 89% of the 346 patients waiting over 7 years had a cRF of 95-
100%, with 223 (64%) being 100% sensitised.
4. Given the great difficulty in finding suitable donors for such patients it was recommended
and agreed that patients waiting over 7 years for transplant should receive absolute priority
for kidney transplantation (second only to any clinically urgent paediatric patients) subject to
their eligibility as defined for the 2006 Kidney Allocation Scheme. That is, that no HLA
mismatch 4 [(2 B mm plus 1 DR mm) or (any 2 DR mm)] transplants are allocated, and HSPs
only receive a level 2 or 3 mismatch if they are local to the donor or have no unexplained
(residual) sensitisation. Long waiting recipients will be ranked according to their total points
score. The length of time on the waiting list that affords such priority will be regularly
reviewed and may change periodically.
5. This prioritisation will be implemented as part of the DCD Kidney Allocation Scheme work
in 2014. The list of patients eligible for this prioritisation will be reviewed with centres in
advance to ensure that all patients remain suitable for transplant.
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Appendix B - KIDNEY ADVISORY GROUP - KAG(14)45a
INCOMPATIBLE LIVING DONOR KIDNEY TRANSPLANTATION AND THE NATIONAL LIVING
DONOR KIDNEY SCHEMES - RECOMMENDATIONS TO MAXIMISE TRANSPLANT ACTIVITY
1. BACKGROUND
An increasing number of donor recipient pairs who are incompatible either by ABO blood
group and/or HLA wish to be considered for living donor kidney transplantation (LDKT).
Options for such pairs include receiving a compatible transplant through the National Living
Donor Kidney Sharing Schemes (NLDKSS) or antibody removal to facilitate incompatible LDKT.
A compatible transplant is the preferred option for all recipients if available.
2. NATIONAL LIVING DONOR KIDNEY SHARING SCHEMES (NLDKSS)
The National Living Donor Kidney Sharing Schemes (NLDKSS) were established in 2007 and
have subsequently been developed to maximise transplant activity and patient benefit. The
NLDKSS comprise the following:
· Paired/pooled donation
· Non-directed altruistic donation
· Non-directed altruistic donor chains (introduced in January 2012).
Maximising the clinical and cost effectiveness of the NLDKSS is a key objective of the Living
Donor Kidney Transplantation 2020 (LDKT 2020) Strategy. The NLDKSS currently account for
17% of annual LDKT activity and 118 non-directed altruistic donors donated into the UK
programme in 2013/14.
a) General Recommendations: utilisation of the shared donor pool
The following actions are recommended with immediate effect to maximise the use of
kidneys donated by both non-directed altruistic and paired/pooled donors:
i. Prioritise altruistic donor chains with all non-directed donors during donor preparation to
encourage ‘opt in’ and increase the number of potential transplants per donation.
ii. If a donated kidney from either an altruistic or paired/pooled donor cannot be implanted
into the intended recipient on the day of surgery, the kidney is offered through the national
allocation scheme for an alternative recipient on the national transplant list.
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iii. Ensure that all non-directed altruistic donor offers are accepted within 24hours by the
recipient centre, as previously approved by KAG.
iv. Permit donating centres to specify dates of surgery for donations from non-directed
altruistic donors to a single recipient on the national transplant list.
v. As previously approved by KAG, if multiple offers from a single nondirected altruistic donor
are refused or unsuitable once a date of surgery has been scheduled, the donating centre can
choose to allocate the kidney to a local recipient, to minimise disruption to the donor.
The following actions (b,c, and d) are proposed to commence from April 2015, with an
opportunity to pilot some aspects in the January 2014 kidney donor matching run:
b) Increase the length of altruistic donor chains
This is a key priority to maximise transplant activity from a single non-directed altruistic
donor. The inclusion of an additional donor recipient pair from the paired/pooled donation
scheme each time an altruistic donor opts in to form a ‘chain’ would increase the transplant
potential from 2 (currently) to 3 transplants.
c) Introduction of National Sharing Weeks for NLDKSS
i. Every participating transplant centre will be asked to commit to a two week ‘sharing’ period
for NLDKSS surgery. During these weeks, centres will be asked to reserve routine living donor
lists for ‘shared’ living donor transplants until:
· It is confirmed that there are no matched pairs for a centre in any given matching run.
Or Dates of surgery are agreed for matched pairs
ii. ‘Sharing fortnights’ will be linked with the matching run timetable and published with the
annual matching run schedule via NHSBT. To enable all centres to accommodate this, a
phased implementation is proposed: the sharing periods will initially be scheduled within a
maximum of 10 weeks of the matching run, reducing to a maximum of 8 weeks to meet the
clinical standard by April 2016. (Current average time frame from matching to scheduling
surgery is 12 weeks).
d) Non-simultaneous donor surgery within the NLDKSS
i. Simultaneous donor surgery is the preferred option for both altruistic donor chains and
paired/pooled donations. To enable centres to accommodate longer altruistic donor chains
and, where necessary, paired pooled donations within the 8 week clinical standard, flexibility
to arrange staggered donor surgery within the ‘sharing fortnight’ is recommended. This
means that:
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· Appropriate consent must be obtained from all donors and recipients prior to registration in
the scheme re the option for staggered surgery
· In an altruistic donor chain, the non-directed altruistic donor must donate first in the chain
e) Increase Frequency of Kidney Donor Matching Runs (KDMRs)
i. Increasing the frequency of KDMRs from quarterly to two monthly would encourage donors
and recipients to register into the NLDKSS and increase the transplant potential. If KAG
approves this, the feasibility of streamlining existing paper registration and ‘manual’
processes will be explored first.
3. ABO BLOOD GROUP INCOMPATIBLE (ABOi) TRANSPLANTATION
The following outcomes and actions were agreed by the NHSBT Workshop for ABOi
transplantation for endorsement by KAG:
i. Publication and dissemination of existing data to support the development of a model for
standardised testing of haemagglutinin titre levels.
ii. Improve quality and approach to data collection through the NHSBT antibody incompatible
transplantation (AAiT) registry to inform future guidelines.
iii. Encourage all laboratories to send samples to a single reference laboratory for pre-
antibody removal and day of transplantation antibody quantification to reference local
testing when standardised methodology is evaluated against existing local method.
iv. Ensure that ABOi LDKT is included as part of the inclusive transplant tariff and explore the
feasibility of innovative therapies e.g. Eculizumab.
4. HLA INCOMPATIBLE (HLAi) TRANSPLANTATION KAG(14)45a AAiT and NLDKSS KAG paper
02-12-2014 Final 4
The following outcomes and actions were agreed by the NHSBT Workshop for HLAi
transplantation for endorsement by KAG:
i. Agree definitions for high, medium and low HLAi transplantation.
ii. Agree guidelines, dependent on clinical urgency and patient choice to include:
· CDC positive crossmatch pairs are only considered for HLAi LDKT in exceptional
circumstances.
· All HLAi pairs are entered into the NLDKSS
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· ABOi LDKT within the NLDKSS is preferable to HLAi LDKT
iii. Improve quality and approach to data collection through the NHSBT antibody incompatible
transplantation (AAiT) registry to inform evaluation of outcomes and commissioning.
iv. Ensure that HLAi LDKT is included as part of the inclusive transplant tariff and commission
through evaluation of outcomes.
RECOMMENDATIONS
KAG is asked to:
1. Approve the proposals to maximise utilisation of donated kidneys within the NLDKSS as
described in section 2.
2. Endorse the outcomes and actions from the NHSBT Workshop for ABOi and HLAi living
donor kidney transplantation in sections 3 and 4.
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ABSTRACT
Rejection caused by donor-speciﬁc antibodies (principally
ABO and HLA antibodies) has become one of the major bar-
riers to successful long-term transplantation. This review
focuses on clinical outcomes in antibody-incompatible trans-
plantation, the current state of the science underpinning clin-
ical observations, and how these may be translated into further
novel therapies. The clinical outcomes for allografts facing
donor-speciﬁc antibodies are at present determined largely by
the use of agents developed in the 20th century for the treat-
ment of T-lymphocyte-mediated cellular rejection, such as
interleukin-2 agents and anti-thymocyte globulin. These treat-
ments are partially effective, because acute antibody-mediated
rejection is mediated to a considerable extent by T lympho-
cytes. However these treatments are essentially ineffective in
chronic antibody-mediated rejection. Future therapies for the
prevention and treatment of antibody-mediated rejection are
likely to fall into the categories of those that reduce antibody
production, extracorporeal antibody removal and disruption
of the effector arms of antibody-mediated tissue damage.
Keywords: ABO, antibody, antibody-mediated rejection,
HLA, kidney transplant
INTRODUCTION
Antibodies directed against transplants are becoming recog-
nized as a critical barrier to further improvements in the
access of patients to transplantation and in the survival of allo-
grafts. This review will summarize the current results of trans-
plantation in the presence of donor-speciﬁc antibodies (DSA),
and the possible research pathways that will lead to the control
and prevention of such antibodies and the effective treatment
of antibody-mediated rejection (AMR), both acute (AAMR)
and chronic (CAMR).
The modern era of renal transplantation began in the 1960s
with the introduction of azathioprine. Within a few years the
importance of blood group incompatibility and HLA-speciﬁc
antibodies was recognized, and their presence essentially
vetoed transplantation outside experimental settings [1]. A
focus on T-lymphocyte-mediated cellular rejection over the
next half century has resulted in a therapeutic toolkit that has
eliminated the vast majority of graft losses from this cause in
adherent patients. Ultimately the therapies required to prevent
T-lymphocyte-mediated rejection proved relatively simple,
namely effective multipoint targeting of the interleukin-2
pathway and lymphocyte deletion therapy. An international
focus from clinicians, scientists and industry on developing
new treatments for antibody-mediated rejection (AMR) argu-
ably began only a decade ago, and we are currently in an excit-
ing era characterized by a rapid series of new discoveries about
anti-graft antibodies, their mechanisms of production and
action and the treatment of antibody-mediated rejection.
CURRENT CLINICAL OUTCOMES
HLA antibodies
Donor-speciﬁc HLA antibodies may be preformed or
develop de novo after a transplant. The current status of trans-
plantation across preformed HLA antibodies (HLAi trans-
plantation) is that acceptable graft outcomes can be achieved
in living donor transplantation, so long as the pre-transplant
complement dependent cytotoxic (CDC) crossmatch is
© The Author 2014. Published by Oxford University Press
on behalf of ERA-EDTA. All rights reserved.
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negative [2]. However such transplants do require antibody
screening and careful management. It is not enough simply to
transplant across a negative CDC crossmatch without taking
account of preformed HLA antibodies. In many patients with
low pre-treatment levels of donor-speciﬁc HLA antibodies,
successful engraftment may be achieved using standard im-
munosuppression of tacrolimus, mycophenolate, prednisolone
and basiliximab. However, in cases with higher levels of DSA,
for example where the ﬂow cytometric (FC) crossmatch is
positive, antibody removal and induction immunosuppression
or therapies for antibody-mediated rejection are required [3–7].
As a generalization, current clinical outcomes seem to indi-
cate a mortality and graft loss rate about twice that of ‘antibody-
compatible’ transplantation in the ﬁrst year, unless the CDC is
positive when the graft loss rate is higher, rising to 50% at
5 years using CDCmethodology where there is no enhancement
with anti-human globulin [2], and 30% graft loss when the more
sensitive technique using AHG is used [7]. Other adverse prog-
nostic features that can be identiﬁed pre-transplant are DSA that
are combinations of Class I and Class II, and DSA that bind the
complement component C1q in microbead assays [7, 8].
Therapies used in such clinical series include antibody
removal pre-transplantation (plasma exchange, plasmapher-
esis or immunoadsorption), cellular depleting therapies (anti-
thymocyte globulin, rituximab, alemtuzumab), intravenous
immunoglobulins and proteasome inhibitor therapy (bortezo-
mib), but there is no consensus on which of these approaches
is most effective, and randomized trials are awaited. Transplant-
ation across preformed HLA antibodies is best performed with
living donors where there is time to achieve effective antibody
removal, and possibly the graft is better equipped to cope with
the rigours of early post-transplant antibody assault [2–9].
The outcomes in the face of CAMR due either to de novo
HLA antibody production or persistent preformed DSA pro-
duction are less encouraging [7–11]. For example one series
showed a 10-year graft survival of <60% in those with de novo
DSA, compared with >90% for those without DSA [12]. Rejec-
tion takes the form of glomerular basement membrane
damage (transplant glomerulopathy), with proteinuria and
progressive graft failure, usually over 2–3 years. There is no ef-
fective therapy for this condition, though we have seen it
resolve durably if the DSA levels fall. Often transplant glomer-
ulopathy may be associated with some active cellular inﬁltra-
tion in the peritubular capillaries and this may be temporarily
amenable to therapy, but ultimately nearly every case of trans-
plant glomerulopathy progresses to graft failure within 3–5 years
(Figure 1).
ABO antibodies
Transplantation across ABO incompatibility (ABOi) gener-
ally produces excellent outcomes, and the experience in Japan
over a period of decades indicates that outcomes are equivalent
to ABO-compatible transplantation [13]. However, in the
USA and in the UK, ABOi renal transplantation seems to have
a slightly increased risk of severe AAMR which may result in
graft loss, with catastrophic rejection progressing over a period
of hours. This rejection may occur without any warning, and
may indeed occur in those with very low pre-transplant
antibody levels [14]. Further multicentre studies of this rare
phenomenon (2–4% of grafts) are required.
ABOi transplantation does differ from HLAi transplant-
ation in that chronic antibody-mediated rejection is not attrib-
utable to ABO antibodies. Biopsies may be ongoing staining
for C4d on the peritubular basement membrane suggesting that
there is some form of inﬂammation but the clinical outcome is
not adversely affected. The signiﬁcance of peritubular C4d
differs from the same ﬁnding in HLAi transplantation, since the
C4d deposition is a sign of CAMR. When CAMR is reported in
ABOi grafts, this seems to be due to the concurrent presence of
HLA antibodies [15].
Other antibodies
Non-HLA antibodies may be important players in AMR.
Antibodies directed against the angiotensin receptor are of
particular interest. These were ﬁrst observed as a cause of spor-
adic AAMR associated with severe hypertension. Subsequent
studies have extended their possible role to the causation of
CAMR, and their presence has been associated with graft loss,
independent of HLA antibodies [16, 17]. They may be auto-
and allo-antibodies, and further work will deﬁne better the
extent of their role in the causation of graft loss.
THE BIOLOGY OF ANTIBODY PRODUCTION
AND REJECTION
Decades of focus on T-cell-mediated rejection and the lack of
a clinical model of antibody incompatible transplantation
mean that our understanding of the biology of antibody pro-
duction, and the mechanisms of AMR are at a relatively early
stage, but knowledge is accumulating rapidly.
F IGURE 1 : Graft survival at University Hospitals Coventry and
Warwickshire in HLA antibody incompatible transplantation, for pa-
tients with pre-treatment complement dependent cytotoxic (CDC)
positive crossmatch (n = 21) compared with those with DSA but with
a negative CDC crossmatch (includes ﬂow cytometric crossmatch
positive and negative) (n = 91). Five- and 10-year death-censored
graft survivals were 84.8% for the CDC-negative group, 57.5 and
33.6% respectively for the CDC-positive group.
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Production of antibodies
Antibodies are synthesized by memory B lymphocytes and
plasma cells. Both of these ultimately derive from imma-
ture cells of the B-lymphocyte lineage and receive T-cell help.
It is possible that induction immunosuppression, enhanced
beyond the level necessary to prevent most T-lymphocyte-
mediated cellular rejection, may reduce the production of
de novo HLA antibodies [18], and prospective and randomized
studies are awaited.
In HLAi transplantation, pre-formed donor-speciﬁc HLA
antibodies may have been present for many years before the
transplant, and detailed monitoring of their levels in the early
post-transplant period may show large changes in their levels,
with both rises and falls. Figure 2 shows a case with a heteroge-
neous response, the rates of post-transplant increases in DSA,
the pre- to peak variation and the rate of fall of DSA showing
variation. The rises and falls in HLA antibody levels post-
transplant are not uniform across a range of patients, and
there is no clear pattern governing the responses, though HLA
Class II antibodies may show greater responses than Class I,
with the proﬁles of HLA DQ and DP similar to HLA DR [19].
It is likely that insights can be gained from more detailed
studies of the characteristics of the antibodies, for example the
classes and IgG subclasses of the responses (Table 1). New
antibody production is initially of the IgM class, and IgM
donor-speciﬁc HLA antibodies have been associated with
AAMR in the absence of equivalent IgG antibodies [20] and
reported in de novo HLA antibody production [21]. HLA
antibodies of the IgA class may also occur frequently, though
their signiﬁcance is not yet understood [26]. IgM antibody
production may switch to IgG3 subclass, then to IgG1, IgG2
and ultimately IgG4. There is currently much interest in exam-
ining antibody subclasses in more detail [21], and we have ob-
served some differences in subclass distribution, for example a
higher incidence of IgG3 subclass in pregnancy-stimulated
HLA antibodies and an association between pre-transplant
IgG4 levels and subsequent AMR and graft survival [22].
One of the most remarkable observations in clinical practice
is that DSA may disappear after transplantation. This has been
observed in both ABO and HLA antibody-incompatible trans-
plantation [13, 14, 19]. However, it seems likely that the me-
chanisms are different.
In HLA antibody-incompatible transplantation, many groups
have noted that in some patients HLA antibodies may disappear
after the transplant, even when sensitive microbead analysis
is used. While some groups have attributed this to particular
treatments administered, we have seen that this phenomenon is
independent of any particular therapy over and above the stand-
ard immunosuppression of basiliximab, tacrolimus, mycophe-
nolate and prednisolone [19]. The phenomenon does seem to be
commoner when there is a vigourous antibody response post-
transplant, and daily sampling shows that the fall in antibody
levels occurs rapidly. This implies some form of ‘active’ removal
of antibody from the circulation, and this is the subject of
ongoing research. If it proved possible to induce the disappear-
ance of DSA pre-transplant, that would be very useful. However,
F IGURE 2 : HLA and ABO antibody levels pre- and post-transplant showing variation in antibody responses within the same patient, both
in terms of rate of increase, magnitude of change from pre- to peak levels, and the rates of fall. The patient received a living donor transplant
from his father. DSA levels were as shown in the legend. The CDC crossmatch was positive at a titre of 1 in 16, and there was additional ABO in-
compatibility, donor blood group A1 and recipient B. The recipient received plasma exchange pre-transplant, and post-transplant at Days 21
and 22 only. Immunosuppression was with prednisolone, tacrolimus, mycophenolate and basiliximab, with anti-rejection treatment including
ATG (Days 1–15) and eculizumab (Days 24 and 31). The graft is still functioning at 5 years post-transplant, though with proteinuria and
reduced function. DSA levels were measured by microbead assay (OneLambda). MFI levels were DR9—pre 2148, peak 14821 (Day 9), late 776;
DR52—pre 5982, peak 12952 (Day 9), Day 141 8162; DQ9—pre 864, peak 1468 (Day 9), late 618; A2—pre 2774, peak 7258 (Day 45), late 2612.
Follow-up at 2 years post-transplant showed little change in antibody levels from the Day 140 data shown here. Haemagglutination titres to
blood group A1 were, IgG, pre 1, peak 128 (Day 10), late 4; IgM, pre 4, peak 128 (Day 10), late 32.
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it is not clear whether this requires exposure to donor HLA (and
if so in what form of delivery), as well as immunosuppression.
In ABOi transplantation, successful engraftment is often
followed by the disappearance of antibody, but biopsies of the
graft show ongoing C4d staining in peritubular capillaries, as
if there is some persistent immunological stimulation, making
it possible that some antibodies are being produced and then
absorbed by the graft. It will be interesting to see what
happens to ABO antibodies in patients who later lose their
grafts from causes other than ABO-related rejection, and then
have graft nephrectomy—will their ABO antibodies reappear
or not? ABOi heart transplants in neonates may result in long-
term tolerance to the transplanted ABO, but this could be a
special case owing to the neonatal timing of the transplant.
Binding of antibodies to an allograft
There is much current research examining how antibody
binds to antigen at a molecular level, and then how that re-
sponse evolves into clinical rejection, since the simple act of
antibody binding to antigen alone does not seem to cause re-
jection. Although the development of microbead assays have
enabled far better measurement of antibody levels than was
previously possible, they do not measure the concentration
of antibody, even in a semi-quantitative manner, but measure
a combination of concentration and afﬁnity, as shown in
Figure 3. Table 1 lists some of the antibody characteristics that
could be associated with clinical outcomes; we are still at a
preliminary stage of the understanding of which of these are
important, and which could be manipulated for therapeutic
beneﬁt.
HLA is profoundly polymorphic, and the binding of anti-
body to an HLA molecule is determined not by the whole
HLA molecule, but by small areas of polymorphism within the
protein structure known as epitopes. An epitope may be deter-
mined by as little as a single amino acid substitution in a critic-
al area of the molecule, even though the binding footprint of
an antibody molecule is much larger. Different HLA mole-
cules are deﬁned by a series of epitopes, many of which are
shared between different HLA speciﬁcities. This is why an
antibody generated against one HLA allele will bind to many
others [27].
A better understanding of exactly how the antibody-
antigen reaction develops may allow for the development of
therapies that disrupt this interaction. Hence, research groups
are studying antibody afﬁnity for antigen, the atomic structure
and biophysical properties of HLA, especially in relation to
glycosylation as well as the amino acid backbone.
Clinical studies of the mechanisms of rejection are ham-
pered by the inability of current techniques usefully to
measure the binding of antibody to the graft [15]. It is not
clear why this is the case, but the clinical classiﬁcations of anti-
body-mediated rejection depend on the detection of effector
responses such as complement and cells, and not on whether
there is any donor-speciﬁc antibody in the graft. A test that
gave an accurate readout of the levels of donor-speciﬁc anti-
body bound to graft endothelium would give immediate and
important insights into AMR.
Complement
It is widely acknowledged that activation of the comple-
ment system is a major driver of antibody-mediated tissue
damage and subsequent transplant rejection. A good indicator
of this is the CDC assay that correlates positively with risk of
donor organ failure [2]. The presence of the complement
protein fragment C4d in renal rejection is also a ‘smoking gun’
Table 1. HLA characteristics of antibody and antigen that might affect
clinical outcomes
Comment Reference
HLA antibody
Concentration Not currently possible to
measure antigen-speciﬁc
concentration of antibody
(see Figure 3)
Antibody binding to HLA in
solid phase assay (readout
a combination of avidity
and concentration)
Measureable by microbead
assays
[2, 4]
Class Mostly IgG, early reports
of IgM mediated AMR and
occurrence of IgA
[20, 21]
Subclass Early studies show
heterogeneity in responses
[21, 22]
Afﬁnity Measurement under
investigation
Glycosylation Measurement under
investigation
Cellular binding CDC and FC crossmatches
Endothelial binding
[2, 23]
Inhibitors
Soluble HLA Early reports of methods to
quantify
HLA-E Early reports of correlation
with clinical outcomes
[24]
Idiotypic antibodies Hard to measure with
current tools but could be
important
[25]
Immune complexes
HLA-sHLA immune
complexes
Not currently measureable
F IGURE 3 : Dose response curve showing Luminex bead MFI value
against concentrations of two human monoclonal HLA-A2-speciﬁc
antibodies. The same concentrations of antibody may give markedly dif-
ferent MFI levels (e.g. <2000 and >10000, respectively, at 1.95 µg/mL).
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for activation of the complement cascade, which occurs down-
stream of C1q binding to clustered complexes of IgG and IgM
antibodies on a cell surface. The antibody classes and sub-
classes typically found are IgG1 (HLA antibodies) and IgM
(ABO antibodies), which are strong C1q binders and thus clas-
sical pathway activators. However, clinical investigation is
made more difﬁcult by the difﬁculties in measuring DSA in
graft biopsies, and also by the observations that AAMR may
occur in the absence of C4d deposition, and that C4d depos-
ition may not reﬂect ongoing rejection; this could partly be
due to endothelial synthesis of C4, so C4d should not neces-
sarily be assumed to have been deposited on endothelium
from circulating C4 [28].
Cellular response
The cellular aspect of acute antibody-mediated rejection is
interesting, because although hyperacute rejection looks more
like an innate response, with neutrophils and macrophages
predominately, AAMR is characterized by a marked T-
lymphocyte inﬁltration into the graft, visible using immuno-
histochemistry, and indistinguishable from T-cell-mediated
cellular rejection at a molecular level [29, 30].
Response of endothelium
The predominant target of antibody-mediated rejection is
vascular endothelium in the blood vessels (and glomeruli) of
the allograft. Endothelial cells express ABO and HLA (classes I
and II). Endothelium is not a passive victim of antibody
binding and the rejection process, but has an adaptive re-
sponse that may be protective to the graft. Indeed, clinical
acute antibody-mediated rejection generally resolves in the
presence of donor-speciﬁc antibody, and while this may be
due to therapies which down-regulate the cellular responses, it
is also possible that the graft becomes resistant to rejection
[23, 28]. In the clinical setting, it is possible to measure vascu-
lar stress in the allograft by RNA analysis of renal biopsy ma-
terial, the ‘molecular microscope’. This approach can also help
characterize the T- and B-cell activity within the allograft [31].
In some cases, the antibody binds to endothelium but does
not cause rejection, for example in ABOi transplantation,
where staining for complement C4d in the peritubular capil-
laries of well-functioning grafts seems to indicate accommoda-
tion of the graft to antibody. In HLAi transplantation, by
contrast, longer term C4d staining is likely to indicate low
grade-AMR, though in some cases there does seem to be DSA
present for many years without causing rejection or C4d stain-
ing on biopsy.
NEW THERAPIES
The successful treatment and ideally prevention of antibody-
mediated rejection will require the development of new ther-
apies that have speciﬁc new actions. It is not yet clear exactly
which are the ideal targets, or whether there will be a solution
as conceptually simple as the targeting of interleukin-2 in T-
lymphocyte-mediated rejection. Therapies under consider-
ation can be grouped into three main categories; (i) those that
target the cells responsible for antibody production; (ii) those
that target mediators of antibody damage, including comple-
ment; (iii) more effective removal of antibody using extracor-
poreal techniques.
Targeting the cells responsible for antibody production
Once the body has been programmed to produce the anti-
body in the long term, the cells responsible for this can be hard
to target. For example, while bone marrow ablative therapy for
haematological malignancies may appear to result in deletion
of the host immune system, many antibody responses induced
by prior vaccination may persist. We have seen HLA antibody
production persist after chemotherapy and total lymphoid
irradiation conditioning for cord cell transplantation.
There are some candidate therapies in use that could prove
beneﬁcial, but have not yet been tested in randomized trials.
Rituximab (CD20 monoclonal antibody) and alemtuzumab
(CD52 monoclonal antibody) are both capable of killing B
lymphocytes, though do not have speciﬁc action against
plasma cells, and both may spare memory B lymphocytes [18,
31, 32]. In the case of alemtuzumab, any beneﬁts in clinical
use might be due to deletion of effector leucocytes rather than
effects on antibody production, and its use has even been
reported to be associated with increases in the production of
de novo HLA antibody levels in previously unsensitised trans-
plant recipients [33]. In clinical use, neither agent can complete-
ly prevent increases in preformed HLA antibody levels after
transplantation, though some data suggest that de novo HLA
antibody production after transplantation may be reduced by
prior administration of anti-CD20 therapy.
Anti-thymocyte globulin has potentially a very wide action,
and may be particularly effective in dealing with cells in the
effector arm of the rejection process, but again does not seem
to completely prevent post-transplant synthesis of preformed
DSA, although in a non-randomized study, its use was asso-
ciated with less production of de novo HLA antibodies in the
ﬁrst 2 years post-transplant [33].
The cells that produce antibody could be targeted by means
other than cytolytic therapies, and there are some candidate
therapies available. Intravenous immunoglobulins (IVIg) have
been used for some time. This product has a range of actions,
but may down-regulate the production of HLA antibodies,
and may be combined with anti-CD20 therapy [34]. Cytokine
inhibition may be another route available, and studies are cur-
rently underway to evaluate the possible beneﬁts of inhibitors
of interleukin-6 and BAFF (B-cell activating factor). BAFF is
an attractive target, as studies are emerging that associate
BAFF with clinical outcomes in transplantation [35].
A further approach to reducing antibody production is
targeting the protein synthetic capacity of plasma cells using
proteasome inhibitors. Although these agents were initially
conceived selectively to target malignant plasma cells, it is pos-
sible that they may impact on metabolically active cells produ-
cing DSA post-transplant, and uncontrolled studies have shown
successful transplantation in the face of active immune re-
sponses [36, 37]. The effects of bortezomib on pre-transplant
antibody production have been less encouraging, but randomized
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trials and the introduction of second generation proteasome
inhibitors are welcomed with great interest.
Extracorporeal antibody removal
Most protocols for clinical antibody-incompatible trans-
plantation involve extracorporeal antibody removal, at least in
those with higher antibody levels. While the effects of antibody
removal are partial and temporary with the current technol-
ogy, it is generally believed to be beneﬁcial [38, 39]. Rando-
mized trials in the setting of preformed antibodies are lacking,
but it does seem that removing antibodies to a level below the
threshold of CDC crossmatch positivity prevents hyperacute
rejection, and that plasma exchange is an effective therapy for
AAMR.
Antibody removal therapies are constrained by several difﬁ-
culties. These include the problem of providing long hours of
therapy during times when there is a risk of bleeding; the pool
of IgG outside the vascular compartment, which re-equili-
brates only slowly with the vascular compartment; by rapid
production of the antibody in the post-transplant period and
by the inability of current therapies to selectively remove HLA
antibodies, as all therapies remove total immunoglobulin,
often together with other desirable blood components such
as ﬁbrinogen [39]. Similar constraints are also faced when
total immunoglobulin removal methods are used in ABO-
incompatible transplantation [40].
There is therefore a need for more selective therapies and
modes of delivery that will allow removal of enough antibody
at the times before and after transplant, and maybe soon after
biopsy, and will impact on rejection at times when there is
rapid antibody production (a doubling time of 12 h has been
observed in some of our patients) [41]. The availability of
large amounts of HLA protein has allowed the production of a
selective HLA absorption column that indicates as proof of
principle that HLA antibody removal therapy could be im-
proved. Speciﬁc immunoadsorption therapy is already avail-
able to remove ABO antibodies [40, 42].
Mediators of antibody damage
Inhibition and modulation of complement activation is
an attractive therapeutic route, with FDA-approved biophar-
maceuticals already in clinical use for rare conditions such as
hereditary angioedema (HA) and paroxysmal nocturnal
haematuria (PNH). These include the drugs cinryze (C1 ester-
ase inhibitor) for HA and eculizumab (anti-complement C5
monoclonal antibody) for PNH [43, 44]. These two agents act
at different points within the complement activation cascade
with potential to protect cells and tissues directly from aggres-
sive lytic mechanisms and also broader immune activation. C1
esterase inhibitor is a protein that blocks the enzymatic func-
tion of the complement C1s component. This results in the
proteolytic activation cascade being arrested upstream of power-
ful inﬂammatory and cytotoxic mechanisms such as C3/C4
opsonisation, anaphylatoxin release (a powerful leucocyte
chemoattractant mechanism) and assembly of the membrane
attack complex.
Eculizumab acts further downstream through functional
blockade of the complement component C5, resulting in
abrogated membrane attack complex formation and C5a ana-
phylatoxin release. Recruitment into an international rando-
mized clinical trial of eculizumab in patients with pre-formed
HLA antibodies has been completed, and results should be
available in 2015. If a positive effect of this agent is shown, this
will be pivotal in the future therapy of AMR, and possibly in
the prevention of CAMR. If the randomized trial shows a
marked reduction in AAMR rates in line with preliminary
studies, there will be important questions to answer on the
cost-effective application of the drug, and also whether its
beneﬁt will be extended to those with higher DSA levels who
were not eligible for the current study.
SUMMARY
Antibody-incompatible transplantation has become a clinical
reality in the 21st century, though graft survival rates are still
suboptimal. Many patients with very high levels of preformed
DSA, both HLA and ABO, are considered untransplantable
with current technology. Treatment for CAMR when it leads
to transplant glomerulopathy is almost completely ineffective.
The understanding of the drivers of antibody production and
mechanisms of AMR is progressing rapidly, and it is likely that
combinations of new therapies targeting antibody production,
complement and extracorporeal antibody removal will
improve graft survival rates in the coming decades.
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Available online 20 November 2013Immunizing events including pregnancy, transfusions, and transplantation promote strong alloantibody
responses to HLA. Such alloantibodies to HLA preclude organ transplantation, foster hyperacute rejection,
and contribute to chronic transplant failure. Diagnostic antibody-screening assays detect alloreactive
antibodies, yet key attributes including antibody concentration and isotype remain largely unexplored.
The goal here was to provide a detailed proﬁle of allogeneic antibodies to class II HLA. Methodologically,
alloantibodies were puriﬁed from sensitized patient sera using an HLA-DR11 immunoafﬁnity column and
subsequently categorized. Antibodies to DR11 were found to ﬁx complement, exist at a median serum
concentration of 2.3 lg/mL, consist of all isotypes, and isotypes IgG2, IgM, and IgE were elevated. Because
multimeric isotypes can confound diagnostic determinations of antibody concentration, IgM and IgA iso-
types were removed and DR11-IgG tested alone. Despite removal of multimeric isotypes, patient-to-
patient antibody concentrations did not correlate with MFI values. In conclusion, allogeneic antibody
responses to DR11 are comprised of all antibody isotypes at differing proportions, these combined iso-
types ﬁx complement at nominal serum concentrations, and enhancements other than the removal of
IgM and IgA multimeric isotypes may be required if MFI is to be used as a means of determining anti-
HLA serum antibody concentrations in diagnostic clinical assays.
 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights
reserved.1. Introduction plant. Post-transplantation, antibodies to the organ-donor’s HLADonor-speciﬁc antibodies to class I and class II human leukocyte
antigens (HLA) represent a contraindication to organ transplanta-
tion. Before transplantation, sensitized patients who produce
HLA-speciﬁc antibodies typically wait longer to receive a trans-contribute to hyperacute, acute, and chronic transplant rejection
[1,2]. These alloantibodies mediate rejection by a number of mech-
anisms that include activation of the complement cascade, killing
via FccRs following innate immune cell recruitment, inﬂammation
accompanying epithelial cell migration, and cell apoptosis [3–10].
While antibodies represent a substantial barrier to allogeneic
transplants, antibody responses can differ substantially from
patient-to-patient depending upon the HLA antigen in question,
the route of immunization, and the immune status of the
responder; substantial heterogeneity is expected among antibody
responses to HLA. Indeed, variability among allogeneic immune
responses has led to the observation that not all antibodies to
HLA promote graft failure [11–13]. As such, a more thorough
understanding of anti-HLA antibodies in transplant patients would
provide new avenues for pinpointing those immunoglobulins that
are truly a contraindication.
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antibodies to HLA remains challenging for several reasons. First,
anti-HLA antibody responses can be polyclonal, recognizing multi-
ple epitopes on an allogeneic HLA. Second, sensitized individuals
can target multiple HLA, whereby it is not clear whether one
antibody response is crossreactive with various HLA or whether
individual serologic responses target different HLA. Third, anti-
HLA antibodies are intermingled in a complex blend of serum
immunoglobulins. Clearly, the isolation of antibodies to a given
HLA molecule would enable subsequent studies of anti-HLA anti-
body concentration, isotype, epitope speciﬁcity, and afﬁnity. Such
measurements could then be compared to transplant function/
survival in order to correlate distinct humoral responses with
clinical outcomes. In addition to shedding light on how antibody
variables inﬂuence clinical outcomes, the ability to isolate anti-
HLA antibodies would help to unravel the impact that antibody
isotype, concentration, and afﬁnity have on diagnostic bead-based
assays – an area of considerable interest [11–13]. In particular,
clinicians and HLA laboratory technicians share an interest in
assigning an antibody titer to their HLA-sensitized patients to
determine risk, a calculation that is especially effected by antibody
heterogeneity.
The hypothesis tested here is that the isolation and proﬁling of
anti-HLA immunoglobulins will demonstrate person-to-person
differences in alloreactivity and lead to a better understanding of
how this variability inﬂuences diagnostic tests and clinical
outcomes. To test this hypothesis, appreciable quantities of native
class II HLA molecules were produced and utilized to construct the
ﬁrst reported HLA immunoafﬁnity column. Patient sera containing
anti-HLA immunoglobulins were then passed over this column.
Antibodies speciﬁc for a particular class II HLA were retained on
the column, these immunoglobulins were recovered, and these
anti-HLA antibodies were proﬁled for concentration, isotype, cross-
reactivity, complement activation, and impact on antibody screen-
ing assay outcomes. The resulting phenotypic and functional
proﬁles represent a substantial advance in our understanding of
anti-HLA antibody variability, providing new insight as to how
immunoglobulin heterogeneity can inﬂuence diagnostic tests and
transplant outcomes. More robust applications of this HLA
antibody isolation and proﬁling technology are discussed, includ-
ing the potential provision of an HLA-based therapeutic antibody
removal tool for patients with antibodies to allogeneic HLA.2. Methods
2.1. Patient samples
Patient ‘G’ serum is a HLA-DR11antiserum with complement
ﬁxing activity (Gen-Probe, WI). Patient 1 serum was gathered from
a DR11 sensitized kidney recipient (informed consent approved by
UT Southwestern institutional review). Sensitized serum from
patients 2 to 12 were collected according to a protocol approved
by the University of Warwick institutional review board. For sensi-
tized patients 13–14, 600 mL of double ﬁltration plasmapheresis
retentate was recovered as approved by the University of Warwick
institutional review board. For Patient 13, 600 mL of retentate was
diluted in 1.8 L of PBS, for patient 14 350 mL of retentate was
diluted in 1.8 L HLA antibody-negative plasma.2.2. HLA-DR11 protein production
To produce secreted HLA-DR11 (sHLA) molecules, a-chain
cDNA of HLA-DRA1⁄01:01 and b-chain cDNA of HLA-DRB1⁄11:01
were modiﬁed by PCR mutagenesis to delete codons encoding
the transmembrane and cytoplasmic domains. For DRA1⁄01:01, a7 amino acid linker (DVGGGGG) followed by leucine-zipper
ACIDp1 was added [14]. For DRB1⁄11:01, this linker was followed
by leucine zipper BASEp1 [14]. sHLA-DRA1⁄01:01/DRB1⁄11:01
were cloned into the mammalian expression vector pcDNA3.1(–)
(Life Technologies, CA). A B-LCL cell line was transfected by electro-
poration simultaneously with sHLA-DRB1⁄11:01 and DRA1⁄01:01.
Drug resistant stable transfectants were tested for production of
sHLA class II molecules by sandwich ELISA using capture antibody
L243 (Leinco Technologies) and a class II detection antibody (One
Lambda Inc., CA). Approximately 75 mg of sHLA-DR11 was pro-
duced in AccuSyst-Maximizer bioreactors (Biovest International)
and puriﬁed using an L243 immunoaffﬁnity column.
2.3. Mass spectrometry
10 lg of sHLA-DR11 was reduced with dithiothreitol (Sigma–
Aldrich, MO) at 95 C for 5 min and alkylated using iodoacetamide
(Thermo Scientiﬁc, MA). Denatured protein was digested with
trypsin (Thermo Scientiﬁc, MA), reconstituted in 30% acetic acid,
and loaded onto an UltiMate 3000 HPLC system (Dionex) with a
PepMap100 C18 75 lm  15 cm, 3 lm 100 Å reverse-phase
column. Peptides were analyzed on a QTOF Qstar Elite mass spec-
trometer (ABSciex, MA) and Mascot (Matrix Science, MA) software.
2.4. Immunoafﬁnity columns
A 1 mL DR11 gravity column and a 65 mL DR11 pump-ﬂow
column were prepared using NHS-activated Sepharose 4 FastFlow
matrix (GE Life Sciences, NJ) at a ratio of 1 mg of sHLA-DR11 per
1 mL of matrix. A 1 cm diameter glass gravity column enclosure
was used for the 1 mL column. A 65 mL Glycosorb column enclo-
sure (Glycorex, Sweden) was utilized for the large DR11 column.
2.5. Alloantibody puriﬁcation
Passing 1 mL of undiluted sera over the 1 mL gravity column
puriﬁed patient antibodies. The column was washed with 7 mL of
PBS pH 7.4 and eluted with 4 mL of 0.1 M glycine, pH 11. Eluate
was neutralized in 1 M TRIS, pH 7.0 at a ratio of 1:5 TRIS:Eluate.
For patients 13 and 14, 2.4 L and 2.1 L respectively of plasma was
passed over the 65 mL column at a ﬂow rate of 35 mL/min, washed
with 1 L of PBS pH 7.4, and antibodies eluted with 240 mL of 0.1 M
glycine. After each load/elution cycle, the columns were mock
eluted with glycine and washed with PBS. For the L243 column test
(SFig. 2), 1 mL of L243 at 200 lg/mL was absorbed by gravity and
25/200 lL ﬂow-through fractions collected. Antibodies were eluted
using 5 mL of 50 mM DEA pH 11.3. 20 fractions were collected,
immediately neutralized with 1 M TRIS, and antibody content
determined by OD280.
2.6. Single antigen bead assays
For the single antigen bead experiments (Figs. 1 and 2) anti-HLA
antibodies in the pre-column serum, ﬂow-through, and eluate
were identiﬁed using LIFECODES LSA Class II single antigen assay
(Gen-Probe, WI). Brieﬂy, bead suspension was incubated with test
sample at room temperature for 30 min on an orbital shaker
according to the manufacturer’s ratio of beads to sample. Beads
were washed and incubated with supplied LSA Conjugate Concen-
trate (goat anti-human IgG PE diluted ten-fold) for 30 min. Alterna-
tively, LabScreen Class II Single Antigen Beads (Lot#009) were used
to determine MFI values (One Lambda Inc., CA). Brieﬂy bead
suspension was incubated with sample and incubated at room
temperature for 30 min. Beads were washed and incubated with
50 ll the detecting antibody (anti-human IgG PE secondary
antibody diluted 100-fold & supplied by One Lambda) for 30 min.
Fig. 1. Speciﬁc depletion and recovery of DR11 Alloantibodies from sensitized sera. Data in A–C, is shown as both a histogram as well a heatmap. 1 mL of DR11 sensitized sera
was passed over a 1 mL sHLA-DR11 column, washed, and eluted off the column. MFI values of the sera before (A) and after (B) passage over the DR11 column. (C) MFI values of
the neutralized column eluate. (D) MFI values of approximately 160 ll (3 drop) fractions of the ﬂow-through (1 mL of sera followed by 1 mL of PBS). (E) MFI values of
approximately 160 ll (3 drop) fractions of the elution. In D and E each line represents MFI values from the indicated allomorph.
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washed and analyzed on a Luminex 100 analyzer. To account for
technical variations in the assay, MFI values were normalized to
20,000 using the positive control beads according to the following
equation: Normalized MFI = (20,000/positive control bead MFI)⁄
MFI. A normalized value of 20,000 is the rounded average
maximum positive control bead MFI.2.7. Immunoglobulin isotyping
Antibody isotyping and quantiﬁcation were completed using
the Bio-Plex Pro immunoglobulin isotyping kit (Bio-Rad, CA).
Brieﬂy, 10-fold sample dilutions in 50 ll were incubated with50 ll of bead suspension for 30 min. Beads were washed and
incubated with a biotynlated secondary antibody for 30 min. Beads
were then washed and incubated with streptavidin PE for 30 min.
Last, beads were washed and analyzed on a Luminex 100. Sample
MFI values were translated into Ig concentration using the Ig
speciﬁc standard curves and the Bio-Plex Manager software.2.8. Complement dependent cytolysis
Complement dependent cytolysis (CDC) was determined using
the Lambda Cell Tray: 30 B cell panel (One Lambda Inc., CA). Lysis
was performed according to manufacturer protocols. Rabbit
complement was used as a source of complement. After lysis,
Fig. 2. Puriﬁcation of DR11 speciﬁc alloantibodies from multiple patient sera. Heatmap indicating MFI values for each allomorph on the panel for the sera before the column
(PRE), after the column (POST), or in the elution (ELUTION) in patients G-12. Scale of the heatmap is shown on the bottom panel. For clarity, values below the threshold are
blacked out. HLA-DR11 MFI values are outlined in blue. Threshold values for PRE and POST were determined by taking the average bead MFI of negative sera plus 5 standard
deviations. Threshold values for ELUTION were determined by taking the average DQ bead MFI plus 5 standard deviations.
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dium bromide, (One Lambda Inc., CA) was used to differentiate live
from lysed cells. Live and lysed cells were analyzed using a Nikon
TE200-E ﬂuorescent microscope (Nikon, NY). Whole well images
were generated using the 4x objective lens for the green (excita-
tion: 490 nm bp 20, emission: 520 nm bp 38) and the red ﬁlter
(excitation: 555 nm bp 28, emission: 617 nm bp 73). Total ﬂuores-
cence was determined using MetaMorph v 7.5.5.0 and percent cell
death was calculated: red ﬂuorescence/(red ﬂuorescence + green
ﬂuorescence).
2.9. Size exclusion chromatography
IgM and IgA multimers were separated from monomeric Ig
using size exclusion chromatography. Human IgM, IgA, and IgGcontrols were from Sigma–Aldrich, CA. 10 ll at 1 mg/mL of human
IgM, IgA, IgG, or puriﬁed alloantibodies were injected into a Para-
digm MS4 HPLC (Michrom, CA) and run over a Biosep-SEC-s4000
SEC column (Phenomenex, CA) (4.6 mm ID  300 mm length) at a
ﬂow rate of 220 ll. Antibody elution chromatograms were mea-
sured by absorbance at 215 nM of the eluting species.
2.10. Statistical analysis
All statistical analyses were performed using GraphPad Prism 5
software. Data variance was determined using a D’Agostino and
Pearson omnibus normality test. On parametrically distributed
data, mean and standard deviation is used to describe the data.
Signiﬁcant differences in mean values were determined using an
unpaired t-test. On non-parametric data, medians and interquartile
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values were determined using a Mann–Whitney test.3. Results
3.1. HLA class II immunoafﬁnity columns
The isolation of anti-class II HLA antibodies requires a source of
plentiful, native class II HLA. Here we prepared DNA constructs for
a secreted HLA-DRA1⁄01:01/HLA-DRB1⁄11:01 alpha/beta heterodi-
mer by replacing the transmembrane domain of the alpha and beta
chains with a 7 amino acid linker followed by an ACIDp1 or BASEp1
leucine zipper domain respectively (SFig. 1A) [14]. This approach
was implemented so that (1) the lack of a transmembrane domain
would make the class II complex soluble whereby transfected B
lympoblastoid cell lines would continually secrete the desired al-
pha/beta/peptide complex, and (2) the leucine zipper domain
would bring and keep the HLA-DRA1⁄01:01/HLA-DRB1⁄11:01 het-
erodimer together in solution.
To conﬁrm that the secreted class II HLA molecules puriﬁed
from tissue culture harvests were indeed HLA-DRA1⁄01:01/HLA-
DRB1⁄11:01 heterodimers, the puriﬁed class II protein was di-
gested with trypsin and subjected to liquid chromatography mass
spectrometry (LCMS) analysis. In a BLAST analysis, the only protein
sequences detected were derived from the transfected sHLA-DR11
alpha and beta chains of the class II complexes produced and iso-
lated here (SFig. 1B).
Pure sHLA-DR11 was covalently coupled to Sepharose-4 Fast
Flow to create an immunoafﬁnity column. In order to conﬁrm
the serologic activity of secreted class II HLA was maintained fol-
lowing its coupling to a column, the anti-HLA-DR monoclonal anti-
body L243 that recognizes intact class II HLA proteins was passed
over the HLA afﬁnity column. Fractions of 200 ll were collected
during the L243 loading process (ﬂow through) and L243 antibod-
ies that bound to the class II HLA on the column were then eluted
from the column intact. A total of 200 lg of L243 was passed over
the HLA-DR11 column, 170.7 lg (78%) of which was recovered:
122.9 lg (72%) bound to the class II HLA column and was recov-
ered in the eluate while 47.8 lg (28%) passed through the column
and was recovered in the ﬂow through (SFig. 2A). Recovered L243
antibody maintained its activity and speciﬁcity in an HLA single
antigen bead assay (SAB) (SFig. 2B). These data demonstrate thatTable 1
Patient sample information.
Sample Age* DR1 DR1 DR345 DQ DQ Previous
Tx
Probable DR sensitis
GTI Unk Unk Unknown
1 50 1 First graft DR4 DR11
2 61 7 13 52, 53 2 7 0 No known sentitizin
3 29 1 7 53 2 5 3 First graft no DR mi
unknown
4 42 1 4 53 5 8 1 First graft DR7 mism
5 43 1 4 53 5 8 1 First graft type unkn
6 22 9 17 52, 53 2 9 1 First graft DR4 mism
7 65 4 17 52, 53 2 7 0 Two pregnancies; pa
8 34 10 15 51 1 First graft type unkn
9 43 13 13 52 0 Two pregnancies; pa
10 47 1 5 0 No known sentitizin
11 61 1 17 2 5 1 First graft DR7 mism
12 48 1 7 2 5 1 First graft DR17 mis
13 75 9 17 52,53 2 9 0 Blood transfusion; t
14 62 4 17 52,53 2 7 1 First graft DR11 mis
⁄
At time of blood draw.
 Patients used in large-scale antibody puriﬁcation expriments.a sHLA-DR11 column can be used to recover anti-HLA antibodies
that are intact and suitable for use in immunoassays.
3.2. Afﬁnity puriﬁcation of alloantibodies
Anti-sera cytotoxic to only DR11 expressing cells purchased
from Genprobe GTI Diagnostics were passed over the column. This
DR11 serum was crossreactive with DR, DQ and DP speciﬁcities
(Fig. 1A). Following passage through the DR11 column, DR reactive
antibodies bound to the column while DP and DQ speciﬁcities ﬂo-
wed through (Fig. 1B, D). Antibodies to DR11 eluted from the col-
umn did not react to DQ or DP (Fig. 1C, E). The recognition of
several HLA-DR by the puriﬁed antibodies suggests that amino
acids 70D 73A and 37Y 38 V of the class II beta chain are likely
serologic epitopes for these sera.
In addition to the GTI serum, a panel of DR11 sensitized patient
sera was passed over the column (Table 1). All patient sera were
positive for DR11 activity by either SAB, ﬂow crossmatch, or both
(Table 1). For each of these twelve patients, antibodies in the
pre-column sera, post-column ﬂow through, and antibody eluate
were compared using an HLA single antigen bead assay (Fig. 2).
The column completely depleted DR11 speciﬁcities from the sera
of 11 patients with the exception being patient 1 who exhibited
an extremely high titer of antibodies to DR11. The DR11 antibodies
recovered from the column were positive on SAB with the excep-
tion of the antibodies recovered from patient 2. Eluted antibodies
reacted with multiple DR whereby patterns of DR crossreactivity
were consistent with known serologic epitopes [15]. Antibodies
puriﬁed from patients 7 and 9 reacted with DR and DP via a shared
DRB1–57D 58E and DPB1–55D 56E epitope [16–18]. There was no
evidence of DQ activity in the recovered/puriﬁed antibodies (Fig. 2)
and the DR11serologic epitopes recognized by patient antibodies
could be deﬁned on the basis of crossreactivity with other DR/DP
molecules.
3.3. Alloantibody serum concentration
The class II HLA column removed most of the DR11 reactivity in
the 13 patient samples tested. When the total antibody recovered
from the column was assessed, and column loss was adjusted to
approximately 25%, the serum concentration of DR11 alloantibod-
ies ranged between 0.76 and 26.1 lg/mL with a median concentra-
tion of 2.3 lg/mL. The average bulk serum Ig concentration wasing events DR11 IgG
FXM
DR11 IgM
FXM
DR11
SAB
N.T. N.T. +
mismatch N.T. N.T. +
g event + + 
smatch. Four pregnancies; partner type   +
atch   +
own +  +
atch   +
rtner DR7 +  
own + + +
rtner type unknown +  
g event   +
atch +  +
match +  +
ype unknown +  +
match +  +
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um Ig were DR11 reactive.3.4. Alloantibody isotype proﬁle
DR11 column-isolated antibodies were proﬁled for their immu-
noglobulin isotype. All isotypes were detected in all patient sera,
including IgG, IgM, IgA, and IgE (Fig. 3A). Antibody ratios differed
from patient to patient: Patient 1 had substantial IgG1 while
>70% of patient 2 antibodies were IgM. In comparison to bulk Ig,
a pattern emerged whereby isotype IgG1 was underrepresented
and IgG2 was overrepresented. IgG3 and 4 levels were unchanged
as compared to total serum IgG (Fig. 3B). Taken together, the IgG
isotypes were under represented and the IgM isotype compensated
for this drop as IgM accounted for 31% of the anti-DR11 Ig. The
percentage of IgA in the eluate was similar to that observed in bulk
serum IgA while the percentage of DR11 IgE alloantibodies were
signiﬁcantly higher than levels found in sera. In summary, everyFig. 3. Isotype proﬁles of the puriﬁed DR11 speciﬁc alloantibodies. (A) Isotype proﬁles of
were analyzed: IgG1 (blue), IgG2 (red), IgG3 (green), IgG4 (purple), IgM (teal), IgA (oran
antibodies compared to bulk serum antibodies. Line represents the median value and bar
t-test.isotype was represented among the eluted DR11 alloantibodies,
IgG2, IgM, and IgE are enriched, and IgG1 is underrepresented.3.5. Alloantibodies to DR11 ﬁx complement
Puriﬁed DR11 alloantibodies were tested for their ability to ﬁx
complement. Four different DR11 expressing B-cell lines served
as target cells. The commercial serum ‘sample G’ had only DR11
speciﬁc complement ﬁxation activity (Fig. 4A). After column
absorption, complement-ﬁxing activity was recovered in the
eluted antibodies with no cytolysis in the ﬂow-through: Column
puriﬁed DR11 alloantibodies ﬁx complement. Next, alloantibodies
from the 12 patients were column puriﬁed and tested for comple-
ment-ﬁxing activity (Fig. 4B). Antibodies from 10 patients exhib-
ited cell lysis >40%, including the predominantly IgM antibodies
of patient 2. Patient 5 had little cytolytic activity even with an
isotype proﬁle similar to other patients, and patient 1 had no
CDC activity despite a prevalence of IgG1 alloantibodies – anthe puriﬁed antibodies from all of the patients in the study. Seven different isotypes
ge), and IgE (light blue). (B) Proportion of indicated isotype in puriﬁed HLA-DR11
s show the interquartile range. P values are shown as the result of a Mann–Whitney
Fig. 4. CDC activity of puriﬁed DR11 speciﬁc alloantibodies. (A) Sera from patient
‘G’ was passed over the column and the eluted antibodies were collected. These
three samples (PRE, POST, ELUTION) were then added to 4 different HLA-DR11
positive B-cells (C433 blue, C418 red, C428 green, C432 purple) in the presence of
complement. Cell death was measured according to the materials and methods and
is shown in the histogram. A representative image of the assay (cell line C428) is
shown below the histogram. Class II haplotype of each cell line is shown in the table
inlay. (B) Complement dependent cell death of the eluted antibodies from patients
G-12.
(A)
(B)
(C)
Fig. 5. Correlation of DR11 alloantibody concentration and MFI values. Serum MFI
values of 13 different patients plotted against the total serum Ig (A). or IgG1–4 (B).
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sistently ﬁxed complement and this was likely due to the large
proportions of IgM.Puriﬁed antibody MFI values from the same patients plotted against the IgG1–4
concentration (C). Data was ﬁt to linear model and shown with the 95% conﬁdence
bands. R2 values for each line are shown.3.6. MFI and antibody concentration
HLA column puriﬁcation enabled the determination of DR11
alloantibody concentration in DR11 patient sera. Hence, we were
next able to assess the correlation of MFI values and serum anti-
body concentration. A comparison of serum antibody concentra-
tions and MFI values in patients ‘G’ and 1–12 Fig. 5A indicates a
variable but signiﬁcant (R2 = 0.3247) linear correlation. When
plotted in terms of serum IgG concentration (having subtracted
IgA, M, & E), this correlation remained (R2 = 0.3678) (Fig. 5B).
Antibody puriﬁcation further reduced MFI versus IgG variability
(R2 = 0.4154) (Fig. 5C). However, antibody concentrations for many
patients fell outside the 95% conﬁdence level, including three
patients with low antibody concentrations yet consistently high
MFI values. Thus, a high degree of variation makes it difﬁcult to
assign serum antibody concentrations using MFI values.3.7. Multimeric immunoglobulins and MFI
Multiple factors are positioned to inﬂuence the behavior of anti-
bodies in a diagnostic test: Different isotypes, antibody afﬁnity,
and the recognition of different epitope speciﬁcities. The removal
of IgM multimers by either DTT reduction or size exclusion has
been reported to provide more meaningful determinations of IgG
concentration [19], and we hypothesized that MFI values would
more accurately reﬂect patient-to-patient IgG concentrations were
IgM and IgA multimers removed. Milligrams of DR11 reactive allo-
antibody were puriﬁed from patients 13 and 14 (the patients with
large quantities of available sample; see materials and methods),
and the IgM and IgA were separated from IgG by size-exclusion
Fig. 6. SEC–HPLC of puriﬁed DR11 alloantibodies. 10 lg of puriﬁed human IgM
(blue), IgA (red), and IgG (black) were run individually over a size-exclusion column
(A). 10 lg of neat DR11 alloantibodies from patients 13 (B), 14 (C) was run over a
size-exclusion column. The collected Ig monomeric fraction is shaded in grey.
Fig. 7. MFI values of total Ig or monomeric Ig. HLA-DR11 MFI values of the different
antibody preparations. For patients 13 and 14 MFI values were determined for
native antibodies (all), monomeric antibodies (Mono), saturating concentration of
200 lg/mL. P values are shown as the result of unpaired t-test.
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antibodies were >88% IgG (SFig. 3). These IgG preparations were
adjusted to 20 lg/mL and tested by SAB assay. As a note, these
puriﬁed samples had CV values ranging from 7.4% to 10.0%, and be-
cause these CV values are well within those reported for this MFI
range [20], a statistical comparison within three replicates was
completed. Patient 13 had an average MFI value of 10,660 and pa-
tient 14 had an MFI of 15,075; a signiﬁcant (p = 0.0285) difference
of 4415 MFI remained between these equilibrated samples. More-
over, the removal of considerable IgM and IgA did not signiﬁcantly
change the DR11 MFI values (Fig. 7). Thus, multimeric IgM and IgA
had little effect on MFI values within a patient and multimer re-
moval did not make MFI values comparable between patients.4. Discussion
Donor speciﬁc anti-HLA antibodies represent a pre-transplant
contraindication and a post-transplant risk for graft loss. While itis clear that antibodies to HLA mediate graft rejection and loss,
not all anti-HLA antibodies are detrimental to allografts [11–13].
Substantial heterogeneity exists between antibody responses, and
there is a great interest in distinguishing pathogenic anti-HLA anti-
bodies from those that are not a threat to the transplanted organ.
To date, the antibodies that warrant clinical intervention remain
ambiguous from those responses that do not impact clinical out-
comes. Here, we developed an HLA-DR11 immunoafﬁnity column
to purify HLA alloantibodies and, once puriﬁed, we proﬁled these
antibodies. This ability to isolate anti-HLA antibodies is positioned
to augment both clinical and basic scientiﬁc endeavors to unravel
the complex nature of humoral responses to HLA.
Through the recognition of epitopes that are shared by multiple
HLA allomorphs, alloantibodies to HLA cross-react with several
HLA antigens [15,21–23]. Here, puriﬁed DR11 alloantibodies were
cross-reactive with numerous DR and some DP molecules. In many
cases, the broad cross-reactivity of these puriﬁed alloantibodies
made it difﬁcult to deﬁne the epitopes recognized without sequen-
tial absorption and/or blocking experiments. Nonetheless, several
serologic epitopes were readily apparent when the DR11 column
puriﬁed antibodies were tested. For example, the cross-reactivity
of sera from patients 7 and 10 with DR11 and multiple DP (HLA-
DP2, 3, 04:02, 6, 9, 10, 14, 16, 17, 18, 28) is likely due to a shared
57D 58E epitope. Epitope 57D 58E is deﬁned by an Asp at position
57 and a Glu at position 58 on the beta chain of DR11, with the ex-
act same amino acids found at positions 55 and 56 on the DP beta
chain [16–18]. Another commonly observed class II HLA epitope is
10YST, deﬁned by residues Y10, S11, T12, and S13 that are con-
served on DR11, DR17, DR18, DR13, and DR14. Interestingly, these
amino acids are located underneath the peptide groove, suggesting
that DR11 alloantibodies can recognize an epitope or epitopes out-
side/underneath the binding groove. A similar HLA-DR epitope has
been reported by Muro et.al. [24]. Thus, the anti-DR11 antibodies
puriﬁed in this study were cross-reactive with other allomorphs
in a way that is consistent with known epitopes.
Multiple IgG subtypes, IgA, and IgM can target HLA alloantigens
[25–30]. Such antibody heterogeneity is understandable when one
considers the different routes of sensitization (pregnancy, previous
transplant, transfusions, etc.) as well as the many different HLA
speciﬁcities that can serve as immunogens [30]. Here we ﬁxed
the speciﬁcity by characterizing only anti-HLA-DR11 alloantibod-
ies and, by purifying microgram quantities of DR11 reactive anti-
bodies, we were able to elucidate HLA reactive isotypes
representing as little as 0.001% of the total Ig. In each patient every
isotype was detectable, including low abundance IgE antibodies.
Because these patients were sensitized via a variety of antigenic
exposures, no single alloantibody isotype was consistently under
or over represented when compared to bulk serum antibodies:
there was a large degree of variation among patients. Nonetheless,
the IgG1 isotype, which has a high afﬁnity for Fc receptors (FcR),
was underrepresented throughout the patient panel, suggesting
that IgG-mediated ADCC may play a minor role in the class II
alloresponse. IgG subtypes 1 and 3 have a high afﬁnity for C1q,
and the lack of these alloantibodies should result in low CDC activ-
ity. However, most patients had a relatively large proportion of
IgM, an isotype that exhibits the highest afﬁnity for C1q; IgM
may compensate for any dearth of IgG-mediated C1q interaction.
Indeed, when tested for CDC activity, most patient’s puriﬁed
alloantibodies lysed >50% of the DR11 expressing cells. A high pro-
portion of IgM class II speciﬁc antibodies may provide ample CDC
activity when IgG1 and IgG3 proportions are low.
The proﬁling of puriﬁed DR11 alloantibodies demonstrates that
heterogencous alloantibody mixtures as a whole ﬁx complement.
The one exception, patient 1, merits some discussion because this
patient’s puriﬁed Abs were predominantly IgG1, an isotype that
readily ﬁxes complement. Patient one’s results highlight previous
C. McMurtrey et al. / Human Immunology 75 (2014) 261–270 269observations showing that CDC activity is mediated by multiple
factors. For example, Dequesnoy et.al. have shown that the recog-
nition of an HLA epitope and its surrounding regions (or paratopes)
by multiple CDR loops of an alloantibody will inﬂuence the ability
of that antibody to bind C1q and ﬁx complement [22]: An anti-
body’s avidity increases as more CDR loops of the antibody interact
with a particular allomorph, increased avidity leads to a change in
antibody conformation, and antibodies in an optimal conformation
more readily bind C1q. Here we found a counter-intuitive example
whereby patient (patient 1) had nearly 70% IgG1 yet had little com-
plement ﬁxing activity. It is possible that patient one’s IgG1 alloan-
tibodies did not optimally interact with DR11 or that various
alloantibodies in the mixture were competing for epitopes and
thereby inhibiting each others ability to optimally bind DR11.
While mechanistic studies will be required to deﬁnitively address
this case, these data demonstrate that isotype alone is not sufﬁcient
for complement ﬁxation and that factors such as avidity may inﬂu-
ence complement activation.
As a clinical diagnostic, single antigen bead assays are widely
used to screen for HLA-speciﬁc antibodies in patient sera. Such as-
says are very effective at determining reactivity to a given HLA
allotype, but it remains difﬁcult to determine antibody concentra-
tion or functional relevance via gradations in MFI. Several explana-
tions might explain a lack of correlation between MFI and antibody
concentration, and here we examined how changes to the antibody
milieu impact correlations of MFI and IgG concentration. Interfer-
ence of IgM is thought to effect SAB assay MFI values [19], and
we postulated that a lack of consistency between MFI and IgGmea-
surement might be due to IgM and IgA multimeric alloantibodies
interfering with the detection of IgG. However, the removal of mul-
timeric antibodies by physical separation failed to align MFI values
and IgG levels in the patients tested. These data suggest that mul-
timeric antibodies have a modest inﬂuence on MFI values and that
variables including antibody afﬁnity and epitope speciﬁcity must
also inﬂuence MFI indications of IgG concentration. Future studies
that test puriﬁed antibodies by surface plasmon resonance may
best assess the correlation of antibody afﬁnity and diagnostic MFI.
HLA proteins have proven their worth in diagnostic assays but
they have not been tested as a therapeutic. Given the data pre-
sented here, one could envision the development of an HLA anti-
body absorption device for the depletion of humoral immune
responses to HLA, leaving otherwise beneﬁcial humoral immunity
intact. Today, antibody reduction therapies such as plasma ex-
change deplete bulk antibodies to facilitate transplants for recipi-
ents who are otherwise serologically incompatible. By adding the
element of HLA speciﬁcity to these existing reduction therapies it
might be possible to remove only the deleterious anti-HLA anti-
bodies in pre and post-transplant scenarios. Antigen-speciﬁc anti-
body depletion columns are used to remove antibodies to blood
group A and B antigens, and in this report we show that liters of
patient plasma can be processed over columns equivalent in pro-
portion to the Glycosorb and Immunosorba columns used for blood
group desensitization [31–36]. More than 20 mg of DR11 reactive
antibody were isolated in both patients 13 and 14, signiﬁcantly
reducing MFI values in the plasma ﬂow through (data not shown).
While an HLA absorption device remains distant from the clinic,
the columns tested here demonstrate that complement-ﬁxing anti-
bodies to HLA can be absorbed from patient samples. In addition to
serving as diagnostic tools, HLA proteins may be developed as fu-
ture transplant therapies.
In summary, milligram quantities of native class II HLA proteins
were produced and coupled to a column support for use in HLA
antibody puriﬁcation. The recovered DR11 reactive antibodies
were functionally active and cross-reactive with DR and DP allo-
morphs. Detectable amounts of every antibody isotype were pres-
ent in each patient and the IgG2, IgM, and IgE isotypes wereenriched. Although IgG1 and IgG3 levels were not elevated, the
HLA alloantibody mixtures remained active in complement ﬁxa-
tion assays. Testing of the puriﬁed alloantibodies with HLA SAB
conﬁrmed the lack or association between MFI values and antibody
concentration, an inconsistency not remedied by the removal of
multimeric antibody isotypes. Future column studies with other
class II and class I allormorphs will be needed to better elucidate
the character, reactivity, and quantity of alloantibodies and to bet-
ter deﬁne those antibodies that promote transplant rejection.
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Abstract
Background: HLA directed antibodies play an important role in acute and chronic allograft rejection. During viral infection
of a patient with HLA antibodies, the HLA antibody levels may rise even though there is no new immunization with antigen.
However it is not known whether the converse occurs, and whether changes on non-donor specific antibodies are
associated with any outcomes following HLA antibody incompatible renal transplantation.
Methods: 55 patients, 31 women and 24 men, who underwent HLAi renal transplant in our center from September 2005 to
September 2010 were included in the studies. We analysed the data using two different approaches, based on; i) DSA levels
and ii) rejection episode post transplant. HLA antibody levels were measured during the early post transplant period and
corresponding CMV, VZV and Anti-HBs IgG antibody levels and blood group IgG, IgM and IgA antibodies were quantified.
Results: Despite a significant DSA antibody rise no significant non-donor specific HLA antibody, viral or blood group
antibody rise was found. In rejection episode analyses, multiple logistic regression modelling showed that change in the
DSA was significantly associated with rejection (p = 0.002), even when adjusted for other antibody levels. No other antibody
levels were predictive of rejection. Increase in DSA from pre treatment to a post transplant peak of 1000 was equivalent to
an increased chance of rejection with an odds ratio of 1.47 (1.08, 2.00).
Conclusion: In spite of increases or decreases in the DSA levels, there were no changes in the viral or the blood group
antibodies in these patients. Thus the DSA rise is specific in contrast to the viral, blood group or third party antibodies post
transplantation. Increases in the DSA post transplant in comparison to pre-treatment are strongly associated with
occurrence of rejection.
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Introduction
Antibodies are major factors not only in the human immune
response against bacteria and viruses but also for allograft rejection
and transplant kidney survival. The determinants of the levels of
antibodies are not fully understood. Until recently it has been
difficult to study the characteristics of human leukocyte antigen
(HLA) antibodies after transplantation in the face of preformed
HLA antibodies, first because the methods used to measure
antibody levels were neither sensitive nor specific, and secondly
because the results of such transplants were poor. It is now possible
to follow the levels of HLA antibodies closely after renal
transplantation.
There has always been a theoretical concern that infections can
trigger rejection episodes and increase HLA antibodies. A recent
study has shown that there is a strong association between the
development of infection and increases in both breadth and
strength of HLA antibodies [1]. The increase in the breadth of
HLA antibodies was mainly due to expansion of reactivity among
other antigens of a cross-reactive group (CREGs). Other studies
have shown that in transplant kidney biopsies of acutely rejecting
patients with viral infections the presence of plasma cell infiltrates
and C4d deposition [2,3]. The relationship between infection and
rise in HLA antibodies is thought to be secondary to the presence
of a robust memory B-cell response to the release of pro-
inflammatory cytokines.
It is of interest to find out if rises in DSA levels with or without
rejection is associated with rise in viral and blood group antibodies.
The response of blood group and viral antibodies in pre-sensitized
patients to a renal allograft is not fully understood. Changes in the
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e68663
levels of these antibodies soon after transplantation might
illuminate the relationship between DSA and these antibodies
and there may be insights into the processes determining the
production and elimination of HLA antibodies [4].
With regards to blood group antibody levels after blood group
incompatible transplantation, studies have shown a reduction in
the levels of blood group antibodies in the long term, to
undetectable levels in many patients. Higher levels of antibodies
were associated with short-and long term dysfunction in some
patients [5]. The rapid disappearance of blood group antibodies
soon after transplantation in many patients with good functioning
grafts contrasts with the reports in HLA antibody incompatible
transplantation [6,7,8]. Looking at blood group antibody levels
after HLA antibody incompatible transplantation would confirm
whether the changes observed after blood group incompatible
transplantation are specific to that setting, or also occur when
there is a marked humoral response to HLA after transplantation.
The aims of this study were to examine in detail the wider
humoral response during a period of intense re-synthesis of HLA
antibodies after renal transplantation. The choice of antibodies
studied meant we studied antibodies that had been stimulated by
infection, immunization, and ‘natural’ antibodies.
Methods
The study was approved by the West Midlands Research Ethics
committee, U.K. Patients sensitized to HLA antigens were selected
after obtaining consent for our program of antibody incompatible
transplantation if they had current reactivity with donor specific
HLA antigens measured by cytotoxic crossmatch (CDC), flow
crossmatch (FC), or by microbead assay. We analysed 55 such
patients, 31 women and 24 men, who underwent HLAi renal
transplant at our center from September 2005 to September 2010.
Pre-transplant, patients were treated with five alternate day
sessions of double filtration plasmapheresis, the aim being to
achieve a negative flow crossmatch at the time of surgery. In some
cases with low starting levels of DSA, fewer sessions of
plasmapheresis were administered. In some cases with high
starting levels of DSA, more sessions of plasmapheresis were
administered, and/or the transplant was performed in the
presence of positive crossmatch. The number of plasmapheresis
sessions administered varied between two to seven, with the
majority getting five sessions. Patients who had blood group
antibody incompatibility or who died in the early post-transplant
period were excluded from our study.
Serum samples for antibody analysis were done at four time
points, namely pre-treatment, at peak DSA post transplant, at
rejection and late sample which was around six weeks to three
months post transplant. Peak DSA was defined as the highest level
of DSA within the first six weeks post transplant. As samples were
collected from patients on a daily basis, the peak time point was
chosen on retrospective analysis. Third party antibodies (TPA)
were defined as HLA antibodies in the recipient, which were not
specific for epitopes expressed on the donor antigens. Though
there were many potential TPA’s, the one which was predominant
in that individual patient, was studied.
Immunosuppression
Imunosuppression consisted of mycophenolate mofetil 1000 mg
bd started five days before transplant, with dose reduced if white
cell count fell below 4.06109/l. Tacrolimus was started three days
before transplant at a dose of 0.15 mg/kg/day in divided doses,
with a target trough level of 10–15 mg/l in the first month.
Prednisolone 20 mg od was started at the time of surgery, and
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Figure 1. Antibody response in patients with an acute rise in donor specific HLA antibody after HLA antibody incompatible renal
transplant. This shows the changes in A) the donor kidney specific antibody (DSA) for HLA class I & II and third party class I & II, B) IgG, IgM and IgA
blood group antibodies and C) viral antibody levels in patients with significantly higher post-transplant peak DSA levels compared to pre-transplant
levels. There was no rise in third party HLA antibodies or blood group antibodies. The viral antibodies showed a significant fall in serum antibody
levels; cytomegalovirus (CMV) IgG (p,0.001), varicella zoster virus (VZV) IgG (p,0.0001) and Hepatitis B surface antigen (HBsAg) IgG antibody
(p = 0.006). Only patients with measurable viral antibody levels pre-transplant were included. Graphs show individual patients (solid thin lines). Mean
values are illustrated with the thick dashed line.
doi:10.1371/journal.pone.0068663.g001
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Figure 2. Antibody response during the first few weeks after HLA antibody incompatible renal transplant in patients with an acute
rise in donor specific HLA antibody. This shows the changes in A) the donor kidney specific antibody (DSA) for HLA class I and II, B) third party
class I and II, C) blood group antibodies and D) viral antibody levels in patients with significantly higher post-transplant peak DSA levels compared to
pre-transplant levels over the first couple of months. Over a longer observation period there was no significant change in third party HLA antibody,
IgG, IgM or IgA blood group antibody, cytomegalovirus (CMV) IgG, varicella zoster virus (VZV) IgG and Hepatitis B surface antigen (HBsAg) IgG
antibody observed. Only patients with measurable viral antibody levels pre-transplant were included. Box plot shows the statistical significant
changes in the groups J- p,0.05 pre-transplant vs. post-transplant; £ - p,0.05 post-transplant vs. late; $ - p,0.05 pre-transplant vs. late and ¥ -
p,0.05 overall trend.
doi:10.1371/journal.pone.0068663.g002
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Figure 3. Antibody response during the first few weeks after HLA antibody incompatible renal transplant in patients with an acute
fall in donor specific HLA antibody. This shows the changes in A) the donor kidney specific antibody (DSA) for HLA class I and II, B) third party
class I and II, C) blood group and D) viral antibody levels in patients with significantly lower post-transplant peak DSA levels compared to pre-
transplant levels over the first couple of months. Over a longer observation period there was no significant change in third party HLA antibody, IgG,
IgM or IgA blood group antibody, cytomegalovirus (CMV) IgG, varicella zoster virus (VZV) IgG and Hepatitis B surface antigen (HBsAg) IgG antibody
observed. Only patients with measurable viral antibody levels pre-transplant were included. Box plot shows the statistical significant changes in the
groups J- p,0.05 pre-transplant vs. post-transplant; £ - p,0.05 post-transplant vs. late; $ - p,0.05 pre-transplant vs. late and ¥ - p,0.05 overall
trend.
doi:10.1371/journal.pone.0068663.g003
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methylprednisolone 500 mg was given as a single intravenous dose
during the transplant operation. Two doses of basiliximab 20 mg
were given, at days zero and four. The protocol was the same as
stated in our previous publications [9,10].
Rejection
Rejection was diagnosed by renal biopsy if the renal function
deteriorated, or clinically if there was rapid onset oliguria with a
rise in both creatinine and in DSA levels. Biopsies were when
clinically indicated and these were independently analysed by
pathologists. Diagnosis of antibody mediated rejection, cellular
rejection or mixed were made according to Banff classification of
transplant biopsies [11,12]. Rejection was treated with three days
high dose methylprednisolone and OKT3 early on in the series or
ATG later on. Rituximab was not given to any of our patients; two
patients received IVIG one month post transplant and four
patients received post-transplant plasmapheresis.
Microbead Assays
The main DSA, cumulative DSA and the third party HLA Abs
both HLA Class I and Class II specific antibodies were analysed
using microbead assay manufactured by One Lambda Inc
(Canoga Park, CA, USA), analysed on the Luminex platform
(XMap 200, Austin, TX, USA) as used in similar studies
previously [13]. Raw mean fluorescence intensity (MFI) values
were used to follow antibody levels. All assays were performed
using serum/bead volume ratios and one thousand MFI was used
as the cut off for positive and negative beads according to the
manufacturer’s instructions.
Flowcytometric estimation of blood group antibodies.
Plasma samples were analysed using flowcytometry for estimating
IgG, IgM and IgA blood group antibodies against reagent cells.
We have used the method previously published by us [14].
Quantification of viral antibodies using LIAISONH
analyzer. Using the LIAISON H analyzer (DiaSorin S.p.A,
Saluggia, Italy), Cytomegalovirus (CMV), Varicella Zoster (VZV)
and Anti Hepatitis B Surface antigen (Anti-HBsAg) IgG antibodies
were quantified from the corresponding serum samples according
to manufactures instructions. The LIAISONH viral antibody test is
a fully automated two-step direct sandwich immunoassay for
in vitro quantitative determination of antibodies to the specific viral
antigen, based on chemiluminescent technology, to be run on the
LIAISON. The method for quantitative determination of specific
IgG to viral antigen is an indirect chemiluminesence immunoassay
(CLIA) [15].
CMV screening and prophylaxis. Routine CMV screening
is done one, three and six months post transplant in all patients
using quantitative PCR (Argene PCR, Biomerieux, CMV R- gene
quantification assay) with the cut-off for positivity being 400 CMV
copies/ml of plasma. As per protocol all CMV IgG negative (R-)
recipients who receive CMV IgG positive (D+) kidneys and any
recipient receiving ATG or OKT3 will get prophylaxis with
Valganciclovir for three months. Primary CMV infection is
defined as CMV viremia post transplant in a sero-negative
recipient. Secondary infection is CMV viremia in a sero positive
patient post transplant.
Statistical Analysis
For comparison of baseline characteristics between groups,
including rejection status defined, the chi-squared test was used for
categorical variables. Means and their differences were compared
using the t-test and Wilcoxon non-parametric test as appropriate
and the level of significance was set at P,0.05.
To investigate the influence of antibody levels and changes in
levels from pre-transplant to post transplant peak on the risk of
rejection, allowing for the effects of other antibodies and
potentially confounding variables, multiple logistic regression
modelling was used. In all logistic models, age, sex, DR mismatch
and number of previous transplants were retained as potentially
confounding. The combined DSA (classes I & II) antibodies levels,
pre-transplant, post transplant peak and change (peak – pre) were
investigated as the main explanatory factor for rejection. Pre-
transplant, peak and changes in other antibodies were included in
models, to examine their influence on the DSA antibody effects.
IBM SPSS software version –19 was used to compare the
antibody levels between the groups. The overall trend over time
was analysed using Kendall test.
Results
We analysed the data using two different approaches; i) based
on DSA levels and ii) based on rejection episode post transplant.
Since the primary study aim was to see if non-HLA antibody levels
increased along with the HLA antibodies, the patients were
divided into 2 groups; 1) Group 1 - Patients who had higher post
transplant peak DSA than pre-treatment levels and 2) Group 2 -
those that had lower post transplant peak DSA than pre-treatment
levels. Patient characteristics are summarized in Table 1. There
were 34 patients in Group 1 and 21 in Group 2. The mean age
was similar in both the groups (38.9 and 40.9). The mean and the
range (given in parentheses) pre-treatment class I & II DSA were
3875 (220, 9181) and 5317 (331, 11055) in Group 1 and 7847
(799, 60605) and 7281 (315, 19652) in Group 2 respectively. And
the mean peak class I & II DSA post transplant were 7024 (193,
12383) and 7195 (514, 12811) in Group 1 and 4449 (120, 15914)
and 5757 (447, 27756) in Group 2 respectively. Two patients
received IVIG one month post transplant and four patients
received post-transplant plasmapheresis. Analysis was repeated
excluding these patient samples and there was no difference in the
results.
Though some of the patients were negative for CMV IgG, anti-
HBsAg or VZV IgG pre- transplant, they were included in the
study. This is because we measured the actual values to obtain a
continuous data to see if there was a rise in the level of these
antibodies along with the DSA’s or not. If the patients were
negative at pre-treatment and stayed negative throughout the four
time points, they were excluded from the analysis, as it was not
possible to differentiate between a lack of response and a lack of
prior immunization. Thus in Group 1, 25 patient samples were
analysed for CMV; 32 for VZV and 23 for anti- HBsAg. Similarly
in Group 2, 13 patient samples were analysed for CMV, 20 for
VZV and eight for anti-Hbs.
When measuring the viral antibodies, if the samples had
reached the saturation of the assay, they were retested in 1 in 10
dilutions. There was no increase detected in the viral antibody
level even on dilutions. Five patients had CMV viremia post
transplant. Two of them had primary infection with concomitant
change of CMV antibodies from negative pre-treatment to positive
in late samples. Out of the three who had secondary infection one
had no change in antibodies whereas the other two showed a slight
increase in the late samples. Analysis was repeated excluding these
patient samples and there was no difference in the results.
Thirty two patient samples from group 1 and 20 from group 2
were analysed for blood group antibodies and rejection outcome.
There were three patients in total who were excluded for analysis
of blood group antibodies from the two groups, as they had
received both blood group incompatible and HLA incompatible
Behaviour of Non-DSA in HLAi Renal Transplantation
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e68663
kidney transplantation. Twenty three out of 32 patients had an
episode of rejection in group 1 as opposed to three out of 20 in
group 2, which was statistically significant (p = 0.0001). Fourteen
patients had antibody mediated rejection, five had cellular
rejection, two had mixed and five were treated as rejection
clinically though the biopsies did not show evidence of rejection.
There was a statistically significant increase in the DSA levels
between pre-treatment and peak level post transplant in class I and
Figure 4. Patient with rise in third party HLA antibody after an HLA antibody incompatible renal transplant. Exceptionally a change in
third party HLA antibodies was not noted which was not explained by the current understanding of epitope sharing of the third party HLA with
donor specific HLA. In this example donor-specific antibodies to HLA A30 and B60 were going down post transplant, but the third party antibody HLA
A2 was increasing. Though the HLA A2 is known to share epitopes with HLA A30, the behaviour of these two antibodies was very different to each
other. Also, the patient did not receive any blood products after the transplant.
doi:10.1371/journal.pone.0068663.g004
Table 2. Results of multiple logistic regression modelling, comparing the occurrence of rejection in relation to DSA.
Baseline pre-transplant DSA Changes in DSA(Peak to Pre) Changes in DSA(Peak to Pre)
Model 1 Model 2 Model 3
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Any DSA pre-Tx (1000s)# 1.08 (0.93, 1.25) 0.2989 1.30 (1.06, 1.58) 0.0116 1.47 (1.08, 2.00) 0.015
Sex (F vs. M) 1.32 (0.22, 7.95) 0.7613 0.58 (0.08, 4.54) 0.6067 0.45 (0.03, 6.56) 0.5593
Age 1.05 (0.98, 1.13) 0.178 1.07 (0.98, 1.18) 0.141 1.05 (0.96, 1.14) 0.2964
Previous Tx (Yes vs. No) 2.49 (0.36, 17.03) 0.3532 2.57 (0.27, 24.4) 0.4111 1.00(0.07, 15.08) 0.997
DR mismatch (0 vs 1 or 2) 3.78 (0.65, 21.93) 0.138 7.48 (0.85, 65.7) 0.0696 29.34 (1.96, 440.0) 0.0145
Any TPA pre-Tx. 1.00 (0.98, 1.02) 0.8166 1.00 (0.98, 1.02) 0.9205 1.00 (0.97, 1.03) 0.7664
VZV pre-Tx. 0.44 (0.20, 0.96) 0.038 0.37 (0.16, 0.84) 0.0172 2.32 (0.67, 8.05) 0.1853
CMV pre-Tx. 0.95 (0.87, 1.03) 0.1869 0.93 (0.85, 1.02) 0.1031 0.81 (0.66, 1.01) 0.0623
antiHBsAg pre-Tx. 1.00 (1.00, 1.00) 0.3648 1.00 (1.00, 1.00) 0.2416 1.02 (1.00, 1.03) 0.0346
IgA pre-Tx. 0.80 (0.51, 1.27) 0.349 0.69 (0.43, 1.11) 0.1249 0.92 (0.62, 1.37) 0.689
IgG pre-Tx. 1.02 (0.98, 1.06) 0.4639 1.02 (0.98. 1.07) 0.3514 1.04 (0.97. 1.11) 0.2683
IgM pre-Tx. 1.02 (0.99, 1.05) 0.2334 1.02 (0.99, 1.06) 0.1917 0.90 (0.80, 1.01) 0.0773
Model 1 is for DSA baseline level adjusted for age, sex, DR mismatch (0 vs. 1 or 2), previous transplant (Tx) (Yes vs. No), and baseline levels of TPA, CMV, VZV, IgA, IgG and
IgM antibodies.
Model 2 is for change in DSA level (peak – pre-transplant), adjusted for age, sex, DR mismatch (0 vs. 1 or 2), previous Tx (Yes vs. No) and baseline levels of TPA, CMV, VZV,
IgA, IgG and IgM antibodies.
Model 3 is for change in DSA level (peak – pre-transplant), adjusted for age, sex, DR mismatch (0 vs. 1 or 2), previous Tx (Yes vs. No) and changes in all antibody levels
(peak – pre-transplant levels of TPA, CMV, VZV, IgA, IgG and IgM antibodies).
#In all models, DSA pre-transplant and change levels have been expressed in 1000s, so the OR presented are for an increase of 1000 DSA units.
doi:10.1371/journal.pone.0068663.t002
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class II antibodies in group 1. This was associated with a
simultaneous statistically significant decrease in the viral titres, but
no change in blood group antibodies. With regards to the third
party antibodies, though class I showed an increasing trend this
was not statistically significant. Figure 1 shows the changes in the
DSA class I and II, third party class I and II, viral and blood group
antibody levels in group I patients, comparing pre-treatment levels
to peak DSA levels.
In group 2, there was a statistically significant fall in the DSA
levels between pre-treatment and peak post transplant. The fall in
the viral titres was also significant, but there was no change in the
blood group antibody levels. Figures 2 and 3 show the trend of the
different antibodies over time points of pre-treatment, peak post
transplant and late samples in group 1 and group 2 respectively.
Though most of the rise or fall in class I third party antibodies
could be attributed to shared epitopes with the DSA, some third
party antibodies behaved completely different to the DSA. This
cannot be explained by the current understanding of epitope
sharing of the third party HLA with donor specific HLA. Figure 4
shows a patient wherein the DSAs HLA A30 and B60 were going
down post transplant, but the third party antibody HLA A2 was
rising and the patient did not receive any blood products after the
transplant. In four other patients there was similar dissociation
between donor specific and third party HLA antibody levels.
The second sets of analyses were done on 52 patients (excluding
three as alluded to above) with reference to rejection as the
outcome. Multiple logistic regression modelling was used to
compare the occurrence of rejection with factors age, gender, DR
mismatch, number of previous transplants, and DSA, TPA, viral
and blood group antibodies (Table 2). Baseline levels of all
variables including DSA were not predictive of rejection. This was
true both in the crude model with no adjustments and in the ones
following adjustment for age, sex previous transplant, DR
mismatch and other baseline antibody levels. No other variables
except change in the DSA were significantly associated with
rejection (p = 0.01) consistently in all models with or without
adjustment (all data not shown). An increase in DSA of 1000 units
from pre treatment to a post transplant peak was equivalent to an
increased odds of rejection of 30%, 1.30 (1.06, 1.58) if the
adjustment was made for other antibodies at baseline. The odds
increased to 50%, 1.47(1.08, 2.00) if it was adjusted for changes in
the level of all other antibodies from pre to peak post transplant.
Though VZV, anti Hbs and DR mismatch showed significance on
isolated models, the effect was not constant.
Discussion
The particular stimulus to this study was the observation that
HLA antibodies may rise after an infection or blood transfusion,
even though the HLA antigen is not being directly represented to
the subject [1]. This raised important questions about the
specificity of the humoral immune response. Hypotheses to
explain the increase in HLA antibody levels during a viral
infection include cross reactivity between epitopes on HLA
molecules and viruses, immune up regulation secondary to a
polyclonal antibody response to a single antigen, or an increase in
non-self HLA expression on any non-self cells in the host
expressing HLA [16]. One way interrogate these hypotheses was
to look at the reverse situation in clinical practice, ie, during a
response when the subject is synthesising HLA antibodies rapidly,
do other antibody levels change?
This study has examined in detail, for the first time, the levels of
HLA and several non-HLA antibodies after HLA antibody
incompatible transplantation. The study has shown several novel
findings. First, although HLA antibodies may rise during a viral
infection, viral antibodies did not rise during an intense HLA
antibody response. Second, there were some unexplained antibody
responses to non-donor HLA antibodies, not explained by the
current understanding in epitope sharing. On regrouping the
patients with reference to rejection as the outcome and studying
the relationship of all the variables, it was evident that the increase
in the DSA peak post transplant in comparison to the pre-
treatment level was the only factor significantly associated with
occurrence of rejection.
Viral and blood group antibodies did not rise during intense re-
synthesis of HLA antibodies, indicating specificity in the immune
response and the lack of a bystander effect between plasma cell
clones. Studies have shown that vaccination expands both specific
and bystander memory T cells but antibody production remained
vaccine specific [17]. Some other studies have shown that
influenza vaccine in stable kidney transplant patients is not
associated with the risk of acute rejection or increase in DSA levels
[18,19]. In contrast, other studies have shown vaccination to
potentiate allograft rejection [20]. This is thought to occur due to
non-specific immune activation and induction of cross-reactive
immunity, resulting in enhanced humoral or cellular responses
against the donor antigens [21,22,23]. A recent study from
Switzerland showed that multiple doses of influenza vaccine may
lead to the production of anti-HLA antibodies in a significant
proportion of kidney transplant recipients [24].
We compared quantitative antibody analysis of latent viral
antigens at different time points, to see if there was a rise in these
antibodies due to non-antigen specific stimulation i.e. bystander
activation of memory cells due to antigenically unrelated
activation. This study was not designed to look at the dominant
type of immune response (humoral and cellular) generated for
controlling specific viral infections. A recent study looked at the
longitudinal quantitative analysis of antibody titres specific for
various viral antigens including varicella-zoster virus for a period
of up to 26 years [25]. They showed that in spite of vaccinations,
viral infections, and reactivation the antibody changes were very
specific, thus ruling out bystander activation as a cause of antibody
production.
Zachary and associates have previously shown that in HLA
incompatible renal transplantation, the viral antibodies detected
by ELISA did not change in relation to plasmapheresis [26]. It
could be that the immunosuppressive medications could have
profoundly decreased the humoral immune responsiveness [27].
However, in these patients the concomitant administration of
cytomegalovirus immune globulin (CMVIg) with high levels of
CMV antibodies meant that the samples used for testing were
some weeks after the transplant. The timing of testing was based
on calculated time for clearance of the CMVIg originated
antibodies. This is the first study that has been able to examine
the memory immune response early after transplantation,
particularly during an intense donor-specific humoral response.
In our study patients received pre transplant plasmapheresis to
remove DSA prior to transplantation. Also some patients received
OKT3 or ATG for treatment of humoral and steroid resistant
rejection post transplant. This could have modified all antibody
levels post transplant. However, more than half of the study
patients (29/52) had a significant rise in DSA levels post
transplant, out of whom 18 patients received ATG/OKT3 for
treatment of rejection. Thus it can be said that in spite of the
overall immunosuppression there was an exquisite rise in the HLA
antibodies and hence did not affect the analyses.
With regards to TPAs, many of these did follow the donor
specific antibody levels, and this could be explained by epitope
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sharing. Because of the extent of possible epitope sharing it was not
easy to exclude epitope sharing as the reason for change in non-
donor specific HLA antibody levels in nearly all cases. However, in
five cases there was evidence of a response in non-donor specific
HLA antibody levels that was not explicable by any possible
epitope sharing. It is possible that this observation is due to shared
epitopes not previously described or another form of shared
antigenicity such as denaturing of antigen on the microbeads. This
requires further investigation with techniques such as absorption
studies using donor specific HLA protein.
There are some shortcomings in this study. Samples were
collected prospectively for studies on antibodies on a daily basis in
the early post transplant period, so that changes in antibody levels
were closely tracked. However, the inevitable heterogeneity in a
clinical series means that patients did receive different treatments.
Also, a more qualitative analysis like mapping of viral epitopes and
the change over time, would aid in a better understanding of the
infection-alloimmunity connection. Unfortunately this was outside
the scope of this study. Further studies are needed in this area to
increase our understanding about the immunological response.
Conclusions
During a period of intense re-synthesis of donor specific HLA
antibodies, it was possible to follow in detail the levels of non-
donor specific HLA antibodies, and other antibodies previously
stimulated by infection, immunization, or ‘natural’ blood group
antibodies. Our results showed that the immune response was
generally specific for donor HLA in contrast to the viral, blood
group or third party antigens post transplantation and the increase
in the DSA post transplant in comparison to pre-treatment is
strongly associated with occurrence of rejection.
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CLINICAL AND TRANSLATIONAL RESEARCH
Human Leukocyte Antigen Antibody-Incompatible
Renal Transplantation: Excellent Medium-Term
Outcomes With Negative Cytotoxic Crossmatch
Robert Higgins,1,4 David Lowe,2 Mark Hathaway,2 Clare Williams,2 For T. Lam,1 Habib Kashi,1
Lam Chin Tan,1 Chris Imray,1 Simon Fletcher,1 Klaus Chen,1 Nithya Krishnan,1 Rizwan Hamer,1,3
Sunil Daga,1,3 Matthew Edey,1,3 Daniel Zehnder,1,3 and David Briggs2
Background. Human leukocyte antigen (HLA) antibody-incompatible renal transplantation has been increasingly
performed since 2000 but with few data on the medium-term outcomes.
Methods. Between 2003 and 2011, 84 patients received renal transplants with a pretreatment donor-specific antibody
(DSA) level of more than 500 in a microbead assay. Seventeen patients had positive complement-dependent cytotoxic
(CDC) crossmatch (XM), 44 had negative CDC XM and positive flow cytometric XM, and 23 had DSA detectable by
microbead only.We also reviewed 28 patients withHLA antibodies but noDSA at transplant. DSAs were removedwith
plasmapheresis pretransplant, and patients did not routinely receive antithymocyte globulin posttransplant.
Results. Mean follow-up posttransplantation was 39.6 (range 2–91) months. Patient survival after the first year was
93.8%. Death-censored graft survival at 1, 3, and 5 years was 97.5%, 94.2%, and 80.4%, respectively, in all DSAve
patients, worse at 5 years in the CDCve than in the CDCve/DSAve group at 45.6% and 88.6%, respectively
(P0.03). Five-year graft survival in the DSAve group was 82.1%. Rejection occurred in 53.1% of DSAve patients
in the first year compared with 22% in the DSAve patients (P0.003).
Conclusions.HLA antibody-incompatible renal transplantation had a high success rate if the CDC XM was negative.
Further work is required to predict which CDCve XM grafts will be successful and to treat slowly progressive graft
damage because of DSA in the first few years after transplantation.
Keywords: HLA antibodies, Plasmapheresis, Antibody-incompatible transplantation, Antibody-mediated rejection,
Antithymocyte globulin.
(Transplantation 2011;92: 900–906)
Donor-specific human leukocyte antigen (HLA) antibod-ies are being increasingly recognized as amajor problem
in renal transplantation. In the United Kingdom, approxi-
mately 30% of those waiting for a deceased donor transplant
have HLA antibodies, and more than 200 potential living do-
nor transplants per annum are complicated during work by
the discovery of donor-specific HLA antibodies (DSA). Each
year in the United Kingdom, more than 400 transplants fail
after the first year posttransplant, and in themajority of these,
DSAs probably play a part.
Treatments for acute and chronic HLA antibody-
mediated damage are not yet fully effective. The main ad-
vances that have occurred in the past two decades are the
ability to identifyDSAwith a sensitivemicrobead assay and to
transplant with some early success across all but the highest
levels of DSA (1–3).
Although national consensus meetings and national
guidelines for best practice in HLA antibody-incompatible
transplantation have been produced (4, 5), national registry
data have only recently been collected (6), and there is only
one fully published randomized controlled trial in this field
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(7). Thus, the optimal treatment protocols and the outcomes
of this type of transplant are not fully defined.
Several centers have identified retrospectively the pa-
tients who were transplanted across DSA but who were not
part of a program of antibody-incompatible transplantation.
Transplants with complement-dependent cytotoxic (CDC)
crossmatch (XMve)/DSAve pretransplant had inferior
outcome (8–11). Even transplants with negative CDC and
flow cytometric (FC) XM and DSA detectable by microbead
only have been reported to have an inferior outcome (12).
Single centers using who have transplanted across DSA
with prospective identification of DSA and interventions in-
cluding antibody removal have reported better outcomes.
However, there was a reduced rate of graft survival in those
with high DSA levels, and transplant glomerulopathy devel-
oped in some transplants over a longer follow-up (13–19).
In our center, HLA antibody-incompatible transplants
have been performed since 2003, and these transplants were
reviewed to determine the factors affecting rates of acute
antibody-mediated rejection (AMR), graft and patient sur-
vival, and the longer term development of proteinuria and
chronic antibody-mediated graft damage.
RESULTS
Between June 2003 and February 2011, 84 patients
received transplantation across pretreatment DSA, mean
follow-up was 39.6 (range 2–91) months. The total numbers
with follow-up for 1, 3, and 5 years were 75, 48, and 17, re-
spectively. Those at risk for events of death at 1, 3, and 5 years
were 70, 43, and 12, respectively, and those at risk for events of
graft loss after censoring for death at 1, 3, and 5 years were 67,
41, and 8, respectively. With increasing DSA levels, there was
a higher proportion of patients with regrafts, more patients
who started treatment for established renal failure as chil-
dren, andmore patients on longer time on renal replacement
therapy (Table 1). The DSA-ve were more likely to be from
deceased donors, with better HLA matching.
Pretransplant DSA and Plasmapheresis
The relationship between XM status and Luminex lev-
els is shown in Figure 1. The numbers of sessions of plas-
mapheresis given pretransplant are listed in Table 1, together
with the numbers of patients still positive at that level of an-
tibody testing immediately pretransplant.
Patient Survival and Other Complications
Actuarial patient survival was 93.8% at 1, 3, and 5 years
in the DSAve patients. Of the five deaths, four were FC
XM ve patients: a 66-year-old woman with chronic dialysis
hypotension developed small bowel infarction 3 days posttrans-
plant (had received double filtration plasmapheresis [DFPP]); a
25-year-old woman developed postoperative pulmonary
edema and capillary leak syndrome (had received DFPP and
alemtuzumab); a 61-year-old woman developed pneumonia
at 2 weeks (had received DFPP and antithymocyte globulin
[ATG]); and a 44-year-old woman developed cytomegalovi-
rus infection at 11 months (had received DFPP and ATG).
One patient whose DSAs were only microbeadve died: a
47-year-old man who developed ascending biliary sepsis in
the early postoperative period (had receivedDFPP andATG).
Two DSAve patients died: a 41-year-old diabetic man from
hypoglycemia at 4 months and a woman aged 50 years at
transplant from lung cancer at 5 years.
Infectious complications are listed in Table 2. Only
three patients with cytomegalovirus infection required intra-
venous ganciclovir. There were a number of other complica-
tions associated with recipient comorbidity, either because of
previous transplant surgery or complications associated with
long-term renal failure. Ten DSAve patients, apart from
thosewhodied, required unplanned admission to critical care
for circulatory or respiratory support.
Early Acute AMR
Figure 2 shows rejection-free survival according to the
pretreatment DSA level. Early rejection episodes were almost
exclusively compatible with AMR, showing glomerulitis and
peritubular capillaritis with little tubulits. The findings in many
of these patients have recently been published in detail (20).
In theDSAve patients, acute AMRwasmore frequent
in women who received transplants from a partner or child
than in other transplants, 13 of 18 (72%) vs. 34 of 66 (52%),
respectively (P0.01).
Of 38 episodes of early AMR, one graft failed in the first
3months and another at just over 3months, giving a rejection
reversal rate of 94.7%. The early failure was a transplant with
positive CDC XM due to donor-specific HLA DR4, whose
CDC XM was not fully reversed by DFPP and the graft never
functioned. The failure at just over 3monthswas another case
with positive CDC XM, who developed a glomerular throm-
botic microangiopathy after early AMR.
Treatment for AMR evolved during the series. Initially,
DFPP, intravenous immunoglobulin (IVIg), and rituximab
were used, but these were replaced by cellular depletion ther-
apies using OKT3 or ATG. Eleven patients were treated with
OKT3 for acute AMR. Four were CDC XMve before treat-
ment, five were FCve, and two were microbeadve only.
Three patients were positive forHLA class 1DSAonly and the
other nine for various combinations of classes 1 and 2 DSA.
There were no deaths. Three of these grafts failed at 3, 15, and
32months.Theother eight grafts are functioning at follow-upof
38 to 60months.
Longer TermGraft Survival
Figure 2 shows death-censored graft survival and
proteinuria-free survival according to pretreatment DSA lev-
els assessed by cellular crossmatching, and Figure 3 shows
graft survival according to DSA measured by microbead. Of
the 15 patients with proteinuria, 5 have not yet progressed to
serious graft dysfunction; in 1 patient, the proteinuria may
have been related to recurrent urinary tract infections and in
the other 4 patients, proteinuria declined and renal function
improved or stabilized as DSA levels slowly declined in the
first 3 years posttransplant. All graft losses have been because
of rejection or transplant glomerulopathy, except one
CDCve graft with severe early rejection who had mitral
valve replacement at 33 months posttransplant followed by
graft failure.
Other Complications
Table 2 shows other major complications. Two DSAve
patients developed malignancy. A 20-year-old man treated
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with OKT3 developed testicular cancer at 6 months post-
transplant, resolved 4 years later after chemotherapy and ra-
diotherapy. A woman aged 42 years at transplant with no
early rejection and no ATG or OKT3 developed a squamous
cell carcinoma of the skin at 2 years, treated with radiother-
apy, and at 3 years developed a squamous cell carcinoma of
the rectum and is currently receiving radiotherapy with a
view to surgical resection.
DISCUSSION
This series of HLA antibody-incompatible renal trans-
plants is large enough to show the impact of different DSA
levels on clinical outcomes without having to use historical
controls. We have shown that intensive monitoring and in-
terventions in CDCve/DSAve transplants produced ex-
cellent graft survival with no graft losses from rejection in the
first 6 months after transplantation. However, outcomes in
positive CDC XM transplants or those with microbead DSA
more than 10,000 were less good. Perhaps because intensive
immunosuppression was given on demand routinely, mor-
tality was acceptable.
Pretransplant
DSAmeasured by Luminex showed considerable over-
lap between the CDCve and FCve XM groups. Further
work is required to examine these HLA antibodies in more
TABLE 1. Patient characteristics
CDC ve Flow ve Microbead ve DSA ve P
N 17 44 23 28
Male:female 11:6 11:33 8:15 13:15 0.005
Age, mean (SD), yr 37.5 (11.5) 43.4 (11.2) 46.3 (14.1) 44.2 (14.2) NS
Graft number, n (%)
1 5 (29) 13 (30) 13 (57) 17 (61) 0.005
2 10 (60) 24 (54) 7 (30) 10 (36)
3 1 (5.5) 5 (11) 1 (4) 1 (3)
4 1 (5.5) 2 (5) 2 (9) 0
Years renal replacement therapy, mean (SD) 14 (8.8) 11.7 (7.0) 9.3 (9.7) 7.4 (6.3) 0.003a
Number started RRT age17 yr, n (%) 6 (35) 8 (18) 3 (14) 1 (4) 0.001
Number with significant comorbidity, n (%) 9 (53) 23 (52) 6 (26) 8 (29) 0.005
HLA mismatch, mean (SD) 3.3 (1.3) 2.6 (1.2) 3.0 (1.1) 1.5 (1.4) 0.005b
DR mismatch, mean (SD) 1.1 (0.6) 0.8 (0.6) 1.1 (0.7) 0.25 (0.44) 0.005b
Living donor relation
Sibling 4 14 4 3
Partner/child to mother 3 9 6 0
Other living related 6 16 6 5
Other living unrelated 3 2 4 6
Deceased donor, n (%) 1 (6) 3 (7) 3 (13) 14 (50) 0.01
HLA DSA main specificity
Class1 4 28 16 0 0.01c
DR 7 5 3 0
DP/DQ/DRB3–4 6 11 4 0
Class 1 and any class 2 12 16 8 0 0.01c
Class 1 and DR 10 13 5 0 0.01c
HLA DSA mean no. 3 (1.4) 2.2 (1.2) 1.4 (0.7) 0 0.05c
Luminex single highest, mean (SD) 8461 (2542) 5502 (3632) 1514 (1211) — 0.01c
Luminex total, mean (SD) 18,423 (8397) 8006 (6395) 1740 (1275) —
RMF pretreatment 22.9 (11.4) 7.6 (5.5) 2.3 (1.5) — 0.01c
RMF pretransplant, mean (SD) 15.6 (11.0) 5.5 (4.9) 2.0 (1.9) — 0.01c
No sessions plasmapheresis, mean (SD) 5.9 (2.8) 3.8 (2.0) 1.2 (1.6) 0 0.01c
Crossmatch negative after plasmapheresisd 9/16 19/37 2/9 —
a Significance for CDCve against all other groups and FCve or microbeadve against DSAve.
b All DSAve grafts vs. DSAve grafts.
c DSAve cases not included.
d Number (%) of patients receiving plasmapheresis whose crossmatch was a level lower after plasmapheresis, i.e., CDCve who becameCDCve but could
be either FCve or FCve; FCve became FCve; microbeadve becamemicrobeadve,500 U. The aimwith plasmapheresis inmicrobeadve cases was
to reduce the microbead level to below 2000 U, not to below 500 U.
CDC, complement-dependent cytotoxic; DSA, donor-specific antibody; SD, standard deviation; RRT, renal replacement therapy; HLA, human leukocyte
antigen; RMF, relative median fluorescence; FC, flow cytometric; NS, not significant.
902 | www.transplantjournal.com Transplantation • Volume 92, Number 8, October 27, 2011
detail. Issues may include variation in sensitivity of the beads
between specificities or isotypes, or saturation of microbeads
at high levels of antibody (in this study, we present only anal-
ysis with “neat” serum). The presence of HLA antibodies in-
hibitory to the microbead assay, which may be of IgM class,
may also be an issue as we have observed marked changes in
Luminex activity after treatment of serumwith dithiothreitol
(DTT), as previously described (21).
Many of the patients in this program had significant
comorbidity, and the comorbidity count increased with in-
creasing levels of DSA. To achieve successful early engraft-
ment and simultaneously to minimize recipient morbidity
and mortality, the intensity of treatment was kept to a mini-
mum. In the pretransplant period, plasmapheresis was felt to
be the key intervention, and we used this as intensively as
possible. The choice ofDFPP enabled us to double the plasma
volumes treated per session compared with plasma exchange
(22). Despite this, many patients were transplanted across
persistent DSA with early rejection, as we have previously
discussed.However,wewereable to reduce the intensityofother
agents pretransplant, such as cellular depleting therapies.
Risk of Rejection
In the presence of DSA at transplant, approximately
50% of the cases in this series experienced early acute AMR.
The rejection rates in 119 patients transplanted across HLA
antibody barriers at the Mayo Clinic have recently been re-
ported (14). For patients with a total DSA level of median
fluorescence intensity (MFI) more than 10,000 as measured
by microbead, or a positive anti-human globulin-enhanced
CDCXM, they reported an early AMR rate of 50%.However,
with lower DSA levels, their rate was approximately 20%,
which is lower than in this series. The difference may be be-
FIGURE 1. Relationship between Luminex levels and
XMstatus. (Left) Single highest DSA, (right) sumof all DSA’s.
Microbead analysis performed with serum at standard di-
lution only. XM, crossmatch; DSA, donor-specific antibody.
TABLE 2. Outcomes after transplantation
CDC ve Flow ve Microbead ve DSA ve P
N 17 44 23 28
Died, n (%) 0 4 (9) 1 (4) 2 (7) NSa
Graft failure, n (%) 6 (35) 1 (2) 3 (13) 2 (7) 0.03a
Number with acute rejection, n (%) 11 (65) 26 (59) 10 (44) 7 (25) 0.01a
Rejection in female recipients with child or partner donor, n (%) 3/3 (100) 7/9 (78) 3/6 (50) 0/1 0.01
Rejection in transplants from other donors, n (%) 8/14 (57) 19/35 (54) 7/17 (42) 7/27 (26)
Dialysis dependent during rejection, n (% of patients with rejection) 4 (36) 7 (27) 2 (20) 0 0.01
Rejection treatment, n (% of patients with rejection)
Methylprednisolone 10 (91) 25 (96) 8 (80) 7 (100)
PP 5 (45) 5 (19) 2 (20) 0
ATG 2 (18) 13 (50) 4 (40) 1 (14)
OKT3 4 (36) 2 (8) 2 (20) 0
IVIg 3 (27) 1 (4) 0 0
Eculizumab 0 1 (4) 0 0
Complications
Serious bacterial infection 3 11 3 5
CMV 1 5 5 3
BK 1 3 1 0
Other, including fungal 1 2 1 1
Malignancy 1 0 1 1
eGFR in functioning grafts, mL/min/1.73 m2, mean (SD)
12 mo 53.8 (16.9) 57.2 (25) 73.0 (39.1) 67.4 (30.6) NS
36 mo 45.4 (18.9) 54.2 (28.7) 46.9 (19.2) 56.7 (12.2) NS
Complications are for the first year after transplantation, except malignancy, which is to latest follow-up.
a Significance calculated from Kaplan-Meier analysis, see Figures.
CDC complement-dependent cytotoxic; DSA, donor-specific antibody; PP, plasmapheresis; ATG, antithymocyte globulin; IVIg, intravenous immunoglob-
ulin; CMV, cytomegalovirus; BK, BK virus; eGFR, estimated glomerular filtration rate; NS, not significant.
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cause routine ATG induction was administered. Given the
excellent outcomes of prompt treatment of AMR with ATG,
we continue to use ATG only on demand, meaning that
nearly half of our patients are not exposed to this augmented
immunosuppression.
The risk of rejection was high in women receiving
transplants from partners or children. This is presumably a
consequence of the presentation of the same antigens to
which they have been sensitized. Further work is required to
examine the contributions to risk of the behavior of the DSA
(e.g., affinity or resynthesis rates), or an associated T-cell re-
sponse (some T cells may recognize different epitopes on
HLA to antibodies, so transplanting across exactly the sensi-
tizing HLA antigen may expose the graft to a specific T cell
and a specific antibody challenge).
Treatment of Rejection
We have previously shown in this series of transplants
that glomerular leukocyte infiltration precedingAMRmay be
initiated within 30 min of graft reperfusion even at low DSA
levels (20). Over the next few days, there may be progressive
cellular infiltration of glomeruli and peritubular capillaries
with T lymphocytes, monocytes, and neutrophils, but few B
lymphocytes. Staining for C4d may be negative for the first
few days. DSA levelsmay rise sharply to peak levels at approx-
imately 12 days posttransplant (23), then the graft will func-
tion in the presence of DSA, and then DSA levels may fall
rapidly in the second and third weeks after transplantation.
This understanding led us to focus on early administra-
tion of cellular depletion therapy for the treatment of AMR,
either T-cell depletion alone using OKT3 or polyclonal ATG.
Either of these strategies achieved early reversal of rejection in
more than 95% of cases.
Proteinuria
It was encouraging that no new proteinuria developed
in our patients after 3 years, perhaps suggesting that the DSA
present pretransplantation will cause problems either fairly
early after transplantation or not at all. However, the num-
bers of patients with long-term follow-upwas small, and pro-
teinuria and transplant glomerulopathy continued to develop
after 3 years in the larger Mayo Clinic series (13, 14). More
detailed follow-up is indicated.
Graft Loss
The CDCXMwas the best predictor of outcome in our
series. Unfortunately, within the CDCve group, there was
no consistent difference between those with good outcome
and those with failure or progressive dysfunction. For exam-
ple, one case with good outcome had positive CDC XM with
class 1 HLA, though this became negative after DFPP. We
FIGURE 2. Death-censored out-
comes according to pretreatment
levels of cellular crossmatch. Solid
line, positive CDC crossmatch;
dashed line, positive FC cross-
match, negative CDC crossmatch;
dashed/dotted line, positive mi-
crobead DSA, negative cross-
match; dotted line, negative DSA.
(a) Rejection-free survival, P less
than 0.03; (b) proteinuria-free sur-
vival; (c) graft survival P less than
0.03; and (d) graft survival, P less
than 0.03. The FC XMve and
microbeadve/XMve groups are
combined in thedashed line.CDC,
complement-dependent cytotoxic;
FC, flow cytometric; DSA, donor-
specific antibody; XM, crossmatch.
FIGURE 3. Death-censored graft survival according to
pretreatment microbead DSA level, P less than 0.05. Mi-
crobead DSA less than 500, dotted line; 500 to 1000, dashed
line interrupted by two dots; 1000 to 5000, dashed line inter-
rupted by single dots; and 5000 to 10,000, dashed line; more
than 10,000, solid line. DSA, donor-specific antibody.
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would not transplant across a positive CDC XM for class 1 or
DR that could not be rendered negative by DFPP, but we
transplanted successfully across positive CDC XM in the op-
erating theater for HLA DQ and DP and DRB3–4.
The 5-year death-censored graft survival in the United
Kingdom for all first deceased donor transplants is 82% (95%
CI: 81–83) and for first living donor transplants is 89% (95%
CI: 87%–90%; NHS BT data, accessed March 2011 at
www.transplant.org.uk). Outcomes in our CDCve grafts
were equivalent, indicating that transplantation across HLA
antibodies can be achieved successfully with an intensive
treatment program.
Without prospective identification of DSA and appro-
priate therapy, results seem to be less good. The Royal Lon-
don Hospital showed that CDCve/DSAve status was
associated with a relative risk of graft failure at 5 years of 6.5
compared with those with no HLA antibodies and non-
donor-reactiveHLA antibodies. Graft survival was 62% in the
CDCve/DSAve group and 79% in theDSAve group (8).
The St. Louis Hospital, Paris, reported 5-year death-censored
graft survival of 71.2%withCDCve/DSAve, comparedwith
89.2% in nonsensitized patients and 92.5% sensitized with
no DSA (9). The University of Wisconsin showed, using
alemtuzumab induction, increased rejection was observed in
CDCve/DSAve transplants, and there was reduced graft
survival in those withDSA againstHLADR atMFImore than
1000 (54.3% vs. 86.5%) (10).
Other recent single-center reports fromHLA antibody-
incompatible programs show outcomes in DSAve patients
with FCve or CDCve crossmatches. The Cedars Sinai
Medical Centre used IVIgs and rituximab pretransplant in a
series of 76 transplants and reported overall 2-year patient
and nondeath-censored graft survival rates of 95% and 84%,
respectively; these were divided between living and deceased
donors at 100%/90% and 91%/80%, respectively (24). Risk of
AMR was associated with the level of DSA. The University of
Maryland reported the outcomes in a series of 41 patients, in
whom 1- and 5-year graft survival was 89.9% and 69.4%,
respectively. These patients were FCve, though it is not
clear how many were CDCve as well (15).
Despite the excellent early outcomes in our CDCve
transplants, a number of grafts were lost from rejection and
transplant glomerulopathy between 9 and 36months posttrans-
plant. Numerically the number of losses was greater in the
microbeadve group than the FCve group, suggesting that
the starting levelofDSAwas less important in thesepatients than
the evolution of DSA posttransplant and/or the response of the
graft to that DSA.
Mortality
Mortality after HLA antibody-incompatible transplan-
tation is a concern, especially as the patients with highest DSA
levels require more intense treatment and also tend to have
spentmore time on renal replacement therapy and havemore
comorbidities (Table 1). Four of the five deaths in this series
were in patients who had received DFPP and cellular de-
pletion therapies. We try to avoid combinations of these
therapies, normally using DFPP only pretransplant and ad-
ministering cellular depletion therapies only on demand.
Mortality is also critically dependent on patient selection,
which is difficult to define in single-center studies. Larger
studies and registry data may cast more light on how patient
selection and choice of immunosuppression affect graft out-
come and mortality.
Summary
This series indicates that good outcomes can be
achieved in HLA antibody-incompatible renal transplanta-
tion using a strategy of careful monitoring and “on demand ”
intervention with leukocyte depletion therapy. Longer term
outcomes were satisfactory in CDCve transplants although
there were graft losses at 9 to 36months, even in patients with
low starting levels of DSA. Further work is required to im-
prove the early and long-term outcomes in HLA antibody-
incompatible renal transplantation.
MATERIALS ANDMETHODS
Patients
Patients were included if transplanted across a total pretreatment DSA
level of at least MFI 500 as measured by microbeads. ABO-incompatible
transplantswere excluded. Patients transplanted between 2003 and 2011who
had a panel reactive antibody level of more than 10% but no DSA-detectable
pretransplant were used as a comparison group. The study was approved by
the Coventry Research Ethics Committee.
Double Filtration Plasmapheresis
DFPP was performed using an HF-440 (Infomed, Geneva, Switzerland)
machine with a Plasmacure plasma separator (Kuraray Medical Inc.,
Okayama, Japan) and Evaflux 2A plasma fractionator (Kawasimi Laborato-
ries, Tokyo, Japan), as previously described (22).
IVIgs (Sandoglobulin, CSL Behring, West Sussex, United Kingdom) were
used in a few patients at the start of the program, either as a single dose after
the course of pretransplant DFPP or during an episode of rejection, but
subsequently were not used.
Immunosuppression and Rejection
Immunosuppression consisted of mycophenolate mofetil 500 or 1000mg
twice daily started 10 days before transplant, with dose reduced if white cell
count fell below 4.0109/L. Tacrolimus was started 4 days before transplant
at a dose of 0.15 mg/kg/day in divided doses, with a target trough level of 10
to 15 g/L in the first month. Prednisolone 20 mg once daily was started at
the time of surgery, and methylprednisolone 500 mg was given as a single
intravenous dose during the transplant operation. Two doses of basiliximab
20 mg were given at days 0 and 4.
Posttransplant serum samples for antibody analysis were taken daily for
the first 2 weeks and then three times a week for the next 2 weeks. Rejection
was diagnosed by renal biopsy if the renal function deteriorated or clinically
if there was rapid onset oliguria with a rise in both creatinine and in DSA
levels. Rejection was treated with high-dose methylprednisolone and daily
plasmapheresis for 3 days if DSA levels were raised, until patient 37 when
posttransplant plasmapheresis was phased out, and with OKT3 (muro-
momab-CD3) (Orthoclone) or rabbit (ATG) (Genzyme, Cambridge, MA) if
rejection was steroid resistant. Some patients felt to be at high risk of early
rejection were started on ATG shortly after transplant if there was oliguria.
Crossmatching and HLA Antibody Detection
Cellular crossmatching was performed on B cells and T cells separated
from peripheral blood (living donors) and either peripheral blood or spleen
(deceased donors). ForCDC crossmatching, 2L serum1L cells (2106/
mL) were incubated for 60 min at room temperature with and without DTT.
Five microliters complement (rabbit serum) was added and incubated for 60
min at room temperature. Cytotoxicity was visualized using acridine orange/
ethidium bromide cocktail. Anti-human globulin enhancement was not used.
FC crossmatching and microbead testing were performed as previously
described (23, 25). For the FC XM, the readout was the ratio of the median
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channel fluorescence of the test sample over that for a negative control AB
serum as relative median fluorescence. The threshold for a positive XM was
set at a relative median fluorescence of 4.0 for primary grafts and 2.5 for
regrafts.
HLA classes I- and II-specific antibodies were identified using microbead
assaymanufactured byOne Lambda Inc. (Canoga Park, CA) analyzed on the
Luminex platform (XMap 200; Luminex, Austin, TX). Phenotype-coated
beads were used until 2009, and single-antigen beads have been used to retest
most of the prior samples to confirm specificities.
A positive cellular XM was only considered to be due to DSA if the mi-
crobead assay confirmed the presence of a DSA. Uncertainty in the interpre-
tation of the assays was resolved with auto-crossmatching and/or further
testing of the microbead samples using reduction of IgM antibodies with
DTT or dilutions of the serum samples.
Statistical Analysis
Kaplan Meier survival analysis was performed using Med Calc (Mariakerke,
Belgium), andchi-squaredand t testingusingExcel (Microsoft,Redmond,WA).
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